CA2103059C - Method for making humanized antibodies - Google Patents
Method for making humanized antibodies Download PDFInfo
- Publication number
- CA2103059C CA2103059C CA002103059A CA2103059A CA2103059C CA 2103059 C CA2103059 C CA 2103059C CA 002103059 A CA002103059 A CA 002103059A CA 2103059 A CA2103059 A CA 2103059A CA 2103059 C CA2103059 C CA 2103059C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- residue
- variable domain
- human
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 136
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 133
- 229920001184 polypeptide Polymers 0.000 claims abstract description 132
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 132
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 21
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 21
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 170
- 239000000427 antigen Substances 0.000 claims description 139
- 108091007433 antigens Proteins 0.000 claims description 135
- 102000036639 antigens Human genes 0.000 claims description 135
- 230000027455 binding Effects 0.000 claims description 104
- 230000008676 import Effects 0.000 claims description 100
- 125000000539 amino acid group Chemical group 0.000 claims description 91
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 77
- 150000001413 amino acids Chemical class 0.000 claims description 65
- 238000006467 substitution reaction Methods 0.000 claims description 48
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 46
- 230000013595 glycosylation Effects 0.000 claims description 27
- 238000006206 glycosylation reaction Methods 0.000 claims description 27
- 241000894007 species Species 0.000 claims description 22
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 20
- 108091035707 Consensus sequence Proteins 0.000 claims description 20
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 17
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims description 17
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 17
- 102000054751 human RUNX1T1 Human genes 0.000 claims description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 15
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 description 120
- 108020004414 DNA Proteins 0.000 description 100
- 235000001014 amino acid Nutrition 0.000 description 68
- 229940024606 amino acid Drugs 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 61
- 102000004169 proteins and genes Human genes 0.000 description 59
- 239000012634 fragment Substances 0.000 description 57
- 239000013598 vector Substances 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 37
- 230000000875 corresponding effect Effects 0.000 description 35
- 150000007523 nucleic acids Chemical group 0.000 description 34
- 238000003556 assay Methods 0.000 description 31
- 230000035772 mutation Effects 0.000 description 30
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 239000002253 acid Substances 0.000 description 26
- 238000002703 mutagenesis Methods 0.000 description 26
- 231100000350 mutagenesis Toxicity 0.000 description 25
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 24
- 230000036541 health Effects 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- 239000013615 primer Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 19
- 239000012491 analyte Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 241001529936 Murinae Species 0.000 description 16
- -1 aspartyl Chemical group 0.000 description 16
- 125000004429 atom Chemical group 0.000 description 16
- 239000011575 calcium Substances 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 230000001472 cytotoxic effect Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 239000012636 effector Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000000302 molecular modelling Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- 230000001028 anti-proliverative effect Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 241000880493 Leptailurus serval Species 0.000 description 8
- 102220498086 Lipoma-preferred partner_K75T_mutation Human genes 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010039491 Ricin Proteins 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 8
- 108010022394 Threonine synthase Proteins 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 102000004419 dihydrofolate reductase Human genes 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 108010065920 Insulin Lispro Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 108010015792 glycyllysine Proteins 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 150000003568 thioethers Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108010073969 valyllysine Proteins 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 6
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 108010092854 aspartyllysine Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102220317648 rs1553902415 Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 230000010474 transient expression Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 5
- 229940127174 UCHT1 Drugs 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000002596 immunotoxin Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010029020 prolylglycine Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 4
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 4
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 4
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- 108010066427 N-valyltryptophan Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 4
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 4
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 4
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- MFEVVAXTBZELLL-GGVZMXCHSA-N Tyr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-GGVZMXCHSA-N 0.000 description 4
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 4
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 4
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108010068265 aspartyltyrosine Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 108010010147 glycylglutamine Proteins 0.000 description 4
- 108010081551 glycylphenylalanine Proteins 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 229940051026 immunotoxin Drugs 0.000 description 4
- 230000002637 immunotoxin Effects 0.000 description 4
- 231100000608 immunotoxin Toxicity 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108010026333 seryl-proline Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108010044292 tryptophyltyrosine Proteins 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100464197 Caenorhabditis elegans pak-1 gene Proteins 0.000 description 3
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 3
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 3
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 3
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 3
- 108091027305 Heteroduplex Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 3
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 3
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 3
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 3
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 3
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 3
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 3
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 3
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 3
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 3
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 3
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 3
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 3
- BWUHENPAEMNGQJ-ZDLURKLDSA-N Thr-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O BWUHENPAEMNGQJ-ZDLURKLDSA-N 0.000 description 3
- YKRQRPFODDJQTC-CSMHCCOUSA-N Thr-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN YKRQRPFODDJQTC-CSMHCCOUSA-N 0.000 description 3
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 3
- WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 3
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000012219 cassette mutagenesis Methods 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 3
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 108010070643 prolylglutamic acid Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102220005153 rs33922018 Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 108010048818 seryl-histidine Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000003573 thiols Chemical group 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- 108010051110 tyrosyl-lysine Proteins 0.000 description 3
- 108010009962 valyltyrosine Proteins 0.000 description 3
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 2
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 2
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 2
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 2
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 2
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 2
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 2
- RATVAFHGEFAWDH-JYJNAYRXSA-N Arg-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCN=C(N)N)N RATVAFHGEFAWDH-JYJNAYRXSA-N 0.000 description 2
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 2
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 2
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 2
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 2
- BSWHERGFUNMWGS-UHFFFAOYSA-N Asp-Ile Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(O)=O BSWHERGFUNMWGS-UHFFFAOYSA-N 0.000 description 2
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 2
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 2
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 2
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 2
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 2
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 2
- GFYOIYJJMSHLSN-QXEWZRGKSA-N Asp-Val-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GFYOIYJJMSHLSN-QXEWZRGKSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 2
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- SSHIXEILTLPAQT-WHFBIAKZSA-N Gln-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSHIXEILTLPAQT-WHFBIAKZSA-N 0.000 description 2
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 2
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 2
- SIGGQAHUPUBWNF-BQBZGAKWSA-N Gln-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O SIGGQAHUPUBWNF-BQBZGAKWSA-N 0.000 description 2
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 2
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 2
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 2
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 2
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- FPNWKONEZAVQJF-GUBZILKMSA-N His-Asn-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N FPNWKONEZAVQJF-GUBZILKMSA-N 0.000 description 2
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 2
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 2
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 2
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 2
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 2
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 2
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 2
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 2
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 2
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 2
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 2
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 2
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 2
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 2
- FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102220513987 PCI domain-containing protein 2_T57S_mutation Human genes 0.000 description 2
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 2
- WEQJQNWXCSUVMA-RYUDHWBXSA-N Phe-Pro Chemical compound C([C@H]([NH3+])C(=O)N1[C@@H](CCC1)C([O-])=O)C1=CC=CC=C1 WEQJQNWXCSUVMA-RYUDHWBXSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 2
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 2
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 2
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 2
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 2
- 102220520173 Protein patched homolog 1_V63F_mutation Human genes 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 description 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 2
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 2
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 2
- SBMNPABNWKXNBJ-BQBZGAKWSA-N Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO SBMNPABNWKXNBJ-BQBZGAKWSA-N 0.000 description 2
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 2
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 2
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 2
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 2
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 102220494897 Stromal cell-derived factor 2-like protein 1_E55H_mutation Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 101150006914 TRP1 gene Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 2
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 2
- CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 description 2
- LUMXICQAOKVQOB-YWIQKCBGSA-N Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O LUMXICQAOKVQOB-YWIQKCBGSA-N 0.000 description 2
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 2
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 2
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 2
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 2
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 2
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 2
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 2
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052614 beryl Inorganic materials 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 102220408281 c.161G>T Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 101150087654 chrnd gene Proteins 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220148488 rs201147592 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010058119 tryptophyl-glycyl-glycine Proteins 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 101150070733 81 gene Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- DWINFPQUSSHSFS-UVBJJODRSA-N Ala-Arg-Trp Chemical compound N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O DWINFPQUSSHSFS-UVBJJODRSA-N 0.000 description 1
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- OMCKWYSDUQBYCN-FXQIFTODSA-N Ala-Ser-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O OMCKWYSDUQBYCN-FXQIFTODSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- QDGMZAOSMNGBLP-MRFFXTKBSA-N Ala-Trp-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N QDGMZAOSMNGBLP-MRFFXTKBSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 241000270650 Alytes Species 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- DJAIOAKQIOGULM-DCAQKATOSA-N Arg-Glu-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O DJAIOAKQIOGULM-DCAQKATOSA-N 0.000 description 1
- PPPXVIBMLFWNSK-BQBZGAKWSA-N Arg-Gly-Cys Chemical compound C(C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N PPPXVIBMLFWNSK-BQBZGAKWSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- FNXCAFKDGBROCU-STECZYCISA-N Arg-Ile-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FNXCAFKDGBROCU-STECZYCISA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 1
- XNSKSTRGQIPTSE-ACZMJKKPSA-N Arg-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XNSKSTRGQIPTSE-ACZMJKKPSA-N 0.000 description 1
- QUBKBPZGMZWOKQ-SZMVWBNQSA-N Arg-Trp-Arg Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 QUBKBPZGMZWOKQ-SZMVWBNQSA-N 0.000 description 1
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 1
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 1
- PPCORQFLAZWUNO-QWRGUYRKSA-N Asn-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N PPCORQFLAZWUNO-QWRGUYRKSA-N 0.000 description 1
- YWFLXGZHZXXINF-BPUTZDHNSA-N Asn-Pro-Trp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 YWFLXGZHZXXINF-BPUTZDHNSA-N 0.000 description 1
- SUIJFTJDTJKSRK-IHRRRGAJSA-N Asn-Pro-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SUIJFTJDTJKSRK-IHRRRGAJSA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- JWQWPRCDYWNVNM-ACZMJKKPSA-N Asn-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N JWQWPRCDYWNVNM-ACZMJKKPSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- VBKIFHUVGLOJKT-FKZODXBYSA-N Asn-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)N)O VBKIFHUVGLOJKT-FKZODXBYSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 1
- KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 description 1
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
- NYLBGYLHBDFRHL-VEVYYDQMSA-N Asp-Arg-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NYLBGYLHBDFRHL-VEVYYDQMSA-N 0.000 description 1
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 1
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- ODNWIBOCFGMRTP-SRVKXCTJSA-N Asp-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CN=CN1 ODNWIBOCFGMRTP-SRVKXCTJSA-N 0.000 description 1
- GBSUGIXJAAKZOW-GMOBBJLQSA-N Asp-Ile-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GBSUGIXJAAKZOW-GMOBBJLQSA-N 0.000 description 1
- CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- UAXIKORUDGGIGA-DCAQKATOSA-N Asp-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O UAXIKORUDGGIGA-DCAQKATOSA-N 0.000 description 1
- DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 1
- GHAHOJDCBRXAKC-IHPCNDPISA-N Asp-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N GHAHOJDCBRXAKC-IHPCNDPISA-N 0.000 description 1
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
- KNDCWFXCFKSEBM-AVGNSLFASA-N Asp-Tyr-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KNDCWFXCFKSEBM-AVGNSLFASA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- CPMKYMGGYUFOHS-FSPLSTOPSA-N Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O CPMKYMGGYUFOHS-FSPLSTOPSA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- GYNUXDMCDILYIQ-QRTARXTBSA-N Asp-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N GYNUXDMCDILYIQ-QRTARXTBSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000251204 Chimaeridae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 description 1
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 1
- AVFGSUXQKHIQJS-QEJZJMRPSA-N Cys-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CS)N)C(O)=O)=CNC2=C1 AVFGSUXQKHIQJS-QEJZJMRPSA-N 0.000 description 1
- NXTYATMDWQYLGJ-BQBZGAKWSA-N Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CS NXTYATMDWQYLGJ-BQBZGAKWSA-N 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- IXPSSIBVVKSOIE-SRVKXCTJSA-N Cys-Ser-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O IXPSSIBVVKSOIE-SRVKXCTJSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 101100315388 Danio rerio tshz1 gene Proteins 0.000 description 1
- 244000309456 Decussocarpus nagi Species 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000003550 Eusideroxylon zwageri Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 1
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 1
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 1
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 1
- CLSDNFWKGFJIBZ-YUMQZZPRSA-N Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O CLSDNFWKGFJIBZ-YUMQZZPRSA-N 0.000 description 1
- ILKYYKRAULNYMS-JYJNAYRXSA-N Gln-Lys-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ILKYYKRAULNYMS-JYJNAYRXSA-N 0.000 description 1
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 1
- UKKNTTCNGZLJEX-WHFBIAKZSA-N Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UKKNTTCNGZLJEX-WHFBIAKZSA-N 0.000 description 1
- KVQOVQVGVKDZNW-GUBZILKMSA-N Gln-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KVQOVQVGVKDZNW-GUBZILKMSA-N 0.000 description 1
- JILRMFFFCHUUTJ-ACZMJKKPSA-N Gln-Ser-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O JILRMFFFCHUUTJ-ACZMJKKPSA-N 0.000 description 1
- OUBUHIODTNUUTC-WDCWCFNPSA-N Gln-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O OUBUHIODTNUUTC-WDCWCFNPSA-N 0.000 description 1
- MRVYVEQPNDSWLH-XPUUQOCRSA-N Gln-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O MRVYVEQPNDSWLH-XPUUQOCRSA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- BPDVTFBJZNBHEU-HGNGGELXSA-N Glu-Ala-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 BPDVTFBJZNBHEU-HGNGGELXSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- OWVURWCRZZMAOZ-XHNCKOQMSA-N Glu-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N)C(=O)O OWVURWCRZZMAOZ-XHNCKOQMSA-N 0.000 description 1
- MGHKSHCBDXNTHX-WDSKDSINSA-N Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MGHKSHCBDXNTHX-WDSKDSINSA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- QMOSCLNJVKSHHU-YUMQZZPRSA-N Glu-Met-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QMOSCLNJVKSHHU-YUMQZZPRSA-N 0.000 description 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- ZSIDREAPEPAPKL-XIRDDKMYSA-N Glu-Trp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N ZSIDREAPEPAPKL-XIRDDKMYSA-N 0.000 description 1
- BKMOHWJHXQLFEX-IRIUXVKKSA-N Glu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)O)N)O BKMOHWJHXQLFEX-IRIUXVKKSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 1
- FUESBOMYALLFNI-VKHMYHEASA-N Gly-Asn Chemical compound NCC(=O)N[C@H](C(O)=O)CC(N)=O FUESBOMYALLFNI-VKHMYHEASA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- KTSZUNRRYXPZTK-BQBZGAKWSA-N Gly-Gln-Glu Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KTSZUNRRYXPZTK-BQBZGAKWSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- XVYKMNXXJXQKME-XEGUGMAKSA-N Gly-Ile-Tyr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XVYKMNXXJXQKME-XEGUGMAKSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 1
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 1
- IDQNVIWPPWAFSY-AVGNSLFASA-N His-His-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O IDQNVIWPPWAFSY-AVGNSLFASA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
- JMSONHOUHFDOJH-GUBZILKMSA-N His-Ser-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 JMSONHOUHFDOJH-GUBZILKMSA-N 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- GIRSNERMXCMDBO-GARJFASQSA-N His-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O GIRSNERMXCMDBO-GARJFASQSA-N 0.000 description 1
- ALPXXNRQBMRCPZ-MEYUZBJRSA-N His-Thr-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ALPXXNRQBMRCPZ-MEYUZBJRSA-N 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 description 1
- 101000578940 Homo sapiens PDZ domain-containing protein MAGIX Proteins 0.000 description 1
- 101000727826 Homo sapiens Tyrosine-protein kinase RYK Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- RCFDOSNHHZGBOY-ACZMJKKPSA-N Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(O)=O RCFDOSNHHZGBOY-ACZMJKKPSA-N 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
- JSZMKEYEVLDPDO-ACZMJKKPSA-N Ile-Cys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O JSZMKEYEVLDPDO-ACZMJKKPSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- GTSAALPQZASLPW-KJYZGMDISA-N Ile-His-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N GTSAALPQZASLPW-KJYZGMDISA-N 0.000 description 1
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 1
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- QLROSWPKSBORFJ-BQBZGAKWSA-N L-Prolyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 1
- HFKJBCPRWWGPEY-BQBZGAKWSA-N L-arginyl-L-glutamic acid Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HFKJBCPRWWGPEY-BQBZGAKWSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100536883 Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513) thi5 gene Proteins 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- JYOAXOMPIXKMKK-YUMQZZPRSA-N Leu-Gln Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCC(N)=O JYOAXOMPIXKMKK-YUMQZZPRSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
- BJWKOATWNQJPSK-SRVKXCTJSA-N Leu-Met-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N BJWKOATWNQJPSK-SRVKXCTJSA-N 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 description 1
- 108010055685 Leukocyte-Adhesion Receptors Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 description 1
- HQVDJTYKCMIWJP-YUMQZZPRSA-N Lys-Asn-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HQVDJTYKCMIWJP-YUMQZZPRSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- CFVQPNSCQMKDPB-CIUDSAMLSA-N Lys-Cys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N CFVQPNSCQMKDPB-CIUDSAMLSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- FGMHXLULNHTPID-KKUMJFAQSA-N Lys-His-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 FGMHXLULNHTPID-KKUMJFAQSA-N 0.000 description 1
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 1
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 1
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 1
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 1
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- IIPHCNKHEZYSNE-DCAQKATOSA-N Met-Arg-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O IIPHCNKHEZYSNE-DCAQKATOSA-N 0.000 description 1
- JMEWFDUAFKVAAT-WDSKDSINSA-N Met-Asn Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O JMEWFDUAFKVAAT-WDSKDSINSA-N 0.000 description 1
- QWTGQXGNNMIUCW-BPUTZDHNSA-N Met-Asn-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QWTGQXGNNMIUCW-BPUTZDHNSA-N 0.000 description 1
- ABHVWYPPHDYFNY-WDSOQIARSA-N Met-His-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 ABHVWYPPHDYFNY-WDSOQIARSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 description 1
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 description 1
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 101100038125 Mus musculus Rora gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241001635529 Orius Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100028326 PDZ domain-containing protein MAGIX Human genes 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- IWRZUGHCHFZYQZ-UFYCRDLUSA-N Phe-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 IWRZUGHCHFZYQZ-UFYCRDLUSA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- WGXOKDLDIWSOCV-MELADBBJSA-N Phe-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O WGXOKDLDIWSOCV-MELADBBJSA-N 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- HWMGTNOVUDIKRE-UWVGGRQHSA-N Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 HWMGTNOVUDIKRE-UWVGGRQHSA-N 0.000 description 1
- FRPVPGRXUKFEQE-YDHLFZDLSA-N Phe-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FRPVPGRXUKFEQE-YDHLFZDLSA-N 0.000 description 1
- SXJGROGVINAYSH-AVGNSLFASA-N Phe-Gln-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SXJGROGVINAYSH-AVGNSLFASA-N 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
- INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 description 1
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- 241000404883 Pisa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- QAAYIXYLEMRULP-SRVKXCTJSA-N Pro-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 QAAYIXYLEMRULP-SRVKXCTJSA-N 0.000 description 1
- NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- UGDMQJSXSSZUKL-IHRRRGAJSA-N Pro-Ser-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O UGDMQJSXSSZUKL-IHRRRGAJSA-N 0.000 description 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- UIUWGMRJTWHIJZ-ULQDDVLXSA-N Pro-Tyr-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O UIUWGMRJTWHIJZ-ULQDDVLXSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100014660 Rattus norvegicus Gimap8 gene Proteins 0.000 description 1
- 102220471505 Replication factor C subunit 4_L78A_mutation Human genes 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101100240664 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nmt1 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 1
- INCNPLPRPOYTJI-JBDRJPRFSA-N Ser-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N INCNPLPRPOYTJI-JBDRJPRFSA-N 0.000 description 1
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 1
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 1
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 description 1
- DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 1
- UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 1
- IOWJRKAVLALBQB-IWGUZYHVSA-N Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O IOWJRKAVLALBQB-IWGUZYHVSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 1
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 1
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- GUZGCDIZVGODML-NKIYYHGXSA-N Thr-Gln-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O GUZGCDIZVGODML-NKIYYHGXSA-N 0.000 description 1
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- APIDTRXFGYOLLH-VQVTYTSYSA-N Thr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O APIDTRXFGYOLLH-VQVTYTSYSA-N 0.000 description 1
- LHNNQVXITHUCAB-QTKMDUPCSA-N Thr-Met-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O LHNNQVXITHUCAB-QTKMDUPCSA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 1
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- PRTHQBSMXILLPC-XGEHTFHBSA-N Thr-Ser-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PRTHQBSMXILLPC-XGEHTFHBSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 description 1
- XVHAUVJXBFGUPC-RPTUDFQQSA-N Thr-Tyr-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XVHAUVJXBFGUPC-RPTUDFQQSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- LVRFMARKDGGZMX-IZPVPAKOSA-N Thr-Tyr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 LVRFMARKDGGZMX-IZPVPAKOSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- GRQCSEWEPIHLBI-JQWIXIFHSA-N Trp-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 GRQCSEWEPIHLBI-JQWIXIFHSA-N 0.000 description 1
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- UYKREHOKELZSPB-JTQLQIEISA-N Trp-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(O)=O)=CNC2=C1 UYKREHOKELZSPB-JTQLQIEISA-N 0.000 description 1
- WSGPBCAGEGHKQJ-BBRMVZONSA-N Trp-Gly-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WSGPBCAGEGHKQJ-BBRMVZONSA-N 0.000 description 1
- FBGDDUKYOBNZJL-WDSOQIARSA-N Trp-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N FBGDDUKYOBNZJL-WDSOQIARSA-N 0.000 description 1
- IQIRAJGHFRVFEL-UBHSHLNASA-N Trp-Ser-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N IQIRAJGHFRVFEL-UBHSHLNASA-N 0.000 description 1
- ARKBYVBCEOWRNR-UBHSHLNASA-N Trp-Ser-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O ARKBYVBCEOWRNR-UBHSHLNASA-N 0.000 description 1
- YXSSXUIBUJGHJY-SFJXLCSZSA-N Trp-Thr-Phe Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@H](O)C)C(O)=O)C1=CC=CC=C1 YXSSXUIBUJGHJY-SFJXLCSZSA-N 0.000 description 1
- TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 1
- BABINGWMZBWXIX-BPUTZDHNSA-N Trp-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BABINGWMZBWXIX-BPUTZDHNSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- ONWMQORSVZYVNH-UWVGGRQHSA-N Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ONWMQORSVZYVNH-UWVGGRQHSA-N 0.000 description 1
- WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 1
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 1
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- XDGPTBVOSHKDFT-KKUMJFAQSA-N Tyr-Met-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O XDGPTBVOSHKDFT-KKUMJFAQSA-N 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- AUZADXNWQMBZOO-JYJNAYRXSA-N Tyr-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 AUZADXNWQMBZOO-JYJNAYRXSA-N 0.000 description 1
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 1
- XGZBEGGGAUQBMB-KJEVXHAQSA-N Tyr-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)N)O XGZBEGGGAUQBMB-KJEVXHAQSA-N 0.000 description 1
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 1
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 1
- 102100029759 Tyrosine-protein kinase RYK Human genes 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- IQQYYFPCWKWUHW-YDHLFZDLSA-N Val-Asn-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N IQQYYFPCWKWUHW-YDHLFZDLSA-N 0.000 description 1
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- JXGWQYWDUOWQHA-DZKIICNBSA-N Val-Gln-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N JXGWQYWDUOWQHA-DZKIICNBSA-N 0.000 description 1
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 1
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 1
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 1
- BRPKEERLGYNCNC-NHCYSSNCSA-N Val-Glu-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N BRPKEERLGYNCNC-NHCYSSNCSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- BNQVUHQWZGTIBX-IUCAKERBSA-N Val-His Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CN=CN1 BNQVUHQWZGTIBX-IUCAKERBSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 1
- XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 1
- FMQGYTMERWBMSI-HJWJTTGWSA-N Val-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N FMQGYTMERWBMSI-HJWJTTGWSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 1
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- SSKKGOWRPNIVDW-AVGNSLFASA-N Val-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SSKKGOWRPNIVDW-AVGNSLFASA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000001348 anti-glioma Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010094001 arginyl-tryptophyl-arginine Proteins 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010071185 leucyl-alanine Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010034507 methionyltryptophan Proteins 0.000 description 1
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108010043535 protease S Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108010091078 rigin Proteins 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 102200017973 rs12259370 Human genes 0.000 description 1
- 102220125995 rs144185168 Human genes 0.000 description 1
- 102220056660 rs28936686 Human genes 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108010036320 valylleucine Proteins 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F15/00—Digital computers in general; Data processing equipment in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Computer Hardware Design (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
Description
W~ 92/22653 ~ ~ Q ~ ~ ~ ~ PCI'/US92/U5126 METHOD FOIL h9Ai~ING-HUMANIZED ANTIBODIES.
i Field of the Invention This invention relates to methods for the preparation and use of variant antibodies and 1o finds application particularly in the fields of immunology and cancer diagnosis and therapy.
t3~kg_r~~ of the Inven~i~n Naturally occurring antibodies (immunogfobulins) comprise two heavy chains linked Z5 'together by disulfide bonds and two light chains, one light chain being linked to each of the heavy chains by disulfide bonds. Each heavy chain has at one end a variable domain (V,~) followed by a number of constant domains. Each light chain has a variabie domain 4~J~) at one end and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is 2o aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light end heavy chain variable domains, see e.g.
Chothia et al., J lNol. Biol. 186:651-868 (1985); Novotny and Naber, 'roc.
Matt. Aca~f Sci.
USA 8:4592-4596 (1985).
The constant domains are not involved directly in binding the antibody to an antigen, 25 but are involved in various effector functions, such as participation of the antibody in antibody-dependent ~ellufar cytotoxicity. The variabl~ domains of each pair of tight and heavy chains are involved directly pn binding the antibody to the antigen. The domains of natural light and heavy chains have the sarcie general structure, and each domain comprises four framework (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variable 30 or complementarity determining regions tCDRs) (see tCabat, E. A. et al., See~s~errces of Pr~teens of Imenunoldgecal lnte~est, National institutes of He~9th, Bethesda, ~!I~, (198?)). The four framework regions largely adopt a ~-sheet conformation and the CCRs form loops connecting, and in some cases forming part of, the ~-sheet structure. The CDRs in each chain are held ire close proximity by the framework regions and, with the CDRs from the other chain, contribute z ~c-rlu~~~eom26 W~ 92!22653 to the formation of the antigen binding site.
Widespread use has been made of monoclonal antibodies, particularly those derived from radents including mice, however they are frequently antigenic in human clinical use. For example, a major limitation in the clinical use of rodent monoclonal antibodies is an anti-globulin response during therapy (Miller, R. A. et al., Blood 62:988-995 (1983); Schroff, R. W. et al., Cancer Res. 45:879-885 41985)).
The art has attempted to overcome this problem by constructing "chimeric"
antibodies in which an animal antigen-binding variable domain is coupled to a human constant domain (Cabilly et al., U.a. patent No. 4,816,56?; IVlorri~on, S. L. et al., Proc.
Natl. .~lcad. Sci. UBA
81:6851-6855 41984); Boutianne, G. L. et al., Nature 312:643-646 (1984);
Neuberger, M. S.
et al., Nature 314:268-270 (1985)). The term "chimeric" antibody is used herein to describe a polypeptide comprising at least the antigen binding portion of an antibody molecule linked to at least part of another protein (typically an immunogiobuiin constant domain).
The isotype of the human constant domain may be selected to tailor the chimeric °~ antibody for participation in antibody-dependent cellular cytotaxicity (ADCC) and complement-dependent cytotoxicity (see e.g. Bruggemann, l~If. et al., J. Exp.
IVled.
186:1351-1361 (1987); Riechmann, L. et al., Nature 332:323-327 (1988); Love et al., IVlethods in Enzymology 178:515-527 (1989): Bindon et al., J. Exp. MecJ.
168:127-142 1988).
2o In the typical embodiment, such chimeric antibodies contain about one third rodent 4or other non-human species) sequence and thus are capable of eliciting a significant anti-globulin response in humans. For example, in the case of the murine anti-CD3 antibody, ~KT3, much of the resulting anti-globulin response is directed against the variable region rather than the constant region tJaffers, G. J. et al., transplantation 41:572-578 11986)).
In a further eff~art to resolve the antigen binding functions of antibodies and to minimize the us~ of h~terologous sequences in human antibodies, Winter and colleagues (Jones, P. T.
et al., Nature 321:5'22-525 (1986): Riechmann, L. et al., Nature 332:323-327 11988);
Verhoeyen, iVi. etal., Science 239:1534-1536 (1988)) have substituted rodent CDRs or CDR
sequences for the corresponding segments of a human antibody. As used herein, the term 30 ''humanized" antibody is an embodiment of chimeric antibodies wherein substantiaNy less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, hdmanized antibodies are typically human antibodies in which some CDR residues and possib6y some FR residues are substituted by residues from analogous sites in rodent antibodies.
,..,..r. '',, . . . ;'~, . . : .~ . ~', W092/2265~ 3 ~ ~ ~'~ ~~ ~ ~ PCT/US92/OS126 The therapeutic promise of this approach is supported by the clinical efficacy of a hs..~nanized antibody specific for the CAMPATH-1 antigen with two non-Hodgkin lymphoma patients, one of whom had previously developed an anti-globulin response to the parental rat antibody tRiechmann, L. et al., Nature 332:323-327 (1988); Hale, G. et ai., Lancet 1:1394-1399 (1988)). A murine antibody to the interfeukin 2 receptor has also recently been.
humanized (Queen, C. et ai., Prac. Nath Acad. Sci. USA 8f:10029-10033 (1989)) as a potential immunosuppressive reagent. Additional references related to humanization of antibodies include Co et al., Prac. Nat/. Acad. Sci. USA 88:2869-2873 11991 );
Gorman et al., Prac. Nat/. Acad. Sci. USA 88:4181-4185 (1991 ); Daugherty et al., G1/uc%ic Acids Research 19(9):2471-2476 t 1991 ); Brown et al., Proc. Nat/. Acad Sci. USA 88:2663-2667 t 1991 );
,lunghans et al., Cancer Research 50:1495-1502 11990).
In some cases; substituting CDRs from rodent antibodies for the human CDRs in human frameworks is sufficient to transfer high antigen binding affinity (Jones, P.
T, et al., Nature 321:522-525 t 1986): Verhoeyen, M. etal.; Science 239:1534-153611988)), whereas in other -cases it has been necessary to additionally replace one tRiechmann, L. et al"
Nature 332:323-327 t1988D? or several (Queen, C. et ai., Proc. Natl. Acad, Sci. USA
86:10029-10033 (1989)) framework region tFR1 residues. See also Co et al., supra.
For a given antibody a small number of FR residues are anticipated to be important for antigen binding. Firstly for example, certain antibodies have been shown to contain a few FR
residues which directly contact antigen in crystal structures of antibody-antigen complexes te:g:; reviewed in Davies, D. R: et al., Ann. Rev. Biochem. 59:439-473 11990)). Secondly, a number of FR residues have been proposed by Chothia, Lesk and colleagues lChothia, C. &
Lesk, A. M.; J. Mol. Bi~l. 196:901-917 11987); Chothia, C. et al.~, Nature 342:877-883 ti 989); Tramontano, A. et al.; J. Mol. Biol. 215:175-182 (1990)) as critically affecting the cpnformation of particular tDRs and thus their contribution to antigen binding. See also Margolies ef al.; Proc. lVatl. ~8cad. Sci. USA 72:2180-2184 11975).
It is also known that; in a few instances, an antibody variable domain (either V" or V~) may contain glycosylation sites; and that this glycosylation may improve or abolish antigen binding, Pluclcthun, Biotechnology 9:545-51 (1991 ); Spiegelberg etal., Biochemistry 9:4217-4223 (1970); Wal)ic ef al., J: Exp. Med. 168:1099-1109 11988); Sox etal., Prac. Nat/. Acad.
Sci: USA 66:975-982' (19701; Margni et al:, Ann. Rev. lmmunol. 6:535-554 (1988).
Ordinarily, however, glycosyl-. ion has: no influence on the antigen-binding properties of an antibody. Pluckthun, supra, t : a91 ).
The three-dimensional structure of irnmunoglobulin chains has been studied, and crystal Pi.'T/US92/05126 ~f structures for intact immunoglobulins, for a variety of immunoglobulin fragments, and for antibody-antigen complexes have been published (see e.g., Saul et al., Journal of Biological Chemistry 25:585-97 (1978); Sheriff etal., Prac. Nat/. Acad Sci. USA 84:8075-79 11987);
Segal et al,, Proc. Nat/. Acad. Sci. USA 71:4298-4302 11974); Epp et al., Biochemistry 14(22):4943-4952 (1975); Marquart et al., J. Mol. Biol. 141:369-391 11980);
Furey et al., J. Mol. Biol. 167:661-692 (1983); Snaw and Amzel, Protein: Structure, Function, and Genetics 1:267-279, Alan R. Liss, Inc. pubs. 11986): Chothia and Lesk, J. Mal.
Biol. 196:901-917 (1987); Chothia et al., Nature 342:877-883 (1989); Chothia et al., Science 233:755-58 (1986); Huber et al., Nature 264:415-420 11976); Bruccaleri et al., Nature 335:564-568 11988) and Nature 336:266 (1988): Sherman etal., JournalofBiological Chemistry 263:4064-4074(1988); Amzel and Pa)jak, Ann. Rev. Biochem. 48:961-67 (1979); Silverton etal., Proc.
Nat/. Acad Sci. USA ?4:5140-5144 11977); and Gregory et al., Molecular Immunology 24:821-829 (1987). It is known that the function of an antibody is dependent on its three dimensional structure, and that amino acid substitutions can change the three-dimensional ''structure of an antibody, Snow and Amzel, supra. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riechmann; L. etal., Nature 332:323-327 (1988): Queen, C.
etal., Proc.
Natl. Acad. Sci. USA 86:10029-10033 (1989)).
Humanizing an antibody with retention of high affinity for antigen and other desired biological activities is at present difficult to achieve using currently available procedures.
Methods are needed for ratibrralizing the selection of sites for substitution in preparing such antib~dies and thereby increasing, the efficiency of antibody humanization.
The proto-onco~ene HER,2 (human epidermal growth factor receptor 2) encodes a protein tyrosine kinase tp'185HER2'that is related to and somewhat homologous to the human epidermal growth factor receptor lsee CoussenS, L. et al., Science 230:1132-1139 (1985);
Yamamoto; T. et al., Nature 319:230-234 (1986); King, C. R, et al., Science 229:974-976 1985)). HER2 is also known in the field as c-erbB-2, and sometimes by the name of the rat homolog, neu. AmpiifiGation and/or overexpression of HER2 is associated with multiple human malignancies and appears to be integrally involved in progression of 25-30°~ of human breast ' 30 and ovarian cancers tSP'amon, D. J. et al.; Science 235:177-182 (1987), Siamon, D. J. et al., Science 244:707-712 E 1989)): Furthermore, the extent of amplification is inversely correlated with the observed median patient survival time (Slamon, supra, Science 1989).
The murine monoclonal antibody known as muMAb4D5 tFendly, 13. M. et al., Cancer Res. 50:1550-1558 t1 X90)), directed against the extracellular domain, (ECD) of p185HER2, WO 92/22653 . ~ .i ~ ~ ~ ~ ~ PCT/US92/~512G
specifically inhibits the growth of tumor cell lines overexpressing p185RER2 in monolayer culture or in soft agar (Hudziak, R. M. et al., Molec. Cell. Biol. 9:1165-1172 (1989D; Lupu, R.
et al., Science 243:1552-1555 (1990)). MuMAb4D5 also has the potential of enhancing tumor cell sensitivity to tumor necrosis factor, an important effector molecule in 5 macrophage-mediated tumor ce!! cytotaxicity (Hudziak, supra, 1989; Shepard, H. M. and t_ewis, G. D. J. Clinical Immunology 8:333-395 (1988)). Thus muMAb4D5 has potential far . clinical intervention in and imaging of carcinomas in which p185H~R2 is averexpressed. The muMAb4D5 and its uses are described in PGT application WO 89/06692 published 27 July 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL
10463.
However, this antibody may be immunogenic in humans.
tt is therefore an object of this invention to provide methods for the preparation of antibodies which are less antigenic in humans than non-human antibodies but have desired antigen binding and other characteristics and activities.
It is a further object of this irwention to provide methods for the efficient humanization ~of antibodies; i.e. selecting non-human amino acid residues for importation into a human antibody background sequence in such a fashion as to retain or improve the affinity of the non human donor antibody for a given antigen.
It is another object of this invention to provide humanized antibodies capable of binding pIB~HER2 2o C?ther objects; features, and characteristics of the present invention will became apparent upon consideration of the following description and the appended claims.
~ummaw of the invention The objects of this invention are accomplished by a method for making a humanized antibody comprising amino acid sequence of an import, non-human antibody and a human antibody, c~mprising the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable darnain and of a consensus variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an impart CDFi amino-acid sequence far the corresponding human CDR amino acid sequence;
d. aligning the ameno acid sequences of a Framework Region (FR) of the import ".': -'. .'. , .n'. . , "' ; .;~ ,:.. . :.. ~', ... ;;
.. ... ,.,, .,-.,;... ..... ,:.. > "...; .. ,.,..... ~ , ...' :.!.~: . , ,.;
~...,.. . . ' : .. ~ ~ . .. . a W~ 92/22653 ; ', . 6 PGT/US921~5126 antibody and the corresponding FR of the consensus antibody;
e. identifying impart antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably expected to have at least one of the following effects:
1. non-covalantly binds antigen directly, 2. interacts with a CDR; or 3. participates in the VL - VH interface: and g, for any non-homologous import antibody amino acid residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody I~R sequence.
f3ptionally, the method of this invention comprises the additional steps of determining if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step r 15 rtf), retaining the consensus residue.
Additionally; in certain embodiments the method of this invention comprises the feature wherein the corresponding consensus antibody residues identified in step (e) above are salect~d from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, COL; 71 L, ?3L, 85L; 8?L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 20 45H, 49H, 58H, 60H; 67H, 68H; 69H, ?~DH, ?3H, ?4H, 75H, 76H, ?8H, 91 H, 92H, 93H, and t03H tutilizing the numbering system set forth in Rabat, E. A. et al., SeQuences of Proteins of trrrmunologica! Inter~~t (National Institutes of Health, Bethesda, MD, 1987)).
in certain embodiments; the method of this invention comprises the additional steps of searching either or both of the import, non-human end the consensus variable domain 25 sequences for glycosylation sites, deternnining if the glycosytation is reasonably expected to be irnportarvt for the desired antigen binding and biological activity of the antibody (i.e., determinincd if the glycosyiation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosytation bnhanees or weakens antigen binding, or is important for maintaining antibody affiriityD: If the import sequence bears the glycosylation 3p site, it is preferred to Substitute that site for the corresponding residues in the consensus human if the glycosyiation site is re~sonat~ly expeoted to be important. if only the consensus sequence, end hot the import; bears the gtycosyfati~n site, it is preferred to eliminate that glycosyiation site or substitute therefor'ths corresponding amino acid residues from the import s~q~ience:
,.' .. :s: ;..,.,. . ... ., ::; ,;~' .. . 'v . . '.': :v..-; .,::'.' ,;: ~: ,:
v.
W~ X2/22653 ~ ~, o ~ ~ PLT/US92/05126 Another embodiment of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR residues which are non-homologous with the aligned consensus FR sequence, and far each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
Certain alternate embodiments of the methods of this invention comprise obtaining the amino acid sequence of at feast a portion of an import, non-human antibody variable domain 1o having a CDR and a FR, obtaining the amino acid sequence of at least a portion of a consensus antibody variable domain having a CDR and a FR, substituting the non-human CDR
for the human CDR in the consensus antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a, tin the FR of the variable domain of the tight chain) 4L, 35L, 36L, 38L, 43L, '~ ~ 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, ?OL, 71 L, 73L, 85L, 87L, 98L, or b. tin the FR,of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H; 43H, 45H; 49H, 58H, 60H, 67H, 68H, 69H, 70H, ?3H, 74H, 75H, 76H, ?8H, 91 H, 92H, 93H, and 103H.
In preferred embodiments, the non-CDR residue substituted at the consensus FR
site is the residue found at the corresponding location of the non-human antibody.
Dptionally, this just-recited embodiment comprises the additional steps of following the method steps appearing at the beginning of this summary and determining whether a particular amino acid residue can reasonably be expected to have undesirable effects.
This invention also relates to a humanized antibody comprising the CDR
sequence of an irnp~rt, non-human antibody and the FR sequence of a human antibody, wherein an amino acid residue within the human FR sequence located at any one of the sites 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L64L, 65L; 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H; 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H92H, 93H, and 103H has been substituted by another residue.
In preferred embodiments, the residuq substituted at the human FR site is the residue found at the corresponding location of the non-human antibody from which the non-human CDR was obtaified. In other embodiments, no human FR residue other than those set forth in this group has been substituted.
1 and SEQ. 1D NO. 3, respectively). FIGURE 1 B shows the comparison between the VH
domain amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig_ 1 B, SEQ. ID N0. 6, SEO. 1D N0. 2 and SEQ. ID NO. 4, respeciively)_ Both Figs 1 A and 1 B
use the generally accepted numbering scheme from Kabat, E. A., et al , Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda; MD
(1987)). !n both Fig_ 1 A and Fig. i B, tfie CDR residues determined according to a standard sequence definition (as in Kabat, E. A. et al., Sequences of Proteins oflmmunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath the sequences, and the CnR residues determined according to a structur<~I
definition (as in Choihia, C. & Lesk, A. M., J. MoL Biol. 19fi:901-917 (1987)) are indicated by the second, lower underlines. The mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 Vt. and Vti by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative i 5 cell proliferation was determined as described (Hudziak, R. N1. et al., Molec. Cell. Biol.
9:1165-1172 (1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows a stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH _ The CDR residues (Kabat, E. A. et al., Sequences of Proteins of ImmunologicaJ Interest (National Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A?1, T73, A78. S93, Y102 and V~ residues Y55 plus R66 (see Table 3) are shown.
FIGURE 5 shows an amino acid sequence comparison of V~ (top panel) and VH
(tower pane!) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 (1992) with a humanized variant of this;antibody (ImxC:1).sv I Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely V~ K i and VH III upon which the humanized sequences are based (Kabat, E. A. et aL, Sequences of Proteins of ImmunolopicaJ Interest, 5'" edition, National Institutes of Health, Bethesda, MD, USA (1991)). The light chain sequences--muxCD3, )~tlxCD3 v 1 and huKl--correspond to SEQ.ID.NOs 16, 17, and i 8, respectively. 'The heavy chain sequences muxCD3, huxCD3v1 and hutd correspond to SEQ.
ID. NOs 19, 20, and 21 respectively. Residues which differ between muxCD3 and huxCD3v1 are identified by an asterisk ('), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (ll). A bullet (°) denotes that a residue at this position has been found to contact antigen in one or more crystallographic structures of antibodylantigen complexes (Kabat et al., 1991; Mian, i_ S. et al , J. Mol_ Biol.
217, 133-151 (1991)). The location of CDR residues according to a sequence definition SUBSTITUTE SHEET
2/22653 ~ ~ ~ ~ ~ 'a ~ pCT/US92/0512b 'WU 9 amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig.
1 B, SEQ
ID NO. 6, SEO.. ID NO. 2 and SECT. ID NO. 4, respectively). Both Figs 1 A and 1 B use the generally accepted numbering scheme from Kabat, E. A., et ai., Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD (1987)).
In both Fig. 1A
and Fig. 1 B, the CDR residues determined according to a standard sequence definition tas in Kabat, E. A. et al" Sequences of Proteins of lmmunolagical Interest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath tha sequences, and the CDR residues determined according to a structural definition (as in Chothia, C. & Lesk, A.
M., J, Mol. Biol. 996:901-917 (198?I) are indicated by the second, Lower underlines. The to mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 VE and VH by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative cell proliferation was determined as described tHudziak, R. M. et al., Mo%c.
Cell. Biol.
'9 1165-1172 ( 1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows ~ stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH . The CDR residues (Kabat, E. A: et aL, Sequences of Proteins of Immunological Interest (NationaE Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A71, T 73, A78, S93: Y 102 and VL residues Y55 plus R66 (s~e Table 3) are shown.
FIGURE 5 shows an amino acid Sequence comparison of V~ (top panel) and VH
(lower panel) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 ( 1992) with a humanized variant of this antibody (huxCD3v9). Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely VL K 1 and VH II) upon which the humanized sequences are based (Kabat, E. A. et al.; Sequences of Proteins of Immuno%gical Interest, 5'"
edition; National institutes of Health; Bethesda, MD, USA (1991 )). The light chain sequences--muxCD3, huxCD3v9 and huKl--correspond to SEQ.ID.NOs 16, 17, and 18, respectively. The hea~ey chain sequences--muxCD3; huxCD3v9 and huKt--correspond to SEa.ID.NOs 19, 20, and 21; respectively: Residues which differ between muxCD3 and huxCD3v9 are identified by an asterisk ('" ), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (#). A b~rllet (a) denotes that a residue at this position has been found to contact antigen in- one or more crystallographic structures of antibodyiantigen °nf, ,~'.~;r~~rt~:~~.a~y 7,~' a.'i%ji4rr~..~,~i&5il~su :~~'~d~~t~r ~
n,s~!~~r~t~.:al~a;. . <.u',~i~":x:..~,.~~r.~i<. ..":rk;sso.,:<:.a ; .tea., .:~..
17V0 92/22653 , . , complexes iKabat et al., 1991; Mian, t. S. et al., J. Mol. Biol. 217, 133-151 (1991 )). The location of CDR residues according to a sequence definition (Kabat et al., 1991 ) and a structural definition tChothia and t-esk, supra 1987) are shown by a line and carats t") beneath the sequences, respectively.
FIGURE 6A compares marine and humanized amino acid sequences for the heavy chain of an anti-CD18 antibody. H52H4-160 tSEa. ID. NO. 22) is the marine sequence, and pH52-8.0 tSECI. ID. N0. 23) is the humanized heavy chain sequence, pH52-8.0 residue 143S is the final amino acid in the variable heavy chain domain VH, and residue 144A is the first amino acid in the constant heavy chain domain CH1.
FIGURE 6s compares marine and humanized amino acid sequences for the light chain of an anti-CD18 antibody. H52L6-158 tSEQ. ID. NO. 24> is the marine sequence, and pH52-9.0 tSEQ. ID. NO. 25) is the Humanized light chain sequence. pH52-9.0 residue 128T is the final amino acid in the light chain variable domain VL, and residue 129V is the first amino acid in the light chain constant domain CL, ' Defiled Descrio~on of the Invention pefinition~
In general, the following words or phrases have the indicated definitions when used in the description, examples, and claims:
The mutine monoclonal antibody known as muMAb4D5 tFendly, B. M. et al., Cancer Res. 50:1550-1558 119901) is directed against the extracellular domain tECD) of p185HER2, The muMAb4D5 and its uses are described in PCT application W0 89/06692 published 27 July 1989. This marine antibody was deposited with the ATCC and designated ATCC CRt-10463.
Inthis description and claims, the terms muMAb4D5~ chMAb4D5 and huMAb4D5 represent marine, chimerized and humanized versions pf the mor~oclonai antibody 4D5, respectively.
A humanized antibody- for the purposes herein is an immunoglobulin amino acid sequence variant ar fragment thereof which is capable, of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a 'CDR having substantially the amino acid sequence of a non-human imenunogtobulirr.
'Generally, a humanized antibody has one ~r more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are referred to hereirt as "impbrt" residues, which are typically taken from an "import°' antibody domain, W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/vS92/05126 particularly a variable domain. An import residue, sequence, or antibody has a desired affinity and/or specificity, or other oesirable antibody biological activity as discussed herein.
In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains (Fob, Fab', F(ab')z, Fabc, Fv) in which all or substantially all of the CDR regions correspond to these of a non-human immunoglobulin and all ar substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
The humanized antibody optimally also will comprise at Least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Ordinarily, the antibody will contain both the light chain as well as at least the variable domain of a heavy chain. The i0 antibody also may include the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain.
The humanized antibody will be selected from any class of tmmunoglobufins, including IgM, IgG, IgD, IgA and Ig~, and any isotype, including IgG 1, IgG2, IgG3 and IgG~4. Usually the constant domain is a complement fixing constant domain where it is desired that the humanized antibody exhibit cytotoxic activity, and the class is typically IgG,. Where such ''cytotoxic activity is not desirable, the constant domain may be of the IgGz class. The humanized antibody may comprise sequences from mare than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
The FR and CDR regions of the humanized antibody need not correspond precisely to the parent~t sequences, e.g., the import CDR or the consensus FR may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or FR residue at that site does not correspond to either the consensus or the import antibody. Such mutations, however, wilt not be extensive. Usually, at least 75°~ of the humanized antibody,residues will correspond to those of the pareritat FR and CDR sequences, more often 90%, and mast preferably greater than 95,%.
In general, humanized antibodies prepared by the method of this invention are produced by a procoss of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglabulin models are commonly available and are familiar to those skilled in the art.
Computer programs are available which illustrate and display probable three dimensional conformational structures of selected candidate immunoglobulin sequences.
Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunogtobulin to bind its antigen.
PC1'/US92/05126 Iz Residues that influence antigen binding are defined to be residues that are substantially responsible for the antigen affinity or antigen specificity of a candidate immunoglobulin, in a positive or a negative sense. The invention is directed to the selection and combination of FR
residues from the consensus and import sequence so that the desired immunoglobutin characteristic is achieved. Such desired characteristics include increases in affinity and greater specificity for the target antigen, although it is conceivable that in some circumstances the opposite effects might be desired. In general, the CDR residues are directly and most substantially involved in influencing antigen binding talthough not all CDR
residues are so involved and therefore need not be substituted into the consensus sequence).
However, FR
to residues also have a significant effect and can exert their influence in at least three ways:
They may noncovalently directly bind to antigen, they may interact with CDR
residues and they may affect the interface between the heavy and light chains.
A residue that nancovalently directly binds to antigen is one that, by three dimensional analysis, is reasonably expected to noncovalently directly bind to antigen.
Typically, it is a necessary to impute the position of antigen from the spatial location of neighboring CDRs and the dimensions and structure of the target antigen. In general, only those humanized antibody residues that are capable of forming salt bridges, hydrogen bands, or hydrophobic interactions are likely to be involved in non-covalent antigen binding, however residues which have atoms which are separated from antigen spatially by 3.2 Angstroms or less may also non-covalently 2p interact with antigen. Such residues typically are the relatively larger amino acids having the side chains with the greatest bulk; such as tyrosine, arginine, and lysine.
Antigen-binding FR
residues also typically will have side chains that are oriented into an envelope surrounding the solvent oriented face of a CDR which extends about 7 Angstroms into the solvent from the CDR domain and about 7 Angstroms on either side of the CDR domain, again as visualized by three dimensional modeling.
A residue that interacts with a CDR generally is a residue that either affects the conformation of the CDR polypeptide backbon~ ar forms a noncovalent bond with a CDR
residue side chain: Conformation-affecting residues ordinarily are those that change the spatial position of any CDR backbone atom IN; Ca, C, 0, C,B') by more than about 0.2 Angstroms.
' 30 ' Backbone atoms of CDR sequences are displaced far example by residues that interrupt or modify organized structures such as beta sheets, helices or loops. Residues that can exert a profound affect on the conformation of neighboring sequences include proline and giycine, both of which are capable of introducing bends into the backbone. Other residues that can displace backbone atoms are those that are capable of participating in salt bridges and hydrogen bonds.
WO ~Z/2~653 _ I~ ~ ~ ~ ~ ~ J ~~ . ~ ~ f'~/US92/05126 A residue that interacts with a CDR side chain is one that is reasonably expected to form a noncovalent bond with a CDR side chain, generally either a salt bridge or hydrogen bond. Such residues are identified by three dimensional positioning of their side chains. A salt or ion bridge could be expected to form between two side chains positioned within about 2.5 -3.2 Angstroms of one another that bear opposite charges, for example a lysinyl and a.
giutamyl pairing. A hydrogen bond could be expected to form between the side chains of residue pairs such as Beryl or threonyl with aspartyl or glutamyl for other hydrogen accepting residues). Such pairings are well known in the protein chemistry art and will be apparent to the artisan upon three dimensional modeling of the candidate immunoglobulin.
1o lmmunoglobulin residues that affect the interface between heavy and light chain variable regions t"the V~ - V" interface") are those that affect the proximity or orientation of the fiwo chains with respect to ane another. Certain residues involved in interchain interactions are already known and include V~ residues 34, 36, 38, 44, 46, 87, 89, 91, 96, and 98 and V" residues 35, 37, 39, 45, 47, 91, 93; 95, 100, and 103 (utilizing the nomenclature set forth '' n Kabat et al.; Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD, 1987)1. Additional residues are newly identified by the inventors herein, and include 43t., 85L, 43H and 60H. While these residues are indicated for IgG
only, they are applicable across species: In the practice of this invention, import antibody residues that are reasonably expected to be involved in interchain interactions are selected for substitution into 20' the consensus sequence: It is believed that heretofore no humanized antibody has been prepared-with an intrachain-a>fecting residue selected from an import antibody sequence.
Since it is not entirely possible to predict in advance what the exact impact of a given substitution will be it may be necessary to make the substitution and assay the candidate antibody for the desired characteristic. These steps, however, are per se routine and welt within the ordinary skill of the art.
CDR and FR residues are deternnined according to a standard sequence definition tKabat et al. , Sequences of Proteins of lmmcen~lagical Interest, National institutes of Health, Bethesda MD (1987), and a structural definition tas in Chothia and Lesk, J. Mol. Bi~l.
196:901-917 (1987). Where these two methods result' in slightly different identifications of a CDR, the 3o structural definition is preferred, but the residues identified by the sepuence definition method are considered important FR residues for determination of which framework residues to import into a consensus ~equence.
Throughout this description; reference is made to the numbering scheme from Kabat, E. A., et el., Sequences of Proteins of lmmunological Interest (National Institutes of Health, WO 92/22653 ~ ~ ~ ~ ~ ~ ~ ~' I P(.'T/US92/OS126 ''i Bethesda, MD 11987) and (1991 ). In these compendiums, Kabat lists many amino acid sequences for antibodies for each subclass, and lists the most commonly occurring amino acid for each residue position in that subclass. Kabat uses a mefihod for assigning a residue number to each amino acid in a Listed sequence, and this method for assigning residue numbers has become standard in the field. The Kabat numbering scheme is followed in this description.
For purposes of this invention, to assign residue numbers to a candidate antibody amino acid sequence which is not included in the Kabat compendium, one follows the following steps. Generally, the candidate sequence is aligned with any immunoglobulin sequence or any consensus sequence in Kabat. Alignment may' be done by hand, or by computer using commonly accepted computer programs; an example of such a program is the Align 2 program discussed in this description. Alignment may be facilitated by using some amino acid residues which are common to mast Fab sequences. For example, the light and heavy chains each typically have two cysteines which have the same residue numbers; in V~ domain the two cysteines are typically at residue numbers 23 and 38, and in the VH domain the two cysteine residues are typically numbered 22 and 92. Framework residues generally, but not always, have approximately the same number of residues, however the CDRs will vary in size. For example, in the case of a CDR from a candidate sequence which is longer than the CDR in the sequence in Kabat to which it is aligned, typically suffixes are added to the residue number to indicate the insertion of additional residues (see, e.g. residues 'i OOabcde in Fig. 5). For candidate sequences which, for example, align with a Kabat sequence for residues 34 and 3f but have no residue betv~reen ther~n to align with residue 35, the number 35 is simply not assigned to a residue.
Thus, in humanization of an import variable sequence, where one cuts out an entire human or consensus CDR and r~places it with an import CDR sequence, (a) the exact number z5 of residues may be swapped, leaving the numbering the same, Ib) fewer import amine acid residues may be introduced than are cut, in w~Oich ease there will be a gap in the residue numbers, or (c) a larger number of'amino acid residues may be introduced then were cut, in which case the numbering will involve the use of suffixes such as 100abcde.
The terms "consensus sequence°' and "consensus antibody" as used herein refers to ' 30 ' an amine acid sequence which comprises the most frequently occurring amino acid residues at each location in ail immunoglobulins of any particular subclass or subunit structure. The consensus sequence may be based on immunogiobulins of a particular species or of many species. A "consensus" sequence, structure, or antibody is understood to encompass a consensus human sequence as described in certain embodiments of this invention, and to refer P~'1US92/0512G
'NVO 92/22653 ' 15 to an amino acid sequence which comprises the most frequently occurring amino acid residues at each location in all human immunoglobulins of any particular subclass or subunit structure.
This invention provides consensus human structures and consensus structures which consider other species in addition to human.
The subunit structures of the five immunogiobulin classes in humans are as follows:
IgG Y Y1, Y2, Y~, Y4 x or ~l (Y~2) (Ya~a) IgA a a1, a2 x or A (a~rz)" , (~2JI2)~
IgM ~ none ~ x or e1 (~.~zx~)s , G~.~z~z)s IgD a none x or /I (c3ax2) , (d~Jlz) IgE a none x or ~l (e~re2) , (E~12) (" may equal 1, 2, or 3) Pn preferred embodiments of an IgGY1 human c~nserysus sequence, the consensus variable domain sequences are derived from the most abundant subclasses in the sequence compilation of Kabat etal., Sequencesnf~roteins oflmmuncl~gicalfnterest, National Institutes of Health, Bethesda MD (1987), namely V~ x Subgroup I and Vy group Ill. In such preferred embodiments, the V~ consensus domain has the amino acid sequence:
SGSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT (SEQ. ID NO. S);
the VH consensus domain has the amino acid sequence:
EV~1LVESGGGLVQPGGSLRLSCAA~GFTFSf~YAMSWVRQAPGKGLEWVAVISENGGYTRYAD
SVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS (SEQ.
ID NC. 4).
These sequences include consensus CDRs as well as consensus FR residues (see for eacample irk Fig. 1 ).
While not wishing to be limited to any particular theories, it may be that these preferred embodiments are less likely to be imrnunogenic ire an individuaa than less abundant subclasses.
however, in other embodiments, the consensus sequence is derived from other subclasses of human immunogiobulin variable domains: In yet other embodiments, the consensus sequence is derived from human constant domains.
Identity or homology with respect to a specified amino acid sequence of this invention is defined herein as the percentage of amino acid residues in a candidate sequence that are ' PCTlUS92/U5126 WO 92/22653 - , . ' , identical with the specified residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal or internal extensions, deletions, or insertions into the specified sequence shall be construed as affecting homology. All sequence alignments called for in this invention are such maximal homology alignments. While such alignments may be done by hand using conventional methods, a suitable computer program is the "Align 2°' program far which protection is being sought from the U.S. Register of Copyrights (Align 2, by Genentech, Inc., application filed 9 December 1991 ).
"Non-homologous" import antibody residues are those residues which are not identical to the amino acid residue at the analogous or corresponding location in a consensus sequence, after the import and consensds sequences are aligned.
The term °'computer representation" refers to information which is in a form that can be manipulated by a computer. The act of staring a computer representation refers to the act ~ of placing the information in a form suitable for manipulation by a computer.
This invention is also directed to novel polypeptides, and in certain aspects, isolated novel humanized anti-p185HER2 antibodies are provided. These novel anti-p185HER2 antibodies are sometimes collectively referred to herein as huMAb4D5, and also sometimes as the light or heavy chain variable domains of huMAb4D5, and are defined herein to be any 2o polypeptide sequence which possesses a biological property of a polypeptide comprising the following polypeptide sequence:
DIO.MTt~SPSSLSASVGDRVTITCRASaDVNTAVAWYQQKPGKAPKLLIYSASFLESGVP
SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGO,GTKVEIKRT (SEQ. ID NO. 1, which is the light chain variable domain of huMAb4.D5); or EVQLVESGGGLV~PGGSLRLSCAASGFNIKDTYiHWVRQAPGKGLEWVARIYPTNGYTR
YADSVKGRFTfSADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLV
TVSS (SECT. ID NO. 2, which is the heavy chain variable domain of huMAb4D5?.
30 "Biological property", as relates for example to anti-p185RER2, for the purposes herein means an in a~ivo effector or antigen-binding function or activity that is directly or indirectly performed by huMAb4D5 (whether in its native or denatured conformation).
Effector functions include p185HER2 binding, any hormonal or hormonal antagonist activity, any mitogenic or agonist or antagonist activity, any cytotoxic activity. An antigenic function means possession WO 92/22653 ~ ~ '~ ~ I . , PCT~US92/05126 I~
of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against t.::polypeptide sequence of huMAb4D5.
Biologically active huMAb4D5 is defined herein as a polypeptide that shares an effectar function of huMAb4D5. A principal known effector function of huMAb4D5 is its ability to bind to p185HERZ_ Thus, the biologically active and antigenically active huMAb4D5 palypeptides that are the subject of certain embodiments of this invention include the sequence of the entire translated nucleotide sequence of huMAb4D5; mature huMAb4D5; fragments thereof having a consecutive sequence of at Least 5, 10, 15, 20, 25, 30 or 40 amino acid residues comprising sequences from muMAb4D5 plus residues from the human FR of huMAb4D5; amino acid sequence variants of huMAb4D5 wherein an amino acid residue has been inserted N- or C-terminat ta, ar within, huMAb4D5 ar its fragment as defined above; amino acid sequence variants of huMAb4D5 or its fragment as defined above wherein an amino acid residue of huMAb4D5 or its fragment as defined above has been substituted by another residue, including ~~predetermined mutations by, e.g., site-directed or PCR mutagenesis;
derivatives of huMAb4D5 or its fragments as defined above wherein huMAb4D5 or its fragments have been covalent modified, by substitution, chemical, enzymatic, or other appropriate means, with a moiety other than a naturally occurring amino acid: and gtycosylation variants of huMAb4D5 tinsertion s~f a gtycosytation site or dehtion of any glycosylation site by deletion, insertion or substitution of suitable residues). Such fragments and variants exclude any potypeptide heretofore identified, includir~g~muMAb4D5 or any known polypeptide fragment, which are anticipatory order 35 U.S.C.102 as well as polypeptides obvious thereaver under 35 U.S.C.
103.
An "isolated" polypeptide means polypeptide which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous salutes. In preferred embodiments, far example, a polypeptide product comprising huMAb4D5 wilt be purified from a cell culture or other synthetic environment t1 to greater than 95% by weight of protein as determined by the Lowry method, and most preferably mare than 99°~ by weight, i2) to a degree sufficient to obtain at least 15 residues of N-terminal ar internal amino acid sectuence by use of a gas- ar liquid-phase sequenator tsuch as a commercially availabt~, Applied Biasystems sequenator Model 470, 477, or 4731, or t3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. isolated huMAb4D5 includes huMAb4D5 in,~tu within recombinant P~GT/US9~/OS1Z5 WO 92/2653 ' -t$
Gcll$ since at least or~~ component of the huMAb4D5 natural envirorlrr~ent will not be present.
Drdinarity, however, Isolated huMAb4I~5 will be prepared by at least one purification step.
in accordance with this invention. huMAb4D5 nucteiC acid is I~NA or DNA
containing greater than ten bases that encodes a biologically or antigenically active huMAb4D5, is complementarlr to nucleic acid sequence encoding such huMAb4D5. or hybridizCS
tb nuCIeiC
acid sequence encoding such huMAb~t05 and remains sfabty bound to it under stringent conditions, and comprises nuClt~ic acid from s muMAb4D5 CDR and a human FR
region.
Preferably. the huMAb4a5 riucleic~f~cid ~sncodes a palypeptida sharing ax least 75°~6 sequenaa idantixy, more preferably at least BO°/s, still more praf8tably at l6ast 8596, oven more i0 preferably at 90%, and most prCfarabty 959b, with the huMAb4D5 amino acid sos~uance.
Preferably, a nucleic acid molecule that hybridizes to the huMAb4D5 nucleic said contains at . least 20, more proferably.. Vin, and most preferably 9D bases. Such hybridizing or comrilementary nucleic acid, however, is further defined as being novel under 35 U-S.C. 10~
and unobvious under 35 U:S.~. t 03 over any prior art nuCleiC acid.
is ~' ~ Stringent conditions era those that f 1 i employ law ionic svength and high temperature for washing, for exempts, O.Oi S M NaC110.00t 5 M sodium citratel0/1 %
NaDodSO; at 80° G:
t2) employ during hybridixatlon a ,denaturing agent such as formamide, for example, &096 lvol/vol) .formamide with 0:9 96~ bavina serum albuminl0ll °.6 ~colh~l9 °~ polyvinylpyrrolidona150 mM sodium~phosphate. buffer at pH 6.,6 with 75o rnM NaGI, T5 mM sodium citrate at 42° G:
D' v w or: (3) employ 5096 form>~mida, 6.x';SSC 10.76 M, NeCI, 0.0'Y5 M sodium Gitratef, 50 mM
sodiury phosphate lphl f.$i. O-t °.~ sQdlum pyrophosphate, 5 x D$nhardt's solution, sonicaxed .. $atmowsperm DNA I50.g1m11, 0.1:% SDS. and 1096 dextran sulfate at 4~ C, with washes at - . ~,~ C in 0.2 x SSC arid 0.~1.% S~S..
w . ~ Tha~term .'cant~ol sequerzc~s" refers to UNA soquertces necessary for the expression ~f:':an~operabty linkqdycoding. sequence yin a.parti.uuler host organism. The Contr4l Setluencss ' , that era suitable for-~~prokaryotes, for example; include a promoter.
aptionaliy an operattrr $equence,~ a ribosome binding site; and possibly, other as yet poorly understood sequences.
Eukaryotic cells. are knows to utiliaa promoters, polyadenylation signals and enhancers.
Nucleic acid is "oparably linked." when it is placed into a functional relationship with ~' so ancrthar nucleic acrd sequence: °FCir example, 17NA for a presaqu~nce or secretory leader is Qperpbly,lihked to DNA for a polypeptide if it is expressed as $ grpprptein that participates in the. secretion' of the ~ potypeptide; a promoter ~or enhanaor is aperably linked to a Coding sequence if It affects the transcription of the seguence; ar a ribosome binding site is aperably linked ~to a ,coding ~ sequersce ii it is positioned. so as to facilitate translation. Generally, *-trademark _WO 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT%US92/05126 1 '~
"operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
An "exogenous" element is defined herein to mean nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.
As used herein, the expressions "cell,"~ "cell line," and "cell culture" are used 1o interchangeably and all such designations include progeny. Thus, the words "transformants"
and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that alt progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell '"'are included. Where distinct designations are intended, it will be clear from the context.
"Oiigonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphate, or phosphoramidite chemistry, using solid phase techniques such as described in EP 266,432 published 4 May 1988, o~ via deoxynucleoside H-phosphonate intermediates as described by Froehler et a6.; Nu_cl__ Acids Res., 14: 5399-5407 ( 19861). They are then purified on polyacrylamide gels:
The technique of "polymerase bhain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA
and/or DNA, are amplified as described in U.S. Pat. No. 4;683,195 issued 28 July 1987.
Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences; specific DNA sequences from total genomic DNA, and cDNA
3o transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et aL, Cold Sarinca Harbor- Symn. Quant. Biol., ,~: 263 (1987); Erlich, ed., P R
Technoioav: tStockton f~ress, NY; 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polyrryerase reaction method for amplifying a nucleic acid 'test sample, comprising he use of ~ known nucleic acid (DNA or RNA) as a primer and ~:~U~~J~
WO 92/22$53 ~ PGT/US92/0~126 ,, zo utilizes a nucleic acid polymerise to amplify or generate a specific piece of nucleic acid or to amplify or generate a specific piece of nucleic acid which is complementary to a particular nucleic acid.
Su~able Metho~i~ for Practicing ~h~ Invention Some aspects of this invention include obtaining an import, non-human antibody variable domain, producing a desired humanized antibody sequence and for humanizing an antibody gene sequence are described below. !~ particularly preferred method of changing a to gene sequence, such as gene conversion from a non-human or cons~nsus sequence into a humanized nucleic acid sequence, is the cassette mutagenesis procedure described in ~xampl8 1. Additionally, methods are given for obtaining and producing antibodies generally, which apply equally to native non-human antibodies as well as to humanized antibodies.
Generally, the antibodies and antibody variable domains of t6rois invention are i5 'conventionally prepared in recombinant cell culture, as described in more detail below.
Recombinant synthesis is preferred for reasons of safety and economy, but it is known to prepare peptides by chemical synthesis and to purify them from natural sources; such preparations are included within the definition of antibodies herein.
2o Molecular Modeling An integral step in our approach to antibody humanization is construction of computer graphics models of the import and humanized antibodies. These models are used to determine if the six complementarity-determining regions (CDRs? can be successfully transplanted from the import framework to a human one and to determine which framework residues from the 25 import antibody: if any, need-to be incorporated into the humanized antibody in order to maintain CDR conformation. In addition, analysis of the sequences of the import and humanized antibodies and reference to the- models can help to discern which framework residues are unusual and hereby might be involved in antigen binding or maintenance of proper antibody structure.
30 All of the humanized antibody models of this invention are based ~an a single three-dimensional'computer graphics structure hereafter referred to as the consensus structure. This consensus structure is ~ key distinction from the qpproach of previous workers in the field, who ty~icalty begin by selecting a human antibody structure which has an amino acid sequence which is similar to tl~e sequence of their import antibody.
WO 92/22653 . ~ ~ ~ ~ ~ ~ PC"f/US92/05126 z~
The consensus structure of one embodiment of this invention was built in five steps as described below.
Step 1: Seven Fab X-ray crystal structures from the Brookhaven Protein Data Bank were used (entries ZFB4, 2RHE, 3FAB, and 1 REI which are human structures, and 2MCP, 1 FBJ, and 2HFL which are murine structures). For each structure, protein mainchain geometry and hydrogen bonding patterns were used to assign each residue to one of three secondary structure types: alpha-helix, beta-strand or other (i.e. non-helix and non-strand). The immunoglobutin residues used in superpositioning and those included in the consensus structure are shown in Table 1.
aWWO 9WZ26s3 PCT/'U~'~2/OS126 ~Z
Table I
Immunoglobulin Residues in Superpositioningand Those Used Included in the Consensus Structure ~l,t~ domain Iga 2FB4 2RIiE 2MCP 3FAB iFBJ 2I~'~. 11tE1 Consensush 60-56 62-58 57-72 53-65 60=65 50-55 61-66 59-77 RMSe 0.40 0.60 0.53 0.54 0.48 0.50 VB domain Iga 2hB4 2MCP 3FAB 1FBJ 2I~r. Consensusb ~~- 3-8 58-71 70-73 57-?0 58-71 58-71 66-?1 78-84 80-86 77-8~ 78-84 78-84 75-82 82_99 94-101 91-98 92-99 92-99 88-94 RMSe 0.43 0.85 0.62 0.91 RMSd 0.91 0.73 0.77 0.92 a Four-letter code Bank file.
for Protein Data b Residue numbers the crystalstructures ire from the Protein Data for taken Bank files. Residuenumbers f~r the consensus structure are according to Kabat et al.
c Root-mean-s9uare ation for (N,Ca;C) superimposed 2FB4.
devi in ~ atoms on d Root~aean-square atioa~ for (Id,Ca;C) superira~poscd2IIFL.
devi in ;~ atones on W(~ 92/22653 '~ ~ 0 ~ ~ j ~ PCT/US92/05126 z~
Step 2: Having identified the alpha-helices and beta-strands in each of the seven structures, the structures were superimposed on one another using the INSIGHT
computer program (Biosym Technologies, San Diego, CA) as follows: The 2FB4 structure was arbitrarily chosen as the template (or reference? structure. The ~FB4 was held fixed in space and the S other six structures rotted and translated in space so that their common secondary structural elements ti.e. alpha-helices and beta-strands) were oriented such that these common elements ware as close in position to one another as possible. (This superpositioning was performed using accepted mathematical formulae rather than actually physically moving the structures by hand.) t0 Step 3: With the seven structures thus superimposed, for each residue in the template (ZFB41 Fab one calpulates the distance from the template alpha-carbon atom (Ca) to the analogous Ca atom in each of th~ other six superimposed structures. This results in a table of Ca Ca distances for each residue pdsition in the sepuence. Such a table is necessary in order to determine which residue positions will be included in the consensus model. Generally, 15 '~if all Ca-Ca distances for a given residue position were ~ 1.0~, that position was included in the consensus structure. If for a given position only one Fab crystal structure was > 1.0~, the position was included but the outlying crystal structure was not included in the next step (for this position anlyl. In gene~al~ the seven ~B-strands were included in the consensus structure while some of the loops connecting the ~B-.strands, e.g.
complementarity-determining 20 regions (CDRs?, were not included in view of Ca divergence.
Step 4: For each residue which was included in the consensus structure after step 3, the average of the coordinates for individual mainchain N, Ca, C, O and C~
atoms were calculated. D~ae to the averaging procedure,- as well as variation in bond Isngth, band angle and dihedral angle among the crystal structures, this "average" structure contained some bond 25 lengths and angles which deviated from standard geometry. For purposes of this invention, "standard geometry" is understood to include geometries commonly accepted as typical, such as the compilation of bond lengths and angles from small molecule structures in Weiner, S.J.
et, al.; J. Artier. Chem. Soc., 106: ?65-784'(1984).
Step 5: In order to correct these deviations; the final step was to subject the 30 "average" structure t'o 50 cyc6e~ of energy minimization (DISCOVER program, Biosym Technologies) using the AMBER fllVeiner, S.J. er: al., J. Amer. Chem. S~c., 106: 765-784 (1984.x? parameter set with only the Ca coordinates fixed (i:e. all other atoms are allowed to mtDVe) (energy minimization is described belowl. This allowed any deviant bond lengths and angles to assume a standard (chemically acceptable) geometry. See Table It.
PCT/US92/OSl2G
2 'i Table II
Average Bond Lengths and Angles for "Average" (Before) and Energy-Minimized Consensus (After SO Cycles) Structures VLK V1,K Vg VH Standard before after before after Geometry (~) (A> (~) (~) (~) N-Ca 1.459(0.012)1.451(0.004)1.451(0.023)1.452(0.004)1.449 Ca-C 1.515(0.012)1.523(0.005)1.507(0.033)1.542(0.005)1.522 ~C 1.208(0.082)1.229(0.003)1.160(0.1??)1.231(0.003)1.229 C-N 1.288(0.049)1.33?(0.002)1.282(0.065)1.335(0.004)1.335 Ca-C~ 1.508(0.026)1.530(0.002)1.499(0.039)1.530(0.002)1.526 b C-N-Ca 123.5(4.2) 123.8(1.1) 125.3(4.6) 124.0(1.1) 121.9 N-Ca-C 110.0(4.0) 109.5(1.9) 110.3(2.8) 109.5(1.6) 110.1 Ca-C-N 116.6(4.0) 116.6(1.2) 11?.6(5.2) 116.6(0.8) 116.6 C~C 123.1 (4.1 123.4(0.6) 122.2(4.9) 123.3(0.4) 122.9 N ) N-Ca-C~110.3(2.1) 109.8(0.?) 110.6(2.5) 109.8(0.6) 109.5 C~-Ca-C111.4(2.4) 111.1(0.?) 111.2(2.2) .111.1(0.6)111.1 ~ialues in parentheses are standard deviations. Note that while some bond length and angle averages did not change appreciably after energy-minimization, the corresponding standard deviations arc reduced due to deviant geometries assuming standard values after energy-minimization. standard geometry values are from the AMBER forcefield as implennented in I)ISCOVEFt (Biosym Technologies).
~r:s::. -_-_"._,_ __,__ _..
.WO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/US9zio~1z6 zs The consensus structure might conceivably be dependent upon which crystal structure was chosen as the template an which the others were superimposed. As a zest, the entire procedure was repeated using the crystal structure with the worst superposition versus 2Ft34, i.e. the 2HFL Fab structure, as the new template Ireference). The two consensus structures corlnp8re favorably (root-mean-squared deviation of x.11 ~ for alt N, Ca and C
atoms).
Note that the consensus structure only includes mainchain IN, Co. C. a. CB
atoms) coordinates far only those residues which are part of a conformation common to all seven X
' ray cryøtal structures. Fvr iha Fob structures, these include the common ~
strands Iwhich comprisB two ~-shoat$1 and a few non-~DFi lobes which connect these -strands.
The >.o consensus structure does not include GDRs yr sidachains, both of which vary in their conformation. among the seven structures. Also, note that the consensus structure includes only the VL and VH domains.
This aansansus structure is u$ed as the archetype. It is not particular to any species.
aryd has only the basic sh~p~ without side chains. starting with this consensus structure the is ~-rinodal of any import, human, or humanized Fab can be constructed as follows. lJsing the amino said seQuence of tha..particular antibody VL and VH domains of interest, a computer graphics prv~ram iau~b as INSIGHT*Bio$ym Technologies) is used to add sidechains and CDRs to the congarysus strirctura. When a 'sidechatn is added, its conformation is chosen on the basis of knbwn Fab erystal structures lsee the Background acotian fw publications of such . Zo . ~ crystal struaturesl and rotamer libraries (Ponder. J.W. & Richards, F. M.. J. Mwi. Biol. 1g3:
77~-791 (t sa$7I1. The modet also. is constructed so that the atoms of the sidechain are positioned s4. as to not collid,a with other atoms in the s=ob. , CDRS are coifed to fthe model Inow having the backbone plus 5ida chains) as follows.
The- size Ii.e. number-.of amino acids? of each import GDR is compared to canonical CDR
as structuras.~tabuiated by Chothia et al., Nature, 342:877-883 ('I 9B9)1 and which ware derived from. Fab cnistals. Each CDR svquanca is also reviewed for the prssancs or absence of certain specific arinino acid rasiduas v~ihich era identified by Chathia as structurally important: e.g. light chain residues 29 (CCiR1 i and' 95' (GDR3), dnd heavy chain residues 26. 27.
29 IGDR1 f and 55 ICDR2?. For light chain .CpR2, and heavy chain CDR3, only the size of the GDR i5 3o compered to~the Chvtliia. canonical structure. if the size and sequence li_e. inctusiar< of the specific, structurally impartant~.residuas as denoted by Chothia et al.l of the import CdR agrees in size and ha$ the same structurally. important residues asr those of a canonical CPR, than the mainchsiwconfonnation of the irnpoft CDR in the model is taken to be the same as that of the canonical CDR- This means that the import seduance is assigned the structural configuration *-trademark _ ,, . ~v,.-,. -.;~:
,,, r ': ~: r..~.. ~:.; x, , . /,'~.~ZS:":' 7, ~~\ e.h.
~.~'1'~.":.' _1i :': .~,..,.. ., ... .
f..:rwl:~ ~~ , . .. ... ..
S ~.~' L. f '~,~iy,,' ' y..,ffS ~.~:,,~1,~; ~~~.
~ . ,S.~'n':~:~:~lf:n 7 .... ... 'f~.
5...: ..
wa gxiz~~~ ~ ~ ~ ~ Pcr~us9zro~rzra of the canonical ~(?R, which is then incorporated in the evolving model.
Wowevar, if no matcriing canonical CDR can be assigned far the import CDR, than one of two options can bs exercised. First, using a program such as INSIGHT
iRiosym Technologie$), the 8rookhavan protein Data Bank can bs searched far loops with a similar size to that of the import CDR and these loops can be evaluated as possible conformations for the .
import CDR in thn model. Minimally. such loops must sxhibtt a conformation in which na loop atom overlaps with other protein atoms. Second, one can use available Programs which calculate possible laop~ conformations. assuming a given loop size, using methods such as tiescribsd by ~r~coleri et at , Natwe 335: b6a-ggg t'1988).
Wh~n all CDRS and sidechains have been added to the aonsansus structure to give the final rrvodal timport. human or, humanixad), the model is preferably subjected to energy minimization using programs which era available commerCi811Y (a-g~ Ci~CaVpR;
BioBym Tpchnolog)as)'. This technique .uses complex mathematical formulae to refine the model by performing such tasks as ohecking.that ail atoms ors within appropriate distances from cue ~, 15 'another and checking that band lengths and angles are within chemically acceptable limits.
nnodels of ~a humanized, import, or human antibody sequence era used in the practice of thi3 invent;on to understand the impact' of selected amino acid re$idues of tire activity of the seqwanca being modet~d. For exarhple, such a model can show residues which may be important in antigen binding. br for ma)ntaining the conformation of the $ntit~ody, as discussed _ in mare detail below. Modeling can also be used to explore the potential impact of Gharlgin$
. sny amino~acid residue in the antibody sequence.
M ini tn the praatJce~ af,. tills : invention, the first stop in humanizing an irnPort antibody is deriving a aonsensirs amine acid. sequence into which to incorporate the import sequences.
HBO ~ ~Qdel. is.'gdnera~tad far.these sequences using the methods described above. in certain ~~b~imqnts of this lnvenxian~ the consensus human sequences are derived from the mast $bundant~ ~~~)assas- iri the' seqWenca ccmp)lation of Kabat et al. IKabat. !!.
A. et al..
Sd4uences of Proteins of lri~rmuriological interest National Institutes of Health: Etethesda. MD, 3p ~ 1987)1,, namely V4 K subgroup 1 arid VM group III, and have th$
setluances indicated in the ~
. . definitions above.. , . . Whileahese steps may. ba. takbn in different order, typically a structure for the Candidate h~ariized antibod~r is~'crpated by transfsrring~ the at least one GOR from the non-human.
import sequence into thd consensus human structure, after the entire corresponding human . *--trademark i .t~' ~ ...' ,. ~_,..~... .. . .;~.,' ' ...:.:.: , ':_~'_;... ... -.;....~
.~..~:.~ . ...:. , :~;' . ;-,,~.. .. ~:r:. ' . .,:, . ~, ~',,.;..' .::... ,.' ,:..; ,...,...:~ ..: w~...~.~. '....,,. .. ; .''. .
.:..:.~v . ~.~.~':.... ~,:. ~:.~ . '. ... ,.. ., , ....
WO 92/22653 ~ ~ ~ 1 Q j ~ ~ ~ PC'T/US921U512~b CDR has been removed. The humanized antibody may contain human replacements of the non-human import residues at positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of Immunoiagica! Interest (National Institutes of Health, Bethesda, MD, 1987)) or as defined by structural variability (Chothia, C. & t-esk, A. M., J. Mol.
Biol. 196:901-917 (1987)). For example, huMAb4D5 contains human replacements of the muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of lmmunoiogical Interest tNational Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C.
& Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)): V~-CDR1 K24R, V~-CDR2 R54L and V~-CDR2 T56S.
Differences between the non-human import and the human consensus framework residues are individually investigated to determine their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is desirably performed through modeling, by examination of the characteristics of the amino acids at particular locations, or determined experimentally through evaluating the effects of substitution or t5 '"mutagenesis of particular amino acids.
In certain preferred embodiments of this invention, a humanised antibody is made comprising amino acid sequence of an import, non-human antibody and a human antibody, utilizing the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable domain and of a consensus human variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence;
d. aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody;
e. identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably 3o expected to have at least one of the following effects:
1. r9on-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V~ - VH interface; and g. far any'non-homologous import antibody amino said residue which is reasonably ~~.03~~j WO 92l226S3 ~CT/US92/05126 2$
expected to have at feast one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence.
aptionally, one determines if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step tf), one may retain the consensus residue.
Additionally, in certain embodiments the corresponding consensus antibody residues identified in step te) above are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 6?L, 68L, 69L, ?4L, ?1 L, ?3L, 85L, 8?L, 98L, 2H, 4H, 24H, 36H, 3?H, 39H, 43H, 45H, 49H, 58H, 6tJH, 6?H, 68H, 69H, ?OH, ?3H, ?4H, ?5H, io ?6H, 78H, 91 H, 92H, 93H, and 1 ~D3H (utilizing the numbering system set forth in Rabat, E.
A. et al., SeQuences of Proteins of lmmunologica! Interest (National Institutes of Health, 8ethesda, nIID, 19871).
In preferred embodiments, the method of this invention comprises the additional steps of searching either or both of the import, non-human bnd the consensus variable domain ~~sequences for glycosylatian sites, determining if the glycosylation is reasonably expected to be important for the desired antigen binding and biological activity of the antibody ti.e., determining if the glycosylation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosyiation enhances or weakens antigen binding, or is important for maintaining antibody affinity). If the import sequence bears the glycosylation site, it is preferred to substitute that site for the corresponding residues in the consensus human sequence if the glycosylation site is reasonably expected to be important. if only the consensus sequence; and not the import, bears the glycosylation site, it is preferred to eliminate that glycosylation site or substitute therefor the corresponding amino acid residues from the import sequence.
Another preferred embodiment of the methods of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR
residues which are non-homologous with the aligned consensus FR sequence, and for each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, 3o and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
tn certain alternate embodiments, one need not utilize the modeling and evaluation steps described above, and may instead proceed with the steps of obtaining the amino acid sequence of ~t least a portion of an import, non-human antibody variable domain having a GDR and a FR, WC? X2/22653 ~ ~ ~ PCT/US92/~5126 obtaining the amino acid sequence of at least a portion of a consensus human antibody variable domain having a CDR and a FR, substituting the non-human CDR for the human CDR
in the consensus human antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a. tin the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98Lr or b. !in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60Hr 67H, 68H, 69H, 70H, 73H, 74Hr 75H, 76H, l0 78H, 91 H, 92H, 93H, and 103H.
Preferably, the non-C~R residue substituted at the consensus FR site is the residue found at the corresppnding location of the non-human antibody» If desired, one may utilize the other method steps described above for determining whether a particular amino acid residue can reasonably be expected to have undesirable effects, and remedying those effects.
' f if after making a humanized antibody according to the steps above and testing its activity one is not satisfied with . the humanized antibody, one preferably reexamines the potential effects of the amino acids at the specific locations recited above.
Additionally, it is desirable to reinvestigate any buried residues which are reasonably expected to affect the ~h -V" interface but may not directly affect CDR conformation. It is also desirable to reevaluate the humanized antibody utilizing the steps of the methods claimed herein.
In certain embodiments of this invention, amino acid residues in the consensus human sequence are substituted for by other amino acid residues. In preferred embodiments, residues from a particular non-human import sequence are su~st~tute~i, however there are circumstances where it is desired to evaluate the effects of other amino acids. For example, if after making a humanized antibody according to the steps above and testing its activity one is hot satisfied with the humanized antibody, one may compare the sequences of other classes or subgroups of human antibodies, or classes or subgroups of antibodies from the particular non-human species, and determine which other amino acid side chains and amino acid residues are found at particular locations and substituting such other residues.
Antibodies Certain aspects of this invention are directed to natural antibodies and to monoclonal antibodies, as illustrated in the Examples below and by antibody hybridomas deposited with the ATCC tae described below). Thus, the references throughout this description to the use ~~Q ~~ ~~ , V~IG 92/22653 PCT/US92/0512b of monoclonal antibodies are intended to include the use of natural or native antibodies as well as humanized and chimeric antibodies. As used herein, the term "'antibody"
includes the antibody variable domain and other separable antibody domains unless specifically excluded.
In accordance with certain aspects of this invention, antibodies to be humanized timport 5 antibodies) are isolated from continuous hybrid cell tines formed by the fusion of antigen-primed immune lymphocytes with myeloma cells.
in certain embodiments, the antibodies of this invention are obtained by rautine screening. Polyclonat antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections'of the antigen and an adjuvant. It may be 1o useful to conjugate the antigen or a fragment containing the target amino acid sequence to a protein that is immunogenib in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sultosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide tthrough lysine'residuesl, glutaraldehyde, succinic ~r iS anhydride, SOC12, or R'N = C = NR; where R and R' are different alkyl groups.
The raute and schedule of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. While rnice are frequently employed as the test madel° it is contemplated that any mammalian subjECt including human subjects or antibody-producing 20 cells obtained therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines.
Animals are typically immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 ,ug of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund°s complete adjuvant and injecting the solution intradermally at multiple sites. One 25 month later the animals are boosted with 1 /5 to 1 /10 the original amount of conjugate in Freund's complete adjuvant for other suitable adjuvant) by subcutaneous injection at multiple sites. 7 to 14 days later animals are-bled and the serum is assayed for antigen titer. Animals erg boosted until the titer plateaus. Preferably; the animal is boasted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking 30 agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.
After immunization; monoclonal antibodies are prepared by recovering immune lymphoid cells--typically spleen cells or lymphocytes from lymph node tissue--from immunized animals and immortalizing the ceps in con~rentional fashion, e.g. by fusion with myeloma cells or by f .,r ~. . ~ .~.. , ~.~~ ~, ~ .. ... . . ,.,..,. ~~ ' .. ., . . ,." y WO 92/22653 ~ ~ ~ '~ ~ '~ '~ PCT/US92/U5126 3!
Epstein-Barr tEB)-virus transformation and screening for clones expressing the desired antibody.
The hybridoma technique described originally by ICohler and Milstein, Eur. J.
Irrrmunol. 6:51 1 ( 1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens.
It is possible to fuse cells of one species with another. However, it is preferable that .
the source of the immunized antibody producing cells and the myeloma be from the same species.
The hybrid call lines can be maintained in culture in rritrp in cell culture media. The cell lines of this invention can be selected and/or maintained in a composition comprising the to continuous cell line in hypoxanthin~-aminapterin thymidine tMAT) medium. In fact, once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media. Moreover, the hybrid cell lines can be stored and preserved in any number of conventional ways. including freezing and storage under liquid nitrogen.
Frozen calf lines can be revived and cuttured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ton exchange chromatography, affinity chromatography, or the like. The antibodies described herein are also recovered from hybridoma celP
cultures by conventional methods for purification of IgG or IgM as the case may bs that heretofore have been used to purify these irnmunoglobulins from pooled plasma, e.g. ethanol or polyethylene 2o glycol precipitation procedures. ~'he purified antibodies are sterile filtered, and optionally are conjugated to a detectable marker such as an enzyme or spin label for use in diagnostic assays of the antigen in test samples.
While routinely rodent monoclonal antibodies are used as the source of the import antibody, the invention is not limited to any species. Additionally, techniques developed for the production of chirneric antibodies ~Morrison etal., Froc. Nall. cad. Sci., 81:6851 t1984);
Neuberger ef al., Nature 312:6~4 (1984); Takeda at al., Nature 314:452 t1985)) by splicing the genes from a mouse antipody molecule of appropriate antigen specificity together with ga3nes from a human antibody molecule o~f appropriate biological activity tsuch as ability to activate human complement and mediate ADCC) can be used; such antibodies are within the scope of this invention.
Techniques for creating recombinant DNA versions of the antigen-binding regions of antibody molecules (known ae Fab fragments) which bypass the generation of monoclonal antibt~dies are encornpassed within the practice of this invention. One extracts antibody-specific messenger RW 0. molecules from immune system cells taken from an immunized animal, .. :,.'... ;..; .... . ,w.., ' :, .. ,.. .'' ..:.: , :,; ;.: ,. .,'; ; ;;.:, .,..;; ,, . . :... , ,, . ...
WO 92/22653 , . PC1'/US92/05126 .
3z transcribes these into complementary DNA (cDNA), and clones the ,DNA into a bacterial expressions system. One example of such a technique suitable for the practice of this invention was developed by researchers at Scripps/Stratagene, and incorporates a proprietary bacteriophage lambda vector system which contains a leader sequence that causes the expressed Fab protein to migrate to the periplasmic space (between the bacterial cell membrane and the cell watt) or to be secreted. One can rapidly generate and screen great numbers of functional FAb fragments for those which bind the antigen. Such FAb fragments with specificity for the antigen are specifically encompassed within the term "antibody" as it is defined, discussed, and claimed herein. ' Aming Acid Seauence Variants Amino acid sequence variants of the antibodies and polypeptides of this invention (referred to in herein as the target polypeptidel are prepared by introducing appropriate nucleotide changes into the DNA encoding thb target polypeptide, or by in vitro synthesis of the desired target polypeptide. Such variants include, for example, humanized variants of non-human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the target po[ypeptide; such as changing he number ar position of glycosylation sites, altering any membrane anchoring characteristics, and/or altering the intro-cellular location of the target polypeptid~ by inserting, deleting, ;or otherwise affecting any leader sequence of the native target polypeptide.
in designing, amino acid sequence variants of target polypeptides, the location of the mutation site and th~ nature of ' the mutation will depend an the target polypeptide Gharacteristicts) to' be modified. The sites for mutation can be modified individually or in series, e.g.; by t 1 ) substituting first v~ith conservative amine acid choices and then with more radical selections depending upon the results achieved, d2) deleting the target residue, or f3) inserting residues of the same'or a different class adjacent to the located site, ar combinations of options 1-3. tn certain embodiments, these choices are guided by the methods far creating humanized sequences set forth above.
A useful method for identification of certain residues or regions of the target polype~rtide that are preferred locafians far mutagenesis i~ called "alanine scanning mutagenesis" as described by Cunningham and Wells tS~,ience, 244: 1081-1085 (19891).
WU 92!22653 3 3~ ~ I~ ~ ~ j ~ PCT/t1S92/05126 Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably ~tanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensetivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon ar region and the expressed target polypeptide variants are screened for the optimal combination of desired activity.
There are two principal variables in the construction of amino acid sequence variants:
the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the target polypeptide characteristic to be -modified.
Amino acid sequence deletions of antibodies are generally not preferred, as maintaining the generally configuration of an antibody is believed to be necessary for its activity. Any deletions will be selected so as to preserve the structure of the target antibody.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging zo in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of singte or multiple amino acid residues.
Intrasequence insertions li.e., insertions within the target polypeptide sequence) may range generally from about 1 to 't 0 residues, more preferably 1 to 5, mast preferably 1 to 3, Examples of terminal insertions include the target polypeptide with an N-terminal methionyl residue, an artifact of the direct expression of target potypeptide in bacterial recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the target polypeptide molecule to facilitate the secretion of the mature target polypeptide from recombinant host cells. Such signal sequences generally will; be otitair~ed from, and thus homologous to, the intended host cell species: Suitable sequences include STIt or Ipp for ~ call, alpha factor for yeast, and viral ssgnals such 'as herpes, gD for mammalian cells.
Other insertional variants of 'the target polypeptide include the fusion to the N- or C-tecminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptides such as beta~lactamase ar an enzyme encoded by the E: coli trp locus, or yeast protein, and C-terminal fusions with proteins having a tong half-fife such as immunogiobulin constant ~~ 92/22653 ~ ~ ~ '~ ~ ') ~ ~ PCT/US92/05126 3 ~9 regions Ior other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.
Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the target polypeptide molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active sites) of the target polypeptide, and sites where the amino acids found in the target poiypeptide from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. Other sites for substitution are described infra, considering the effect of the substitution of ' the antigen binding, affinity and other characteristics of a particular target antibody.
Other sites of interest are those in which particular residues of the target polypeptides obtained from various species ara identical. These positions may be important for the biological activity of the target polypeptide. These sites, especially those falling within a sequence of at least three other identicalty conserved sites, are substituted in s relatively conservative manner. If such substitutions result in a change in biological activity, then other changes are introduced and the products screened until the desired effect is obtained.
Substantial modifications ire furictian or immunolagical identity of the target polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the palypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or tcl the bulk of th~ side chain. Naturally occurring residues are divided into groups based on common side chain properties:
t1 ) hydrophobic: norfeucine, met, ala> val, leu; ile; , t2) neutral hydrophilic: cys, ser, thr;
t3) acidic: asp, glu;
t4) basic: a5n, gln, his:' lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp; tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes ' 30 for another. Such substituted residues may be introduced into regions of the target polypeptide that are homologous with other antibodies of the same class or subclass, or, more preferably, into the non-homologous regions of the molecule.
any cysteine residues not involved' in maintaining the proper conformation of target polypeptide also may be substituted, generally with serine, to improve the oxidative stability ' ,;.. ...
WO 92/22653 . ~ ~ ~ J ~ ~ ~ PCg'/US92/U5126 3s of the molecule and prevent aberrant crasslinking.
DNA encoding amino acid sequence variants of the target polypeptide is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source tin the case of naturally occurring amino acid sequence variants) or preparation by oligonucleatide-mediated (or site-directed) mutagenesis, PCR
mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the target polypeptide. A particularly preferred method of gene conversion mutagenesis is described below in Example 1. These techniques may utilized target potypeptide nucleic acid tDNA or RNA), or nucleic acid complementary to the target polypeptide nucleic acid.
to Otigonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of target polypeptide DNA. This technique is well known in the art as described by Adetman et al., _D_N~A, ~: 183 (1983). Briefly, the target polypeptide DNA
is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the target potypeptide. After hybridization, a DNA
potymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the otigonucleotide primer, and wilt code for the selected alteration in the target polypeptide DNA:
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucteotide wilt have 12 to 15 nucleotides that are camptetely complementary to the template on either side of the nucleotidets) coding for the mutation. This ensures that the otigonucteotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crew et al. tProg: Na~rl. Acad. Sci. USA, ~: 6765 (19781).
Single-stranded DNA template may also be generated by denaturing doubts-stranded plasmid for other) DNA usirfg standard techniques.
For alteration of the native DNA sequence tto generate amino acid sequence variants, fer example), the oligonucteotide is hybridized to the single-stranded template under suitable hybridization conditions: A DNA polymerizing enzyme, usually the Ktenow fragment of DNA
polymerase t, is then added to synthesize the complementary strand of the template using the otigonucleotide as a primer for synthesis. A heteroduptex molecule is thus formed such that one stand of DNA encodes he mutated form of the target polypeptide, and the other strand tthe original template) encodes the native, unaltered sequence of the target potypeptide. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such :,';~: .; ,'.'.,,.,., ': .~.... . . '..:,~... ..
WO 92/22653 ~ ~ ~ '~ ~ '~ ~ 1'CT/1JS92/05126 3~
as E, coil ,lM101. After the cells are grown, they are plated onto agarase plates and screened using the oliganucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.
The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the ptasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosins tdATP); deoxyriboguanosine tdGTP), and deoxyribothymidine tdTTP), is combined with a modified thin-deoxyribocytosine called dCTP-taS) twhich can be obtained from Amersham Corporation). This mixture is added to the template-oligonucieotide complex.
Uport addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. ln~ addition, this new strand Ot UNA wul contain dCTP-taS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.
After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme; the template strand can be digested with VIII
nuclease or another appropriate nuclease past the region that contains the sitets) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA tigase. This homoduplex molecule can then be transformed into a suitable host cell such as E. coil JM10'6, as described above.
DNA encoding target polypeptide variants with more than one amino acid to be substituted may be generated i~ one of several ways. If the amino acids are located close tog~ther in the polypep~tide chain, they may be mutated simultaneously using one o6igonuctdotide that podes for alt of the desired amino acid substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to 'generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
tn the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA
simultaneously, and the second strand of DNA that is synthesized from the template will encode alt of the desired amino acid substitutions.
WU 92/22653 ~ ~ ~ ~ ~ J ~ PCTlUS92lOSf26 3 '~
The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitutions) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round Zo of mutagenesis, and so on.
PCR mutagenesis is also suitable for making amino acid variants of target polypeptide.
While the following discussion refers to DNA, it is understaad that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are ~5 Bused as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions whore the primers differ from the template. Far introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation;
20 the sequence of th~ other primer must be identical to a stretch of sequence of the apposite strand of the ptasmid, but this sequence can be Located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 2~0 nucleotides from that of the first, such that in the end the entire amplified region of DNA
bounded by the primers can be easily sequenced. PCR amplification using a primer pair like 25 the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.
If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to 30 replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or rreore?-part ligation.
,v, n ' ~:. , ,.,~~.", ~.,...., ..~ ,~,~,~'~~~v~. ;~... ; .., ,.,~:.' ~.:w,, .
. .~...;.,:,. ;.-i,~~..~~ ~~.,;:
PCTlUS92l05126 WO 92!22653 In a specific example of PCR mutagenesis, template plasmid DNA (1 ,ug) is lineariaed by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide tri-phosphates and is included in the GeneAmp'~ kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each aligonuclsotide primer, to a final volume of 50 Nl. The reaction mixture is overlayed with 35 NI mineral oil. The reaction is denatured for 5 minutes at 100~C, placed briefly an ice, and then 1 NI Thermus aquaticus (Taql DNA polymerise t5 unitslNl, purchased from Perkin-Elmer Cetus, Norwalk, CT and Emeryvilie, CA) is added below the mineral oil layer.
to The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Eimer Cetus) programmed as fol!~ws: 2 min. at 55~C, then 30 sec. at 72~C, then 19 cycles of the following: 30 sec. at 94~C, 30 sec. at 55~C, and 30 sec. at 72~C.
At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chlorafarm t50:50:vo1), and 'ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.
Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells etal. tGen_e,~4: 315 (19851). The starting material is the plasmid for other vector? comprising the target polypeptide DNA to be mutated. The cadants) in the target polypeptide DNA to be mutated are identified. There must be a unique restriction endonuclease site an each side of the identified mutation sitets). If no such restriction sites exist, they may be generated using the above-described oliganucleatide-mediated mutagenesis method to introduce them at appropri to locations in the target polypeptide DNA. After the restriction sites have been introduced into the plasmid, the piasmid is cut at these sites to finearize it. A double-stranded oligonucleatide encoding the sequence of the DNA between the restriction sites but containing tho desired mutatiants) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be ditectiy ligated to the plasmid. This plasmid now contains the mutoted target polypeptide DNA sequence.
Insertion of DNA into a Cloning 'Vehicle The cDNA or gertomic DNA encoding the target palypeptide is inserted into a replicable ,.
.., . . "e~. ...
. . . " . ,. . ,,,. ~ , .'. , . .:. . . .,. . ,. ,. ,..
:,.::. ,.~' '.'.~~ ~~..;~, . ',. .. .. ~...; , ~ 7, .. r..., .' :.,, .,..,.
.., . . . .. . . . . ~ ~
~_~.~ ~~~J~
'WO 92!22653 PCT/US92105126 vector for further cloning tamplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1 ) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNAI and the bast cell for which it is compatible. The vector components generally include, but are not limited to, one or mare of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
(a) ,signal Se uenc~ Component In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector.
The target poiypeptides of this invention may be expressed not only directly, but also i5 gas a fusion with a heteraiagous polypeptide, preferably a signal sequence or ether polypeptide having a specific cleavage site at the N~terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. Included within the scope of this invention are target paiypeptides with any native signal sequence deleted and replaced with a heterotogaus signs! sequence. The heterologaus signal sequence selected should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not reGOgnize and process the native target paiypeptide signet sequence, the signal sequence is substituted by a prokaryotic signal sequence Selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable 'enterotoxin If leaders, For yeast seG~etion the native target polypeptide signal sequence may be substituted by the yeast invprtase, dlpha,factor, or acid phasphatase leaders. in mammalian cell expression the native signal sequence is satisfactory, although ether mammalian signal sequences may be suitable.
(b) ~?rigin of Replication Comaonent Both expressiart and cloning vectors contain s nucleic acid sequence that enables the vector to replicate in one or more 'selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal ,,;, ;., . , . :, ,,:
~ ~;.,. . .. . ,. . ,~, , ~; .. .'' , . , ...,' , ..y( .y' ,. !.. ..~.~. ..., ':. ' ..,' ~ ,. . .. . . y" . , ~..
PC'f'JUS92/OSI z6 wo 9zJZZ~s3 2 ~ ~ ~ ~ '~ ~
~0 DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2N
plasmid origin is suitable for yeast, and various viral origins tSV40, polyoma, adenovirus, VSV
or BPV) are useful for cloning vectors'in' mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoters.
Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For io example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.
DNA may also be amplified by insertion' into the host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in the vector a DNA
sequence that is complementary to a sequence found in Bacillus genomic DNA.
Transfection of Bacillus with this vector results in homologous recombination with the genome and insertion of the target poiypeptide DNA. However, the recovery of genomic DNA encoding the target polypeptide i~ more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the target poiypeptide DNA.
tc) ~~ c.t~~ene Component Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown 'in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that ta) confer resistance to antibiotics or other toxins, e.g. ampiciltin, neomycin, methotrexate; or tetracycline; tb) complement auxotrophic deficiencies, or tc) supply critical nutrients not available frorro complex media, e.g. the gene encoding D-alanine racemase for Bacilli.
One example of a selection scheme utilizes a drug to arrest growth of a host cell.
Those calls that are successfully-transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., ~. Motec. Appl. Genet., 1:
S27 (19821), Frtt/ ,~ 9Q ';. S V .III ;Yr''~,2~W~P .ir.'P(j~.a=.,..
~nt,"','.~."
~~a~~JJ
''YO 92/2265 P~1'/US921o5126 '-I I
mycophenolic acid (Mulligan et al., cien~_e., 209: 1422 [ 19801) or hygromycin (Sugden et al. , Mol. Cell. Biol., 5_: 410-413 (19851). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug 6418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the target polypeptide nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed; thereby leading to amplification of both the selection gene and the DNA that encodes the target polypeptide. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem ~vyithin the chromosomes of successive generations of recombinant cells.
Increased quantities 15 of the target polypeptide are synthesized from the amplified DNA.
For example, cells transformed with the DHFR selection gene are first identified by cultdring all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of Di~FR. An appropriate host cell when wild-type DHFR
is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and 20 propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 ~1980~.
Tne transfocrned cells are then exposed to increased levels of methotrexate.
This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising thd expression vectors, such as the DNA encoding the target polypeptide.
This amplification technique can be used with any otherwise suitable host, e.g., ATCC No.
CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060?.
Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequendes encoding the target polypeptide, wild-type DHFR protein, and another selectable marker such as arninoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibibtic, e:g., kanamycin, neomycin, or 6418. See U.S. Pat.
No.
i Field of the Invention This invention relates to methods for the preparation and use of variant antibodies and 1o finds application particularly in the fields of immunology and cancer diagnosis and therapy.
t3~kg_r~~ of the Inven~i~n Naturally occurring antibodies (immunogfobulins) comprise two heavy chains linked Z5 'together by disulfide bonds and two light chains, one light chain being linked to each of the heavy chains by disulfide bonds. Each heavy chain has at one end a variable domain (V,~) followed by a number of constant domains. Each light chain has a variabie domain 4~J~) at one end and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is 2o aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light end heavy chain variable domains, see e.g.
Chothia et al., J lNol. Biol. 186:651-868 (1985); Novotny and Naber, 'roc.
Matt. Aca~f Sci.
USA 8:4592-4596 (1985).
The constant domains are not involved directly in binding the antibody to an antigen, 25 but are involved in various effector functions, such as participation of the antibody in antibody-dependent ~ellufar cytotoxicity. The variabl~ domains of each pair of tight and heavy chains are involved directly pn binding the antibody to the antigen. The domains of natural light and heavy chains have the sarcie general structure, and each domain comprises four framework (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variable 30 or complementarity determining regions tCDRs) (see tCabat, E. A. et al., See~s~errces of Pr~teens of Imenunoldgecal lnte~est, National institutes of He~9th, Bethesda, ~!I~, (198?)). The four framework regions largely adopt a ~-sheet conformation and the CCRs form loops connecting, and in some cases forming part of, the ~-sheet structure. The CDRs in each chain are held ire close proximity by the framework regions and, with the CDRs from the other chain, contribute z ~c-rlu~~~eom26 W~ 92!22653 to the formation of the antigen binding site.
Widespread use has been made of monoclonal antibodies, particularly those derived from radents including mice, however they are frequently antigenic in human clinical use. For example, a major limitation in the clinical use of rodent monoclonal antibodies is an anti-globulin response during therapy (Miller, R. A. et al., Blood 62:988-995 (1983); Schroff, R. W. et al., Cancer Res. 45:879-885 41985)).
The art has attempted to overcome this problem by constructing "chimeric"
antibodies in which an animal antigen-binding variable domain is coupled to a human constant domain (Cabilly et al., U.a. patent No. 4,816,56?; IVlorri~on, S. L. et al., Proc.
Natl. .~lcad. Sci. UBA
81:6851-6855 41984); Boutianne, G. L. et al., Nature 312:643-646 (1984);
Neuberger, M. S.
et al., Nature 314:268-270 (1985)). The term "chimeric" antibody is used herein to describe a polypeptide comprising at least the antigen binding portion of an antibody molecule linked to at least part of another protein (typically an immunogiobuiin constant domain).
The isotype of the human constant domain may be selected to tailor the chimeric °~ antibody for participation in antibody-dependent cellular cytotaxicity (ADCC) and complement-dependent cytotoxicity (see e.g. Bruggemann, l~If. et al., J. Exp.
IVled.
186:1351-1361 (1987); Riechmann, L. et al., Nature 332:323-327 (1988); Love et al., IVlethods in Enzymology 178:515-527 (1989): Bindon et al., J. Exp. MecJ.
168:127-142 1988).
2o In the typical embodiment, such chimeric antibodies contain about one third rodent 4or other non-human species) sequence and thus are capable of eliciting a significant anti-globulin response in humans. For example, in the case of the murine anti-CD3 antibody, ~KT3, much of the resulting anti-globulin response is directed against the variable region rather than the constant region tJaffers, G. J. et al., transplantation 41:572-578 11986)).
In a further eff~art to resolve the antigen binding functions of antibodies and to minimize the us~ of h~terologous sequences in human antibodies, Winter and colleagues (Jones, P. T.
et al., Nature 321:5'22-525 (1986): Riechmann, L. et al., Nature 332:323-327 11988);
Verhoeyen, iVi. etal., Science 239:1534-1536 (1988)) have substituted rodent CDRs or CDR
sequences for the corresponding segments of a human antibody. As used herein, the term 30 ''humanized" antibody is an embodiment of chimeric antibodies wherein substantiaNy less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, hdmanized antibodies are typically human antibodies in which some CDR residues and possib6y some FR residues are substituted by residues from analogous sites in rodent antibodies.
,..,..r. '',, . . . ;'~, . . : .~ . ~', W092/2265~ 3 ~ ~ ~'~ ~~ ~ ~ PCT/US92/OS126 The therapeutic promise of this approach is supported by the clinical efficacy of a hs..~nanized antibody specific for the CAMPATH-1 antigen with two non-Hodgkin lymphoma patients, one of whom had previously developed an anti-globulin response to the parental rat antibody tRiechmann, L. et al., Nature 332:323-327 (1988); Hale, G. et ai., Lancet 1:1394-1399 (1988)). A murine antibody to the interfeukin 2 receptor has also recently been.
humanized (Queen, C. et ai., Prac. Nath Acad. Sci. USA 8f:10029-10033 (1989)) as a potential immunosuppressive reagent. Additional references related to humanization of antibodies include Co et al., Prac. Nat/. Acad. Sci. USA 88:2869-2873 11991 );
Gorman et al., Prac. Nat/. Acad. Sci. USA 88:4181-4185 (1991 ); Daugherty et al., G1/uc%ic Acids Research 19(9):2471-2476 t 1991 ); Brown et al., Proc. Nat/. Acad Sci. USA 88:2663-2667 t 1991 );
,lunghans et al., Cancer Research 50:1495-1502 11990).
In some cases; substituting CDRs from rodent antibodies for the human CDRs in human frameworks is sufficient to transfer high antigen binding affinity (Jones, P.
T, et al., Nature 321:522-525 t 1986): Verhoeyen, M. etal.; Science 239:1534-153611988)), whereas in other -cases it has been necessary to additionally replace one tRiechmann, L. et al"
Nature 332:323-327 t1988D? or several (Queen, C. et ai., Proc. Natl. Acad, Sci. USA
86:10029-10033 (1989)) framework region tFR1 residues. See also Co et al., supra.
For a given antibody a small number of FR residues are anticipated to be important for antigen binding. Firstly for example, certain antibodies have been shown to contain a few FR
residues which directly contact antigen in crystal structures of antibody-antigen complexes te:g:; reviewed in Davies, D. R: et al., Ann. Rev. Biochem. 59:439-473 11990)). Secondly, a number of FR residues have been proposed by Chothia, Lesk and colleagues lChothia, C. &
Lesk, A. M.; J. Mol. Bi~l. 196:901-917 11987); Chothia, C. et al.~, Nature 342:877-883 ti 989); Tramontano, A. et al.; J. Mol. Biol. 215:175-182 (1990)) as critically affecting the cpnformation of particular tDRs and thus their contribution to antigen binding. See also Margolies ef al.; Proc. lVatl. ~8cad. Sci. USA 72:2180-2184 11975).
It is also known that; in a few instances, an antibody variable domain (either V" or V~) may contain glycosylation sites; and that this glycosylation may improve or abolish antigen binding, Pluclcthun, Biotechnology 9:545-51 (1991 ); Spiegelberg etal., Biochemistry 9:4217-4223 (1970); Wal)ic ef al., J: Exp. Med. 168:1099-1109 11988); Sox etal., Prac. Nat/. Acad.
Sci: USA 66:975-982' (19701; Margni et al:, Ann. Rev. lmmunol. 6:535-554 (1988).
Ordinarily, however, glycosyl-. ion has: no influence on the antigen-binding properties of an antibody. Pluckthun, supra, t : a91 ).
The three-dimensional structure of irnmunoglobulin chains has been studied, and crystal Pi.'T/US92/05126 ~f structures for intact immunoglobulins, for a variety of immunoglobulin fragments, and for antibody-antigen complexes have been published (see e.g., Saul et al., Journal of Biological Chemistry 25:585-97 (1978); Sheriff etal., Prac. Nat/. Acad Sci. USA 84:8075-79 11987);
Segal et al,, Proc. Nat/. Acad. Sci. USA 71:4298-4302 11974); Epp et al., Biochemistry 14(22):4943-4952 (1975); Marquart et al., J. Mol. Biol. 141:369-391 11980);
Furey et al., J. Mol. Biol. 167:661-692 (1983); Snaw and Amzel, Protein: Structure, Function, and Genetics 1:267-279, Alan R. Liss, Inc. pubs. 11986): Chothia and Lesk, J. Mal.
Biol. 196:901-917 (1987); Chothia et al., Nature 342:877-883 (1989); Chothia et al., Science 233:755-58 (1986); Huber et al., Nature 264:415-420 11976); Bruccaleri et al., Nature 335:564-568 11988) and Nature 336:266 (1988): Sherman etal., JournalofBiological Chemistry 263:4064-4074(1988); Amzel and Pa)jak, Ann. Rev. Biochem. 48:961-67 (1979); Silverton etal., Proc.
Nat/. Acad Sci. USA ?4:5140-5144 11977); and Gregory et al., Molecular Immunology 24:821-829 (1987). It is known that the function of an antibody is dependent on its three dimensional structure, and that amino acid substitutions can change the three-dimensional ''structure of an antibody, Snow and Amzel, supra. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riechmann; L. etal., Nature 332:323-327 (1988): Queen, C.
etal., Proc.
Natl. Acad. Sci. USA 86:10029-10033 (1989)).
Humanizing an antibody with retention of high affinity for antigen and other desired biological activities is at present difficult to achieve using currently available procedures.
Methods are needed for ratibrralizing the selection of sites for substitution in preparing such antib~dies and thereby increasing, the efficiency of antibody humanization.
The proto-onco~ene HER,2 (human epidermal growth factor receptor 2) encodes a protein tyrosine kinase tp'185HER2'that is related to and somewhat homologous to the human epidermal growth factor receptor lsee CoussenS, L. et al., Science 230:1132-1139 (1985);
Yamamoto; T. et al., Nature 319:230-234 (1986); King, C. R, et al., Science 229:974-976 1985)). HER2 is also known in the field as c-erbB-2, and sometimes by the name of the rat homolog, neu. AmpiifiGation and/or overexpression of HER2 is associated with multiple human malignancies and appears to be integrally involved in progression of 25-30°~ of human breast ' 30 and ovarian cancers tSP'amon, D. J. et al.; Science 235:177-182 (1987), Siamon, D. J. et al., Science 244:707-712 E 1989)): Furthermore, the extent of amplification is inversely correlated with the observed median patient survival time (Slamon, supra, Science 1989).
The murine monoclonal antibody known as muMAb4D5 tFendly, 13. M. et al., Cancer Res. 50:1550-1558 t1 X90)), directed against the extracellular domain, (ECD) of p185HER2, WO 92/22653 . ~ .i ~ ~ ~ ~ ~ PCT/US92/~512G
specifically inhibits the growth of tumor cell lines overexpressing p185RER2 in monolayer culture or in soft agar (Hudziak, R. M. et al., Molec. Cell. Biol. 9:1165-1172 (1989D; Lupu, R.
et al., Science 243:1552-1555 (1990)). MuMAb4D5 also has the potential of enhancing tumor cell sensitivity to tumor necrosis factor, an important effector molecule in 5 macrophage-mediated tumor ce!! cytotaxicity (Hudziak, supra, 1989; Shepard, H. M. and t_ewis, G. D. J. Clinical Immunology 8:333-395 (1988)). Thus muMAb4D5 has potential far . clinical intervention in and imaging of carcinomas in which p185H~R2 is averexpressed. The muMAb4D5 and its uses are described in PGT application WO 89/06692 published 27 July 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL
10463.
However, this antibody may be immunogenic in humans.
tt is therefore an object of this invention to provide methods for the preparation of antibodies which are less antigenic in humans than non-human antibodies but have desired antigen binding and other characteristics and activities.
It is a further object of this irwention to provide methods for the efficient humanization ~of antibodies; i.e. selecting non-human amino acid residues for importation into a human antibody background sequence in such a fashion as to retain or improve the affinity of the non human donor antibody for a given antigen.
It is another object of this invention to provide humanized antibodies capable of binding pIB~HER2 2o C?ther objects; features, and characteristics of the present invention will became apparent upon consideration of the following description and the appended claims.
~ummaw of the invention The objects of this invention are accomplished by a method for making a humanized antibody comprising amino acid sequence of an import, non-human antibody and a human antibody, c~mprising the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable darnain and of a consensus variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an impart CDFi amino-acid sequence far the corresponding human CDR amino acid sequence;
d. aligning the ameno acid sequences of a Framework Region (FR) of the import ".': -'. .'. , .n'. . , "' ; .;~ ,:.. . :.. ~', ... ;;
.. ... ,.,, .,-.,;... ..... ,:.. > "...; .. ,.,..... ~ , ...' :.!.~: . , ,.;
~...,.. . . ' : .. ~ ~ . .. . a W~ 92/22653 ; ', . 6 PGT/US921~5126 antibody and the corresponding FR of the consensus antibody;
e. identifying impart antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably expected to have at least one of the following effects:
1. non-covalantly binds antigen directly, 2. interacts with a CDR; or 3. participates in the VL - VH interface: and g, for any non-homologous import antibody amino acid residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody I~R sequence.
f3ptionally, the method of this invention comprises the additional steps of determining if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step r 15 rtf), retaining the consensus residue.
Additionally; in certain embodiments the method of this invention comprises the feature wherein the corresponding consensus antibody residues identified in step (e) above are salect~d from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, COL; 71 L, ?3L, 85L; 8?L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 20 45H, 49H, 58H, 60H; 67H, 68H; 69H, ?~DH, ?3H, ?4H, 75H, 76H, ?8H, 91 H, 92H, 93H, and t03H tutilizing the numbering system set forth in Rabat, E. A. et al., SeQuences of Proteins of trrrmunologica! Inter~~t (National Institutes of Health, Bethesda, MD, 1987)).
in certain embodiments; the method of this invention comprises the additional steps of searching either or both of the import, non-human end the consensus variable domain 25 sequences for glycosylation sites, deternnining if the glycosytation is reasonably expected to be irnportarvt for the desired antigen binding and biological activity of the antibody (i.e., determinincd if the glycosyiation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosytation bnhanees or weakens antigen binding, or is important for maintaining antibody affiriityD: If the import sequence bears the glycosylation 3p site, it is preferred to Substitute that site for the corresponding residues in the consensus human if the glycosyiation site is re~sonat~ly expeoted to be important. if only the consensus sequence, end hot the import; bears the gtycosyfati~n site, it is preferred to eliminate that glycosyiation site or substitute therefor'ths corresponding amino acid residues from the import s~q~ience:
,.' .. :s: ;..,.,. . ... ., ::; ,;~' .. . 'v . . '.': :v..-; .,::'.' ,;: ~: ,:
v.
W~ X2/22653 ~ ~, o ~ ~ PLT/US92/05126 Another embodiment of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR residues which are non-homologous with the aligned consensus FR sequence, and far each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
Certain alternate embodiments of the methods of this invention comprise obtaining the amino acid sequence of at feast a portion of an import, non-human antibody variable domain 1o having a CDR and a FR, obtaining the amino acid sequence of at least a portion of a consensus antibody variable domain having a CDR and a FR, substituting the non-human CDR
for the human CDR in the consensus antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a, tin the FR of the variable domain of the tight chain) 4L, 35L, 36L, 38L, 43L, '~ ~ 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, ?OL, 71 L, 73L, 85L, 87L, 98L, or b. tin the FR,of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H; 43H, 45H; 49H, 58H, 60H, 67H, 68H, 69H, 70H, ?3H, 74H, 75H, 76H, ?8H, 91 H, 92H, 93H, and 103H.
In preferred embodiments, the non-CDR residue substituted at the consensus FR
site is the residue found at the corresponding location of the non-human antibody.
Dptionally, this just-recited embodiment comprises the additional steps of following the method steps appearing at the beginning of this summary and determining whether a particular amino acid residue can reasonably be expected to have undesirable effects.
This invention also relates to a humanized antibody comprising the CDR
sequence of an irnp~rt, non-human antibody and the FR sequence of a human antibody, wherein an amino acid residue within the human FR sequence located at any one of the sites 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L64L, 65L; 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H; 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H92H, 93H, and 103H has been substituted by another residue.
In preferred embodiments, the residuq substituted at the human FR site is the residue found at the corresponding location of the non-human antibody from which the non-human CDR was obtaified. In other embodiments, no human FR residue other than those set forth in this group has been substituted.
1 and SEQ. 1D NO. 3, respectively). FIGURE 1 B shows the comparison between the VH
domain amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig_ 1 B, SEQ. ID N0. 6, SEO. 1D N0. 2 and SEQ. ID NO. 4, respeciively)_ Both Figs 1 A and 1 B
use the generally accepted numbering scheme from Kabat, E. A., et al , Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda; MD
(1987)). !n both Fig_ 1 A and Fig. i B, tfie CDR residues determined according to a standard sequence definition (as in Kabat, E. A. et al., Sequences of Proteins oflmmunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath the sequences, and the CnR residues determined according to a structur<~I
definition (as in Choihia, C. & Lesk, A. M., J. MoL Biol. 19fi:901-917 (1987)) are indicated by the second, lower underlines. The mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 Vt. and Vti by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative i 5 cell proliferation was determined as described (Hudziak, R. N1. et al., Molec. Cell. Biol.
9:1165-1172 (1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows a stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH _ The CDR residues (Kabat, E. A. et al., Sequences of Proteins of ImmunologicaJ Interest (National Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A?1, T73, A78. S93, Y102 and V~ residues Y55 plus R66 (see Table 3) are shown.
FIGURE 5 shows an amino acid sequence comparison of V~ (top panel) and VH
(tower pane!) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 (1992) with a humanized variant of this;antibody (ImxC:1).sv I Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely V~ K i and VH III upon which the humanized sequences are based (Kabat, E. A. et aL, Sequences of Proteins of ImmunolopicaJ Interest, 5'" edition, National Institutes of Health, Bethesda, MD, USA (1991)). The light chain sequences--muxCD3, )~tlxCD3 v 1 and huKl--correspond to SEQ.ID.NOs 16, 17, and i 8, respectively. 'The heavy chain sequences muxCD3, huxCD3v1 and hutd correspond to SEQ.
ID. NOs 19, 20, and 21 respectively. Residues which differ between muxCD3 and huxCD3v1 are identified by an asterisk ('), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (ll). A bullet (°) denotes that a residue at this position has been found to contact antigen in one or more crystallographic structures of antibodylantigen complexes (Kabat et al., 1991; Mian, i_ S. et al , J. Mol_ Biol.
217, 133-151 (1991)). The location of CDR residues according to a sequence definition SUBSTITUTE SHEET
2/22653 ~ ~ ~ ~ ~ 'a ~ pCT/US92/0512b 'WU 9 amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig.
1 B, SEQ
ID NO. 6, SEO.. ID NO. 2 and SECT. ID NO. 4, respectively). Both Figs 1 A and 1 B use the generally accepted numbering scheme from Kabat, E. A., et ai., Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD (1987)).
In both Fig. 1A
and Fig. 1 B, the CDR residues determined according to a standard sequence definition tas in Kabat, E. A. et al" Sequences of Proteins of lmmunolagical Interest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath tha sequences, and the CDR residues determined according to a structural definition (as in Chothia, C. & Lesk, A.
M., J, Mol. Biol. 996:901-917 (198?I) are indicated by the second, Lower underlines. The to mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 VE and VH by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative cell proliferation was determined as described tHudziak, R. M. et al., Mo%c.
Cell. Biol.
'9 1165-1172 ( 1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows ~ stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH . The CDR residues (Kabat, E. A: et aL, Sequences of Proteins of Immunological Interest (NationaE Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A71, T 73, A78, S93: Y 102 and VL residues Y55 plus R66 (s~e Table 3) are shown.
FIGURE 5 shows an amino acid Sequence comparison of V~ (top panel) and VH
(lower panel) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 ( 1992) with a humanized variant of this antibody (huxCD3v9). Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely VL K 1 and VH II) upon which the humanized sequences are based (Kabat, E. A. et al.; Sequences of Proteins of Immuno%gical Interest, 5'"
edition; National institutes of Health; Bethesda, MD, USA (1991 )). The light chain sequences--muxCD3, huxCD3v9 and huKl--correspond to SEQ.ID.NOs 16, 17, and 18, respectively. The hea~ey chain sequences--muxCD3; huxCD3v9 and huKt--correspond to SEa.ID.NOs 19, 20, and 21; respectively: Residues which differ between muxCD3 and huxCD3v9 are identified by an asterisk ('" ), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (#). A b~rllet (a) denotes that a residue at this position has been found to contact antigen in- one or more crystallographic structures of antibodyiantigen °nf, ,~'.~;r~~rt~:~~.a~y 7,~' a.'i%ji4rr~..~,~i&5il~su :~~'~d~~t~r ~
n,s~!~~r~t~.:al~a;. . <.u',~i~":x:..~,.~~r.~i<. ..":rk;sso.,:<:.a ; .tea., .:~..
17V0 92/22653 , . , complexes iKabat et al., 1991; Mian, t. S. et al., J. Mol. Biol. 217, 133-151 (1991 )). The location of CDR residues according to a sequence definition (Kabat et al., 1991 ) and a structural definition tChothia and t-esk, supra 1987) are shown by a line and carats t") beneath the sequences, respectively.
FIGURE 6A compares marine and humanized amino acid sequences for the heavy chain of an anti-CD18 antibody. H52H4-160 tSEa. ID. NO. 22) is the marine sequence, and pH52-8.0 tSECI. ID. N0. 23) is the humanized heavy chain sequence, pH52-8.0 residue 143S is the final amino acid in the variable heavy chain domain VH, and residue 144A is the first amino acid in the constant heavy chain domain CH1.
FIGURE 6s compares marine and humanized amino acid sequences for the light chain of an anti-CD18 antibody. H52L6-158 tSEQ. ID. NO. 24> is the marine sequence, and pH52-9.0 tSEQ. ID. NO. 25) is the Humanized light chain sequence. pH52-9.0 residue 128T is the final amino acid in the light chain variable domain VL, and residue 129V is the first amino acid in the light chain constant domain CL, ' Defiled Descrio~on of the Invention pefinition~
In general, the following words or phrases have the indicated definitions when used in the description, examples, and claims:
The mutine monoclonal antibody known as muMAb4D5 tFendly, B. M. et al., Cancer Res. 50:1550-1558 119901) is directed against the extracellular domain tECD) of p185HER2, The muMAb4D5 and its uses are described in PCT application W0 89/06692 published 27 July 1989. This marine antibody was deposited with the ATCC and designated ATCC CRt-10463.
Inthis description and claims, the terms muMAb4D5~ chMAb4D5 and huMAb4D5 represent marine, chimerized and humanized versions pf the mor~oclonai antibody 4D5, respectively.
A humanized antibody- for the purposes herein is an immunoglobulin amino acid sequence variant ar fragment thereof which is capable, of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a 'CDR having substantially the amino acid sequence of a non-human imenunogtobulirr.
'Generally, a humanized antibody has one ~r more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are referred to hereirt as "impbrt" residues, which are typically taken from an "import°' antibody domain, W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/vS92/05126 particularly a variable domain. An import residue, sequence, or antibody has a desired affinity and/or specificity, or other oesirable antibody biological activity as discussed herein.
In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains (Fob, Fab', F(ab')z, Fabc, Fv) in which all or substantially all of the CDR regions correspond to these of a non-human immunoglobulin and all ar substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
The humanized antibody optimally also will comprise at Least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Ordinarily, the antibody will contain both the light chain as well as at least the variable domain of a heavy chain. The i0 antibody also may include the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain.
The humanized antibody will be selected from any class of tmmunoglobufins, including IgM, IgG, IgD, IgA and Ig~, and any isotype, including IgG 1, IgG2, IgG3 and IgG~4. Usually the constant domain is a complement fixing constant domain where it is desired that the humanized antibody exhibit cytotoxic activity, and the class is typically IgG,. Where such ''cytotoxic activity is not desirable, the constant domain may be of the IgGz class. The humanized antibody may comprise sequences from mare than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
The FR and CDR regions of the humanized antibody need not correspond precisely to the parent~t sequences, e.g., the import CDR or the consensus FR may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or FR residue at that site does not correspond to either the consensus or the import antibody. Such mutations, however, wilt not be extensive. Usually, at least 75°~ of the humanized antibody,residues will correspond to those of the pareritat FR and CDR sequences, more often 90%, and mast preferably greater than 95,%.
In general, humanized antibodies prepared by the method of this invention are produced by a procoss of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglabulin models are commonly available and are familiar to those skilled in the art.
Computer programs are available which illustrate and display probable three dimensional conformational structures of selected candidate immunoglobulin sequences.
Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunogtobulin to bind its antigen.
PC1'/US92/05126 Iz Residues that influence antigen binding are defined to be residues that are substantially responsible for the antigen affinity or antigen specificity of a candidate immunoglobulin, in a positive or a negative sense. The invention is directed to the selection and combination of FR
residues from the consensus and import sequence so that the desired immunoglobutin characteristic is achieved. Such desired characteristics include increases in affinity and greater specificity for the target antigen, although it is conceivable that in some circumstances the opposite effects might be desired. In general, the CDR residues are directly and most substantially involved in influencing antigen binding talthough not all CDR
residues are so involved and therefore need not be substituted into the consensus sequence).
However, FR
to residues also have a significant effect and can exert their influence in at least three ways:
They may noncovalently directly bind to antigen, they may interact with CDR
residues and they may affect the interface between the heavy and light chains.
A residue that nancovalently directly binds to antigen is one that, by three dimensional analysis, is reasonably expected to noncovalently directly bind to antigen.
Typically, it is a necessary to impute the position of antigen from the spatial location of neighboring CDRs and the dimensions and structure of the target antigen. In general, only those humanized antibody residues that are capable of forming salt bridges, hydrogen bands, or hydrophobic interactions are likely to be involved in non-covalent antigen binding, however residues which have atoms which are separated from antigen spatially by 3.2 Angstroms or less may also non-covalently 2p interact with antigen. Such residues typically are the relatively larger amino acids having the side chains with the greatest bulk; such as tyrosine, arginine, and lysine.
Antigen-binding FR
residues also typically will have side chains that are oriented into an envelope surrounding the solvent oriented face of a CDR which extends about 7 Angstroms into the solvent from the CDR domain and about 7 Angstroms on either side of the CDR domain, again as visualized by three dimensional modeling.
A residue that interacts with a CDR generally is a residue that either affects the conformation of the CDR polypeptide backbon~ ar forms a noncovalent bond with a CDR
residue side chain: Conformation-affecting residues ordinarily are those that change the spatial position of any CDR backbone atom IN; Ca, C, 0, C,B') by more than about 0.2 Angstroms.
' 30 ' Backbone atoms of CDR sequences are displaced far example by residues that interrupt or modify organized structures such as beta sheets, helices or loops. Residues that can exert a profound affect on the conformation of neighboring sequences include proline and giycine, both of which are capable of introducing bends into the backbone. Other residues that can displace backbone atoms are those that are capable of participating in salt bridges and hydrogen bonds.
WO ~Z/2~653 _ I~ ~ ~ ~ ~ ~ J ~~ . ~ ~ f'~/US92/05126 A residue that interacts with a CDR side chain is one that is reasonably expected to form a noncovalent bond with a CDR side chain, generally either a salt bridge or hydrogen bond. Such residues are identified by three dimensional positioning of their side chains. A salt or ion bridge could be expected to form between two side chains positioned within about 2.5 -3.2 Angstroms of one another that bear opposite charges, for example a lysinyl and a.
giutamyl pairing. A hydrogen bond could be expected to form between the side chains of residue pairs such as Beryl or threonyl with aspartyl or glutamyl for other hydrogen accepting residues). Such pairings are well known in the protein chemistry art and will be apparent to the artisan upon three dimensional modeling of the candidate immunoglobulin.
1o lmmunoglobulin residues that affect the interface between heavy and light chain variable regions t"the V~ - V" interface") are those that affect the proximity or orientation of the fiwo chains with respect to ane another. Certain residues involved in interchain interactions are already known and include V~ residues 34, 36, 38, 44, 46, 87, 89, 91, 96, and 98 and V" residues 35, 37, 39, 45, 47, 91, 93; 95, 100, and 103 (utilizing the nomenclature set forth '' n Kabat et al.; Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD, 1987)1. Additional residues are newly identified by the inventors herein, and include 43t., 85L, 43H and 60H. While these residues are indicated for IgG
only, they are applicable across species: In the practice of this invention, import antibody residues that are reasonably expected to be involved in interchain interactions are selected for substitution into 20' the consensus sequence: It is believed that heretofore no humanized antibody has been prepared-with an intrachain-a>fecting residue selected from an import antibody sequence.
Since it is not entirely possible to predict in advance what the exact impact of a given substitution will be it may be necessary to make the substitution and assay the candidate antibody for the desired characteristic. These steps, however, are per se routine and welt within the ordinary skill of the art.
CDR and FR residues are deternnined according to a standard sequence definition tKabat et al. , Sequences of Proteins of lmmcen~lagical Interest, National institutes of Health, Bethesda MD (1987), and a structural definition tas in Chothia and Lesk, J. Mol. Bi~l.
196:901-917 (1987). Where these two methods result' in slightly different identifications of a CDR, the 3o structural definition is preferred, but the residues identified by the sepuence definition method are considered important FR residues for determination of which framework residues to import into a consensus ~equence.
Throughout this description; reference is made to the numbering scheme from Kabat, E. A., et el., Sequences of Proteins of lmmunological Interest (National Institutes of Health, WO 92/22653 ~ ~ ~ ~ ~ ~ ~ ~' I P(.'T/US92/OS126 ''i Bethesda, MD 11987) and (1991 ). In these compendiums, Kabat lists many amino acid sequences for antibodies for each subclass, and lists the most commonly occurring amino acid for each residue position in that subclass. Kabat uses a mefihod for assigning a residue number to each amino acid in a Listed sequence, and this method for assigning residue numbers has become standard in the field. The Kabat numbering scheme is followed in this description.
For purposes of this invention, to assign residue numbers to a candidate antibody amino acid sequence which is not included in the Kabat compendium, one follows the following steps. Generally, the candidate sequence is aligned with any immunoglobulin sequence or any consensus sequence in Kabat. Alignment may' be done by hand, or by computer using commonly accepted computer programs; an example of such a program is the Align 2 program discussed in this description. Alignment may be facilitated by using some amino acid residues which are common to mast Fab sequences. For example, the light and heavy chains each typically have two cysteines which have the same residue numbers; in V~ domain the two cysteines are typically at residue numbers 23 and 38, and in the VH domain the two cysteine residues are typically numbered 22 and 92. Framework residues generally, but not always, have approximately the same number of residues, however the CDRs will vary in size. For example, in the case of a CDR from a candidate sequence which is longer than the CDR in the sequence in Kabat to which it is aligned, typically suffixes are added to the residue number to indicate the insertion of additional residues (see, e.g. residues 'i OOabcde in Fig. 5). For candidate sequences which, for example, align with a Kabat sequence for residues 34 and 3f but have no residue betv~reen ther~n to align with residue 35, the number 35 is simply not assigned to a residue.
Thus, in humanization of an import variable sequence, where one cuts out an entire human or consensus CDR and r~places it with an import CDR sequence, (a) the exact number z5 of residues may be swapped, leaving the numbering the same, Ib) fewer import amine acid residues may be introduced than are cut, in w~Oich ease there will be a gap in the residue numbers, or (c) a larger number of'amino acid residues may be introduced then were cut, in which case the numbering will involve the use of suffixes such as 100abcde.
The terms "consensus sequence°' and "consensus antibody" as used herein refers to ' 30 ' an amine acid sequence which comprises the most frequently occurring amino acid residues at each location in ail immunoglobulins of any particular subclass or subunit structure. The consensus sequence may be based on immunogiobulins of a particular species or of many species. A "consensus" sequence, structure, or antibody is understood to encompass a consensus human sequence as described in certain embodiments of this invention, and to refer P~'1US92/0512G
'NVO 92/22653 ' 15 to an amino acid sequence which comprises the most frequently occurring amino acid residues at each location in all human immunoglobulins of any particular subclass or subunit structure.
This invention provides consensus human structures and consensus structures which consider other species in addition to human.
The subunit structures of the five immunogiobulin classes in humans are as follows:
IgG Y Y1, Y2, Y~, Y4 x or ~l (Y~2) (Ya~a) IgA a a1, a2 x or A (a~rz)" , (~2JI2)~
IgM ~ none ~ x or e1 (~.~zx~)s , G~.~z~z)s IgD a none x or /I (c3ax2) , (d~Jlz) IgE a none x or ~l (e~re2) , (E~12) (" may equal 1, 2, or 3) Pn preferred embodiments of an IgGY1 human c~nserysus sequence, the consensus variable domain sequences are derived from the most abundant subclasses in the sequence compilation of Kabat etal., Sequencesnf~roteins oflmmuncl~gicalfnterest, National Institutes of Health, Bethesda MD (1987), namely V~ x Subgroup I and Vy group Ill. In such preferred embodiments, the V~ consensus domain has the amino acid sequence:
SGSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT (SEQ. ID NO. S);
the VH consensus domain has the amino acid sequence:
EV~1LVESGGGLVQPGGSLRLSCAA~GFTFSf~YAMSWVRQAPGKGLEWVAVISENGGYTRYAD
SVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS (SEQ.
ID NC. 4).
These sequences include consensus CDRs as well as consensus FR residues (see for eacample irk Fig. 1 ).
While not wishing to be limited to any particular theories, it may be that these preferred embodiments are less likely to be imrnunogenic ire an individuaa than less abundant subclasses.
however, in other embodiments, the consensus sequence is derived from other subclasses of human immunogiobulin variable domains: In yet other embodiments, the consensus sequence is derived from human constant domains.
Identity or homology with respect to a specified amino acid sequence of this invention is defined herein as the percentage of amino acid residues in a candidate sequence that are ' PCTlUS92/U5126 WO 92/22653 - , . ' , identical with the specified residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal or internal extensions, deletions, or insertions into the specified sequence shall be construed as affecting homology. All sequence alignments called for in this invention are such maximal homology alignments. While such alignments may be done by hand using conventional methods, a suitable computer program is the "Align 2°' program far which protection is being sought from the U.S. Register of Copyrights (Align 2, by Genentech, Inc., application filed 9 December 1991 ).
"Non-homologous" import antibody residues are those residues which are not identical to the amino acid residue at the analogous or corresponding location in a consensus sequence, after the import and consensds sequences are aligned.
The term °'computer representation" refers to information which is in a form that can be manipulated by a computer. The act of staring a computer representation refers to the act ~ of placing the information in a form suitable for manipulation by a computer.
This invention is also directed to novel polypeptides, and in certain aspects, isolated novel humanized anti-p185HER2 antibodies are provided. These novel anti-p185HER2 antibodies are sometimes collectively referred to herein as huMAb4D5, and also sometimes as the light or heavy chain variable domains of huMAb4D5, and are defined herein to be any 2o polypeptide sequence which possesses a biological property of a polypeptide comprising the following polypeptide sequence:
DIO.MTt~SPSSLSASVGDRVTITCRASaDVNTAVAWYQQKPGKAPKLLIYSASFLESGVP
SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGO,GTKVEIKRT (SEQ. ID NO. 1, which is the light chain variable domain of huMAb4.D5); or EVQLVESGGGLV~PGGSLRLSCAASGFNIKDTYiHWVRQAPGKGLEWVARIYPTNGYTR
YADSVKGRFTfSADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLV
TVSS (SECT. ID NO. 2, which is the heavy chain variable domain of huMAb4D5?.
30 "Biological property", as relates for example to anti-p185RER2, for the purposes herein means an in a~ivo effector or antigen-binding function or activity that is directly or indirectly performed by huMAb4D5 (whether in its native or denatured conformation).
Effector functions include p185HER2 binding, any hormonal or hormonal antagonist activity, any mitogenic or agonist or antagonist activity, any cytotoxic activity. An antigenic function means possession WO 92/22653 ~ ~ '~ ~ I . , PCT~US92/05126 I~
of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against t.::polypeptide sequence of huMAb4D5.
Biologically active huMAb4D5 is defined herein as a polypeptide that shares an effectar function of huMAb4D5. A principal known effector function of huMAb4D5 is its ability to bind to p185HERZ_ Thus, the biologically active and antigenically active huMAb4D5 palypeptides that are the subject of certain embodiments of this invention include the sequence of the entire translated nucleotide sequence of huMAb4D5; mature huMAb4D5; fragments thereof having a consecutive sequence of at Least 5, 10, 15, 20, 25, 30 or 40 amino acid residues comprising sequences from muMAb4D5 plus residues from the human FR of huMAb4D5; amino acid sequence variants of huMAb4D5 wherein an amino acid residue has been inserted N- or C-terminat ta, ar within, huMAb4D5 ar its fragment as defined above; amino acid sequence variants of huMAb4D5 or its fragment as defined above wherein an amino acid residue of huMAb4D5 or its fragment as defined above has been substituted by another residue, including ~~predetermined mutations by, e.g., site-directed or PCR mutagenesis;
derivatives of huMAb4D5 or its fragments as defined above wherein huMAb4D5 or its fragments have been covalent modified, by substitution, chemical, enzymatic, or other appropriate means, with a moiety other than a naturally occurring amino acid: and gtycosylation variants of huMAb4D5 tinsertion s~f a gtycosytation site or dehtion of any glycosylation site by deletion, insertion or substitution of suitable residues). Such fragments and variants exclude any potypeptide heretofore identified, includir~g~muMAb4D5 or any known polypeptide fragment, which are anticipatory order 35 U.S.C.102 as well as polypeptides obvious thereaver under 35 U.S.C.
103.
An "isolated" polypeptide means polypeptide which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous salutes. In preferred embodiments, far example, a polypeptide product comprising huMAb4D5 wilt be purified from a cell culture or other synthetic environment t1 to greater than 95% by weight of protein as determined by the Lowry method, and most preferably mare than 99°~ by weight, i2) to a degree sufficient to obtain at least 15 residues of N-terminal ar internal amino acid sectuence by use of a gas- ar liquid-phase sequenator tsuch as a commercially availabt~, Applied Biasystems sequenator Model 470, 477, or 4731, or t3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. isolated huMAb4D5 includes huMAb4D5 in,~tu within recombinant P~GT/US9~/OS1Z5 WO 92/2653 ' -t$
Gcll$ since at least or~~ component of the huMAb4D5 natural envirorlrr~ent will not be present.
Drdinarity, however, Isolated huMAb4I~5 will be prepared by at least one purification step.
in accordance with this invention. huMAb4D5 nucteiC acid is I~NA or DNA
containing greater than ten bases that encodes a biologically or antigenically active huMAb4D5, is complementarlr to nucleic acid sequence encoding such huMAb4D5. or hybridizCS
tb nuCIeiC
acid sequence encoding such huMAb~t05 and remains sfabty bound to it under stringent conditions, and comprises nuClt~ic acid from s muMAb4D5 CDR and a human FR
region.
Preferably. the huMAb4a5 riucleic~f~cid ~sncodes a palypeptida sharing ax least 75°~6 sequenaa idantixy, more preferably at least BO°/s, still more praf8tably at l6ast 8596, oven more i0 preferably at 90%, and most prCfarabty 959b, with the huMAb4D5 amino acid sos~uance.
Preferably, a nucleic acid molecule that hybridizes to the huMAb4D5 nucleic said contains at . least 20, more proferably.. Vin, and most preferably 9D bases. Such hybridizing or comrilementary nucleic acid, however, is further defined as being novel under 35 U-S.C. 10~
and unobvious under 35 U:S.~. t 03 over any prior art nuCleiC acid.
is ~' ~ Stringent conditions era those that f 1 i employ law ionic svength and high temperature for washing, for exempts, O.Oi S M NaC110.00t 5 M sodium citratel0/1 %
NaDodSO; at 80° G:
t2) employ during hybridixatlon a ,denaturing agent such as formamide, for example, &096 lvol/vol) .formamide with 0:9 96~ bavina serum albuminl0ll °.6 ~colh~l9 °~ polyvinylpyrrolidona150 mM sodium~phosphate. buffer at pH 6.,6 with 75o rnM NaGI, T5 mM sodium citrate at 42° G:
D' v w or: (3) employ 5096 form>~mida, 6.x';SSC 10.76 M, NeCI, 0.0'Y5 M sodium Gitratef, 50 mM
sodiury phosphate lphl f.$i. O-t °.~ sQdlum pyrophosphate, 5 x D$nhardt's solution, sonicaxed .. $atmowsperm DNA I50.g1m11, 0.1:% SDS. and 1096 dextran sulfate at 4~ C, with washes at - . ~,~ C in 0.2 x SSC arid 0.~1.% S~S..
w . ~ Tha~term .'cant~ol sequerzc~s" refers to UNA soquertces necessary for the expression ~f:':an~operabty linkqdycoding. sequence yin a.parti.uuler host organism. The Contr4l Setluencss ' , that era suitable for-~~prokaryotes, for example; include a promoter.
aptionaliy an operattrr $equence,~ a ribosome binding site; and possibly, other as yet poorly understood sequences.
Eukaryotic cells. are knows to utiliaa promoters, polyadenylation signals and enhancers.
Nucleic acid is "oparably linked." when it is placed into a functional relationship with ~' so ancrthar nucleic acrd sequence: °FCir example, 17NA for a presaqu~nce or secretory leader is Qperpbly,lihked to DNA for a polypeptide if it is expressed as $ grpprptein that participates in the. secretion' of the ~ potypeptide; a promoter ~or enhanaor is aperably linked to a Coding sequence if It affects the transcription of the seguence; ar a ribosome binding site is aperably linked ~to a ,coding ~ sequersce ii it is positioned. so as to facilitate translation. Generally, *-trademark _WO 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT%US92/05126 1 '~
"operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
An "exogenous" element is defined herein to mean nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.
As used herein, the expressions "cell,"~ "cell line," and "cell culture" are used 1o interchangeably and all such designations include progeny. Thus, the words "transformants"
and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that alt progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell '"'are included. Where distinct designations are intended, it will be clear from the context.
"Oiigonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphate, or phosphoramidite chemistry, using solid phase techniques such as described in EP 266,432 published 4 May 1988, o~ via deoxynucleoside H-phosphonate intermediates as described by Froehler et a6.; Nu_cl__ Acids Res., 14: 5399-5407 ( 19861). They are then purified on polyacrylamide gels:
The technique of "polymerase bhain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA
and/or DNA, are amplified as described in U.S. Pat. No. 4;683,195 issued 28 July 1987.
Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences; specific DNA sequences from total genomic DNA, and cDNA
3o transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et aL, Cold Sarinca Harbor- Symn. Quant. Biol., ,~: 263 (1987); Erlich, ed., P R
Technoioav: tStockton f~ress, NY; 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polyrryerase reaction method for amplifying a nucleic acid 'test sample, comprising he use of ~ known nucleic acid (DNA or RNA) as a primer and ~:~U~~J~
WO 92/22$53 ~ PGT/US92/0~126 ,, zo utilizes a nucleic acid polymerise to amplify or generate a specific piece of nucleic acid or to amplify or generate a specific piece of nucleic acid which is complementary to a particular nucleic acid.
Su~able Metho~i~ for Practicing ~h~ Invention Some aspects of this invention include obtaining an import, non-human antibody variable domain, producing a desired humanized antibody sequence and for humanizing an antibody gene sequence are described below. !~ particularly preferred method of changing a to gene sequence, such as gene conversion from a non-human or cons~nsus sequence into a humanized nucleic acid sequence, is the cassette mutagenesis procedure described in ~xampl8 1. Additionally, methods are given for obtaining and producing antibodies generally, which apply equally to native non-human antibodies as well as to humanized antibodies.
Generally, the antibodies and antibody variable domains of t6rois invention are i5 'conventionally prepared in recombinant cell culture, as described in more detail below.
Recombinant synthesis is preferred for reasons of safety and economy, but it is known to prepare peptides by chemical synthesis and to purify them from natural sources; such preparations are included within the definition of antibodies herein.
2o Molecular Modeling An integral step in our approach to antibody humanization is construction of computer graphics models of the import and humanized antibodies. These models are used to determine if the six complementarity-determining regions (CDRs? can be successfully transplanted from the import framework to a human one and to determine which framework residues from the 25 import antibody: if any, need-to be incorporated into the humanized antibody in order to maintain CDR conformation. In addition, analysis of the sequences of the import and humanized antibodies and reference to the- models can help to discern which framework residues are unusual and hereby might be involved in antigen binding or maintenance of proper antibody structure.
30 All of the humanized antibody models of this invention are based ~an a single three-dimensional'computer graphics structure hereafter referred to as the consensus structure. This consensus structure is ~ key distinction from the qpproach of previous workers in the field, who ty~icalty begin by selecting a human antibody structure which has an amino acid sequence which is similar to tl~e sequence of their import antibody.
WO 92/22653 . ~ ~ ~ ~ ~ ~ PC"f/US92/05126 z~
The consensus structure of one embodiment of this invention was built in five steps as described below.
Step 1: Seven Fab X-ray crystal structures from the Brookhaven Protein Data Bank were used (entries ZFB4, 2RHE, 3FAB, and 1 REI which are human structures, and 2MCP, 1 FBJ, and 2HFL which are murine structures). For each structure, protein mainchain geometry and hydrogen bonding patterns were used to assign each residue to one of three secondary structure types: alpha-helix, beta-strand or other (i.e. non-helix and non-strand). The immunoglobutin residues used in superpositioning and those included in the consensus structure are shown in Table 1.
aWWO 9WZ26s3 PCT/'U~'~2/OS126 ~Z
Table I
Immunoglobulin Residues in Superpositioningand Those Used Included in the Consensus Structure ~l,t~ domain Iga 2FB4 2RIiE 2MCP 3FAB iFBJ 2I~'~. 11tE1 Consensush 60-56 62-58 57-72 53-65 60=65 50-55 61-66 59-77 RMSe 0.40 0.60 0.53 0.54 0.48 0.50 VB domain Iga 2hB4 2MCP 3FAB 1FBJ 2I~r. Consensusb ~~- 3-8 58-71 70-73 57-?0 58-71 58-71 66-?1 78-84 80-86 77-8~ 78-84 78-84 75-82 82_99 94-101 91-98 92-99 92-99 88-94 RMSe 0.43 0.85 0.62 0.91 RMSd 0.91 0.73 0.77 0.92 a Four-letter code Bank file.
for Protein Data b Residue numbers the crystalstructures ire from the Protein Data for taken Bank files. Residuenumbers f~r the consensus structure are according to Kabat et al.
c Root-mean-s9uare ation for (N,Ca;C) superimposed 2FB4.
devi in ~ atoms on d Root~aean-square atioa~ for (Id,Ca;C) superira~poscd2IIFL.
devi in ;~ atones on W(~ 92/22653 '~ ~ 0 ~ ~ j ~ PCT/US92/05126 z~
Step 2: Having identified the alpha-helices and beta-strands in each of the seven structures, the structures were superimposed on one another using the INSIGHT
computer program (Biosym Technologies, San Diego, CA) as follows: The 2FB4 structure was arbitrarily chosen as the template (or reference? structure. The ~FB4 was held fixed in space and the S other six structures rotted and translated in space so that their common secondary structural elements ti.e. alpha-helices and beta-strands) were oriented such that these common elements ware as close in position to one another as possible. (This superpositioning was performed using accepted mathematical formulae rather than actually physically moving the structures by hand.) t0 Step 3: With the seven structures thus superimposed, for each residue in the template (ZFB41 Fab one calpulates the distance from the template alpha-carbon atom (Ca) to the analogous Ca atom in each of th~ other six superimposed structures. This results in a table of Ca Ca distances for each residue pdsition in the sepuence. Such a table is necessary in order to determine which residue positions will be included in the consensus model. Generally, 15 '~if all Ca-Ca distances for a given residue position were ~ 1.0~, that position was included in the consensus structure. If for a given position only one Fab crystal structure was > 1.0~, the position was included but the outlying crystal structure was not included in the next step (for this position anlyl. In gene~al~ the seven ~B-strands were included in the consensus structure while some of the loops connecting the ~B-.strands, e.g.
complementarity-determining 20 regions (CDRs?, were not included in view of Ca divergence.
Step 4: For each residue which was included in the consensus structure after step 3, the average of the coordinates for individual mainchain N, Ca, C, O and C~
atoms were calculated. D~ae to the averaging procedure,- as well as variation in bond Isngth, band angle and dihedral angle among the crystal structures, this "average" structure contained some bond 25 lengths and angles which deviated from standard geometry. For purposes of this invention, "standard geometry" is understood to include geometries commonly accepted as typical, such as the compilation of bond lengths and angles from small molecule structures in Weiner, S.J.
et, al.; J. Artier. Chem. Soc., 106: ?65-784'(1984).
Step 5: In order to correct these deviations; the final step was to subject the 30 "average" structure t'o 50 cyc6e~ of energy minimization (DISCOVER program, Biosym Technologies) using the AMBER fllVeiner, S.J. er: al., J. Amer. Chem. S~c., 106: 765-784 (1984.x? parameter set with only the Ca coordinates fixed (i:e. all other atoms are allowed to mtDVe) (energy minimization is described belowl. This allowed any deviant bond lengths and angles to assume a standard (chemically acceptable) geometry. See Table It.
PCT/US92/OSl2G
2 'i Table II
Average Bond Lengths and Angles for "Average" (Before) and Energy-Minimized Consensus (After SO Cycles) Structures VLK V1,K Vg VH Standard before after before after Geometry (~) (A> (~) (~) (~) N-Ca 1.459(0.012)1.451(0.004)1.451(0.023)1.452(0.004)1.449 Ca-C 1.515(0.012)1.523(0.005)1.507(0.033)1.542(0.005)1.522 ~C 1.208(0.082)1.229(0.003)1.160(0.1??)1.231(0.003)1.229 C-N 1.288(0.049)1.33?(0.002)1.282(0.065)1.335(0.004)1.335 Ca-C~ 1.508(0.026)1.530(0.002)1.499(0.039)1.530(0.002)1.526 b C-N-Ca 123.5(4.2) 123.8(1.1) 125.3(4.6) 124.0(1.1) 121.9 N-Ca-C 110.0(4.0) 109.5(1.9) 110.3(2.8) 109.5(1.6) 110.1 Ca-C-N 116.6(4.0) 116.6(1.2) 11?.6(5.2) 116.6(0.8) 116.6 C~C 123.1 (4.1 123.4(0.6) 122.2(4.9) 123.3(0.4) 122.9 N ) N-Ca-C~110.3(2.1) 109.8(0.?) 110.6(2.5) 109.8(0.6) 109.5 C~-Ca-C111.4(2.4) 111.1(0.?) 111.2(2.2) .111.1(0.6)111.1 ~ialues in parentheses are standard deviations. Note that while some bond length and angle averages did not change appreciably after energy-minimization, the corresponding standard deviations arc reduced due to deviant geometries assuming standard values after energy-minimization. standard geometry values are from the AMBER forcefield as implennented in I)ISCOVEFt (Biosym Technologies).
~r:s::. -_-_"._,_ __,__ _..
.WO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/US9zio~1z6 zs The consensus structure might conceivably be dependent upon which crystal structure was chosen as the template an which the others were superimposed. As a zest, the entire procedure was repeated using the crystal structure with the worst superposition versus 2Ft34, i.e. the 2HFL Fab structure, as the new template Ireference). The two consensus structures corlnp8re favorably (root-mean-squared deviation of x.11 ~ for alt N, Ca and C
atoms).
Note that the consensus structure only includes mainchain IN, Co. C. a. CB
atoms) coordinates far only those residues which are part of a conformation common to all seven X
' ray cryøtal structures. Fvr iha Fob structures, these include the common ~
strands Iwhich comprisB two ~-shoat$1 and a few non-~DFi lobes which connect these -strands.
The >.o consensus structure does not include GDRs yr sidachains, both of which vary in their conformation. among the seven structures. Also, note that the consensus structure includes only the VL and VH domains.
This aansansus structure is u$ed as the archetype. It is not particular to any species.
aryd has only the basic sh~p~ without side chains. starting with this consensus structure the is ~-rinodal of any import, human, or humanized Fab can be constructed as follows. lJsing the amino said seQuence of tha..particular antibody VL and VH domains of interest, a computer graphics prv~ram iau~b as INSIGHT*Bio$ym Technologies) is used to add sidechains and CDRs to the congarysus strirctura. When a 'sidechatn is added, its conformation is chosen on the basis of knbwn Fab erystal structures lsee the Background acotian fw publications of such . Zo . ~ crystal struaturesl and rotamer libraries (Ponder. J.W. & Richards, F. M.. J. Mwi. Biol. 1g3:
77~-791 (t sa$7I1. The modet also. is constructed so that the atoms of the sidechain are positioned s4. as to not collid,a with other atoms in the s=ob. , CDRS are coifed to fthe model Inow having the backbone plus 5ida chains) as follows.
The- size Ii.e. number-.of amino acids? of each import GDR is compared to canonical CDR
as structuras.~tabuiated by Chothia et al., Nature, 342:877-883 ('I 9B9)1 and which ware derived from. Fab cnistals. Each CDR svquanca is also reviewed for the prssancs or absence of certain specific arinino acid rasiduas v~ihich era identified by Chathia as structurally important: e.g. light chain residues 29 (CCiR1 i and' 95' (GDR3), dnd heavy chain residues 26. 27.
29 IGDR1 f and 55 ICDR2?. For light chain .CpR2, and heavy chain CDR3, only the size of the GDR i5 3o compered to~the Chvtliia. canonical structure. if the size and sequence li_e. inctusiar< of the specific, structurally impartant~.residuas as denoted by Chothia et al.l of the import CdR agrees in size and ha$ the same structurally. important residues asr those of a canonical CPR, than the mainchsiwconfonnation of the irnpoft CDR in the model is taken to be the same as that of the canonical CDR- This means that the import seduance is assigned the structural configuration *-trademark _ ,, . ~v,.-,. -.;~:
,,, r ': ~: r..~.. ~:.; x, , . /,'~.~ZS:":' 7, ~~\ e.h.
~.~'1'~.":.' _1i :': .~,..,.. ., ... .
f..:rwl:~ ~~ , . .. ... ..
S ~.~' L. f '~,~iy,,' ' y..,ffS ~.~:,,~1,~; ~~~.
~ . ,S.~'n':~:~:~lf:n 7 .... ... 'f~.
5...: ..
wa gxiz~~~ ~ ~ ~ ~ Pcr~us9zro~rzra of the canonical ~(?R, which is then incorporated in the evolving model.
Wowevar, if no matcriing canonical CDR can be assigned far the import CDR, than one of two options can bs exercised. First, using a program such as INSIGHT
iRiosym Technologie$), the 8rookhavan protein Data Bank can bs searched far loops with a similar size to that of the import CDR and these loops can be evaluated as possible conformations for the .
import CDR in thn model. Minimally. such loops must sxhibtt a conformation in which na loop atom overlaps with other protein atoms. Second, one can use available Programs which calculate possible laop~ conformations. assuming a given loop size, using methods such as tiescribsd by ~r~coleri et at , Natwe 335: b6a-ggg t'1988).
Wh~n all CDRS and sidechains have been added to the aonsansus structure to give the final rrvodal timport. human or, humanixad), the model is preferably subjected to energy minimization using programs which era available commerCi811Y (a-g~ Ci~CaVpR;
BioBym Tpchnolog)as)'. This technique .uses complex mathematical formulae to refine the model by performing such tasks as ohecking.that ail atoms ors within appropriate distances from cue ~, 15 'another and checking that band lengths and angles are within chemically acceptable limits.
nnodels of ~a humanized, import, or human antibody sequence era used in the practice of thi3 invent;on to understand the impact' of selected amino acid re$idues of tire activity of the seqwanca being modet~d. For exarhple, such a model can show residues which may be important in antigen binding. br for ma)ntaining the conformation of the $ntit~ody, as discussed _ in mare detail below. Modeling can also be used to explore the potential impact of Gharlgin$
. sny amino~acid residue in the antibody sequence.
M ini tn the praatJce~ af,. tills : invention, the first stop in humanizing an irnPort antibody is deriving a aonsensirs amine acid. sequence into which to incorporate the import sequences.
HBO ~ ~Qdel. is.'gdnera~tad far.these sequences using the methods described above. in certain ~~b~imqnts of this lnvenxian~ the consensus human sequences are derived from the mast $bundant~ ~~~)assas- iri the' seqWenca ccmp)lation of Kabat et al. IKabat. !!.
A. et al..
Sd4uences of Proteins of lri~rmuriological interest National Institutes of Health: Etethesda. MD, 3p ~ 1987)1,, namely V4 K subgroup 1 arid VM group III, and have th$
setluances indicated in the ~
. . definitions above.. , . . Whileahese steps may. ba. takbn in different order, typically a structure for the Candidate h~ariized antibod~r is~'crpated by transfsrring~ the at least one GOR from the non-human.
import sequence into thd consensus human structure, after the entire corresponding human . *--trademark i .t~' ~ ...' ,. ~_,..~... .. . .;~.,' ' ...:.:.: , ':_~'_;... ... -.;....~
.~..~:.~ . ...:. , :~;' . ;-,,~.. .. ~:r:. ' . .,:, . ~, ~',,.;..' .::... ,.' ,:..; ,...,...:~ ..: w~...~.~. '....,,. .. ; .''. .
.:..:.~v . ~.~.~':.... ~,:. ~:.~ . '. ... ,.. ., , ....
WO 92/22653 ~ ~ ~ 1 Q j ~ ~ ~ PC'T/US921U512~b CDR has been removed. The humanized antibody may contain human replacements of the non-human import residues at positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of Immunoiagica! Interest (National Institutes of Health, Bethesda, MD, 1987)) or as defined by structural variability (Chothia, C. & t-esk, A. M., J. Mol.
Biol. 196:901-917 (1987)). For example, huMAb4D5 contains human replacements of the muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of lmmunoiogical Interest tNational Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C.
& Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)): V~-CDR1 K24R, V~-CDR2 R54L and V~-CDR2 T56S.
Differences between the non-human import and the human consensus framework residues are individually investigated to determine their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is desirably performed through modeling, by examination of the characteristics of the amino acids at particular locations, or determined experimentally through evaluating the effects of substitution or t5 '"mutagenesis of particular amino acids.
In certain preferred embodiments of this invention, a humanised antibody is made comprising amino acid sequence of an import, non-human antibody and a human antibody, utilizing the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable domain and of a consensus human variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence;
d. aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody;
e. identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably 3o expected to have at least one of the following effects:
1. r9on-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V~ - VH interface; and g. far any'non-homologous import antibody amino said residue which is reasonably ~~.03~~j WO 92l226S3 ~CT/US92/05126 2$
expected to have at feast one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence.
aptionally, one determines if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step tf), one may retain the consensus residue.
Additionally, in certain embodiments the corresponding consensus antibody residues identified in step te) above are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 6?L, 68L, 69L, ?4L, ?1 L, ?3L, 85L, 8?L, 98L, 2H, 4H, 24H, 36H, 3?H, 39H, 43H, 45H, 49H, 58H, 6tJH, 6?H, 68H, 69H, ?OH, ?3H, ?4H, ?5H, io ?6H, 78H, 91 H, 92H, 93H, and 1 ~D3H (utilizing the numbering system set forth in Rabat, E.
A. et al., SeQuences of Proteins of lmmunologica! Interest (National Institutes of Health, 8ethesda, nIID, 19871).
In preferred embodiments, the method of this invention comprises the additional steps of searching either or both of the import, non-human bnd the consensus variable domain ~~sequences for glycosylatian sites, determining if the glycosylation is reasonably expected to be important for the desired antigen binding and biological activity of the antibody ti.e., determining if the glycosylation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosyiation enhances or weakens antigen binding, or is important for maintaining antibody affinity). If the import sequence bears the glycosylation site, it is preferred to substitute that site for the corresponding residues in the consensus human sequence if the glycosylation site is reasonably expected to be important. if only the consensus sequence; and not the import, bears the glycosylation site, it is preferred to eliminate that glycosylation site or substitute therefor the corresponding amino acid residues from the import sequence.
Another preferred embodiment of the methods of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR
residues which are non-homologous with the aligned consensus FR sequence, and for each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, 3o and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
tn certain alternate embodiments, one need not utilize the modeling and evaluation steps described above, and may instead proceed with the steps of obtaining the amino acid sequence of ~t least a portion of an import, non-human antibody variable domain having a GDR and a FR, WC? X2/22653 ~ ~ ~ PCT/US92/~5126 obtaining the amino acid sequence of at least a portion of a consensus human antibody variable domain having a CDR and a FR, substituting the non-human CDR for the human CDR
in the consensus human antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a. tin the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98Lr or b. !in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60Hr 67H, 68H, 69H, 70H, 73H, 74Hr 75H, 76H, l0 78H, 91 H, 92H, 93H, and 103H.
Preferably, the non-C~R residue substituted at the consensus FR site is the residue found at the corresppnding location of the non-human antibody» If desired, one may utilize the other method steps described above for determining whether a particular amino acid residue can reasonably be expected to have undesirable effects, and remedying those effects.
' f if after making a humanized antibody according to the steps above and testing its activity one is not satisfied with . the humanized antibody, one preferably reexamines the potential effects of the amino acids at the specific locations recited above.
Additionally, it is desirable to reinvestigate any buried residues which are reasonably expected to affect the ~h -V" interface but may not directly affect CDR conformation. It is also desirable to reevaluate the humanized antibody utilizing the steps of the methods claimed herein.
In certain embodiments of this invention, amino acid residues in the consensus human sequence are substituted for by other amino acid residues. In preferred embodiments, residues from a particular non-human import sequence are su~st~tute~i, however there are circumstances where it is desired to evaluate the effects of other amino acids. For example, if after making a humanized antibody according to the steps above and testing its activity one is hot satisfied with the humanized antibody, one may compare the sequences of other classes or subgroups of human antibodies, or classes or subgroups of antibodies from the particular non-human species, and determine which other amino acid side chains and amino acid residues are found at particular locations and substituting such other residues.
Antibodies Certain aspects of this invention are directed to natural antibodies and to monoclonal antibodies, as illustrated in the Examples below and by antibody hybridomas deposited with the ATCC tae described below). Thus, the references throughout this description to the use ~~Q ~~ ~~ , V~IG 92/22653 PCT/US92/0512b of monoclonal antibodies are intended to include the use of natural or native antibodies as well as humanized and chimeric antibodies. As used herein, the term "'antibody"
includes the antibody variable domain and other separable antibody domains unless specifically excluded.
In accordance with certain aspects of this invention, antibodies to be humanized timport 5 antibodies) are isolated from continuous hybrid cell tines formed by the fusion of antigen-primed immune lymphocytes with myeloma cells.
in certain embodiments, the antibodies of this invention are obtained by rautine screening. Polyclonat antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections'of the antigen and an adjuvant. It may be 1o useful to conjugate the antigen or a fragment containing the target amino acid sequence to a protein that is immunogenib in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sultosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide tthrough lysine'residuesl, glutaraldehyde, succinic ~r iS anhydride, SOC12, or R'N = C = NR; where R and R' are different alkyl groups.
The raute and schedule of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. While rnice are frequently employed as the test madel° it is contemplated that any mammalian subjECt including human subjects or antibody-producing 20 cells obtained therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines.
Animals are typically immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 ,ug of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund°s complete adjuvant and injecting the solution intradermally at multiple sites. One 25 month later the animals are boosted with 1 /5 to 1 /10 the original amount of conjugate in Freund's complete adjuvant for other suitable adjuvant) by subcutaneous injection at multiple sites. 7 to 14 days later animals are-bled and the serum is assayed for antigen titer. Animals erg boosted until the titer plateaus. Preferably; the animal is boasted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking 30 agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.
After immunization; monoclonal antibodies are prepared by recovering immune lymphoid cells--typically spleen cells or lymphocytes from lymph node tissue--from immunized animals and immortalizing the ceps in con~rentional fashion, e.g. by fusion with myeloma cells or by f .,r ~. . ~ .~.. , ~.~~ ~, ~ .. ... . . ,.,..,. ~~ ' .. ., . . ,." y WO 92/22653 ~ ~ ~ '~ ~ '~ '~ PCT/US92/U5126 3!
Epstein-Barr tEB)-virus transformation and screening for clones expressing the desired antibody.
The hybridoma technique described originally by ICohler and Milstein, Eur. J.
Irrrmunol. 6:51 1 ( 1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens.
It is possible to fuse cells of one species with another. However, it is preferable that .
the source of the immunized antibody producing cells and the myeloma be from the same species.
The hybrid call lines can be maintained in culture in rritrp in cell culture media. The cell lines of this invention can be selected and/or maintained in a composition comprising the to continuous cell line in hypoxanthin~-aminapterin thymidine tMAT) medium. In fact, once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media. Moreover, the hybrid cell lines can be stored and preserved in any number of conventional ways. including freezing and storage under liquid nitrogen.
Frozen calf lines can be revived and cuttured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ton exchange chromatography, affinity chromatography, or the like. The antibodies described herein are also recovered from hybridoma celP
cultures by conventional methods for purification of IgG or IgM as the case may bs that heretofore have been used to purify these irnmunoglobulins from pooled plasma, e.g. ethanol or polyethylene 2o glycol precipitation procedures. ~'he purified antibodies are sterile filtered, and optionally are conjugated to a detectable marker such as an enzyme or spin label for use in diagnostic assays of the antigen in test samples.
While routinely rodent monoclonal antibodies are used as the source of the import antibody, the invention is not limited to any species. Additionally, techniques developed for the production of chirneric antibodies ~Morrison etal., Froc. Nall. cad. Sci., 81:6851 t1984);
Neuberger ef al., Nature 312:6~4 (1984); Takeda at al., Nature 314:452 t1985)) by splicing the genes from a mouse antipody molecule of appropriate antigen specificity together with ga3nes from a human antibody molecule o~f appropriate biological activity tsuch as ability to activate human complement and mediate ADCC) can be used; such antibodies are within the scope of this invention.
Techniques for creating recombinant DNA versions of the antigen-binding regions of antibody molecules (known ae Fab fragments) which bypass the generation of monoclonal antibt~dies are encornpassed within the practice of this invention. One extracts antibody-specific messenger RW 0. molecules from immune system cells taken from an immunized animal, .. :,.'... ;..; .... . ,w.., ' :, .. ,.. .'' ..:.: , :,; ;.: ,. .,'; ; ;;.:, .,..;; ,, . . :... , ,, . ...
WO 92/22653 , . PC1'/US92/05126 .
3z transcribes these into complementary DNA (cDNA), and clones the ,DNA into a bacterial expressions system. One example of such a technique suitable for the practice of this invention was developed by researchers at Scripps/Stratagene, and incorporates a proprietary bacteriophage lambda vector system which contains a leader sequence that causes the expressed Fab protein to migrate to the periplasmic space (between the bacterial cell membrane and the cell watt) or to be secreted. One can rapidly generate and screen great numbers of functional FAb fragments for those which bind the antigen. Such FAb fragments with specificity for the antigen are specifically encompassed within the term "antibody" as it is defined, discussed, and claimed herein. ' Aming Acid Seauence Variants Amino acid sequence variants of the antibodies and polypeptides of this invention (referred to in herein as the target polypeptidel are prepared by introducing appropriate nucleotide changes into the DNA encoding thb target polypeptide, or by in vitro synthesis of the desired target polypeptide. Such variants include, for example, humanized variants of non-human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the target po[ypeptide; such as changing he number ar position of glycosylation sites, altering any membrane anchoring characteristics, and/or altering the intro-cellular location of the target polypeptid~ by inserting, deleting, ;or otherwise affecting any leader sequence of the native target polypeptide.
in designing, amino acid sequence variants of target polypeptides, the location of the mutation site and th~ nature of ' the mutation will depend an the target polypeptide Gharacteristicts) to' be modified. The sites for mutation can be modified individually or in series, e.g.; by t 1 ) substituting first v~ith conservative amine acid choices and then with more radical selections depending upon the results achieved, d2) deleting the target residue, or f3) inserting residues of the same'or a different class adjacent to the located site, ar combinations of options 1-3. tn certain embodiments, these choices are guided by the methods far creating humanized sequences set forth above.
A useful method for identification of certain residues or regions of the target polype~rtide that are preferred locafians far mutagenesis i~ called "alanine scanning mutagenesis" as described by Cunningham and Wells tS~,ience, 244: 1081-1085 (19891).
WU 92!22653 3 3~ ~ I~ ~ ~ j ~ PCT/t1S92/05126 Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably ~tanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensetivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon ar region and the expressed target polypeptide variants are screened for the optimal combination of desired activity.
There are two principal variables in the construction of amino acid sequence variants:
the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the target polypeptide characteristic to be -modified.
Amino acid sequence deletions of antibodies are generally not preferred, as maintaining the generally configuration of an antibody is believed to be necessary for its activity. Any deletions will be selected so as to preserve the structure of the target antibody.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging zo in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of singte or multiple amino acid residues.
Intrasequence insertions li.e., insertions within the target polypeptide sequence) may range generally from about 1 to 't 0 residues, more preferably 1 to 5, mast preferably 1 to 3, Examples of terminal insertions include the target polypeptide with an N-terminal methionyl residue, an artifact of the direct expression of target potypeptide in bacterial recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the target polypeptide molecule to facilitate the secretion of the mature target polypeptide from recombinant host cells. Such signal sequences generally will; be otitair~ed from, and thus homologous to, the intended host cell species: Suitable sequences include STIt or Ipp for ~ call, alpha factor for yeast, and viral ssgnals such 'as herpes, gD for mammalian cells.
Other insertional variants of 'the target polypeptide include the fusion to the N- or C-tecminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptides such as beta~lactamase ar an enzyme encoded by the E: coli trp locus, or yeast protein, and C-terminal fusions with proteins having a tong half-fife such as immunogiobulin constant ~~ 92/22653 ~ ~ ~ '~ ~ ') ~ ~ PCT/US92/05126 3 ~9 regions Ior other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.
Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the target polypeptide molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active sites) of the target polypeptide, and sites where the amino acids found in the target poiypeptide from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. Other sites for substitution are described infra, considering the effect of the substitution of ' the antigen binding, affinity and other characteristics of a particular target antibody.
Other sites of interest are those in which particular residues of the target polypeptides obtained from various species ara identical. These positions may be important for the biological activity of the target polypeptide. These sites, especially those falling within a sequence of at least three other identicalty conserved sites, are substituted in s relatively conservative manner. If such substitutions result in a change in biological activity, then other changes are introduced and the products screened until the desired effect is obtained.
Substantial modifications ire furictian or immunolagical identity of the target polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the palypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or tcl the bulk of th~ side chain. Naturally occurring residues are divided into groups based on common side chain properties:
t1 ) hydrophobic: norfeucine, met, ala> val, leu; ile; , t2) neutral hydrophilic: cys, ser, thr;
t3) acidic: asp, glu;
t4) basic: a5n, gln, his:' lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp; tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes ' 30 for another. Such substituted residues may be introduced into regions of the target polypeptide that are homologous with other antibodies of the same class or subclass, or, more preferably, into the non-homologous regions of the molecule.
any cysteine residues not involved' in maintaining the proper conformation of target polypeptide also may be substituted, generally with serine, to improve the oxidative stability ' ,;.. ...
WO 92/22653 . ~ ~ ~ J ~ ~ ~ PCg'/US92/U5126 3s of the molecule and prevent aberrant crasslinking.
DNA encoding amino acid sequence variants of the target polypeptide is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source tin the case of naturally occurring amino acid sequence variants) or preparation by oligonucleatide-mediated (or site-directed) mutagenesis, PCR
mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the target polypeptide. A particularly preferred method of gene conversion mutagenesis is described below in Example 1. These techniques may utilized target potypeptide nucleic acid tDNA or RNA), or nucleic acid complementary to the target polypeptide nucleic acid.
to Otigonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of target polypeptide DNA. This technique is well known in the art as described by Adetman et al., _D_N~A, ~: 183 (1983). Briefly, the target polypeptide DNA
is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the target potypeptide. After hybridization, a DNA
potymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the otigonucleotide primer, and wilt code for the selected alteration in the target polypeptide DNA:
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucteotide wilt have 12 to 15 nucleotides that are camptetely complementary to the template on either side of the nucleotidets) coding for the mutation. This ensures that the otigonucteotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crew et al. tProg: Na~rl. Acad. Sci. USA, ~: 6765 (19781).
Single-stranded DNA template may also be generated by denaturing doubts-stranded plasmid for other) DNA usirfg standard techniques.
For alteration of the native DNA sequence tto generate amino acid sequence variants, fer example), the oligonucteotide is hybridized to the single-stranded template under suitable hybridization conditions: A DNA polymerizing enzyme, usually the Ktenow fragment of DNA
polymerase t, is then added to synthesize the complementary strand of the template using the otigonucleotide as a primer for synthesis. A heteroduptex molecule is thus formed such that one stand of DNA encodes he mutated form of the target polypeptide, and the other strand tthe original template) encodes the native, unaltered sequence of the target potypeptide. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such :,';~: .; ,'.'.,,.,., ': .~.... . . '..:,~... ..
WO 92/22653 ~ ~ ~ '~ ~ '~ ~ 1'CT/1JS92/05126 3~
as E, coil ,lM101. After the cells are grown, they are plated onto agarase plates and screened using the oliganucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.
The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the ptasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosins tdATP); deoxyriboguanosine tdGTP), and deoxyribothymidine tdTTP), is combined with a modified thin-deoxyribocytosine called dCTP-taS) twhich can be obtained from Amersham Corporation). This mixture is added to the template-oligonucieotide complex.
Uport addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. ln~ addition, this new strand Ot UNA wul contain dCTP-taS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.
After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme; the template strand can be digested with VIII
nuclease or another appropriate nuclease past the region that contains the sitets) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA tigase. This homoduplex molecule can then be transformed into a suitable host cell such as E. coil JM10'6, as described above.
DNA encoding target polypeptide variants with more than one amino acid to be substituted may be generated i~ one of several ways. If the amino acids are located close tog~ther in the polypep~tide chain, they may be mutated simultaneously using one o6igonuctdotide that podes for alt of the desired amino acid substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to 'generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
tn the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA
simultaneously, and the second strand of DNA that is synthesized from the template will encode alt of the desired amino acid substitutions.
WU 92/22653 ~ ~ ~ ~ ~ J ~ PCTlUS92lOSf26 3 '~
The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitutions) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round Zo of mutagenesis, and so on.
PCR mutagenesis is also suitable for making amino acid variants of target polypeptide.
While the following discussion refers to DNA, it is understaad that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are ~5 Bused as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions whore the primers differ from the template. Far introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation;
20 the sequence of th~ other primer must be identical to a stretch of sequence of the apposite strand of the ptasmid, but this sequence can be Located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 2~0 nucleotides from that of the first, such that in the end the entire amplified region of DNA
bounded by the primers can be easily sequenced. PCR amplification using a primer pair like 25 the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.
If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to 30 replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or rreore?-part ligation.
,v, n ' ~:. , ,.,~~.", ~.,...., ..~ ,~,~,~'~~~v~. ;~... ; .., ,.,~:.' ~.:w,, .
. .~...;.,:,. ;.-i,~~..~~ ~~.,;:
PCTlUS92l05126 WO 92!22653 In a specific example of PCR mutagenesis, template plasmid DNA (1 ,ug) is lineariaed by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide tri-phosphates and is included in the GeneAmp'~ kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each aligonuclsotide primer, to a final volume of 50 Nl. The reaction mixture is overlayed with 35 NI mineral oil. The reaction is denatured for 5 minutes at 100~C, placed briefly an ice, and then 1 NI Thermus aquaticus (Taql DNA polymerise t5 unitslNl, purchased from Perkin-Elmer Cetus, Norwalk, CT and Emeryvilie, CA) is added below the mineral oil layer.
to The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Eimer Cetus) programmed as fol!~ws: 2 min. at 55~C, then 30 sec. at 72~C, then 19 cycles of the following: 30 sec. at 94~C, 30 sec. at 55~C, and 30 sec. at 72~C.
At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chlorafarm t50:50:vo1), and 'ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.
Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells etal. tGen_e,~4: 315 (19851). The starting material is the plasmid for other vector? comprising the target polypeptide DNA to be mutated. The cadants) in the target polypeptide DNA to be mutated are identified. There must be a unique restriction endonuclease site an each side of the identified mutation sitets). If no such restriction sites exist, they may be generated using the above-described oliganucleatide-mediated mutagenesis method to introduce them at appropri to locations in the target polypeptide DNA. After the restriction sites have been introduced into the plasmid, the piasmid is cut at these sites to finearize it. A double-stranded oligonucleatide encoding the sequence of the DNA between the restriction sites but containing tho desired mutatiants) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be ditectiy ligated to the plasmid. This plasmid now contains the mutoted target polypeptide DNA sequence.
Insertion of DNA into a Cloning 'Vehicle The cDNA or gertomic DNA encoding the target palypeptide is inserted into a replicable ,.
.., . . "e~. ...
. . . " . ,. . ,,,. ~ , .'. , . .:. . . .,. . ,. ,. ,..
:,.::. ,.~' '.'.~~ ~~..;~, . ',. .. .. ~...; , ~ 7, .. r..., .' :.,, .,..,.
.., . . . .. . . . . ~ ~
~_~.~ ~~~J~
'WO 92!22653 PCT/US92105126 vector for further cloning tamplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1 ) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNAI and the bast cell for which it is compatible. The vector components generally include, but are not limited to, one or mare of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
(a) ,signal Se uenc~ Component In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector.
The target poiypeptides of this invention may be expressed not only directly, but also i5 gas a fusion with a heteraiagous polypeptide, preferably a signal sequence or ether polypeptide having a specific cleavage site at the N~terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. Included within the scope of this invention are target paiypeptides with any native signal sequence deleted and replaced with a heterotogaus signs! sequence. The heterologaus signal sequence selected should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not reGOgnize and process the native target paiypeptide signet sequence, the signal sequence is substituted by a prokaryotic signal sequence Selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable 'enterotoxin If leaders, For yeast seG~etion the native target polypeptide signal sequence may be substituted by the yeast invprtase, dlpha,factor, or acid phasphatase leaders. in mammalian cell expression the native signal sequence is satisfactory, although ether mammalian signal sequences may be suitable.
(b) ~?rigin of Replication Comaonent Both expressiart and cloning vectors contain s nucleic acid sequence that enables the vector to replicate in one or more 'selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal ,,;, ;., . , . :, ,,:
~ ~;.,. . .. . ,. . ,~, , ~; .. .'' , . , ...,' , ..y( .y' ,. !.. ..~.~. ..., ':. ' ..,' ~ ,. . .. . . y" . , ~..
PC'f'JUS92/OSI z6 wo 9zJZZ~s3 2 ~ ~ ~ ~ '~ ~
~0 DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2N
plasmid origin is suitable for yeast, and various viral origins tSV40, polyoma, adenovirus, VSV
or BPV) are useful for cloning vectors'in' mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoters.
Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For io example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.
DNA may also be amplified by insertion' into the host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in the vector a DNA
sequence that is complementary to a sequence found in Bacillus genomic DNA.
Transfection of Bacillus with this vector results in homologous recombination with the genome and insertion of the target poiypeptide DNA. However, the recovery of genomic DNA encoding the target polypeptide i~ more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the target poiypeptide DNA.
tc) ~~ c.t~~ene Component Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown 'in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that ta) confer resistance to antibiotics or other toxins, e.g. ampiciltin, neomycin, methotrexate; or tetracycline; tb) complement auxotrophic deficiencies, or tc) supply critical nutrients not available frorro complex media, e.g. the gene encoding D-alanine racemase for Bacilli.
One example of a selection scheme utilizes a drug to arrest growth of a host cell.
Those calls that are successfully-transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., ~. Motec. Appl. Genet., 1:
S27 (19821), Frtt/ ,~ 9Q ';. S V .III ;Yr''~,2~W~P .ir.'P(j~.a=.,..
~nt,"','.~."
~~a~~JJ
''YO 92/2265 P~1'/US921o5126 '-I I
mycophenolic acid (Mulligan et al., cien~_e., 209: 1422 [ 19801) or hygromycin (Sugden et al. , Mol. Cell. Biol., 5_: 410-413 (19851). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug 6418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the target polypeptide nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed; thereby leading to amplification of both the selection gene and the DNA that encodes the target polypeptide. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem ~vyithin the chromosomes of successive generations of recombinant cells.
Increased quantities 15 of the target polypeptide are synthesized from the amplified DNA.
For example, cells transformed with the DHFR selection gene are first identified by cultdring all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of Di~FR. An appropriate host cell when wild-type DHFR
is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and 20 propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 ~1980~.
Tne transfocrned cells are then exposed to increased levels of methotrexate.
This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising thd expression vectors, such as the DNA encoding the target polypeptide.
This amplification technique can be used with any otherwise suitable host, e.g., ATCC No.
CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060?.
Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequendes encoding the target polypeptide, wild-type DHFR protein, and another selectable marker such as arninoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibibtic, e:g., kanamycin, neomycin, or 6418. See U.S. Pat.
No.
4,965;199.
A suitable s~iection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 (Stinchcc~mb et al:; Na ure, 282: 39 (19791; Kingsman et al., Gene, 7:
141 [1979D; or '.. r.;.; , ~
~r,..~ ~.5',. b . .1.~~. ' r ~1.7: . ~~i:9,.. , r . .. . ' .. . '~ . . s... .
~I Z
Tschemper et al., Gene, 10: 157 [1980]?. 'The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85: 12 [19771). The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains tATCC
20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
td) Promoter ramoonent Io Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the target polypeptide nucleic acid.
Promoters are untranslated sequences located upstream t5') to the start codon of a structural gene (generally within about 100 to 1000 bpl that control the transcription and translation of a particular nucleic acid sequence, such as that encoding the target polypeptide, to which they are ~operably linked. Such promoters typically fall into two classes, inducible and constitutive.
Inducible promoters ere promoters that initiate increased levels of transcription from DNA
under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably 2Q linked to DNA encoding the target polypeptide by removing the promoter from the source ANA
by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.
Both the native target polypeptide promoter sequence and many heterologous promoters may be used to direct amplification andlor expression of the target polypeptide DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter.
Promoters suitable for use with prokaryotic haste include the ~B-lactamase and lactose promoter systems tChang et al., _Naturg, 275: 615 [1978]; and Goeddel et al., Nature, 2 1:
544 [ 19791), alkaline phosphatase, a tryptophan ttrp) promoter system (Goeddel, Nu,~leic Aids Res., 8: 4057 119801 and ER 36,761 and hybrid promoters such as the tac promoter tdeBoer ' 3o et al., Proc. Natl. Acad: Sci. USA; ,$Q: 21-25 [19831). However, other known bacterial pr~moters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably: to ligate them to DNA encoding the target polypeptide tSiebenlist et al.Ceii; 20: 269 (1980)) using linkers or adaptors to supply any required restriction sites.
Promoters lot use in bacterial systems also generally will contain a Shine-Dalgarno tS.D.) d1'O 92122653 . ~ ~ ~ ~ ~~ ~ ~ PC.'T/US92105126 ~I 3 sequence operably linked to the DNA encoding the target polypeptide.
Suitable promoting sequences for use with yeast hosts include the promoters for 3-phasphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 2~~'5: 2073 [1980)) or other glyco)ytic -enzymes (Hess et al., J Adv. Enzyme Reg~., 7: 149 (19681; and Holland, Biochemistrv,17: 4900119781), such asenolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarbaxylase, phosphafructakinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isamerase, phasphoglucase isomerase, and glucakinase.
Other yeast promoters, which are inducib)e' promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallathianein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and gafactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,857A.
Yeast enhancers also are advantageously used with yeast promoters.
Promoter sequences are known for eukaryotes. Virtually ail eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide.
At the 3' end of mast eukaryatic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding seauence. All of these sequences are suitably inserted into mammalian expression vectors.
Target polypeptide transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (Ul~
z5 2,211,504 published S July 1989), adenovirus (such as Adenovirus 2), bovine papit)oma virus, avian sarcoma virus, cytamegatovirus, a retrovirus, hepatitis-B virus and mast preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter ar an immunogl~bulin promoter, from heat-shock promoters, and from the promoter normally associated with the target palypeptide sequence, provided such promoters are compatible with the host cell systems.
The early and late promoters of the SV40 virus are conveniently obtained as an restriction fragment that also contains the SV40 viral origin of replication.
Fiers et al" Na ure, 27:113 11978); Mulligan and Berg, fence, 2~9: 1422-1427 (1980): Pavlakis et al., Proc.
N~,~1 Acad Sci USA, 78: 7398-7402 (1981 ). The immediate early promoter of the human .'.~. , ~ . ~~. . .::. ~,....,. u,... ...w, n:' ..."' .,:....,.,. . ~['~.",.
~.' ,... '..:.. ' . .. . . ' ... ... .~ . ..
~ r. ,. . ~.~. ~~ ~ '. . .' '.i ne , -'.:.. . , : ~ , f',.'., :. ... . .. ...
~..'.~ ..'.. :. ' : ? , n,;,. ..;~ n . ~ :'. .' . ' .. . '. : . .. . .
sd.~~Jil:~~~
W~ 92/22653 PCT/US92/05126 cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment.
Greenaway et al. , Gene, 18: 355-360 (198Z). A system for expressing DNA in mairnmalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A
modification of this system is described in U.S. 4,601,978. See also Gray et al,, Nature, ~: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cetts; , Reyes et al., N ure, 297: ~
598-601 (1982) on expression of human ~-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Pr2q,. Natl. Acad.
~;i. USA, 79: 5166-5170 (1982) on expression of the human interferon,81 gene in cultured mouse and rabbit cells, and Gorman et al., Plc. N~tl. Acad. S~;i. USA, ,~Q:
6777-6781 ( 1982) 1o on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the ffious sarcoma virus long terminal repeat as a promoter. ~
(e) Enhan~er Element Camnonent ' Transcription of DNA encoding the target polypeptide of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having 2p been found 5' tLaimins et al., Per ~. Natt. Acad. Sri- USA, 7$: 993 ( 19811) and 3' (Lusky et a/..; Mol: Cell Bio., ~: 1108 t1983)t to the transcription unit, within an intron (Banerji et al., Cell, ,~: 729 f 19t~31) as well as within the coding sequence itself (Osborne et al., M I. ell Bio., 4: 1233 [1984)). Many enhancer sequences are now known from mammalian genes (globin, etastase; albumin, o-fetoprotein and insulin). Typically, however, one will use an enhancer frt~m s eukaryotic cell virus: Examples include the SV40 enhancer on the late side of the replication origin (bp '100-270), the cytpmegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, N_ature_, 297:' 17-18 11982) on enhancing elements for activation of eukaryotic promoters. The enharycer may be spliced into the vector at a position 5' or 3' to the target potypeptide DNA, but is preferably located at a site 5' from the promoter.
(f) Transcription 'termination ComQOnent Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, WO X2/22653 ~ ~ ~ ~ ~ a ~ PCTlUS92/05126 human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA.
Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the target polypepride. The 3' untranslated regions also include transcription termination sites.
Construction of suitable vectors containing one or more of the above listed components the desired coding and control sequences employs standard ligation techniques.
Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform E, coli K12 strain 294 tATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared; analyzed by restriction endonuclease digestion, and/or sequenced °lay the method of Messing e# a/., Nucleic Acids Res., ~,: 309 11981 ) or by the method of Maxam et al., Methods in Enzvmoloqv_, ,~5_: 499 11980).
Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the target polypeptide. in general; trarvsient expression involves the use of an expression vector that is able to replicate efficiently in a host cell; such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the; rapid screening of such .polypeptides for desired biological or physiological properties. Thus: transient expression systems are particularly useful in the invention for purposes of identifying analogs and variants of the target polypeptide that have target polypsptide-like activity:
~ther methods, vectors; and host cells suitable for adaptation to the synthesis of the target poiypeptide in recombinant vertebrate cell culture are described in Gething etal., N re, ' 3o ' 2."~,~: 620-625 (19811; Mantel et al.-, N re, 2 1: 40-46 [19791;
Levinson et al.; EP 117,060;
and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the target poiypeptide is pRKS tEP-pub. no. 307,247) or pSVi6B.
Seie~tsrt~ and Transformation of Host Cells v ~I ~P
Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, E. toll, Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, or Serratia marcescans.
One preferred E. toll cloning host is E. toll 294 (ATCC 31,446), although other strains such as E, cofi B, ,E. toll X1776 (ATCC 31,537), and E. toll W3110 (ATCC 27,325) are suitable.
These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteoPytic enzymes. ,A(ternatively, in vitro methods of cloning, e.g. PCR
or other nucleic acid polymerase reactions, are suitable.
1o In addition to prokaryotes, eukaryotic microbes such as filamsntous fungi or yeast are suitable hosts for target polypeptids-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms.
However, a number of other genera, species, and strains are commonly auaiiable and useful herein, such as Schizosaccharomyces pombe (Beach and Nurse, Na ur , ,2~Q: 140 (1981 ); EP
1S P139,383 published May 2, 19851, Kluyveromyces hosts (U.S. 4,943,529) such as, e.g., K.
lactis (Louvencourt et al., ~. B~~teriol., 737 (1983)), K. arragilis, K.
bulgaricus, K.
thern~otolerans, and K. marxianus, yarrowia tEP 402,2261, Pichia pastoris IEP
183,070;
Sreekrishna et al., J. Basic Microbiol., 28: 265-278 (1988)1, Candida, Trichoderma reesia fEP
244,2341, Neurospora crassa (Case et al., Proc,, Natl. Asad. Sci. USA, ~: 5259-52(3 20 (1979)1, and filamentous fungi such as, e.g, Neurospora, Penicillium, Tolypocladium [WO
91100357 published 10 January 19911, and Aspergillus hosts such as A. nidulans (l3allance etal., Biochem. Bi~phvs. Res. Commun., 112_: 284-289 (1983); Tilburn et al., en , ~6: 205-221 (1983); Yelton et al., Proc. Natl. e4cad. Sci. USA, ~1: 1470-1474 (1984)) and A. niger (Kelly and Hynes, EMBO J., 4: 475-479 (1985)x.
25 Suitable host cells for the expression of glycosylated target polypeptide are derived from multicellular organisms. Such host calls are capable of complex processing and glycosylation activities. Pn principle; any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells.
Numerous baculoviral strains and variants and corresponding permissive insect host cells from 30 hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori host cells have been identified. See, e.g., Luckow et al., B~,Ttechnologv. _6: 47-55 (1988); Miller et al., in ~n Ericlineerine. Setlow, J.K. et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature, 315: 592-594 (1985). A variety of such viral strains are publicly J .~, ~ . . , .
'~ , f ~ ~f~r . ~... .~. .... ,... . ." . ... . . . , . ,. . ..
WtJ 92!22653 ~ ~ ~ ~ ~ ~ f'CT/US92105126 available, e.g, the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cutrtres of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts.
Typically, plant cells are transfected by incubatian with certain strains of the bacterium Agrobacterium tumefaciens, which has been previously manipulated to contain the target polypeptide DNA. During incubation of the plant cell culture with A, tumefaciens, the DNA
encoding target polypeptide is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the target polypeptide DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et aO , ~. Mol. Aopl.
Gen., 1_: 561 ! 1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue: See EP 321,196 published 21 June 1989.
'"~ However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue cultural has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors 11973)1. Examples of useful mammalian host cell tines are monkey kidney CV 1 line transformed by SV40 (COS-7, ATCC CRL
1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham etal., J~Gen Virol., ~: 59 (19771): baby hamster kidney cells (BHK, ATCC CCL
10); Chinese hamster ovary cells/-D!-:FR tCHO, Urtaub and Chasin, PrQc. Natl. Acad. ci.
USA, 77: 4216 (19801): mouse settoli cells tTM4, Mather, Biol: Reorod., 23: 243-251 (19801);
monkey kidney cells tCV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587);
human cervical carcinoma cells tHELA, ATCC CCL 2): canine kidney cells (MDCK, ATCC CCL
34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells tW138, ATCC CCL
75); human liver cells tHep G2, HB 80651; mouse mammary tumor (MMT 060562, ATCC
CCL51); TRI cells (blather et ~1., Annals N:Y. Acad. Sci., ,: 44-68 (19821):
MRC 5 cells;
FS4 cells; and a human hepatoma cell line tHep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.
Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this 'invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desiied sequences.
Transfection refers to the taking up of an expression vector by a host cell whether or Wo ~zm.~~ ~ 3 U j ~ . »crms9vosizs not any COdin9 sequences are in fact eXpr~ssed. Numerous methods of transfeetion are known to the ordinarily skilled artisan, far example, CaPO, and electroporarion.
Successful transfeCtion is generally recognized whorl any indication of the oporati4n of this vector occurs within the host Cell.
Transformation means introducing DIVA into an organism so that the L7NA is replicable, either as an extrachromosbmai element or by chromosomal integrant. Depending on the host cell used, transformation iS done using Standard techniques appropriate to such oeus. The Calcium treatment employing calcium chloride, as described ire section 9.8? of Sambrook et aL, supra, is generally used for prokaryotes or other cells that contain substanGat colt-wall io bar~l8rs. tnfaction with Agrobacteritrm tVmefaciens is used for transformation of certain plant coils, as described by Shaw et al., Gene. 2~' : 315 (19831 and WO 89/Q5859 published 2S
June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.33--t 8,37 of Samhrook et arl, supra, is prefarrgd. General aspects of mammalian cell host system transforrnations have been described bY
Axa1 in U.S. .
15 '4,399.216 issued 16 August '1983. Transformations into yeast are typically carried out according to the method of Van Solingen et at-, .,,1,~t3act., .1~: 946 11977) and Hsiaa et al., Prod. Natl_ A dad. Sci...CUSAL.~: 3829 ~~ 9791. tfawaver, other methods for introducing DNA
into cells such as by nuclear injection, alflctfOp4fatiOn. or protoplast fusion may also be used.
., 20 Culturing the Hpst Cells Prokaryotic tails used.ta produce th9 target polypeptide of thisvnventtan are cu~tured in.suitable media as described gerraraliy in Sambrodk et al., ~utrra.
The mammalian host tails used to produce the target polypeptide of this invention 25 ~ may be'cultured in a variety of media. Corrzme~cially available media such as Ham's F10.
(Sigma). Minimal Essential Medium tIMEnn), Sigma), f;PMI-16~i0 tSigma), and Dulbecco's Modified iragle'$ Medium t(DMEM3, Sigma) are suitable for culturing the host celis_ in addition, any of the media,describ~d-in Harri arid Walface. Meth. Erix.; ~$: 44 (1979), Barnes and Sato, Anal;~BiOCrlem.. ~: 255 11980),; U.S. 4;7fi7;704; 4,857,866; 4.927.762: or 4.580.655:
3o Wp gpl03430; WO 87/~Da195; may be used as culture media for the host cells.
Any of these media may be supplemented as necessary with hormones andlor other growth factors (such as insulin, tr2~nsferring or epidermal growth flGtor), salts (such as sodium ohlaride, calcium, magnesium, and phosphate), buffers (such as HOPES), nucleosides (such a5 adenosine and thymidine), antibiotics (such as GentamycinT"' drug), trace elements ...
I~YO 92l22S53 ~ ~ ~ ~ ~ ~ ~ PCflfJS92/4S126 (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
The culture conditions, such as temperature, pFi, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
It is further envisioned that the target polypeptides of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control io elements introduced into cells already containing DNA encoding the target poiypeptide currently in use in the field. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA
encoding the desired target potypeptide. The control element does not encode the target ~~olypeptide of this invention, but the DNA is present in the host cell genome. One next screens for cells making the target polypeptide of this invention, or increased or decreased levels of expression, as desired:
DetPCting Gene Amnlifi,~tion/Ex_pression Gene amplification and/or expression may be measured in a sample directly; for exampld, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA-tThomas; Prod; Natl. Acad. Sci. USA, 77: 5201-5205 (1980j), dot blotting tDNA
analysis), or in situ hybridization; using an appropriately labeled probe, based on the sequences provided herein, Various labels may be employed, most commonly radioisotopes, particularly 32P~ however, other techniques may also be employed, such as using biotin-modified nucleotides'for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may b~ labeled with a wide variety of labels, such as radionuctides, fluo~escers, enzymes, or the tike. Alternatively, antibodies may be employed that can recognize specific duplexes; including DNA duplexes, RNA duplexes, and DNA-RNA
hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of dd~iex an the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, atternatively, may be measured by immunological methods, such as r~.t i~ ~ ~ ~C't/US91~45126 wo 92izz~~3 so immunohistoehgmicat staining of tissue sectibns and asset' of cell CUItUr9 Or ksadY fluids, to quantitate directly th~ expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, tYPically by dehydration and fixation, followed try reaction with labeled antlb4dies specific far the gene product coupled, where the labels are u$uafly visually detectable, such as enzymatic labels. fluorescorrt labels.
luminescent labals~
and the like. A particularly sensitive staining technique Suitable for use in the present invention is described by Hsu et a~ , ~~.' . W 7~4-X38 11980).
Antibodies useful for immunohistochemicat staining andlor assay of sample fluids may ba either monoclonal or palyclonal, and may be prepared in any mammal.
~o~weniantly, the to antibodies may be prepared ageinst,a native target~patypeptide yr against a synthetic peptide based on the 4~NA sequences, provided herein as described further in Section 4 below-D,urifir.~tinr'~ a ThB~noIyoeDtidB
. The target palypaptid~.pref~arably is racovsred fr~n the culture medium as a secreted '~olypeptide, although it also may be recovered from host call lysatss when directly expressed without a secretory signal.
WfYen the tgrgmt pQIYPePtide is expressed in a recombinant cell other than one of human .origin, the target polypepti~e is completely frees of proteins or polypeptides of human origin.
However, it i$ necessary tc purify the target polypeptide from recombinant cell proteins or Z.p. . ~ polypaptides to obtain preparations that ar,e substantially homogeneous ass to the target pol~rpeptide. As.a first step; ths-cultu~a rnedium or lysate is centrifuged to remove particulate celi~dabris. The membfene ahd soluble protein fraotians are then separated.
The target . paiypeptide maY then be purified frorriahe soluble protein fraction and from the membrane fraction of the ~ cultur~. iysate, depending on whether the target polypeptida is membrane b. The ialt~awing: , proceduies ~ are exemplary of suitable purification procedures:
fractionation.on immuriQaffiiiity ~or iori-exchange columns; ethanol precipitation; reverse phase ~. Hpl:C: , ahromatograptiy: ' an silica, ~ or on a ration exchange resin such as D>"AE;
chrom$tafocusing: 5DS-i'~GE;. ~mvinanium sulfate precipitation: gel filtration using. for example. Sephadex G~75; and.protein A 6aphsrase*columns to remove contaminants such as ;- 30 ~ IQG. ; .
~, ~ :Target palypeptide wariar<ts iii:which residues have been deleted, inserted or substituted are recovered in the.sa~np. ;fashion, taking account of any substantial changes in properties . ac~asiprved by the variation_ Few example, preparation,af a target polypaptide fusion with another,ptatein or polYpeDtide, e.g,a,bacterial or vita! antigen, facilitates purification; an *_trademark ' '' , ... '~' ~ . ' .
VlrO 92f226S3 ~ ~ ~ ~ PCT/gJS92fOS126 immur~oaffinity column containing antibody to the antigen (or containing antigen, where the target polypeptide is an antibody) can be used to adsorb the fusion.
Immunoaffinity columns such as a rabbit polyclonat anti-target polypeptide column can be employed to absorb the target polypeptide variant by binding it to at least one remaining immune epitope. A protease S inhibitor such as phenyl methyl sutfonyl fluoride (~MSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art wile appreciate that purification methods suitable for native target polypeptide may require modification to account for changes in the character of the target polypeptide or its variants upon expression in recombinant cell culture.
Covalent ~llodifica~ions of Tara~e~"F'otvDeptides Covalent modifications of target polypeptides are included within the scope of this invention. One type of covalent modification included within the scope of this invention is a target potypeptide fragment. Target polypeptide fragments having up to about 4O amino acid residues may be conveniently prepared by chemical synthesis, or by enzymatic or chemical cleavage of the full-length target polypeptide or variant target polypeptide.
Other types of covalent modifications of the target polypeptide or fragments thereof are introduced into the molecule by reacting specific amino acid residues of the target polypeptide or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.
Cysteinyl residues most commonly are reacted with a-haloacetates (and corresponding amines), such as chBe~roacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Gysteinyl residues also are derivatized by reactitm with bromotrifluoroacetone, a-bromo,8-(a-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-vitro-Z-pyridyl disulfide, methyl 2-pyridyl disutfid~, p-chloromercuribenzoate, ~-chtoromercuri-4-nitrophenol, or chloro-?-nitrobenzo-2-oxa-1,3-diazole.
Histidyt residues are derivatized by reaction with diethylpyrocarbonate at pH
A suitable s~iection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 (Stinchcc~mb et al:; Na ure, 282: 39 (19791; Kingsman et al., Gene, 7:
141 [1979D; or '.. r.;.; , ~
~r,..~ ~.5',. b . .1.~~. ' r ~1.7: . ~~i:9,.. , r . .. . ' .. . '~ . . s... .
~I Z
Tschemper et al., Gene, 10: 157 [1980]?. 'The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85: 12 [19771). The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains tATCC
20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
td) Promoter ramoonent Io Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the target polypeptide nucleic acid.
Promoters are untranslated sequences located upstream t5') to the start codon of a structural gene (generally within about 100 to 1000 bpl that control the transcription and translation of a particular nucleic acid sequence, such as that encoding the target polypeptide, to which they are ~operably linked. Such promoters typically fall into two classes, inducible and constitutive.
Inducible promoters ere promoters that initiate increased levels of transcription from DNA
under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably 2Q linked to DNA encoding the target polypeptide by removing the promoter from the source ANA
by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.
Both the native target polypeptide promoter sequence and many heterologous promoters may be used to direct amplification andlor expression of the target polypeptide DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter.
Promoters suitable for use with prokaryotic haste include the ~B-lactamase and lactose promoter systems tChang et al., _Naturg, 275: 615 [1978]; and Goeddel et al., Nature, 2 1:
544 [ 19791), alkaline phosphatase, a tryptophan ttrp) promoter system (Goeddel, Nu,~leic Aids Res., 8: 4057 119801 and ER 36,761 and hybrid promoters such as the tac promoter tdeBoer ' 3o et al., Proc. Natl. Acad: Sci. USA; ,$Q: 21-25 [19831). However, other known bacterial pr~moters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably: to ligate them to DNA encoding the target polypeptide tSiebenlist et al.Ceii; 20: 269 (1980)) using linkers or adaptors to supply any required restriction sites.
Promoters lot use in bacterial systems also generally will contain a Shine-Dalgarno tS.D.) d1'O 92122653 . ~ ~ ~ ~ ~~ ~ ~ PC.'T/US92105126 ~I 3 sequence operably linked to the DNA encoding the target polypeptide.
Suitable promoting sequences for use with yeast hosts include the promoters for 3-phasphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 2~~'5: 2073 [1980)) or other glyco)ytic -enzymes (Hess et al., J Adv. Enzyme Reg~., 7: 149 (19681; and Holland, Biochemistrv,17: 4900119781), such asenolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarbaxylase, phosphafructakinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isamerase, phasphoglucase isomerase, and glucakinase.
Other yeast promoters, which are inducib)e' promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallathianein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and gafactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,857A.
Yeast enhancers also are advantageously used with yeast promoters.
Promoter sequences are known for eukaryotes. Virtually ail eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide.
At the 3' end of mast eukaryatic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding seauence. All of these sequences are suitably inserted into mammalian expression vectors.
Target polypeptide transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (Ul~
z5 2,211,504 published S July 1989), adenovirus (such as Adenovirus 2), bovine papit)oma virus, avian sarcoma virus, cytamegatovirus, a retrovirus, hepatitis-B virus and mast preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter ar an immunogl~bulin promoter, from heat-shock promoters, and from the promoter normally associated with the target palypeptide sequence, provided such promoters are compatible with the host cell systems.
The early and late promoters of the SV40 virus are conveniently obtained as an restriction fragment that also contains the SV40 viral origin of replication.
Fiers et al" Na ure, 27:113 11978); Mulligan and Berg, fence, 2~9: 1422-1427 (1980): Pavlakis et al., Proc.
N~,~1 Acad Sci USA, 78: 7398-7402 (1981 ). The immediate early promoter of the human .'.~. , ~ . ~~. . .::. ~,....,. u,... ...w, n:' ..."' .,:....,.,. . ~['~.",.
~.' ,... '..:.. ' . .. . . ' ... ... .~ . ..
~ r. ,. . ~.~. ~~ ~ '. . .' '.i ne , -'.:.. . , : ~ , f',.'., :. ... . .. ...
~..'.~ ..'.. :. ' : ? , n,;,. ..;~ n . ~ :'. .' . ' .. . '. : . .. . .
sd.~~Jil:~~~
W~ 92/22653 PCT/US92/05126 cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment.
Greenaway et al. , Gene, 18: 355-360 (198Z). A system for expressing DNA in mairnmalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A
modification of this system is described in U.S. 4,601,978. See also Gray et al,, Nature, ~: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cetts; , Reyes et al., N ure, 297: ~
598-601 (1982) on expression of human ~-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Pr2q,. Natl. Acad.
~;i. USA, 79: 5166-5170 (1982) on expression of the human interferon,81 gene in cultured mouse and rabbit cells, and Gorman et al., Plc. N~tl. Acad. S~;i. USA, ,~Q:
6777-6781 ( 1982) 1o on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the ffious sarcoma virus long terminal repeat as a promoter. ~
(e) Enhan~er Element Camnonent ' Transcription of DNA encoding the target polypeptide of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having 2p been found 5' tLaimins et al., Per ~. Natt. Acad. Sri- USA, 7$: 993 ( 19811) and 3' (Lusky et a/..; Mol: Cell Bio., ~: 1108 t1983)t to the transcription unit, within an intron (Banerji et al., Cell, ,~: 729 f 19t~31) as well as within the coding sequence itself (Osborne et al., M I. ell Bio., 4: 1233 [1984)). Many enhancer sequences are now known from mammalian genes (globin, etastase; albumin, o-fetoprotein and insulin). Typically, however, one will use an enhancer frt~m s eukaryotic cell virus: Examples include the SV40 enhancer on the late side of the replication origin (bp '100-270), the cytpmegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, N_ature_, 297:' 17-18 11982) on enhancing elements for activation of eukaryotic promoters. The enharycer may be spliced into the vector at a position 5' or 3' to the target potypeptide DNA, but is preferably located at a site 5' from the promoter.
(f) Transcription 'termination ComQOnent Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, WO X2/22653 ~ ~ ~ ~ ~ a ~ PCTlUS92/05126 human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA.
Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the target polypepride. The 3' untranslated regions also include transcription termination sites.
Construction of suitable vectors containing one or more of the above listed components the desired coding and control sequences employs standard ligation techniques.
Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform E, coli K12 strain 294 tATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared; analyzed by restriction endonuclease digestion, and/or sequenced °lay the method of Messing e# a/., Nucleic Acids Res., ~,: 309 11981 ) or by the method of Maxam et al., Methods in Enzvmoloqv_, ,~5_: 499 11980).
Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the target polypeptide. in general; trarvsient expression involves the use of an expression vector that is able to replicate efficiently in a host cell; such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the; rapid screening of such .polypeptides for desired biological or physiological properties. Thus: transient expression systems are particularly useful in the invention for purposes of identifying analogs and variants of the target polypeptide that have target polypsptide-like activity:
~ther methods, vectors; and host cells suitable for adaptation to the synthesis of the target poiypeptide in recombinant vertebrate cell culture are described in Gething etal., N re, ' 3o ' 2."~,~: 620-625 (19811; Mantel et al.-, N re, 2 1: 40-46 [19791;
Levinson et al.; EP 117,060;
and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the target poiypeptide is pRKS tEP-pub. no. 307,247) or pSVi6B.
Seie~tsrt~ and Transformation of Host Cells v ~I ~P
Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, E. toll, Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, or Serratia marcescans.
One preferred E. toll cloning host is E. toll 294 (ATCC 31,446), although other strains such as E, cofi B, ,E. toll X1776 (ATCC 31,537), and E. toll W3110 (ATCC 27,325) are suitable.
These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteoPytic enzymes. ,A(ternatively, in vitro methods of cloning, e.g. PCR
or other nucleic acid polymerase reactions, are suitable.
1o In addition to prokaryotes, eukaryotic microbes such as filamsntous fungi or yeast are suitable hosts for target polypeptids-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms.
However, a number of other genera, species, and strains are commonly auaiiable and useful herein, such as Schizosaccharomyces pombe (Beach and Nurse, Na ur , ,2~Q: 140 (1981 ); EP
1S P139,383 published May 2, 19851, Kluyveromyces hosts (U.S. 4,943,529) such as, e.g., K.
lactis (Louvencourt et al., ~. B~~teriol., 737 (1983)), K. arragilis, K.
bulgaricus, K.
thern~otolerans, and K. marxianus, yarrowia tEP 402,2261, Pichia pastoris IEP
183,070;
Sreekrishna et al., J. Basic Microbiol., 28: 265-278 (1988)1, Candida, Trichoderma reesia fEP
244,2341, Neurospora crassa (Case et al., Proc,, Natl. Asad. Sci. USA, ~: 5259-52(3 20 (1979)1, and filamentous fungi such as, e.g, Neurospora, Penicillium, Tolypocladium [WO
91100357 published 10 January 19911, and Aspergillus hosts such as A. nidulans (l3allance etal., Biochem. Bi~phvs. Res. Commun., 112_: 284-289 (1983); Tilburn et al., en , ~6: 205-221 (1983); Yelton et al., Proc. Natl. e4cad. Sci. USA, ~1: 1470-1474 (1984)) and A. niger (Kelly and Hynes, EMBO J., 4: 475-479 (1985)x.
25 Suitable host cells for the expression of glycosylated target polypeptide are derived from multicellular organisms. Such host calls are capable of complex processing and glycosylation activities. Pn principle; any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells.
Numerous baculoviral strains and variants and corresponding permissive insect host cells from 30 hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori host cells have been identified. See, e.g., Luckow et al., B~,Ttechnologv. _6: 47-55 (1988); Miller et al., in ~n Ericlineerine. Setlow, J.K. et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature, 315: 592-594 (1985). A variety of such viral strains are publicly J .~, ~ . . , .
'~ , f ~ ~f~r . ~... .~. .... ,... . ." . ... . . . , . ,. . ..
WtJ 92!22653 ~ ~ ~ ~ ~ ~ f'CT/US92105126 available, e.g, the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cutrtres of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts.
Typically, plant cells are transfected by incubatian with certain strains of the bacterium Agrobacterium tumefaciens, which has been previously manipulated to contain the target polypeptide DNA. During incubation of the plant cell culture with A, tumefaciens, the DNA
encoding target polypeptide is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the target polypeptide DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et aO , ~. Mol. Aopl.
Gen., 1_: 561 ! 1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue: See EP 321,196 published 21 June 1989.
'"~ However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue cultural has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors 11973)1. Examples of useful mammalian host cell tines are monkey kidney CV 1 line transformed by SV40 (COS-7, ATCC CRL
1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham etal., J~Gen Virol., ~: 59 (19771): baby hamster kidney cells (BHK, ATCC CCL
10); Chinese hamster ovary cells/-D!-:FR tCHO, Urtaub and Chasin, PrQc. Natl. Acad. ci.
USA, 77: 4216 (19801): mouse settoli cells tTM4, Mather, Biol: Reorod., 23: 243-251 (19801);
monkey kidney cells tCV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587);
human cervical carcinoma cells tHELA, ATCC CCL 2): canine kidney cells (MDCK, ATCC CCL
34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells tW138, ATCC CCL
75); human liver cells tHep G2, HB 80651; mouse mammary tumor (MMT 060562, ATCC
CCL51); TRI cells (blather et ~1., Annals N:Y. Acad. Sci., ,: 44-68 (19821):
MRC 5 cells;
FS4 cells; and a human hepatoma cell line tHep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.
Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this 'invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desiied sequences.
Transfection refers to the taking up of an expression vector by a host cell whether or Wo ~zm.~~ ~ 3 U j ~ . »crms9vosizs not any COdin9 sequences are in fact eXpr~ssed. Numerous methods of transfeetion are known to the ordinarily skilled artisan, far example, CaPO, and electroporarion.
Successful transfeCtion is generally recognized whorl any indication of the oporati4n of this vector occurs within the host Cell.
Transformation means introducing DIVA into an organism so that the L7NA is replicable, either as an extrachromosbmai element or by chromosomal integrant. Depending on the host cell used, transformation iS done using Standard techniques appropriate to such oeus. The Calcium treatment employing calcium chloride, as described ire section 9.8? of Sambrook et aL, supra, is generally used for prokaryotes or other cells that contain substanGat colt-wall io bar~l8rs. tnfaction with Agrobacteritrm tVmefaciens is used for transformation of certain plant coils, as described by Shaw et al., Gene. 2~' : 315 (19831 and WO 89/Q5859 published 2S
June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.33--t 8,37 of Samhrook et arl, supra, is prefarrgd. General aspects of mammalian cell host system transforrnations have been described bY
Axa1 in U.S. .
15 '4,399.216 issued 16 August '1983. Transformations into yeast are typically carried out according to the method of Van Solingen et at-, .,,1,~t3act., .1~: 946 11977) and Hsiaa et al., Prod. Natl_ A dad. Sci...CUSAL.~: 3829 ~~ 9791. tfawaver, other methods for introducing DNA
into cells such as by nuclear injection, alflctfOp4fatiOn. or protoplast fusion may also be used.
., 20 Culturing the Hpst Cells Prokaryotic tails used.ta produce th9 target polypeptide of thisvnventtan are cu~tured in.suitable media as described gerraraliy in Sambrodk et al., ~utrra.
The mammalian host tails used to produce the target polypeptide of this invention 25 ~ may be'cultured in a variety of media. Corrzme~cially available media such as Ham's F10.
(Sigma). Minimal Essential Medium tIMEnn), Sigma), f;PMI-16~i0 tSigma), and Dulbecco's Modified iragle'$ Medium t(DMEM3, Sigma) are suitable for culturing the host celis_ in addition, any of the media,describ~d-in Harri arid Walface. Meth. Erix.; ~$: 44 (1979), Barnes and Sato, Anal;~BiOCrlem.. ~: 255 11980),; U.S. 4;7fi7;704; 4,857,866; 4.927.762: or 4.580.655:
3o Wp gpl03430; WO 87/~Da195; may be used as culture media for the host cells.
Any of these media may be supplemented as necessary with hormones andlor other growth factors (such as insulin, tr2~nsferring or epidermal growth flGtor), salts (such as sodium ohlaride, calcium, magnesium, and phosphate), buffers (such as HOPES), nucleosides (such a5 adenosine and thymidine), antibiotics (such as GentamycinT"' drug), trace elements ...
I~YO 92l22S53 ~ ~ ~ ~ ~ ~ ~ PCflfJS92/4S126 (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
The culture conditions, such as temperature, pFi, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
It is further envisioned that the target polypeptides of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control io elements introduced into cells already containing DNA encoding the target poiypeptide currently in use in the field. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA
encoding the desired target potypeptide. The control element does not encode the target ~~olypeptide of this invention, but the DNA is present in the host cell genome. One next screens for cells making the target polypeptide of this invention, or increased or decreased levels of expression, as desired:
DetPCting Gene Amnlifi,~tion/Ex_pression Gene amplification and/or expression may be measured in a sample directly; for exampld, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA-tThomas; Prod; Natl. Acad. Sci. USA, 77: 5201-5205 (1980j), dot blotting tDNA
analysis), or in situ hybridization; using an appropriately labeled probe, based on the sequences provided herein, Various labels may be employed, most commonly radioisotopes, particularly 32P~ however, other techniques may also be employed, such as using biotin-modified nucleotides'for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may b~ labeled with a wide variety of labels, such as radionuctides, fluo~escers, enzymes, or the tike. Alternatively, antibodies may be employed that can recognize specific duplexes; including DNA duplexes, RNA duplexes, and DNA-RNA
hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of dd~iex an the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, atternatively, may be measured by immunological methods, such as r~.t i~ ~ ~ ~C't/US91~45126 wo 92izz~~3 so immunohistoehgmicat staining of tissue sectibns and asset' of cell CUItUr9 Or ksadY fluids, to quantitate directly th~ expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, tYPically by dehydration and fixation, followed try reaction with labeled antlb4dies specific far the gene product coupled, where the labels are u$uafly visually detectable, such as enzymatic labels. fluorescorrt labels.
luminescent labals~
and the like. A particularly sensitive staining technique Suitable for use in the present invention is described by Hsu et a~ , ~~.' . W 7~4-X38 11980).
Antibodies useful for immunohistochemicat staining andlor assay of sample fluids may ba either monoclonal or palyclonal, and may be prepared in any mammal.
~o~weniantly, the to antibodies may be prepared ageinst,a native target~patypeptide yr against a synthetic peptide based on the 4~NA sequences, provided herein as described further in Section 4 below-D,urifir.~tinr'~ a ThB~noIyoeDtidB
. The target palypaptid~.pref~arably is racovsred fr~n the culture medium as a secreted '~olypeptide, although it also may be recovered from host call lysatss when directly expressed without a secretory signal.
WfYen the tgrgmt pQIYPePtide is expressed in a recombinant cell other than one of human .origin, the target polypepti~e is completely frees of proteins or polypeptides of human origin.
However, it i$ necessary tc purify the target polypeptide from recombinant cell proteins or Z.p. . ~ polypaptides to obtain preparations that ar,e substantially homogeneous ass to the target pol~rpeptide. As.a first step; ths-cultu~a rnedium or lysate is centrifuged to remove particulate celi~dabris. The membfene ahd soluble protein fraotians are then separated.
The target . paiypeptide maY then be purified frorriahe soluble protein fraction and from the membrane fraction of the ~ cultur~. iysate, depending on whether the target polypeptida is membrane b. The ialt~awing: , proceduies ~ are exemplary of suitable purification procedures:
fractionation.on immuriQaffiiiity ~or iori-exchange columns; ethanol precipitation; reverse phase ~. Hpl:C: , ahromatograptiy: ' an silica, ~ or on a ration exchange resin such as D>"AE;
chrom$tafocusing: 5DS-i'~GE;. ~mvinanium sulfate precipitation: gel filtration using. for example. Sephadex G~75; and.protein A 6aphsrase*columns to remove contaminants such as ;- 30 ~ IQG. ; .
~, ~ :Target palypeptide wariar<ts iii:which residues have been deleted, inserted or substituted are recovered in the.sa~np. ;fashion, taking account of any substantial changes in properties . ac~asiprved by the variation_ Few example, preparation,af a target polypaptide fusion with another,ptatein or polYpeDtide, e.g,a,bacterial or vita! antigen, facilitates purification; an *_trademark ' '' , ... '~' ~ . ' .
VlrO 92f226S3 ~ ~ ~ ~ PCT/gJS92fOS126 immur~oaffinity column containing antibody to the antigen (or containing antigen, where the target polypeptide is an antibody) can be used to adsorb the fusion.
Immunoaffinity columns such as a rabbit polyclonat anti-target polypeptide column can be employed to absorb the target polypeptide variant by binding it to at least one remaining immune epitope. A protease S inhibitor such as phenyl methyl sutfonyl fluoride (~MSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art wile appreciate that purification methods suitable for native target polypeptide may require modification to account for changes in the character of the target polypeptide or its variants upon expression in recombinant cell culture.
Covalent ~llodifica~ions of Tara~e~"F'otvDeptides Covalent modifications of target polypeptides are included within the scope of this invention. One type of covalent modification included within the scope of this invention is a target potypeptide fragment. Target polypeptide fragments having up to about 4O amino acid residues may be conveniently prepared by chemical synthesis, or by enzymatic or chemical cleavage of the full-length target polypeptide or variant target polypeptide.
Other types of covalent modifications of the target polypeptide or fragments thereof are introduced into the molecule by reacting specific amino acid residues of the target polypeptide or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.
Cysteinyl residues most commonly are reacted with a-haloacetates (and corresponding amines), such as chBe~roacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Gysteinyl residues also are derivatized by reactitm with bromotrifluoroacetone, a-bromo,8-(a-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-vitro-Z-pyridyl disulfide, methyl 2-pyridyl disutfid~, p-chloromercuribenzoate, ~-chtoromercuri-4-nitrophenol, or chloro-?-nitrobenzo-2-oxa-1,3-diazole.
Histidyt residues are derivatized by reaction with diethylpyrocarbonate at pH
5.5-?.0 because this agent is relatively specific for the histidyl side chain. pare-bromophenacyl 3,0 bromide also is useful; the reaction is preferably performed in 0.1 M
sodium cacodytate at pH
fiØ
bysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. C~erivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing Q-amino-containing residues include . ... . .., ~'~~~~ . , :~ .'~~ . o:~:' : ;. r ' , . ~ . ' ~. _ : _~ . , ~.,,.
.. ,,~._:.. . ~.;:. . .
W~ 92/22653 ~ ~ ~ ~ ~ ,'~ ~ )PC°A'/US92/05r26 ,..~ .
Z
imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal;
chloroborohydride;
trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues are modified by reaction with one or several conventional reagents, 5 among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin.
Derivatization of arginine residues requiros that the reactian be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
Th~ specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using'z51 or'3'I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.
Carboxyl side groups taspartyl or glutamyl) are selectively modified by reaction with carbodiimides tR'-N = C = N-R'), where R and R' are different alkyl groups, sash as 1-cyclohexyt-3-(2-morpholinyl-4-ethyl) carbadiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutarninyl residues by reaction with ammonium ions., Derivatization with bifunctional agents is useful for crosslinking target palypeptide to a water-insoluble support matrix ar surface for use in the method for purifying anti-target paiyp~ptids antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1,1-bisidiazoacetyl)-2-phenylethane, glutaraldehyd~, N-hydroxysuccinimide esters, for example, esters with ~-azidosalicylic acid; homobifunctional imidaesters, including disuccinimidyl esters such as 3,3'-dithicrbistsuccinimidylpropionate), and bifunctional maleimides such as bis-N-rnaleimido-1,8-octane. Derivatizing agents such as methyl-3-tIp-azidophenyl)dithiolpropioimi-date yield photoactivatable intermediates that are capable of farming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. 3,969,28?;
3,691,016;
4,195,128; 4,247,642; 4,229.53?; and 4,330,440 are employed far protein immobilization.
Glutaminyl and asp~araginyl residues are frequent6y deamidated to the carresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this inventian.
.,''VO92/22653 ~ ~ ~ ~ P~;f/f.JS92/05i26 Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of Beryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains tT.E. Creighton, Pr ins: Structure and Molecular Pranerj~i, es, W.H. Freeman & Co., San Francisco, pp. 79-86 f 1983)), acetylation of th~ N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the target polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
By altering is meant deleting one or more carbohydrate moieties found in the native target polypeptide, andlor adding one or more glycosylation sites that are not present in the native target pofypeptide.
Clycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X
is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to th~ asparagir~e side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-finked glycosylation refers to the attadhment of one of the sugars N-acetylgalactosamine, galactose, or xytose; to a hydroxyamino acid, most commonly serine or threonine, although hydroxyproline or 5-hydroxylysine may also' be used.
Addition of g[ycosylation sites to the target polypeptide is conveniently accomplished by altering the amino acid sequence such hat it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of; or substitution by, one or more serine or threonine residues to the native target s''' polypeptide sequence tfor O-linked glycosylation sites?. Fat ease, the target polypeptide amino acid sequencb is prgferabl~ altered throughchanges at the DNA level, particularly by mutating the DNA encodieg the target polypeptide at p~esalected bases such that codons are generated than will translate into the desired amino acids. The DNA mutationtsl may be made using methods described above under the heading of "Amino Acid Sequenc8 Variants of Target 'Potypeptide".
Another means of ' increasing the number of carbohydrate moieties on the target polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosyiation capabilities for N- and O- linked glycosylation.
Depending on the coupling mode used, the sugartsf may be attached to ta? arginine and histidine, tb? free ~i'T..,..,.',~ , ~ ,' a :.~... .. ~ .-,. ~ ,:.': .. :..,. .::, ~ . . ~. ~.
.'.~~. ~. ,.:. ;'; _, . ,~. ..' . .,'.,,.'~~. , wo ~z>zz~s3 2 ~. ~ ~ ~ ~ ~ FCT/US9zl05126 carboxyl groups, tc) free sulfhydryl groups such as those of cysteine, td) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, te) aromatic residues such as those of phenytalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine.
These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston (CF1C_ Crit Rev Biochem., pp. 259-306 (1981]).
Removal of carbohydrate moieties present on the native target polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or' ail sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosytation is described by Hakimuddin et al. (Arch Biochem. Bionhys., 259:52 (198?]) and by Edge et al. (Anal. Biachem., 11 :131 ( 19811). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-giycosidases as described by Thatakura et al. (fVleth. Enzvmol., 18:350 (1987]).
Glycosylation at potential ~lycosbtation sites may be prevented by the use of the compound tunicamycin as describ~d by Duskin et al. (J. Bial. them.. 2_x:3105 ( 19821).
Tunicamycin blocks the formation of protein-N-glycoside linkages.
Another type of covalent modification of the target polypeptide comprises linking the target poiypeptide to various nonproteinaceous polymers, e.g. polyethylene glycol, _ polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S.
4,640,835;
4:496,689; 4,301;144; 4;670,417; 4,791,192 ar 4,179,337.
The target polypeptide also may, be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization Ifor example, hydroxymethylcellulase o~ getatir~-microcapsules and poly-(methytmethacylateD
microcapsufes, ~S ' respectively), in colloidal drug delivery systems tfor example, tiposomes, albumin microspheres, microemutsionsnano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Reminaton's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., (1980).
Target polypeptide preparations are also useful in generating antibodies, for screening #or binding partners, as standards in assays for the target polypeptide te.g.
by labeling the target polypeptide for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptar assay), in affinity purification techniques, and in competitive-type receptor binding' assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.
Since it is often difficult to predict in advance the characteristics of a variant target potypeptide, it will be appreciated that some screening of the recovered variant will be needed ~~~~,a : .:F: ;. :' .. .: . .. : . ~ w.r: . ..:.; . ",; , ... ..,, ::; . : ;;
: .
~~t..
,.,~ WO 92/22653 ~ ~ ~ ~ ~ ~ PL'I'/US92/OS126 S S' to select the optimal variant. For example, a change in the immunologicai character of the target polypeptide molecule, such as affinity for a given antigen or antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its activity by comparison to the activity observed for the target polypeptide in the same assay. Other patential modifications of protein or palypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, stability in recombinant calf culture or in plasma, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.
la Diac~na_~ i~,~nd Relatee~~l~,g_s of the Anti odies The antibodies of this invention are useful in diagnostic assays for antigen expression in specific cells or tissues. The antibodies are detectably labeled andJor are immobilized on an insoluble matrix.
The antibodies of this invention find further use far the affinity purification of the - 15 antigen from recombinant cell cult~rre or natural sources. Suitable diagnostic assays for the antigen and its antibodies depend on the particular antigen or antibody.
Generally, such assays include competitive and sandwich assays, and steric inhibition assays.
Competitive and sandwich methods employ a phase-separation step as an integral part of the method white steric inhibition assays are conducted in a single reaction mixture.
Fundamentally, the same 20 procedures are used for the assay of the antigen and for substances that bind the antigen, although certain methods wilt be fav~red depending upon the molecular weight of the substance being assayed: ' Therefore, the substance to be tested is referred to herein as an ar~alyte, irrespective of its status otherwise as an antigen or antibody, and proteins,$hat bind to the analyte, are denominated binding partners, whether they be antibodies, cell surface 25 ' receptors, or antigens.
Analyxical methods far he antigen or its antibodies all use one or more of the following reagents: labeled anaiyte analogue; immobilized ana)yte analogue, labeled binding partner, immobilized bindiryg partner and steric conjugates. The labeled reagents also are known as "tracers."
The label used _tand this is also useful to label antigen nucleic acid for use as a probe) is any detectable functionality 'that dogs not interfere with the binding of ana)yte and its binding partner. Numerous labels are known for use in immunoassay, examples including moieties that gay be detected directly, such as fluorochrome, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized r?,~r k , ., ,.. ,. . ',.
PCT/ US92/0512b W~ 92/22653 5~
to be detected. Examples of such labels include the radioisotopes 3ZP, '4C, '25i, 3H, and '3'I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterbal luciferase tU.S. Pat. No. 4,737,456);.luciferin, 2,3-dihydrophthalazinedianes, horseradish peroxidase 5' tHRP), alkaline phasphatase, ~-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose axidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or micraperoxidase, biotin/avidin, spin labels, bacterrophage labels, stable free radicals, and the like.
Conventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbadiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiiuminescent, and enzyme labels. See, for example, U.S.
Pat. Nos. 3,940,475 tfluarimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); L?avid etal., Biach~mistry, 1~: 1014-1021 (1974); Pain etal., ~
Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem. and Cvtochem., ~0: 407-412 (1982).
Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.
The cpnjugation of such label; including the enzymes, to the antibody is a standard manipulative procedure far one of ordinary skill in immunoassay techniques.
See, for example, O'Sultivan et a/., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Imrnunoassay." in Methods in Enzvmolaav, ed. J.J. Langone and H. Van Vunakis, Vol.
73 (Academic Press, New: Yprk; New York, 1981 ), pp. 147-166. Such bonding methods are suitable for use with the antibodies and polypeptides of this invention.
Immobilization of reagents is required for certain assay methods.
Immobilization entails separating the binding partner from any anatyte that remains Eras in solution.
This conventionally is accomplished by either insoiubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich etal.., U.S. 3,710,760), by covalent coupling (for example, using glutaraldehyde cross-finking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.
Other assay methods, known as competitive or sandwich assays, are well established and widely used in thd commercial diagnostics industry.
Competitive assays rely on the ability of a tracer analogue to compete with the test sample anaiyte for a limited number of binding sites on a common binding partner. The binding ry~,:~,;~.:v" ,. . ., ,.., wo ~2i226~~ ~ ~. ~ ~ ~ J ~~ ~orius~2i~5~z6 S~
partner generally is insolubilized before or after the competition and then the tracer and analyte bound Lo the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsoiubilized? or by centrifuging (where the binding partner was precipitated after the competitive reactiony.
The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA
systems when enzymes are used as the detectable markers. ' to Another species of competitive assay, called a "homogeneous" assay, doss not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, the antigen or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase.
Conjugates are selected for use with antibody so that binding of the antibody inhibits or potentiates the enzyme activity of the label. This method per se is widely practiced under the name of EMIT.
Steric conjugates are used in steric hindrance methods for homogeneous assay.
These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten substantially is unable to bind the conjugate at the same 2o time as anti-analyte. Under this assay procedure the analyte present in the test sample wilt bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore.
., Sandwich assays particularly are useful for the determination of antigen or antibodies.
In sequential sandwich assays an immobilized binding partner is used to adsorb test sample analyte, the tdst sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound nnaterial is then separated from residual tracer.
The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous'° sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-antigen monoclonal antibody as one antibody and a polyclonal anti-antigen antibody ass he other is,useful in testing samples for particular antigen activity.
The foregoing aye merely exemplary diagnostic assays for the import and humanized antibodies of this inventibn. other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassays described -_._ ~ ~'.~ ~ 1 S.f, Y.mrr v.,-r.r WO 9Z/~2653 S$
above.
~mmunotoxins This invention is also directed to immunochamica) derivatives of the antibodies of this invention such as immunatoxins fconjug3tes at the antibody and a cytotoxic moiety).
A_rrtfbodies which carry the apprapriato effector functit5ns, such as with-their constant domains, are also used to induce lysis;thirough the natural complement process, and to interact with antibody dependent cytotoxic cells normally present-For example, purified, sterile filtered antibodies are optionally conjugated to a 1a cytotoxin such as ricin for use in AIDS therapy. 'The methods of this invention, for example, era 'suitable for obtaining humanized antibodies for use as immunotoxins for use in AIDS therapy, The cytotoxic moiety. of the immunatoxin may be a aYtotoxic drug or an enzymaticaNy active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment Qt such a toxin. i:nzymatically active toxins and fragments thereof used are diphtheria A chain, nonbinding active fragments of diprithoria~ .toxin. exotoxin A drain (from Psetrrlamo~as aemginosa), ~ricin A chain, abrin A chain, modaccin A chain, alpha-s9rcin, Aleurites fordii proteins,.dianthin fxoteins;.~hyiclacaamericana proteins iF'APi; PAPI1, and PAF-S), momordica ~.: zo charantia inhibitor, curcirr. . crotin, sapaonaria afficinalis inhibitor, gelonin, mitogellin, restrictocin, phor<omycin. enomycin and the tricothecenes. In another embodiment, the antibod'ses ire conjugated to small molecule anticancer drugs such as cis-platin or 5FU.
. Conjugates of the monoclonal antibody and'such cYtotoxic moieties are made using a variety of bifunotional protein coupling agents. Examples of such reagents are SPDP, IT , bifunctional derivatives af. imidoesters : such . as dimethyl ~ adipimidate HCI, active esters such as . ~ disuccinimidyl ,suberate, aldehydes.such as ~tutaraidehyde. his-azido compounds such as bis fp-azidobenzoyll hekanediamina, bis-diaz4riium-derivatives such as his- tp-diazonium4enzoyll w ~ethylenediamine, .diisocyanates such, as tolylene 2,6-diisocyanate and bis-active fluorine compounds such ~as l,~-difluoro 2;4-dinitrobenzer~e. The (YSing portion of s toxin may be joined to the Fob fragment of the antib6dies.
Imrrmnoioxins can be cnada gin, a variety of ways; as discussed heroin.
Gommoniy . .known crosslinking reager~ta can.be used~to yield stable conjugates.
Advantageously. rE'~onocional antibodies specifically binding the domain of the antigen which is exposed tiry the infected cell 'surface, are con9ugated to ricin A
chain. Most . VVO 92/22653 2 ~ ~ ~ 0 ~ ~ PCT/US92/OS1Z6 advantageously the ricin A chain is deglycosylated and produced through recombinant means.
An advantageous method of making the ricin immunotoxin is described in Vitetta et al., Science 238:1D98 11987).
When used to kill infected human cells in vitro for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a concentration of at least about 10 nM.
The formulation and mode of administration for in vitro use are not critical.
Aqueous formulations that are compatible with the culture or perfusion medium will normally be used.
Cytotoxicity may be read by conventional techniques.
Cytotoxic radiopharmaceuticals for treating infected cells may be made by conjugating radioactive isotopes te.g. l, Y, Pr) to the antibodies. Advantageously alpha particle-emitting isotopes are used. The term 'cytotoxic moiety" as used herein is intended to include such isotopes.
in a preferred embodiment, ricin A chain is deglycosylated or produced without oligosaccharides, to decrease its clearance by irrelevant clearance mechanisms (e.g., the liver).
in another embodiment. whale ricin tA chain plus B chain) is conjugated to antibody if the gatactose binding property of B-chain can be blocked t"blocked ricin").
In a further embodiment toxin-conjugates are made with Fab or Ftab')2 fragments.
Because of their relatively small size these fragments can better penetrate tissue to reach infected cells. -In another embodiment, fusogenic liposomes are filled with a cytotoxic drug and the liposom~s are coated with antibodies specifically binding the particular antigen.
Antibody Denenden~ Cellular Cvtotoxicitv ".w/
Certain aspects of this invention involve antibodies which are ta) directed against a particular antigen acrd tb) belong to a subclass or i~otype that is capable of mediating the lysis of cells to which the antibody molecule 'binds. IVlore specifically, these antibodies should belong to a subclass or isotype than upon c~mplexing with cell surface proteins, activates serum complement and/or mediates antibody dependent cellular cytotoxicity tADCC) by activating effector cells such as natural kilter cells or macrophages.
90 Bioto~ical activity of antibodies is known to be determined, to a large extent, by the constant domains or Fd region of the antibody molecule tUananue and t3enacerraf, Textbook of Jmmuno%gy; 2nd i=dition, Williams & Wilkinsp. 218 11984)). This includes their ability to activate complement and to mediate antibody-dependent cellular cytotoxicity tADCC) as effected by leukocytes. Antibodies of different classes and subclasses differ in this respect, wo ~ziza~s3 ~ ~. ~ ~~ ~ ~~ ~ ~crius9a/asiab coo as do antibodies from the same subclass but different species; according to the present invention, antibodies of, those classes having the desired biological activity are prepared.
Preparation of these antibodies involves the selection of antibody constant domains are their incorporation in the humanized antibody by known technique. For example, mouse immunoglobulins of the IgG3 and IgG2a class are capable of activating serum complement upon binding to the target cells which express the cognate antigen, and therefore humanized antibodies which incorporate IgG~ and IgG2a effector functions are desirable for certain therapeutic applications.
In general, mouse antibodies of the IgG2a and IgG3 subclass and occasionally IgG 1 can to mediate ADCC, and antibodies of the IgG3, IgG2a, and IgM subclasses bind and activate serum complement. Complement activation generally requires the binding of at least two IgG
molecules in close proximity on the target cell. However, the binding of only one IgM molecule activates serum complement.
The ability of any particular antibody to mediate lysis of the target cell by complement activation and/or ADCC can be assayed. The cells of interest are grown and labeled in vitro;
the antibody is added to the cell culture in combination with either serum complement or immune cells which may be activated by the antigen antibody complexes.
Cytolysis of the target cells is detected by the release of label from the lysed cells. 6n fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells. The antibody that is capable of activating complement or mediating ADCC in the in vitro test can then be used therapeutically in that particular patient.
This invention specifically encompasses consensus Fc antibody domains prepared and used according to the teachings of this invention.
-a Thera,~eutic and~ther Uses of the Antibodies When used in ~ivo for therapy, tha antibodies of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect?. They will normally be administered parenterally. The dose and dosage regimen will depend upon the degree of the infecti~n, the characteristics of the particular antibody or 3o immunotoxin used, e.g., its therapeutic index, the patient, and the patient's history.
Advantageously the antibody or immunotoxin is administered continuously over a period of 1 ~2 weeks, intravenously to treat cells in the vasculature and subcutaneously and intraperitoneally to treat regional lymph nodes. Optionally, the administration is made during the course of adjunct therapy such as combined cycles of radiation, chemotherapeutic treatment, or . W4 92/22653 ~ ~ ~ ~ ~ ~ v PC'd'lUS92>05126 (0 4 administration of tumor necrosis factor, interferon or other cytoprotective or immunomodulatory agent.
For parentera! administration the antibodies will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5~~
human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate can aBso be used. Liposomes shay be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
to The antibodies will typically be farmulated in such vehicles at concentrations of about 1 mgiml to 10 mgiml.
Use of lgAl1 antibodies may be preferred for certain applications, however !gG
molecules by being smaller may be more abte than IgM molecules to localize to certain types of infected cells.
There is evidence that complement activation in vivo~leads to a variety of biological effects, including the induction of an inflammatory response and the activation of macrophages tUananue and l3enecerraf, Textbook of lmmunalogy, 2nd Edition, Williams &
Wilkins, p. 218 (1984)). The increased vasodilation accompanying inflammation may increase the ability of various agents to localize in infected cells. Therefore, antigen-antibody combinations of the . 20 type specified by this invention can b~ used therapeutically in many ways. Additionally, purified antigens tHakomori, Ann. Rev, lmmunol. 2:103 (1984)) or anti-idiotypic antibodies (Nepom et aP., Proc. Nat/. Acad. Sci. 81:2864 (1985); Koprowski et al., Proc.
lUatl. Acad. Sci.
81:216 ( 1984)) relating to such antigens could be used to induce an active immune response in human patients. Such a response includes the formation of antibodies capable of activating human complement and mediating ADCC and by such mechanisms cause infected cell destruction.
Optionally, the antibodies of this invention are useful in passively immunizing patients, as exemplified by the administration of humanized anti-HlV antibodies.
The antibody compositions used in therapy are formulated and dosages established in 3o a fashion consistent with good medics! practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the composition, the method of administration and other factors known to practitioners. The antibody compositions are prepared for administration according to the description of preparation of polypeptides for administration, infra.
W~ 92/22653 ~ ~ ~ ~ ~ j ~ PCTlUS92/0512t~
(0 2 Deposit of Materials As described above, cultures of the muMAb4D5 have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA
(ATCC).
This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest.Tr~aty). This assures maintenance of viable cultures for 30 years from the date of the deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures l0 to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 38 USC ~ 122 and the Commissioner's rules pursuant thereto (including 37 CFR ~ 1.12 with particular reference to 886 OG 638).
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPCD
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture.
Availability of the deposited strain is not to be construed as a license to practice the invention in contravention ,~ s of the rights granted under the authority of any government in accordance with its patent Isws.
The foregoing written spepification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiments are intended to illustrate only certain aspects of the invention and any constructs that are functionally equivalent are within the ,, scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode (hereof, nor is it to be construed as limiting the scope of the Maims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those ~.,:..;, ,. ..; ~ ..-.. ...,;..:.;: .,.:.: . ;;. :... .....:".,. .. ._ .. .
~~.~~f~ )~
..,W~ 92/22653 4 ~ PC~'/USl2/05126 skilled in the art from the foregoing description and fall within the scope of the appended claims.
It is understood that the application of the teachings of the present invention to a specific problem or situation will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation, use, and manufacture appear below, but should not be construed to limit the invention.
EXAMPLES
EXAMPLE 1. HUMANIZATION OF muMAb4D5 Here we report the chimerization of muMAb4D5 tchMAb4D5> and the rapid and simultaneous humanization of heavy tVM) and light tV~) chain variable region genes using a novel "gene conversion mutagenesis" strategy. Eight humanized variants thuMAb4D5) were constructed to probe the importance of several FR residues identified by our molecular modeling or previously proposed to be critical to the conformation of particular CDRs tees Chothia, C. & Lesk, A. M., J. Mol. Biol. '196:901-917 (19871; Chothia, C. et al., Nature 342:877-883 11989); Tramontano, A. et al., J Mol. 6~ial. 215:175-182 11990)).
Efficient 2p transient expression of humanized variants in non-myeloma cells allowed us to rapidly inv~stigate the relationship between binding affinity for p185HEgz ECD.and anti-proliferative activity against p185HER2 ~verexpressing carcinoma cells.
flliATERIALS and tUIETHOD9 ,;
Cloning of ilariobte l~egi~ro Genes: The muMAb4D5 VH and VL genes were isolated by potymerase chain reaction (PCR) arnptific~tion of mRNA from the corresponding hybridoma iFer~dly, ~. M. et al., Cancor Res. 5~:1550-1558 11990)) as described by Orlandi et al.
tOrtandi; R. et ~P.; Proc: '!Nato Acid. Sci. LISA 86:3833-3837 11989)). Amino terminal sequencing of muMA64D5 V~ and V~ was used to design the sense strand PCR
primers, whereas the anti-sense PCR primers were based upon consensus sequences of murine framework residues dOrtandi, R. et al., Proc. lUarl. Acad. Sci. USA 86:3833-3837 11989);
Kabat, E. A.' et al., Sequences'of ProPeins of Ira~murrologica! Interest tPlational Institutes of Health, 8ethesda; MD; 1987)) incorporating restriction sites for directional cloning shown by underlining ahd listed after the sequences: V L sense, 5'-TCCGATATCCAGCTGACCCAG~'CTCCA-3' tSEQ. 1D NO. 7), EcoRV; VL anti-sense, 5'-Wo 9zn~s53 ~ ~, ~ ~ ~ ~ ~ P~G'1'/US92/0512b GT'iTGATCTCCAGCTT~~t~iSCDCCGAA-S' (SEO. IQ NO. 8). Asp77 B; vH sense, 5'-AGGTSMARSe.TSAGTGWGGw3' ISEa~ iQ NO- 9f~ Pstl and YH anti-sense, 5'-TGAGGAGAC~~.GTGG~'CCCTTGGCCCCAG-3' (SECZ. ID NO. 10), BstEll; where H =
A or C or T. 8 - C or G. D = A or G or T, M ~ A ar C. R = A or G and W = A or T. The PCR products were cloned iota pli'C11,9 tVielra..f~ & Messing. J., Methods En~ymol. '153:3-1.1 , (19871) and five cibnes for each variakFla domain sequenced bY the dideoxy method (5anger.
F. ei .al., Prac. Natl. Aced. Saj. LISA 74:6463-5487 ! ~ 977)).
Molecular Modelling. Modats for muMAb4D5 VH and VL domains were c~structed separately from oonsensws coordinates based upon seven Fob structures from the Brookhavan 1o protein dad bank (entries 1 F~~ 2RHt~, 2MCP. 31=AB, 1 FBJ, 2HFL and 1 REI).
The pab fragment KCAL lMarquart, M. et al., J. Mal. Bial. '141:3$9-391 (1980)) was first Chosen as a template for V~ and VH domains and additional structures were then superimposed upon this structure using their main chain atom coordinates 11NSIGH~'iprogram. Biosym Techwlogies).
The distance from the template Catv the analvgaus Ca in each of thg superirnposad structures 15. was calculated for each residue position. If alt for nearly all? Ccr-Ca distances far a given residue were 5 1 R, then that position .was included in the aansensus structure. In most cases the ~-sheet framework.rssidues satisfied tflese criteria whereas the CDR loops did not. For each of these selected 'rasidu'as the average coordinates fvr individual N, Ca. C, O and CB
atoms were calGUl~ted and then corrected far resultant deviations from non-standard bond ' geormetry >;y 50 cycles of energy minimization using the DISCOVER"program (Biosym Technologies) .with the yAM,B>'Rk:fotcefield (Weiner, s. J. et al., J. Amer.
Chem. 5oc.
106:766-?84 (1984)) and Cccoordir~ates fixed. The side chains of highly conserved residues, ' , such as the disul8de-bridseii b~lstdine reaidues~ ware then incorporated into the .resultant consensus structure. . Next the saqu~ncBS of muMAb4D6 V~ and VH ware incorporated 5sxartin~ with the CDR fes'idues and using the tabulations of CDR
conformations from Chotnia ex a!: (Chothia:.C~.'et al,, IVatLre' 342:8?7-883 (1989)1 as a guide. Side-chain conformations - were chosen on.the~ basis.of I=ab crystal structures, rotemer libraries (Ponder, ,!. W. ~ Richards.
F. nn,; .1.; Mah viol 193:?75-.791 (19$7)i and pac.kir~g considerations. Since VR-CDR3 could not be assigned a definite #ackbone; conformation from these criteria, two modals were created '~o ~ frpm a search of similar,sized leaps using the INSIGHT program. A third rnadal was derived using packing and solvent expusurd considerations. Each modal was then subjected to 5000 cybles of energy minimization: , In humanizing mulVIAb4D~.''aanssnsUS human sequences were first derived from the mdst~abundant sutxlasses in. he sequence caniliilation of Kabat et al. (Kabat.
E. A. et al_, *-trademarks W4 92122653 ~ ~ ~ J ~ J ~ PC1'/LJ592/0512G
!~ S
SeQuences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)), namely V~ x subgroup I and VH group III, and a molecular model generated for these sequences using the methods described above. A structure for huMAb4D5 was created by transferring the CDRs from the muMAb4D5 model into the consensus human structure. All huMAb4D5 variants contain human replacements of muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Sequences of Proteins of lmmuno%gicallnterest (National Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C. & Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)):
VL-CDR1 K24R, VL-CDR2 R54L and VL-CDR2 TSfS. Differences between muMAb4D5 and l0 the human consensus framework residues (Fig. 1 ) were individually modeled to investigate their possible influence on CDR conformation and/or binding to the p185HER2 ECD.
Construction of Chimeric Genes. Genes encoding chMAb4D5 light and heavy chains were separately assembled in previously described phagemid vectors containing the human cytomegalovirus enhancer and promoter, a 5' intron and SV40 polyadenylation signal (Gorman, 1~ C. M, et al., DNA & Prot. Engin. Tech. 2:3-10 (1990)). Briefly, gene segments encoding muMAb4D5 VL (Fig. 1 A) and REI human K1 light chain CL (Palm, W. & Hilschmann, N., Z.
Physiol. Chem. 356:167-191 (1975)~ were precisely joined as were genes for muMAb4D5 VH
(Fig. i B) and human y1 constant region (Capon, D. J. et al., Nature 337:525-531 (1989)) by simple subcloning (Boyle, A.; in Current Protocols in Molecular Biology, Chapter 3 (F. A.
20 Ausubel et al., eds., Greene Publishing & Wiley-Interscience, New York, 1990)) and site-directed mutagenesis (Carter; P., in Mutagenesis: A Practical Approach, Chapter 1 (IRL
Press, Oxford, UK 1991 )). The y1 isotype was chosen as it has been found to be the preferred human isotype for supporting ADCC and complement dependent cytotoxicity using matched sets of chimeric EBruggemanrv, M. et al.; J. Exp. Med. 166:1351-1361 (1987)) or humanized 25 antibodies (Riechmann; L. eral.; Nature 332:32-327 (1988)). The PCR-generated VL and VH
fragments (Fig. 1 ) were subsequently mutagenized so that they faithfully represent the soquence of muMAb4D5 determined at the protein level: VH Q1 E, VL V104L and tvariants are denoted by the -amino acid residue and number followed by the replacement amino acid). The human yl constant regions are identical to those reported by Ellison et al.
30 (Ellison, J. W. et al., Nucleic Acids Res. 13:4071-4079 (1982)) except for the mutations E359D and M361 L (Eu numbering, as in Kabat, E. A. et al., Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) which we installed to convert the antibody from the naturally rare A allotype vo the much more common non-A
allotypd (Tramont~no, A. et al., J. Mol: Biol. 215:175-182 (1990)). This was an attempt to Vd~ 92!22653 ~ ~ U ~ ~ J ~ PCIf/US92/OS126 reduce the risk of anti-allotype antibodies interfering with therapy.
Construction of Humanized Genes. Genes encoding chMAb4D5 light chain and heavy chain Fd fragment (VH and CH1 domains) were subcloned together into pUC119 (Vieira, J. &
Messing, J., Methods Enzymoi. ''53:3-11 (1987)) to create pAK1 and simultaneously S humanized in a single step rtFig. 2). Briefly, sets of 6 contiguous oligonucleotides were designed to humanize VM and V~ (Fig. 1 ). These oligonucleatides are 28 to 83 nucleotides in length, contain zero to 19 mismatches to the marine antibody template and are constrained to have 8 or 9 perfectly matched residues at each end to promote efficient annealing and iigation of adjacent oligonucleotides. The sets of VH and VL hurnanization oligonucleotides (5 pmol each) wars phosphorylated with either ATP or y-32P-ATP (Carter, P.
Methods Enzymol.
154:382-403 (1987)) and separately annealed with 3.7 pmol of pAK1 template in 40,u1 10 mM Tris-HCl (pH 8.0) and 10 mM MgCl2 by cooling from 100 ~C to room temperature over 30 min. The annealed oligonucleatides were joined by incubation with T4 DNA
ligase ( 12 units; New England Biolabs) in the prqsence of 2 NI 5 mM ATP and 2 /el 0.1 M
DTT for 10 min at 14 ~C. After electrophoresis on a 6°!° acrylamide sequencing get the assembled oligonucleotides were looted by autoradiography and recovered by electroelution. The assembled oligonucleotides ( -- 0.3 pmol each) were simultaneously annealed to 0.15 pmol single-stranded deoxyuridine-containing pAK1 prepared according to Kunkel et al. (Kunkel, T.
A. et aL, Methods Enzymol. 154:367-382 (1987)) in 10 pl 40 mM Tris-HCI (pH
7.5) and ~16 24 mM MgCl2 as above. He'teroduplex DNA was constructed by extending the primers with T7 DNA polymerase and transformed into E, coil 8MH 71-18 mutt as previously described (Carter; P., in Mutagenesis: A Practice! Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )).
The resultant phag~iwid DNA pool was enriched first for huVL by restriction purification using 4_~
Xhol and then for huV~ key restriction selection using Stul as described in Carter, P., in Mutagene5is: A Practical Approach, Chapter 1 tIRL Press, Oxford, UK 1991 );
and in Wells, J. A. et al , Phil: Traps: R. Soc. Lond A 317:415-423 41986). Resultant clones containing both huVL and huVH genes were identified by nucleotide sequencing tSanger, F.
et al., Proc.
IVatl, aAcad. Sci. US~I 74:5463-5467 (19771) and designated pAK2. Additional humanize variants were generated by site-directed mutagenesis (Carter, P., in Mutagenesis: A Practice!
Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )). The muMAb4D5 VL and VH
gene sbgme~nts in the transient expression vectors described above were then precisely replaced with their humanized versions.
Exlaression and Purification of IUlAb4D5 Variants. Appropriate MAb4D5 light and heavy chain cDNA expression vectors were co-transfected into an adenovirus transformed human .,.WO 92/22b53 ~ ~ ~ ~ ~ ~ ~ PGTIU~a9214S~~~
embryonic kidney cell line, 293 (Graham, F. L, et al.. J. Gen. Viro~ 36:68-72 f't 977)) using a high efficiency procedure IGarman, G. M. er al., DNA & Prot. Engin. Tech. 2:3-117 11990);
Gorman, C., in DNA Clanln9. val II, pp 143-'1 g0 (~. M. Glover, ed., IRL
Press, Oxford. UK
19$5?). Media were harvested daily for up to 5 days and the cells re-fed with serum free g madla. An'~bddigs were recovered from the media and affinity purified on protein a sepharose*
CL-4B IPharmacia) as described by the manufacturer. The eluted antibody was buffer-exchanged into phosphate-buffered saline by G25 gel filtration, concentrated by ultrafiltration (Cerrtriprep~i0 or ~er'atriao~i 00. Amiconi, sterile-filtered (Miliex~"sV, Millipore) and stored at 4 ~C. The concentration of antibody was determined by using bath total immunoglobuiin and antigen binding .ELISAs. The staruiard used was huMAb4D5-5, whose concentration had been rJetgrmined by amino acid composition analysis.
Cal! ProtifW"at~n Assay. The off8ct of MAb4D5 variants upon proliferation of the human mammary adenocarcinoma coil line, SK-BR-3, was investigated ss previousty.described ~IFendly, B. M. et al.: Cancer Res. 50:1554-'t 55$ I1 ~g0)f using saturating MAb4~5 rs concentrat;Qns.
AftINty Messuraments. The antigen binding affinity of MAb41~5 variants was determined using a sebrotad.form of the p185HER~ ECD prepared as described in Fendiy. ~.
. M..et al., J. 8iol. Rasp; INod.' 9:449~155.t't9941. Briefly, antibody and plg5HeR2 ECD were . incubated ~in so(ut(on until eqbilibriurh was found to be reached. The concentration of free antibody was th~dn determined'. by ,ELfSA .using immobilized p1$5HE~2 ECD and used to calouiata affinity tKd) according to Friguet et al. (Friguet. 8, et al. .t.
Immunal. Methods 77:305-319 I19135fi: ~ , .
.. , ,; ~. . ;
. . . ~ itF,SULTS
.a:5 , . 1 .. t~hrrhanixation tif'iinuMAb4iD5: Tha muMAb4a5 V~ arid vH gene segments ware first aloned~ by_' PC'R ~ and Sequoi~cBdi tFig. , .11. Ttie variable genes were xhan simultaneously . ,h~e~ized~by.:gene~avnvarsian_mutagenesis,usirip preassemblad ofigonucleotides tFig. xl. A
311 ~mer,: oiigoycleotide;~ontaining ~9 rniarria~chas to the template directed 24 simultaneous amino acid changes, required to humanize muMAb4D5 VL. Humanization of muMAb4D5 VH
requirad.32 amino acid .~char~ga~..~fuph were installed with a 361~mer containing 59 ~.rnismatches to the muN~Ab4D5 tbmplate: Two. out of 8 clones sequenced precisely encode huMAb4D~-5, although:~one of these clones cvittained a aingte nucleotide imporfectian. The 6.other clones were ess~ntialfy humamied but contained a small number of grrQrs_ ~ 3 nucleotide changes and ~ f~ single. nucleotides uelation per kilobe$e.
Additibnai humanized '*-trademarks ' WO 92!22653 ~ ~ ~ ~ ~ ''~ '~ PCTltJS92lg5126 .
!r 8 variants (Table 31 were constructed by site-directed mutagenesis of huMAb4D5-5.
Expression levels of huMAb4D5 variants were in the range of 7 to 15 pglml as judged by ELISA using immobilized p185HER2 ECD. Successive harvests of five 10 cm plates allowed 200 Ng to 500 mg of each variant to be produced in a week. Antibodies affinity purified on protein A gave a single band on a rCoomassie blue stained SDS polyacrylamide gel of mobility consistent with the expected Mr of -150 kDa. Electrophoresis under reducing conditions gave 2 bands consistent with the expected Mr of free heavy (48 kDa) and light (23 kDa) chains Inot shown). Amino terminal sequence analysis ( 10-cycles) gave the mixed sequence expected (see Fig. 1 ) from an equimolar combination of light and heavy chains (not shown).
huMAb4D5 Variants. In general, the FR residues were chosen from consensus human sequences (Kabat, E. A. ex al., Sequences of Proteins of lmmuno!pgica!
Interest (National Institutes of Health, Bethesda, MD, 1987)) and CDR residues Pram muMAb4D5.
Additional variants were constructed by replacing selected human residues in huMAb4D5-1 with their muMAb4D5 counterparts. These are VH residues ? 1, 73, 78, 93 plus 102 and VE
residues 55 plus 66 identified by our molecular modeling. VH residue 71 has previously been proposed by others (Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)) to be critical to the conformation of VH-CnR2: Amino acid sequence differences between huMAb4D5 variant molecules aye shown in Table 3, together with their p185HER2 ECD binding affinity and 2tt maximal anti-proliferative activities against SK-BR-3 cells. Very similar Kd values were obtained for binding of MAb4D5 variants to either SK-BR-3 cells or to p185HER2 ECD (Table 3). However, Kd estimates derived from binding of MAb4D5 variants to p185HER2 ECD were more reproducible with smelter standard errors and consumed much smaller quantities of antibody than binding measurements with whole cells.
The most potent humanized variant designed by molecular modeling, huMAb4D5-8, contains S FR residues from muMAb4D5. This antibody binds the p185HER2 ECD 3-fold mare tightly than does muMAb4D5 itself (Table 3) and has comparable anti-proliferative activity with SK-BR-3 cells (Fig. 3).' In contrast; huMAb4D5-1 is the most humanized but least potent muMAb4D5 va'iant, created by simply installing the muMAb4D5 CDRs into the consensus human sequences. huMAb4D5-l binds the p185RER2 ECD 80-fold less tightly than does the murine antibody and has no detectable anti-proiiferative activity at the highest antibody concentration investigated (16 Ng/m)).
The anti-pPOliferative activity of huMAb4D5 variants against p185HER2 overexpressing SK-i3R-3 cells is not simply co~retated with their binding affinity for the p185HER2 ECD. For -~WO 92/22653 PCf/US92/~D5126 example, installation of three marine residues into the VH domain of huMAb4D5-2 (D73T, L78A and A93S) to create huMAb4D5-3 does not change the antigen binding affinity but does confer significant anti-proliferative activity (Table 3).
The importance of VH residue 71 (Tramontano, A. et el., J. M~!. Biol. 215:175-S (1990)) is supported b~> the observed 5-fold increase in affinity far p185HER2 ECD on .
replacement of R71 in huMAb4D5-1 with the corresponding marine residue, alanine (huMAb4D5-2). In contrast, replacing VH L78 in huMAb4D5-4 with the marine residue, alanine (huMAb4D5-5), does not significantly change the affinity for the p185HER2 ECD or change anti-proliferative activity, suggesting that residue 78 is not of critical functional significance to huMAb4D5 and its ability to interact properly with the extracellular domain of p185HERZ.
VL residue 66 is usually a glycine in human and marine K chain sequences (Kabat, E.
A. et al., Sequences of Proteins of lmmunological Inferest (National Institutes of Health, Bethesda, MD, 1987)) but an arginine occupies this position in the muMAb4D5 k light chain.
The side chain of residue 66 is likely to affect the conformation of VL-CDR1 and V~-CDR2 and the hairpin turn at 68-69 (Fig. 4). Consistent with the importance of this residue, the mutation VL G66R (huMAb4D5-3 --~ huMAb4D5-5) increases the affinity for the p185HER2 ECD by 4-fold with a concomitant increase in anti-proliferative activity.
From maPecular modeling it appears that the tyrosyl side chain of muMAb4D5 VL
residue 55 may either stabilize he conformation of VH-CDR3 or provide an interaction at the VL-V~ interface. The latter function may be dependent upon the presence of VH
Y102. In the context of huMAb4D5-5 the mutations VL E55Y (huMAb4D5-6) and VH V102Y
(huMAb4D5-7) individualty increase the affinity for p185HER2 ECD by 5-fold and 2-fold respectively,, whereas together thuMAb4D5-81 they increase the affinity by 11-fold. This is consistent with either proposed role of VL Y55-and VH Y102.
Secondary Immune Funcdorr of huMAb4D5-8: MuMAb4D5 inhibits the growth of human beast tumor cells which overexpress pl B~HER2 tHudziak, R. M. et el., Malec. Cell.
Biol. 9:1165-1172 (19891). The antibody, however, does not offer the possibility of direct termor cytotoxic effects: This possibility does arise in huMAb4D5-8 as a result of its high affinity (Kd _ 0.1 NM) and its human IgGl subtype. Table 4 compares the ADCC, mediated by huMAb4D5-8 with muMAb4D5 on a narrnal lung epithelial cell line, WI-38, which expresses a low level of p185HER2'and on SK-~R-3, which expresses a high level of p185HER2, The results demonstrate that: (1 D huMAb4D5 has a greatly enhanced ability to carry out ADCC as compared with its marine patent; and (2) that this activity may be selective for cell types WVtD 92!22653 ~ ~ ~ ~ '~ ~ PCg'lUS92l05126 ~0 which overexpress p185H~R2 DlSCUSStON
MuMAb4D5 is potentially useful for human therapy since it is cytostatic towards S human breast and ovarian tumor ~tir°tes overexpressing the /-?ERA-encoded p185RER2 receptor-like tyrosine kinase. Since both breast and ovarian carcinomas are chronic diseases it is anticipated that the optimal MAb4D5 variant molecule for therapy will have low immunogenicity and will be cytotoxic rather than solely cytostatic in effect.
Humanization of muMAb4D5 should accomplish these goals. We have identified 5 different huMAb4D5 variants which bind tightly to p185~ER2 ECD (Kd 5 1 nM) and which have significant anti-proliferative activity (Table 3). Furthermore huMAb4D5-8 but not muMAb4D5 mediates ADCC against human tumor cell lines overexpressing p185HER2 in the presence of human effector cells (Table 4) as anticipated for a human y1 isotype (Bruggemann, M.
et al., ,!. Exp.
Med. 166:1351-1361 (1987); Riechmann, ~.. et al., Nature 332:323-327 (1988)):
Rapid humanization of huMAb4D5 was facilitated by the gene conversion mutagenesis strategy developed here using long preassembled oligonucleotides. This method requires less than half the amount of synthetic DNA as does total gene synthesis and does not require convenient restriction sites in the target DNA. Our method appears to be simpler and more reliable than a variant protocol recently reported (Rostapshov, V. M. e? al., FEBS Gett.
249:379-382 (1989)). Transientexpression of huMAb4D5 in human embryonic kidney calls permitted the isolation of a few hundred micrograms of huMAb4D5 variants for rapid characterization by growth inhibition and antigen binding affinity assays.
Furthermore, different Combinations of light and heavy chain were readily tested by co-transfec~tion of corresponding cDNA expression erectors.
Z5 The crucial role of molecular modeling in the humanization of muMAb4D5 is illustrated by the designad variant huMAb4D5-8 which binds the p185HER2 ECt3 250-fold more tightly than the simple CDR I~op swap variant; huMAb4D5-1. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riedhmann, L: et~l., Na?ure 332:323-327 (1988); C~ueen, C. etal., Proc.
Natl. ~lcaa! Sci. USA 86:10029-10033 ( 1989)). Here we have extended this earlier work by others with a designed humanized antibody which binds its antigen 3-fold more tightly than the parent rodent antibody. While this result is gratifying, assessment of the success of the molecular modeling must await the outcome of X-ray structure determination.
From analysis of huMAb4D5 variants (Table 3) it is apparent that their anti-proliferative activity is not a .~JV~ 92/2265 ~ ~ ~ ~ ~ 7 ~ PCl"/US92JO5126 simple function of their binding affinity for p185HER2 ECD. I=or example the huMAb4D5-8 variant binds p185HER2 8-fold more tightly than muMAb4D5 but the humanized variant is slightly less potent in blocking the proliferation of SIB-BR-3 cells.
Additional huMAb4D5 variants are currently being constructed in an attempt to identity residues triggering the S anti-proliferative activity and in an attempt to enhance this activity.
In addition to retaining tight receptor binding and the ability to inhibit cell growth, the huMAb4D5-8 also confers a secondary immune function (ADCC). This allows for direct cytotoxic activity of the humanized molecule in the presence of human effector cells. The apparent selectivity of the cytotoxic activity for cell types which overexpress p185HER2 allows to for the evolution of a straightforward clinic approach to those human cancers characterized by overexpression of the HER2 protooncogene.
.... _ .. ~.: .. .,-. . ..
ewr~ ~zizz~s3 ~c~ius9zrossz~
~z Table 3. p185HEtt2 FCD binding affinity and anti-protiferative activities of MAb4D5 variants VH Residue° VL Residue°
MAb4D5 71 73 78 93 102 55 66 Rdt Relative cell Variant FR3 FR3 F"R3 FR3 CDR3 CDR2 FR3 nM
proliferationt i0 huMAb4D5-1 R D L A V E G 25 102 huMAb4D5-2 Ala D L A V E G 4.7 101 huMA,b4D5-3 Ala Thr Ala Ser V E G 4.4 66 huMAb4D5-4 Ala Thr L Ser V E Arg 0.82 56 huMAb4D5-S Ala Thr Ala Ser V E Arg 1.1 48 ~5 huMAb4D5-6 Ala Thr Ala Ser V Tyr Arg 0.22 51 huMAb4D5-7 Ala Thr Ala Ser Tyr E Arg 0.62 53 huMAb4D5-8 Ala Thr Ala Ser Tyr Tyr Arg 0.10 54 muMAb4D5 Ala Thr A1a Ser Tyr Tyr Arg 0.30 37 hluman and murine ~e~idues are shown in one letter and three letter amino acid code rd~pectiv~ly.
f Kd values for th~ ~185H~R2 EC~ vvere determined using the method of Friguet et aJ. t~3) and the standard error of each estimate is ~ ~ 1 ~°~.
t Proliferation of SK-8R-3 cells incubated for 98 hr with PVlAb4D5 ~rariants shown as a 25 percentage of the untreated control as described (Hudziak, R. M. et al., IVlulec. dell, Biol.
J:1 i 85-1172 X1989)). Data represent the maximal anti-proliferative effect for each ~rariant (see Fig: ~A) calculated as the mean of triplicate determinations at a A~Ab4D5 concentration of 8 yg/m!. Data are a!I taken from the same experiment with an estimated standard error of CA 02103059 2003-05-20 _..
coupling reaction by S100-HR (Pharmacial size exclusion chromatagraphy (2_5 cm x 100 cm) in the presence of PBS. The BsF/ab')2 samples were passed through a 0.2 mm filter flash frozen in liquid nitrogen and stored at -70' C.
Flow cytometric analysis of Flab' lsbindinp to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Cutture Collection (Rockville, MO) (ATCC TIB 152) and grown as recommended by the ATCC. Aliquots of 108 Juricat cells were incubated with appropriate concentrations of BsF(ab')z (anti-p185"~ / anti-CD3 variant) or control mono-specific anti-p185"E''~ F(ab')z in PBS plus 0.196 (w/v) bovine serum albumin and 10 mM sodium azide for 45 min at 4 ' C.
The cells were washed and then incubated with fluorescein-conjugated goat anti-human F(ab')z (Organon Teknika, West Chester, PA) for 45 min at 4 -C. Cells were washed and ' analyzed on a FACScari (Becton Dickinson and Co., Mountain View, CA). Cells (8 x 10') were acquired by list mode and gated by forward Light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~
and at 37 out of 122 positions within V" (Shalaby et al.,supra) 1992). Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine residues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were originally kept as human sequences in our minimalistic humanization regime. Thus human residues in V" CDR2 of anti-C03 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
'f57S:AGON:DGIQ:S62K:VG3F:GG_SD (SEQ ID NO: ~?0) (Fig. 5~ Similarly, the human residue E55 in V~ CDR2 of anti-CD3 vl was replaced with histidine from the marine anti-C:D3 antibody to generate anti-CD3 v 11. In addition, Vtc framework region (FR) residues 75 and 7G in anti-CD3 v1 were also replaced with their marine counterparts to create anti-CD3 v8: K75S:N7GS. Vtt residues75 and 7G are located in a loop close to Vti CDRI and CDR2 and therefore might influence antigen binding.
Additional variants created by combining mutations at these three sites are described helovv.
Preparation of BsFlab71 fra8ments Soluble and functional anti-p185"E'u and anti-CD3 Fab' fragments were recovered directly from corresponding E. colt fermentation pastes with the single hinge cysteine predominantly in the free thiol form (75-100 96 Fab'-SH) by affinity purification on Streptococcal protein G at pH 5 in the presence of EDTA (Carter et aL, 1992b, supra).
Thioether-Linked BsF(ab')~ fragments were then constructed by directed coupling using o-PDM
Si~i35~i 1 i ~J i:~ Sri~T
V'a'~ 92/226x3 ~ ~ Q ~ ~ 7 ~ P~'/1.JS92/05126 Table 4. Selectivity of antibody dependent tumor cell cytotoxicity mediated by huiVlAb4D5-8 WI-3$° SK-BR-3 E~fector:Target ratf,o'~ m~b4D5 huMAb4D5-8 m~a~3A'b4D5 huMAb4D5-8 A.t 25:1 <1.0 9.3 7.5 40.6 12.5:1 <1.0 11.1 4.7 36.8 6.25:1 <1.0 8.9 0.9 35.2 g0 3.13:1 <1.0 8.5 4.6 19.6 B. 25:1 <1.0 3.1 6.1 33.4 12.5:1 <1.0 1.7 5.5 26.2 6.25:1 1.3 2.2 2.0 21.0 3.13:1 <1.0 0.8 2.4 13.4 Sensitivity to ADCC of two human cell lines (WI-38, normal lung epithelium;
and SK-8R-3, human breast tumor cell line) are compared. WI-38 expresses a low level of p"185~ERZ 10.6 pg p~r pg cell protein) and SK-8Fi-3 expresses a high Devel of p185~ER2 !64 pg p185HER2 per pg cell protdin), as determined by ELISA lFendly et at., J. Biol. Reap. Mod.
9:449-455 (1.90)).
t ADCC assays were' carried out as described in l3rieggemann et al., J. Exp.
Med.
186:1851-1361 l1987D. Effector to target ratios were of 1!.-2 activated human peripheral blood lymphocytes to either WI-38 fibroblasts or SK-8R-8 tumor cells in 96-well microtiter plates for 4 hours at 3T QC. Values given represent percent specific cetl lysis as determined by '1Cr release. i"stimated standard error in these quadruplicate determinations was s t 1096.
t Monoclonal antibody concentrations used were 0.1 yg/ml !AD and 0.1 pg/ml lBi.
WU 92l22b53 '~ ~ ~ ~ ~ ~ ~ PGTlUS92/OSt2b ~5 EXAMPLE 2. Schematirt Method for Humanizinct an Antibody Seguence This example illustrates one stepwise elaboration of the methods for creating a humanised sequence described above. It will be understood that not all of these steps are essential to the claimed invention, and that steps may be taken in different order.
9 . ascertain a consensus human variable domain amino acid sequence and prepare from it a consensus structural model.
2. prepare model of import (the non-human domain to be humanized) variable domain sequences and note structural differences with respect ~o consensus human model.
3. identify CDR sequences in human and in import, both by using Kabat . (supra, 1 ~87> and crystal structure criteria. If there is any difference in CDR identity from the different criteria, use of crystal structure definition of the CDR, but retain the Kabat residues as important framework residues to impart.
4. substitute import CDR sequences for human CDR sequences to obtain initial "humanised" sequence.
5. compare import c~bn~CDR variabl~ domain sequence to the humanized sequence qnd note divergenGes.
6. Proceed through the following analysis for each amino acid residue where the import diverges from the humanized.
28 aIf the humanised residue represents a residue which is generally highly conserved across all species, use the residue in the humanized sequence. If the residue is not conserved across atl species; proceed with the analysis described in 6b.
b. If the residue is not generally conserved across all species, ask if the residue is generally conserved in humans.
i. If the residue is generally conserved in humans but the import ~esid~ae differs, examine the structural models of the i,~port and human sequences and determine if the import eesidue v~ould be likely to affect the binding or biological =,. ... ,,.., , ,:,: ;: ~ . -::- ;: , . , .., .,_ : , .... , . ... ,. ;. .. :......:
. , . >,. ,., .:: . .. , ..... ... ... , .
'6rVCD 92f22653 ~'CT/US92i05126 activity of the CDRs by considering 1 ) could it bind antigen directBy and 2) could it affect the conformation of the CDR.
If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, leave the humanized residue unchanged.
ii. If the residue is also not generally conserved in humans, examine the structural models of the import and human sequences and determine if the import residue would be likely to affect the binding or biological activity of the CDRs be considering 11 could it bind antigen directly and 2) could it affect the conformation of the CDR. If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, proceed to the next step.
a) examine the structural models of the import and human sequences and determine if the residue is exposed on the surface of the domain or is buried within. If th~ residue is exposed, use the residue in the humanized sequence. If the residua is buried, proceed to the next step.
(i) Examine the structural models of the impart and human sequences and determine if the residue is likely to affect the ~J~ - V~, interface. Residues involved with the ~interfac~ include; 34L, 36L, 38L, 43L: 33L: 36L, 85l., 87L, 89l., 91 L, 86L, 88L, X51°!, 3~'t~. 39FI, 43H, 45H, 4711, 60i~, 91 H; 93H~ 95H, 100H, and 103N. If no effect is likely, use the residue in the humanized sequence. If some affect is likely, substitute the import residue.
sodium cacodytate at pH
fiØ
bysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. C~erivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing Q-amino-containing residues include . ... . .., ~'~~~~ . , :~ .'~~ . o:~:' : ;. r ' , . ~ . ' ~. _ : _~ . , ~.,,.
.. ,,~._:.. . ~.;:. . .
W~ 92/22653 ~ ~ ~ ~ ~ ,'~ ~ )PC°A'/US92/05r26 ,..~ .
Z
imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal;
chloroborohydride;
trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues are modified by reaction with one or several conventional reagents, 5 among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin.
Derivatization of arginine residues requiros that the reactian be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
Th~ specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using'z51 or'3'I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.
Carboxyl side groups taspartyl or glutamyl) are selectively modified by reaction with carbodiimides tR'-N = C = N-R'), where R and R' are different alkyl groups, sash as 1-cyclohexyt-3-(2-morpholinyl-4-ethyl) carbadiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutarninyl residues by reaction with ammonium ions., Derivatization with bifunctional agents is useful for crosslinking target palypeptide to a water-insoluble support matrix ar surface for use in the method for purifying anti-target paiyp~ptids antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1,1-bisidiazoacetyl)-2-phenylethane, glutaraldehyd~, N-hydroxysuccinimide esters, for example, esters with ~-azidosalicylic acid; homobifunctional imidaesters, including disuccinimidyl esters such as 3,3'-dithicrbistsuccinimidylpropionate), and bifunctional maleimides such as bis-N-rnaleimido-1,8-octane. Derivatizing agents such as methyl-3-tIp-azidophenyl)dithiolpropioimi-date yield photoactivatable intermediates that are capable of farming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. 3,969,28?;
3,691,016;
4,195,128; 4,247,642; 4,229.53?; and 4,330,440 are employed far protein immobilization.
Glutaminyl and asp~araginyl residues are frequent6y deamidated to the carresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this inventian.
.,''VO92/22653 ~ ~ ~ ~ P~;f/f.JS92/05i26 Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of Beryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains tT.E. Creighton, Pr ins: Structure and Molecular Pranerj~i, es, W.H. Freeman & Co., San Francisco, pp. 79-86 f 1983)), acetylation of th~ N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the target polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
By altering is meant deleting one or more carbohydrate moieties found in the native target polypeptide, andlor adding one or more glycosylation sites that are not present in the native target pofypeptide.
Clycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X
is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to th~ asparagir~e side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-finked glycosylation refers to the attadhment of one of the sugars N-acetylgalactosamine, galactose, or xytose; to a hydroxyamino acid, most commonly serine or threonine, although hydroxyproline or 5-hydroxylysine may also' be used.
Addition of g[ycosylation sites to the target polypeptide is conveniently accomplished by altering the amino acid sequence such hat it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of; or substitution by, one or more serine or threonine residues to the native target s''' polypeptide sequence tfor O-linked glycosylation sites?. Fat ease, the target polypeptide amino acid sequencb is prgferabl~ altered throughchanges at the DNA level, particularly by mutating the DNA encodieg the target polypeptide at p~esalected bases such that codons are generated than will translate into the desired amino acids. The DNA mutationtsl may be made using methods described above under the heading of "Amino Acid Sequenc8 Variants of Target 'Potypeptide".
Another means of ' increasing the number of carbohydrate moieties on the target polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosyiation capabilities for N- and O- linked glycosylation.
Depending on the coupling mode used, the sugartsf may be attached to ta? arginine and histidine, tb? free ~i'T..,..,.',~ , ~ ,' a :.~... .. ~ .-,. ~ ,:.': .. :..,. .::, ~ . . ~. ~.
.'.~~. ~. ,.:. ;'; _, . ,~. ..' . .,'.,,.'~~. , wo ~z>zz~s3 2 ~. ~ ~ ~ ~ ~ FCT/US9zl05126 carboxyl groups, tc) free sulfhydryl groups such as those of cysteine, td) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, te) aromatic residues such as those of phenytalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine.
These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston (CF1C_ Crit Rev Biochem., pp. 259-306 (1981]).
Removal of carbohydrate moieties present on the native target polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or' ail sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosytation is described by Hakimuddin et al. (Arch Biochem. Bionhys., 259:52 (198?]) and by Edge et al. (Anal. Biachem., 11 :131 ( 19811). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-giycosidases as described by Thatakura et al. (fVleth. Enzvmol., 18:350 (1987]).
Glycosylation at potential ~lycosbtation sites may be prevented by the use of the compound tunicamycin as describ~d by Duskin et al. (J. Bial. them.. 2_x:3105 ( 19821).
Tunicamycin blocks the formation of protein-N-glycoside linkages.
Another type of covalent modification of the target polypeptide comprises linking the target poiypeptide to various nonproteinaceous polymers, e.g. polyethylene glycol, _ polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S.
4,640,835;
4:496,689; 4,301;144; 4;670,417; 4,791,192 ar 4,179,337.
The target polypeptide also may, be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization Ifor example, hydroxymethylcellulase o~ getatir~-microcapsules and poly-(methytmethacylateD
microcapsufes, ~S ' respectively), in colloidal drug delivery systems tfor example, tiposomes, albumin microspheres, microemutsionsnano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Reminaton's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., (1980).
Target polypeptide preparations are also useful in generating antibodies, for screening #or binding partners, as standards in assays for the target polypeptide te.g.
by labeling the target polypeptide for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptar assay), in affinity purification techniques, and in competitive-type receptor binding' assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.
Since it is often difficult to predict in advance the characteristics of a variant target potypeptide, it will be appreciated that some screening of the recovered variant will be needed ~~~~,a : .:F: ;. :' .. .: . .. : . ~ w.r: . ..:.; . ",; , ... ..,, ::; . : ;;
: .
~~t..
,.,~ WO 92/22653 ~ ~ ~ ~ ~ ~ PL'I'/US92/OS126 S S' to select the optimal variant. For example, a change in the immunologicai character of the target polypeptide molecule, such as affinity for a given antigen or antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its activity by comparison to the activity observed for the target polypeptide in the same assay. Other patential modifications of protein or palypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, stability in recombinant calf culture or in plasma, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.
la Diac~na_~ i~,~nd Relatee~~l~,g_s of the Anti odies The antibodies of this invention are useful in diagnostic assays for antigen expression in specific cells or tissues. The antibodies are detectably labeled andJor are immobilized on an insoluble matrix.
The antibodies of this invention find further use far the affinity purification of the - 15 antigen from recombinant cell cult~rre or natural sources. Suitable diagnostic assays for the antigen and its antibodies depend on the particular antigen or antibody.
Generally, such assays include competitive and sandwich assays, and steric inhibition assays.
Competitive and sandwich methods employ a phase-separation step as an integral part of the method white steric inhibition assays are conducted in a single reaction mixture.
Fundamentally, the same 20 procedures are used for the assay of the antigen and for substances that bind the antigen, although certain methods wilt be fav~red depending upon the molecular weight of the substance being assayed: ' Therefore, the substance to be tested is referred to herein as an ar~alyte, irrespective of its status otherwise as an antigen or antibody, and proteins,$hat bind to the analyte, are denominated binding partners, whether they be antibodies, cell surface 25 ' receptors, or antigens.
Analyxical methods far he antigen or its antibodies all use one or more of the following reagents: labeled anaiyte analogue; immobilized ana)yte analogue, labeled binding partner, immobilized bindiryg partner and steric conjugates. The labeled reagents also are known as "tracers."
The label used _tand this is also useful to label antigen nucleic acid for use as a probe) is any detectable functionality 'that dogs not interfere with the binding of ana)yte and its binding partner. Numerous labels are known for use in immunoassay, examples including moieties that gay be detected directly, such as fluorochrome, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized r?,~r k , ., ,.. ,. . ',.
PCT/ US92/0512b W~ 92/22653 5~
to be detected. Examples of such labels include the radioisotopes 3ZP, '4C, '25i, 3H, and '3'I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterbal luciferase tU.S. Pat. No. 4,737,456);.luciferin, 2,3-dihydrophthalazinedianes, horseradish peroxidase 5' tHRP), alkaline phasphatase, ~-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose axidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or micraperoxidase, biotin/avidin, spin labels, bacterrophage labels, stable free radicals, and the like.
Conventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbadiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiiuminescent, and enzyme labels. See, for example, U.S.
Pat. Nos. 3,940,475 tfluarimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); L?avid etal., Biach~mistry, 1~: 1014-1021 (1974); Pain etal., ~
Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem. and Cvtochem., ~0: 407-412 (1982).
Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.
The cpnjugation of such label; including the enzymes, to the antibody is a standard manipulative procedure far one of ordinary skill in immunoassay techniques.
See, for example, O'Sultivan et a/., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Imrnunoassay." in Methods in Enzvmolaav, ed. J.J. Langone and H. Van Vunakis, Vol.
73 (Academic Press, New: Yprk; New York, 1981 ), pp. 147-166. Such bonding methods are suitable for use with the antibodies and polypeptides of this invention.
Immobilization of reagents is required for certain assay methods.
Immobilization entails separating the binding partner from any anatyte that remains Eras in solution.
This conventionally is accomplished by either insoiubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich etal.., U.S. 3,710,760), by covalent coupling (for example, using glutaraldehyde cross-finking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.
Other assay methods, known as competitive or sandwich assays, are well established and widely used in thd commercial diagnostics industry.
Competitive assays rely on the ability of a tracer analogue to compete with the test sample anaiyte for a limited number of binding sites on a common binding partner. The binding ry~,:~,;~.:v" ,. . ., ,.., wo ~2i226~~ ~ ~. ~ ~ ~ J ~~ ~orius~2i~5~z6 S~
partner generally is insolubilized before or after the competition and then the tracer and analyte bound Lo the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsoiubilized? or by centrifuging (where the binding partner was precipitated after the competitive reactiony.
The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA
systems when enzymes are used as the detectable markers. ' to Another species of competitive assay, called a "homogeneous" assay, doss not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, the antigen or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase.
Conjugates are selected for use with antibody so that binding of the antibody inhibits or potentiates the enzyme activity of the label. This method per se is widely practiced under the name of EMIT.
Steric conjugates are used in steric hindrance methods for homogeneous assay.
These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten substantially is unable to bind the conjugate at the same 2o time as anti-analyte. Under this assay procedure the analyte present in the test sample wilt bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore.
., Sandwich assays particularly are useful for the determination of antigen or antibodies.
In sequential sandwich assays an immobilized binding partner is used to adsorb test sample analyte, the tdst sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound nnaterial is then separated from residual tracer.
The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous'° sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-antigen monoclonal antibody as one antibody and a polyclonal anti-antigen antibody ass he other is,useful in testing samples for particular antigen activity.
The foregoing aye merely exemplary diagnostic assays for the import and humanized antibodies of this inventibn. other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassays described -_._ ~ ~'.~ ~ 1 S.f, Y.mrr v.,-r.r WO 9Z/~2653 S$
above.
~mmunotoxins This invention is also directed to immunochamica) derivatives of the antibodies of this invention such as immunatoxins fconjug3tes at the antibody and a cytotoxic moiety).
A_rrtfbodies which carry the apprapriato effector functit5ns, such as with-their constant domains, are also used to induce lysis;thirough the natural complement process, and to interact with antibody dependent cytotoxic cells normally present-For example, purified, sterile filtered antibodies are optionally conjugated to a 1a cytotoxin such as ricin for use in AIDS therapy. 'The methods of this invention, for example, era 'suitable for obtaining humanized antibodies for use as immunotoxins for use in AIDS therapy, The cytotoxic moiety. of the immunatoxin may be a aYtotoxic drug or an enzymaticaNy active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment Qt such a toxin. i:nzymatically active toxins and fragments thereof used are diphtheria A chain, nonbinding active fragments of diprithoria~ .toxin. exotoxin A drain (from Psetrrlamo~as aemginosa), ~ricin A chain, abrin A chain, modaccin A chain, alpha-s9rcin, Aleurites fordii proteins,.dianthin fxoteins;.~hyiclacaamericana proteins iF'APi; PAPI1, and PAF-S), momordica ~.: zo charantia inhibitor, curcirr. . crotin, sapaonaria afficinalis inhibitor, gelonin, mitogellin, restrictocin, phor<omycin. enomycin and the tricothecenes. In another embodiment, the antibod'ses ire conjugated to small molecule anticancer drugs such as cis-platin or 5FU.
. Conjugates of the monoclonal antibody and'such cYtotoxic moieties are made using a variety of bifunotional protein coupling agents. Examples of such reagents are SPDP, IT , bifunctional derivatives af. imidoesters : such . as dimethyl ~ adipimidate HCI, active esters such as . ~ disuccinimidyl ,suberate, aldehydes.such as ~tutaraidehyde. his-azido compounds such as bis fp-azidobenzoyll hekanediamina, bis-diaz4riium-derivatives such as his- tp-diazonium4enzoyll w ~ethylenediamine, .diisocyanates such, as tolylene 2,6-diisocyanate and bis-active fluorine compounds such ~as l,~-difluoro 2;4-dinitrobenzer~e. The (YSing portion of s toxin may be joined to the Fob fragment of the antib6dies.
Imrrmnoioxins can be cnada gin, a variety of ways; as discussed heroin.
Gommoniy . .known crosslinking reager~ta can.be used~to yield stable conjugates.
Advantageously. rE'~onocional antibodies specifically binding the domain of the antigen which is exposed tiry the infected cell 'surface, are con9ugated to ricin A
chain. Most . VVO 92/22653 2 ~ ~ ~ 0 ~ ~ PCT/US92/OS1Z6 advantageously the ricin A chain is deglycosylated and produced through recombinant means.
An advantageous method of making the ricin immunotoxin is described in Vitetta et al., Science 238:1D98 11987).
When used to kill infected human cells in vitro for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a concentration of at least about 10 nM.
The formulation and mode of administration for in vitro use are not critical.
Aqueous formulations that are compatible with the culture or perfusion medium will normally be used.
Cytotoxicity may be read by conventional techniques.
Cytotoxic radiopharmaceuticals for treating infected cells may be made by conjugating radioactive isotopes te.g. l, Y, Pr) to the antibodies. Advantageously alpha particle-emitting isotopes are used. The term 'cytotoxic moiety" as used herein is intended to include such isotopes.
in a preferred embodiment, ricin A chain is deglycosylated or produced without oligosaccharides, to decrease its clearance by irrelevant clearance mechanisms (e.g., the liver).
in another embodiment. whale ricin tA chain plus B chain) is conjugated to antibody if the gatactose binding property of B-chain can be blocked t"blocked ricin").
In a further embodiment toxin-conjugates are made with Fab or Ftab')2 fragments.
Because of their relatively small size these fragments can better penetrate tissue to reach infected cells. -In another embodiment, fusogenic liposomes are filled with a cytotoxic drug and the liposom~s are coated with antibodies specifically binding the particular antigen.
Antibody Denenden~ Cellular Cvtotoxicitv ".w/
Certain aspects of this invention involve antibodies which are ta) directed against a particular antigen acrd tb) belong to a subclass or i~otype that is capable of mediating the lysis of cells to which the antibody molecule 'binds. IVlore specifically, these antibodies should belong to a subclass or isotype than upon c~mplexing with cell surface proteins, activates serum complement and/or mediates antibody dependent cellular cytotoxicity tADCC) by activating effector cells such as natural kilter cells or macrophages.
90 Bioto~ical activity of antibodies is known to be determined, to a large extent, by the constant domains or Fd region of the antibody molecule tUananue and t3enacerraf, Textbook of Jmmuno%gy; 2nd i=dition, Williams & Wilkinsp. 218 11984)). This includes their ability to activate complement and to mediate antibody-dependent cellular cytotoxicity tADCC) as effected by leukocytes. Antibodies of different classes and subclasses differ in this respect, wo ~ziza~s3 ~ ~. ~ ~~ ~ ~~ ~ ~crius9a/asiab coo as do antibodies from the same subclass but different species; according to the present invention, antibodies of, those classes having the desired biological activity are prepared.
Preparation of these antibodies involves the selection of antibody constant domains are their incorporation in the humanized antibody by known technique. For example, mouse immunoglobulins of the IgG3 and IgG2a class are capable of activating serum complement upon binding to the target cells which express the cognate antigen, and therefore humanized antibodies which incorporate IgG~ and IgG2a effector functions are desirable for certain therapeutic applications.
In general, mouse antibodies of the IgG2a and IgG3 subclass and occasionally IgG 1 can to mediate ADCC, and antibodies of the IgG3, IgG2a, and IgM subclasses bind and activate serum complement. Complement activation generally requires the binding of at least two IgG
molecules in close proximity on the target cell. However, the binding of only one IgM molecule activates serum complement.
The ability of any particular antibody to mediate lysis of the target cell by complement activation and/or ADCC can be assayed. The cells of interest are grown and labeled in vitro;
the antibody is added to the cell culture in combination with either serum complement or immune cells which may be activated by the antigen antibody complexes.
Cytolysis of the target cells is detected by the release of label from the lysed cells. 6n fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells. The antibody that is capable of activating complement or mediating ADCC in the in vitro test can then be used therapeutically in that particular patient.
This invention specifically encompasses consensus Fc antibody domains prepared and used according to the teachings of this invention.
-a Thera,~eutic and~ther Uses of the Antibodies When used in ~ivo for therapy, tha antibodies of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect?. They will normally be administered parenterally. The dose and dosage regimen will depend upon the degree of the infecti~n, the characteristics of the particular antibody or 3o immunotoxin used, e.g., its therapeutic index, the patient, and the patient's history.
Advantageously the antibody or immunotoxin is administered continuously over a period of 1 ~2 weeks, intravenously to treat cells in the vasculature and subcutaneously and intraperitoneally to treat regional lymph nodes. Optionally, the administration is made during the course of adjunct therapy such as combined cycles of radiation, chemotherapeutic treatment, or . W4 92/22653 ~ ~ ~ ~ ~ ~ v PC'd'lUS92>05126 (0 4 administration of tumor necrosis factor, interferon or other cytoprotective or immunomodulatory agent.
For parentera! administration the antibodies will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5~~
human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate can aBso be used. Liposomes shay be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
to The antibodies will typically be farmulated in such vehicles at concentrations of about 1 mgiml to 10 mgiml.
Use of lgAl1 antibodies may be preferred for certain applications, however !gG
molecules by being smaller may be more abte than IgM molecules to localize to certain types of infected cells.
There is evidence that complement activation in vivo~leads to a variety of biological effects, including the induction of an inflammatory response and the activation of macrophages tUananue and l3enecerraf, Textbook of lmmunalogy, 2nd Edition, Williams &
Wilkins, p. 218 (1984)). The increased vasodilation accompanying inflammation may increase the ability of various agents to localize in infected cells. Therefore, antigen-antibody combinations of the . 20 type specified by this invention can b~ used therapeutically in many ways. Additionally, purified antigens tHakomori, Ann. Rev, lmmunol. 2:103 (1984)) or anti-idiotypic antibodies (Nepom et aP., Proc. Nat/. Acad. Sci. 81:2864 (1985); Koprowski et al., Proc.
lUatl. Acad. Sci.
81:216 ( 1984)) relating to such antigens could be used to induce an active immune response in human patients. Such a response includes the formation of antibodies capable of activating human complement and mediating ADCC and by such mechanisms cause infected cell destruction.
Optionally, the antibodies of this invention are useful in passively immunizing patients, as exemplified by the administration of humanized anti-HlV antibodies.
The antibody compositions used in therapy are formulated and dosages established in 3o a fashion consistent with good medics! practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the composition, the method of administration and other factors known to practitioners. The antibody compositions are prepared for administration according to the description of preparation of polypeptides for administration, infra.
W~ 92/22653 ~ ~ ~ ~ ~ j ~ PCTlUS92/0512t~
(0 2 Deposit of Materials As described above, cultures of the muMAb4D5 have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA
(ATCC).
This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest.Tr~aty). This assures maintenance of viable cultures for 30 years from the date of the deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures l0 to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 38 USC ~ 122 and the Commissioner's rules pursuant thereto (including 37 CFR ~ 1.12 with particular reference to 886 OG 638).
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPCD
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture.
Availability of the deposited strain is not to be construed as a license to practice the invention in contravention ,~ s of the rights granted under the authority of any government in accordance with its patent Isws.
The foregoing written spepification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiments are intended to illustrate only certain aspects of the invention and any constructs that are functionally equivalent are within the ,, scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode (hereof, nor is it to be construed as limiting the scope of the Maims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those ~.,:..;, ,. ..; ~ ..-.. ...,;..:.;: .,.:.: . ;;. :... .....:".,. .. ._ .. .
~~.~~f~ )~
..,W~ 92/22653 4 ~ PC~'/USl2/05126 skilled in the art from the foregoing description and fall within the scope of the appended claims.
It is understood that the application of the teachings of the present invention to a specific problem or situation will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation, use, and manufacture appear below, but should not be construed to limit the invention.
EXAMPLES
EXAMPLE 1. HUMANIZATION OF muMAb4D5 Here we report the chimerization of muMAb4D5 tchMAb4D5> and the rapid and simultaneous humanization of heavy tVM) and light tV~) chain variable region genes using a novel "gene conversion mutagenesis" strategy. Eight humanized variants thuMAb4D5) were constructed to probe the importance of several FR residues identified by our molecular modeling or previously proposed to be critical to the conformation of particular CDRs tees Chothia, C. & Lesk, A. M., J. Mol. Biol. '196:901-917 (19871; Chothia, C. et al., Nature 342:877-883 11989); Tramontano, A. et al., J Mol. 6~ial. 215:175-182 11990)).
Efficient 2p transient expression of humanized variants in non-myeloma cells allowed us to rapidly inv~stigate the relationship between binding affinity for p185HEgz ECD.and anti-proliferative activity against p185HER2 ~verexpressing carcinoma cells.
flliATERIALS and tUIETHOD9 ,;
Cloning of ilariobte l~egi~ro Genes: The muMAb4D5 VH and VL genes were isolated by potymerase chain reaction (PCR) arnptific~tion of mRNA from the corresponding hybridoma iFer~dly, ~. M. et al., Cancor Res. 5~:1550-1558 11990)) as described by Orlandi et al.
tOrtandi; R. et ~P.; Proc: '!Nato Acid. Sci. LISA 86:3833-3837 11989)). Amino terminal sequencing of muMA64D5 V~ and V~ was used to design the sense strand PCR
primers, whereas the anti-sense PCR primers were based upon consensus sequences of murine framework residues dOrtandi, R. et al., Proc. lUarl. Acad. Sci. USA 86:3833-3837 11989);
Kabat, E. A.' et al., Sequences'of ProPeins of Ira~murrologica! Interest tPlational Institutes of Health, 8ethesda; MD; 1987)) incorporating restriction sites for directional cloning shown by underlining ahd listed after the sequences: V L sense, 5'-TCCGATATCCAGCTGACCCAG~'CTCCA-3' tSEQ. 1D NO. 7), EcoRV; VL anti-sense, 5'-Wo 9zn~s53 ~ ~, ~ ~ ~ ~ ~ P~G'1'/US92/0512b GT'iTGATCTCCAGCTT~~t~iSCDCCGAA-S' (SEO. IQ NO. 8). Asp77 B; vH sense, 5'-AGGTSMARSe.TSAGTGWGGw3' ISEa~ iQ NO- 9f~ Pstl and YH anti-sense, 5'-TGAGGAGAC~~.GTGG~'CCCTTGGCCCCAG-3' (SECZ. ID NO. 10), BstEll; where H =
A or C or T. 8 - C or G. D = A or G or T, M ~ A ar C. R = A or G and W = A or T. The PCR products were cloned iota pli'C11,9 tVielra..f~ & Messing. J., Methods En~ymol. '153:3-1.1 , (19871) and five cibnes for each variakFla domain sequenced bY the dideoxy method (5anger.
F. ei .al., Prac. Natl. Aced. Saj. LISA 74:6463-5487 ! ~ 977)).
Molecular Modelling. Modats for muMAb4D5 VH and VL domains were c~structed separately from oonsensws coordinates based upon seven Fob structures from the Brookhavan 1o protein dad bank (entries 1 F~~ 2RHt~, 2MCP. 31=AB, 1 FBJ, 2HFL and 1 REI).
The pab fragment KCAL lMarquart, M. et al., J. Mal. Bial. '141:3$9-391 (1980)) was first Chosen as a template for V~ and VH domains and additional structures were then superimposed upon this structure using their main chain atom coordinates 11NSIGH~'iprogram. Biosym Techwlogies).
The distance from the template Catv the analvgaus Ca in each of thg superirnposad structures 15. was calculated for each residue position. If alt for nearly all? Ccr-Ca distances far a given residue were 5 1 R, then that position .was included in the aansensus structure. In most cases the ~-sheet framework.rssidues satisfied tflese criteria whereas the CDR loops did not. For each of these selected 'rasidu'as the average coordinates fvr individual N, Ca. C, O and CB
atoms were calGUl~ted and then corrected far resultant deviations from non-standard bond ' geormetry >;y 50 cycles of energy minimization using the DISCOVER"program (Biosym Technologies) .with the yAM,B>'Rk:fotcefield (Weiner, s. J. et al., J. Amer.
Chem. 5oc.
106:766-?84 (1984)) and Cccoordir~ates fixed. The side chains of highly conserved residues, ' , such as the disul8de-bridseii b~lstdine reaidues~ ware then incorporated into the .resultant consensus structure. . Next the saqu~ncBS of muMAb4D6 V~ and VH ware incorporated 5sxartin~ with the CDR fes'idues and using the tabulations of CDR
conformations from Chotnia ex a!: (Chothia:.C~.'et al,, IVatLre' 342:8?7-883 (1989)1 as a guide. Side-chain conformations - were chosen on.the~ basis.of I=ab crystal structures, rotemer libraries (Ponder, ,!. W. ~ Richards.
F. nn,; .1.; Mah viol 193:?75-.791 (19$7)i and pac.kir~g considerations. Since VR-CDR3 could not be assigned a definite #ackbone; conformation from these criteria, two modals were created '~o ~ frpm a search of similar,sized leaps using the INSIGHT program. A third rnadal was derived using packing and solvent expusurd considerations. Each modal was then subjected to 5000 cybles of energy minimization: , In humanizing mulVIAb4D~.''aanssnsUS human sequences were first derived from the mdst~abundant sutxlasses in. he sequence caniliilation of Kabat et al. (Kabat.
E. A. et al_, *-trademarks W4 92122653 ~ ~ ~ J ~ J ~ PC1'/LJ592/0512G
!~ S
SeQuences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)), namely V~ x subgroup I and VH group III, and a molecular model generated for these sequences using the methods described above. A structure for huMAb4D5 was created by transferring the CDRs from the muMAb4D5 model into the consensus human structure. All huMAb4D5 variants contain human replacements of muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Sequences of Proteins of lmmuno%gicallnterest (National Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C. & Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)):
VL-CDR1 K24R, VL-CDR2 R54L and VL-CDR2 TSfS. Differences between muMAb4D5 and l0 the human consensus framework residues (Fig. 1 ) were individually modeled to investigate their possible influence on CDR conformation and/or binding to the p185HER2 ECD.
Construction of Chimeric Genes. Genes encoding chMAb4D5 light and heavy chains were separately assembled in previously described phagemid vectors containing the human cytomegalovirus enhancer and promoter, a 5' intron and SV40 polyadenylation signal (Gorman, 1~ C. M, et al., DNA & Prot. Engin. Tech. 2:3-10 (1990)). Briefly, gene segments encoding muMAb4D5 VL (Fig. 1 A) and REI human K1 light chain CL (Palm, W. & Hilschmann, N., Z.
Physiol. Chem. 356:167-191 (1975)~ were precisely joined as were genes for muMAb4D5 VH
(Fig. i B) and human y1 constant region (Capon, D. J. et al., Nature 337:525-531 (1989)) by simple subcloning (Boyle, A.; in Current Protocols in Molecular Biology, Chapter 3 (F. A.
20 Ausubel et al., eds., Greene Publishing & Wiley-Interscience, New York, 1990)) and site-directed mutagenesis (Carter; P., in Mutagenesis: A Practical Approach, Chapter 1 (IRL
Press, Oxford, UK 1991 )). The y1 isotype was chosen as it has been found to be the preferred human isotype for supporting ADCC and complement dependent cytotoxicity using matched sets of chimeric EBruggemanrv, M. et al.; J. Exp. Med. 166:1351-1361 (1987)) or humanized 25 antibodies (Riechmann; L. eral.; Nature 332:32-327 (1988)). The PCR-generated VL and VH
fragments (Fig. 1 ) were subsequently mutagenized so that they faithfully represent the soquence of muMAb4D5 determined at the protein level: VH Q1 E, VL V104L and tvariants are denoted by the -amino acid residue and number followed by the replacement amino acid). The human yl constant regions are identical to those reported by Ellison et al.
30 (Ellison, J. W. et al., Nucleic Acids Res. 13:4071-4079 (1982)) except for the mutations E359D and M361 L (Eu numbering, as in Kabat, E. A. et al., Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) which we installed to convert the antibody from the naturally rare A allotype vo the much more common non-A
allotypd (Tramont~no, A. et al., J. Mol: Biol. 215:175-182 (1990)). This was an attempt to Vd~ 92!22653 ~ ~ U ~ ~ J ~ PCIf/US92/OS126 reduce the risk of anti-allotype antibodies interfering with therapy.
Construction of Humanized Genes. Genes encoding chMAb4D5 light chain and heavy chain Fd fragment (VH and CH1 domains) were subcloned together into pUC119 (Vieira, J. &
Messing, J., Methods Enzymoi. ''53:3-11 (1987)) to create pAK1 and simultaneously S humanized in a single step rtFig. 2). Briefly, sets of 6 contiguous oligonucleotides were designed to humanize VM and V~ (Fig. 1 ). These oligonucleatides are 28 to 83 nucleotides in length, contain zero to 19 mismatches to the marine antibody template and are constrained to have 8 or 9 perfectly matched residues at each end to promote efficient annealing and iigation of adjacent oligonucleotides. The sets of VH and VL hurnanization oligonucleotides (5 pmol each) wars phosphorylated with either ATP or y-32P-ATP (Carter, P.
Methods Enzymol.
154:382-403 (1987)) and separately annealed with 3.7 pmol of pAK1 template in 40,u1 10 mM Tris-HCl (pH 8.0) and 10 mM MgCl2 by cooling from 100 ~C to room temperature over 30 min. The annealed oligonucleatides were joined by incubation with T4 DNA
ligase ( 12 units; New England Biolabs) in the prqsence of 2 NI 5 mM ATP and 2 /el 0.1 M
DTT for 10 min at 14 ~C. After electrophoresis on a 6°!° acrylamide sequencing get the assembled oligonucleotides were looted by autoradiography and recovered by electroelution. The assembled oligonucleotides ( -- 0.3 pmol each) were simultaneously annealed to 0.15 pmol single-stranded deoxyuridine-containing pAK1 prepared according to Kunkel et al. (Kunkel, T.
A. et aL, Methods Enzymol. 154:367-382 (1987)) in 10 pl 40 mM Tris-HCI (pH
7.5) and ~16 24 mM MgCl2 as above. He'teroduplex DNA was constructed by extending the primers with T7 DNA polymerase and transformed into E, coil 8MH 71-18 mutt as previously described (Carter; P., in Mutagenesis: A Practice! Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )).
The resultant phag~iwid DNA pool was enriched first for huVL by restriction purification using 4_~
Xhol and then for huV~ key restriction selection using Stul as described in Carter, P., in Mutagene5is: A Practical Approach, Chapter 1 tIRL Press, Oxford, UK 1991 );
and in Wells, J. A. et al , Phil: Traps: R. Soc. Lond A 317:415-423 41986). Resultant clones containing both huVL and huVH genes were identified by nucleotide sequencing tSanger, F.
et al., Proc.
IVatl, aAcad. Sci. US~I 74:5463-5467 (19771) and designated pAK2. Additional humanize variants were generated by site-directed mutagenesis (Carter, P., in Mutagenesis: A Practice!
Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )). The muMAb4D5 VL and VH
gene sbgme~nts in the transient expression vectors described above were then precisely replaced with their humanized versions.
Exlaression and Purification of IUlAb4D5 Variants. Appropriate MAb4D5 light and heavy chain cDNA expression vectors were co-transfected into an adenovirus transformed human .,.WO 92/22b53 ~ ~ ~ ~ ~ ~ ~ PGTIU~a9214S~~~
embryonic kidney cell line, 293 (Graham, F. L, et al.. J. Gen. Viro~ 36:68-72 f't 977)) using a high efficiency procedure IGarman, G. M. er al., DNA & Prot. Engin. Tech. 2:3-117 11990);
Gorman, C., in DNA Clanln9. val II, pp 143-'1 g0 (~. M. Glover, ed., IRL
Press, Oxford. UK
19$5?). Media were harvested daily for up to 5 days and the cells re-fed with serum free g madla. An'~bddigs were recovered from the media and affinity purified on protein a sepharose*
CL-4B IPharmacia) as described by the manufacturer. The eluted antibody was buffer-exchanged into phosphate-buffered saline by G25 gel filtration, concentrated by ultrafiltration (Cerrtriprep~i0 or ~er'atriao~i 00. Amiconi, sterile-filtered (Miliex~"sV, Millipore) and stored at 4 ~C. The concentration of antibody was determined by using bath total immunoglobuiin and antigen binding .ELISAs. The staruiard used was huMAb4D5-5, whose concentration had been rJetgrmined by amino acid composition analysis.
Cal! ProtifW"at~n Assay. The off8ct of MAb4D5 variants upon proliferation of the human mammary adenocarcinoma coil line, SK-BR-3, was investigated ss previousty.described ~IFendly, B. M. et al.: Cancer Res. 50:1554-'t 55$ I1 ~g0)f using saturating MAb4~5 rs concentrat;Qns.
AftINty Messuraments. The antigen binding affinity of MAb41~5 variants was determined using a sebrotad.form of the p185HER~ ECD prepared as described in Fendiy. ~.
. M..et al., J. 8iol. Rasp; INod.' 9:449~155.t't9941. Briefly, antibody and plg5HeR2 ECD were . incubated ~in so(ut(on until eqbilibriurh was found to be reached. The concentration of free antibody was th~dn determined'. by ,ELfSA .using immobilized p1$5HE~2 ECD and used to calouiata affinity tKd) according to Friguet et al. (Friguet. 8, et al. .t.
Immunal. Methods 77:305-319 I19135fi: ~ , .
.. , ,; ~. . ;
. . . ~ itF,SULTS
.a:5 , . 1 .. t~hrrhanixation tif'iinuMAb4iD5: Tha muMAb4a5 V~ arid vH gene segments ware first aloned~ by_' PC'R ~ and Sequoi~cBdi tFig. , .11. Ttie variable genes were xhan simultaneously . ,h~e~ized~by.:gene~avnvarsian_mutagenesis,usirip preassemblad ofigonucleotides tFig. xl. A
311 ~mer,: oiigoycleotide;~ontaining ~9 rniarria~chas to the template directed 24 simultaneous amino acid changes, required to humanize muMAb4D5 VL. Humanization of muMAb4D5 VH
requirad.32 amino acid .~char~ga~..~fuph were installed with a 361~mer containing 59 ~.rnismatches to the muN~Ab4D5 tbmplate: Two. out of 8 clones sequenced precisely encode huMAb4D~-5, although:~one of these clones cvittained a aingte nucleotide imporfectian. The 6.other clones were ess~ntialfy humamied but contained a small number of grrQrs_ ~ 3 nucleotide changes and ~ f~ single. nucleotides uelation per kilobe$e.
Additibnai humanized '*-trademarks ' WO 92!22653 ~ ~ ~ ~ ~ ''~ '~ PCTltJS92lg5126 .
!r 8 variants (Table 31 were constructed by site-directed mutagenesis of huMAb4D5-5.
Expression levels of huMAb4D5 variants were in the range of 7 to 15 pglml as judged by ELISA using immobilized p185HER2 ECD. Successive harvests of five 10 cm plates allowed 200 Ng to 500 mg of each variant to be produced in a week. Antibodies affinity purified on protein A gave a single band on a rCoomassie blue stained SDS polyacrylamide gel of mobility consistent with the expected Mr of -150 kDa. Electrophoresis under reducing conditions gave 2 bands consistent with the expected Mr of free heavy (48 kDa) and light (23 kDa) chains Inot shown). Amino terminal sequence analysis ( 10-cycles) gave the mixed sequence expected (see Fig. 1 ) from an equimolar combination of light and heavy chains (not shown).
huMAb4D5 Variants. In general, the FR residues were chosen from consensus human sequences (Kabat, E. A. ex al., Sequences of Proteins of lmmuno!pgica!
Interest (National Institutes of Health, Bethesda, MD, 1987)) and CDR residues Pram muMAb4D5.
Additional variants were constructed by replacing selected human residues in huMAb4D5-1 with their muMAb4D5 counterparts. These are VH residues ? 1, 73, 78, 93 plus 102 and VE
residues 55 plus 66 identified by our molecular modeling. VH residue 71 has previously been proposed by others (Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)) to be critical to the conformation of VH-CnR2: Amino acid sequence differences between huMAb4D5 variant molecules aye shown in Table 3, together with their p185HER2 ECD binding affinity and 2tt maximal anti-proliferative activities against SK-BR-3 cells. Very similar Kd values were obtained for binding of MAb4D5 variants to either SK-BR-3 cells or to p185HER2 ECD (Table 3). However, Kd estimates derived from binding of MAb4D5 variants to p185HER2 ECD were more reproducible with smelter standard errors and consumed much smaller quantities of antibody than binding measurements with whole cells.
The most potent humanized variant designed by molecular modeling, huMAb4D5-8, contains S FR residues from muMAb4D5. This antibody binds the p185HER2 ECD 3-fold mare tightly than does muMAb4D5 itself (Table 3) and has comparable anti-proliferative activity with SK-BR-3 cells (Fig. 3).' In contrast; huMAb4D5-1 is the most humanized but least potent muMAb4D5 va'iant, created by simply installing the muMAb4D5 CDRs into the consensus human sequences. huMAb4D5-l binds the p185RER2 ECD 80-fold less tightly than does the murine antibody and has no detectable anti-proiiferative activity at the highest antibody concentration investigated (16 Ng/m)).
The anti-pPOliferative activity of huMAb4D5 variants against p185HER2 overexpressing SK-i3R-3 cells is not simply co~retated with their binding affinity for the p185HER2 ECD. For -~WO 92/22653 PCf/US92/~D5126 example, installation of three marine residues into the VH domain of huMAb4D5-2 (D73T, L78A and A93S) to create huMAb4D5-3 does not change the antigen binding affinity but does confer significant anti-proliferative activity (Table 3).
The importance of VH residue 71 (Tramontano, A. et el., J. M~!. Biol. 215:175-S (1990)) is supported b~> the observed 5-fold increase in affinity far p185HER2 ECD on .
replacement of R71 in huMAb4D5-1 with the corresponding marine residue, alanine (huMAb4D5-2). In contrast, replacing VH L78 in huMAb4D5-4 with the marine residue, alanine (huMAb4D5-5), does not significantly change the affinity for the p185HER2 ECD or change anti-proliferative activity, suggesting that residue 78 is not of critical functional significance to huMAb4D5 and its ability to interact properly with the extracellular domain of p185HERZ.
VL residue 66 is usually a glycine in human and marine K chain sequences (Kabat, E.
A. et al., Sequences of Proteins of lmmunological Inferest (National Institutes of Health, Bethesda, MD, 1987)) but an arginine occupies this position in the muMAb4D5 k light chain.
The side chain of residue 66 is likely to affect the conformation of VL-CDR1 and V~-CDR2 and the hairpin turn at 68-69 (Fig. 4). Consistent with the importance of this residue, the mutation VL G66R (huMAb4D5-3 --~ huMAb4D5-5) increases the affinity for the p185HER2 ECD by 4-fold with a concomitant increase in anti-proliferative activity.
From maPecular modeling it appears that the tyrosyl side chain of muMAb4D5 VL
residue 55 may either stabilize he conformation of VH-CDR3 or provide an interaction at the VL-V~ interface. The latter function may be dependent upon the presence of VH
Y102. In the context of huMAb4D5-5 the mutations VL E55Y (huMAb4D5-6) and VH V102Y
(huMAb4D5-7) individualty increase the affinity for p185HER2 ECD by 5-fold and 2-fold respectively,, whereas together thuMAb4D5-81 they increase the affinity by 11-fold. This is consistent with either proposed role of VL Y55-and VH Y102.
Secondary Immune Funcdorr of huMAb4D5-8: MuMAb4D5 inhibits the growth of human beast tumor cells which overexpress pl B~HER2 tHudziak, R. M. et el., Malec. Cell.
Biol. 9:1165-1172 (19891). The antibody, however, does not offer the possibility of direct termor cytotoxic effects: This possibility does arise in huMAb4D5-8 as a result of its high affinity (Kd _ 0.1 NM) and its human IgGl subtype. Table 4 compares the ADCC, mediated by huMAb4D5-8 with muMAb4D5 on a narrnal lung epithelial cell line, WI-38, which expresses a low level of p185HER2'and on SK-~R-3, which expresses a high level of p185HER2, The results demonstrate that: (1 D huMAb4D5 has a greatly enhanced ability to carry out ADCC as compared with its marine patent; and (2) that this activity may be selective for cell types WVtD 92!22653 ~ ~ ~ ~ '~ ~ PCg'lUS92l05126 ~0 which overexpress p185H~R2 DlSCUSStON
MuMAb4D5 is potentially useful for human therapy since it is cytostatic towards S human breast and ovarian tumor ~tir°tes overexpressing the /-?ERA-encoded p185RER2 receptor-like tyrosine kinase. Since both breast and ovarian carcinomas are chronic diseases it is anticipated that the optimal MAb4D5 variant molecule for therapy will have low immunogenicity and will be cytotoxic rather than solely cytostatic in effect.
Humanization of muMAb4D5 should accomplish these goals. We have identified 5 different huMAb4D5 variants which bind tightly to p185~ER2 ECD (Kd 5 1 nM) and which have significant anti-proliferative activity (Table 3). Furthermore huMAb4D5-8 but not muMAb4D5 mediates ADCC against human tumor cell lines overexpressing p185HER2 in the presence of human effector cells (Table 4) as anticipated for a human y1 isotype (Bruggemann, M.
et al., ,!. Exp.
Med. 166:1351-1361 (1987); Riechmann, ~.. et al., Nature 332:323-327 (1988)):
Rapid humanization of huMAb4D5 was facilitated by the gene conversion mutagenesis strategy developed here using long preassembled oligonucleotides. This method requires less than half the amount of synthetic DNA as does total gene synthesis and does not require convenient restriction sites in the target DNA. Our method appears to be simpler and more reliable than a variant protocol recently reported (Rostapshov, V. M. e? al., FEBS Gett.
249:379-382 (1989)). Transientexpression of huMAb4D5 in human embryonic kidney calls permitted the isolation of a few hundred micrograms of huMAb4D5 variants for rapid characterization by growth inhibition and antigen binding affinity assays.
Furthermore, different Combinations of light and heavy chain were readily tested by co-transfec~tion of corresponding cDNA expression erectors.
Z5 The crucial role of molecular modeling in the humanization of muMAb4D5 is illustrated by the designad variant huMAb4D5-8 which binds the p185HER2 ECt3 250-fold more tightly than the simple CDR I~op swap variant; huMAb4D5-1. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riedhmann, L: et~l., Na?ure 332:323-327 (1988); C~ueen, C. etal., Proc.
Natl. ~lcaa! Sci. USA 86:10029-10033 ( 1989)). Here we have extended this earlier work by others with a designed humanized antibody which binds its antigen 3-fold more tightly than the parent rodent antibody. While this result is gratifying, assessment of the success of the molecular modeling must await the outcome of X-ray structure determination.
From analysis of huMAb4D5 variants (Table 3) it is apparent that their anti-proliferative activity is not a .~JV~ 92/2265 ~ ~ ~ ~ ~ 7 ~ PCl"/US92JO5126 simple function of their binding affinity for p185HER2 ECD. I=or example the huMAb4D5-8 variant binds p185HER2 8-fold more tightly than muMAb4D5 but the humanized variant is slightly less potent in blocking the proliferation of SIB-BR-3 cells.
Additional huMAb4D5 variants are currently being constructed in an attempt to identity residues triggering the S anti-proliferative activity and in an attempt to enhance this activity.
In addition to retaining tight receptor binding and the ability to inhibit cell growth, the huMAb4D5-8 also confers a secondary immune function (ADCC). This allows for direct cytotoxic activity of the humanized molecule in the presence of human effector cells. The apparent selectivity of the cytotoxic activity for cell types which overexpress p185HER2 allows to for the evolution of a straightforward clinic approach to those human cancers characterized by overexpression of the HER2 protooncogene.
.... _ .. ~.: .. .,-. . ..
ewr~ ~zizz~s3 ~c~ius9zrossz~
~z Table 3. p185HEtt2 FCD binding affinity and anti-protiferative activities of MAb4D5 variants VH Residue° VL Residue°
MAb4D5 71 73 78 93 102 55 66 Rdt Relative cell Variant FR3 FR3 F"R3 FR3 CDR3 CDR2 FR3 nM
proliferationt i0 huMAb4D5-1 R D L A V E G 25 102 huMAb4D5-2 Ala D L A V E G 4.7 101 huMA,b4D5-3 Ala Thr Ala Ser V E G 4.4 66 huMAb4D5-4 Ala Thr L Ser V E Arg 0.82 56 huMAb4D5-S Ala Thr Ala Ser V E Arg 1.1 48 ~5 huMAb4D5-6 Ala Thr Ala Ser V Tyr Arg 0.22 51 huMAb4D5-7 Ala Thr Ala Ser Tyr E Arg 0.62 53 huMAb4D5-8 Ala Thr Ala Ser Tyr Tyr Arg 0.10 54 muMAb4D5 Ala Thr A1a Ser Tyr Tyr Arg 0.30 37 hluman and murine ~e~idues are shown in one letter and three letter amino acid code rd~pectiv~ly.
f Kd values for th~ ~185H~R2 EC~ vvere determined using the method of Friguet et aJ. t~3) and the standard error of each estimate is ~ ~ 1 ~°~.
t Proliferation of SK-8R-3 cells incubated for 98 hr with PVlAb4D5 ~rariants shown as a 25 percentage of the untreated control as described (Hudziak, R. M. et al., IVlulec. dell, Biol.
J:1 i 85-1172 X1989)). Data represent the maximal anti-proliferative effect for each ~rariant (see Fig: ~A) calculated as the mean of triplicate determinations at a A~Ab4D5 concentration of 8 yg/m!. Data are a!I taken from the same experiment with an estimated standard error of CA 02103059 2003-05-20 _..
coupling reaction by S100-HR (Pharmacial size exclusion chromatagraphy (2_5 cm x 100 cm) in the presence of PBS. The BsF/ab')2 samples were passed through a 0.2 mm filter flash frozen in liquid nitrogen and stored at -70' C.
Flow cytometric analysis of Flab' lsbindinp to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Cutture Collection (Rockville, MO) (ATCC TIB 152) and grown as recommended by the ATCC. Aliquots of 108 Juricat cells were incubated with appropriate concentrations of BsF(ab')z (anti-p185"~ / anti-CD3 variant) or control mono-specific anti-p185"E''~ F(ab')z in PBS plus 0.196 (w/v) bovine serum albumin and 10 mM sodium azide for 45 min at 4 ' C.
The cells were washed and then incubated with fluorescein-conjugated goat anti-human F(ab')z (Organon Teknika, West Chester, PA) for 45 min at 4 -C. Cells were washed and ' analyzed on a FACScari (Becton Dickinson and Co., Mountain View, CA). Cells (8 x 10') were acquired by list mode and gated by forward Light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~
and at 37 out of 122 positions within V" (Shalaby et al.,supra) 1992). Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine residues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were originally kept as human sequences in our minimalistic humanization regime. Thus human residues in V" CDR2 of anti-C03 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
'f57S:AGON:DGIQ:S62K:VG3F:GG_SD (SEQ ID NO: ~?0) (Fig. 5~ Similarly, the human residue E55 in V~ CDR2 of anti-CD3 vl was replaced with histidine from the marine anti-C:D3 antibody to generate anti-CD3 v 11. In addition, Vtc framework region (FR) residues 75 and 7G in anti-CD3 v1 were also replaced with their marine counterparts to create anti-CD3 v8: K75S:N7GS. Vtt residues75 and 7G are located in a loop close to Vti CDRI and CDR2 and therefore might influence antigen binding.
Additional variants created by combining mutations at these three sites are described helovv.
Preparation of BsFlab71 fra8ments Soluble and functional anti-p185"E'u and anti-CD3 Fab' fragments were recovered directly from corresponding E. colt fermentation pastes with the single hinge cysteine predominantly in the free thiol form (75-100 96 Fab'-SH) by affinity purification on Streptococcal protein G at pH 5 in the presence of EDTA (Carter et aL, 1992b, supra).
Thioether-Linked BsF(ab')~ fragments were then constructed by directed coupling using o-PDM
Si~i35~i 1 i ~J i:~ Sri~T
V'a'~ 92/226x3 ~ ~ Q ~ ~ 7 ~ P~'/1.JS92/05126 Table 4. Selectivity of antibody dependent tumor cell cytotoxicity mediated by huiVlAb4D5-8 WI-3$° SK-BR-3 E~fector:Target ratf,o'~ m~b4D5 huMAb4D5-8 m~a~3A'b4D5 huMAb4D5-8 A.t 25:1 <1.0 9.3 7.5 40.6 12.5:1 <1.0 11.1 4.7 36.8 6.25:1 <1.0 8.9 0.9 35.2 g0 3.13:1 <1.0 8.5 4.6 19.6 B. 25:1 <1.0 3.1 6.1 33.4 12.5:1 <1.0 1.7 5.5 26.2 6.25:1 1.3 2.2 2.0 21.0 3.13:1 <1.0 0.8 2.4 13.4 Sensitivity to ADCC of two human cell lines (WI-38, normal lung epithelium;
and SK-8R-3, human breast tumor cell line) are compared. WI-38 expresses a low level of p"185~ERZ 10.6 pg p~r pg cell protein) and SK-8Fi-3 expresses a high Devel of p185~ER2 !64 pg p185HER2 per pg cell protdin), as determined by ELISA lFendly et at., J. Biol. Reap. Mod.
9:449-455 (1.90)).
t ADCC assays were' carried out as described in l3rieggemann et al., J. Exp.
Med.
186:1851-1361 l1987D. Effector to target ratios were of 1!.-2 activated human peripheral blood lymphocytes to either WI-38 fibroblasts or SK-8R-8 tumor cells in 96-well microtiter plates for 4 hours at 3T QC. Values given represent percent specific cetl lysis as determined by '1Cr release. i"stimated standard error in these quadruplicate determinations was s t 1096.
t Monoclonal antibody concentrations used were 0.1 yg/ml !AD and 0.1 pg/ml lBi.
WU 92l22b53 '~ ~ ~ ~ ~ ~ ~ PGTlUS92/OSt2b ~5 EXAMPLE 2. Schematirt Method for Humanizinct an Antibody Seguence This example illustrates one stepwise elaboration of the methods for creating a humanised sequence described above. It will be understood that not all of these steps are essential to the claimed invention, and that steps may be taken in different order.
9 . ascertain a consensus human variable domain amino acid sequence and prepare from it a consensus structural model.
2. prepare model of import (the non-human domain to be humanized) variable domain sequences and note structural differences with respect ~o consensus human model.
3. identify CDR sequences in human and in import, both by using Kabat . (supra, 1 ~87> and crystal structure criteria. If there is any difference in CDR identity from the different criteria, use of crystal structure definition of the CDR, but retain the Kabat residues as important framework residues to impart.
4. substitute import CDR sequences for human CDR sequences to obtain initial "humanised" sequence.
5. compare import c~bn~CDR variabl~ domain sequence to the humanized sequence qnd note divergenGes.
6. Proceed through the following analysis for each amino acid residue where the import diverges from the humanized.
28 aIf the humanised residue represents a residue which is generally highly conserved across all species, use the residue in the humanized sequence. If the residue is not conserved across atl species; proceed with the analysis described in 6b.
b. If the residue is not generally conserved across all species, ask if the residue is generally conserved in humans.
i. If the residue is generally conserved in humans but the import ~esid~ae differs, examine the structural models of the i,~port and human sequences and determine if the import eesidue v~ould be likely to affect the binding or biological =,. ... ,,.., , ,:,: ;: ~ . -::- ;: , . , .., .,_ : , .... , . ... ,. ;. .. :......:
. , . >,. ,., .:: . .. , ..... ... ... , .
'6rVCD 92f22653 ~'CT/US92i05126 activity of the CDRs by considering 1 ) could it bind antigen directBy and 2) could it affect the conformation of the CDR.
If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, leave the humanized residue unchanged.
ii. If the residue is also not generally conserved in humans, examine the structural models of the import and human sequences and determine if the import residue would be likely to affect the binding or biological activity of the CDRs be considering 11 could it bind antigen directly and 2) could it affect the conformation of the CDR. If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, proceed to the next step.
a) examine the structural models of the import and human sequences and determine if the residue is exposed on the surface of the domain or is buried within. If th~ residue is exposed, use the residue in the humanized sequence. If the residua is buried, proceed to the next step.
(i) Examine the structural models of the impart and human sequences and determine if the residue is likely to affect the ~J~ - V~, interface. Residues involved with the ~interfac~ include; 34L, 36L, 38L, 43L: 33L: 36L, 85l., 87L, 89l., 91 L, 86L, 88L, X51°!, 3~'t~. 39FI, 43H, 45H, 4711, 60i~, 91 H; 93H~ 95H, 100H, and 103N. If no effect is likely, use the residue in the humanized sequence. If some affect is likely, substitute the import residue.
7. search the impot't sequence; the consensus sequence and the humanized sequence for gtycosylation sites outside the CDRs, and . determine if this gly~osylation site is likely to have any affect on . .".;' a%.. ..t,.~~~t ..'.y., .,...': . .:::. ....a....:. . .,:.:.
..,:.ar~. .''.'.: . ; ~:'. , ''...~.., , :',',:-.;.;: ~.~.:...~..;.,. ,,....
,...:.,.,.. , -:"'.y . :;.".~,. . ....' PCI'l1J892l05126 ~. ~VCD 92/22653 antigen binding andlor biological activity. If no effect is likely, use the human sequence at that site; if some affect is likely, eliminate the glycosylation site or use the import sequence at that site.
..,:.ar~. .''.'.: . ; ~:'. , ''...~.., , :',',:-.;.;: ~.~.:...~..;.,. ,,....
,...:.,.,.. , -:"'.y . :;.".~,. . ....' PCI'l1J892l05126 ~. ~VCD 92/22653 antigen binding andlor biological activity. If no effect is likely, use the human sequence at that site; if some affect is likely, eliminate the glycosylation site or use the import sequence at that site.
8. After completing the above analysis, determine the planned humanized sequence and prepare and test a sample. If the sample does not bind well to the target antigen, examine the particular residues listed below, regardless of the puestion of residue identity between the import and humanized residues.
a. Examine particular peripheral (note-CDR) variable domain residues that may, due to their position, possibly interact directly with a macromolecular antigen, including the following residues (where the " indicates residues which have been found to interact with antigen based on crystal structures):
i. Variable light domain: 36, 46, ~9°, 63-70 ii. Variable heavy domain: 2, 47°, 68, 70, 73-7.,.6.
b. Examine particular variable domain residues which could interact uvith, or otherwise affect, the conformation of variable domain CDRs, including the following (not including CDR residues themselves; since it is assumod that, because the CDRs interact with one mother, a~,y resis~ue in one CDR could potentially affect the c~nformation of another CDR residue) (L= LIGHT, H = HEAVY, residues appearing in b~Id are indicated to be structurally important according the Chothia et al., Mature .. ' 34~;1~77 (1989); and residues appearing in italic were altered ~5 during humanizati~n by Queen et al. (PDLD, Proc. Mall. Acad. Sci.
USA gg:10029 (1989) and Proc. Matl. Acad. 8ci, tJSA 88:2869 (1991 ):);
i. Variable tight domain:
aD CDR-1 (residues 24L-3~L): 2L, 4L, 66L-69L, 71 L
b) GDR-2 (residues 50L-56L): 35L, 46L, 47L, 48L, 49L, 58L, 62L. 64L-661:, 71 L, 73L
cl CDR-3 (residues 89L-97L): 2L, ~L, 36L, 98L, 37H, 45H, 47H, 58H, 6QH
ii. Variable heavy domain:
~.~,.,,,::..:, ., ,., :...
°~(~ 92/22b5~ ~ ~ ~ ~ ~ ~~ ~ PCI'/US92/05126 ,~,,>..;
a) CDR-1 (residues 26H-35H): 2H, 4H, 2~H, 36H, 71 H, 73H, 76H, 78H, g2H, ;94H
b) CDR-2 (residues 50H-55H): 49H, 69H, 69H, 7't H, 73H, 78H
c1 CDR-3 (residues 95H-102H): examine atl residues as possibl~~ interaction partners with this loop, because this loop varies in sire and conformation much more than the other CDRs.
a. Examine particular peripheral (note-CDR) variable domain residues that may, due to their position, possibly interact directly with a macromolecular antigen, including the following residues (where the " indicates residues which have been found to interact with antigen based on crystal structures):
i. Variable light domain: 36, 46, ~9°, 63-70 ii. Variable heavy domain: 2, 47°, 68, 70, 73-7.,.6.
b. Examine particular variable domain residues which could interact uvith, or otherwise affect, the conformation of variable domain CDRs, including the following (not including CDR residues themselves; since it is assumod that, because the CDRs interact with one mother, a~,y resis~ue in one CDR could potentially affect the c~nformation of another CDR residue) (L= LIGHT, H = HEAVY, residues appearing in b~Id are indicated to be structurally important according the Chothia et al., Mature .. ' 34~;1~77 (1989); and residues appearing in italic were altered ~5 during humanizati~n by Queen et al. (PDLD, Proc. Mall. Acad. Sci.
USA gg:10029 (1989) and Proc. Matl. Acad. 8ci, tJSA 88:2869 (1991 ):);
i. Variable tight domain:
aD CDR-1 (residues 24L-3~L): 2L, 4L, 66L-69L, 71 L
b) GDR-2 (residues 50L-56L): 35L, 46L, 47L, 48L, 49L, 58L, 62L. 64L-661:, 71 L, 73L
cl CDR-3 (residues 89L-97L): 2L, ~L, 36L, 98L, 37H, 45H, 47H, 58H, 6QH
ii. Variable heavy domain:
~.~,.,,,::..:, ., ,., :...
°~(~ 92/22b5~ ~ ~ ~ ~ ~ ~~ ~ PCI'/US92/05126 ,~,,>..;
a) CDR-1 (residues 26H-35H): 2H, 4H, 2~H, 36H, 71 H, 73H, 76H, 78H, g2H, ;94H
b) CDR-2 (residues 50H-55H): 49H, 69H, 69H, 7't H, 73H, 78H
c1 CDR-3 (residues 95H-102H): examine atl residues as possibl~~ interaction partners with this loop, because this loop varies in sire and conformation much more than the other CDRs.
9. If after step 8 the humanized variable~domain still is lacking in desired binding, repeat step 8. In addition, re-investigate any' buried residues which might affect the 'J~ -,/H interface (but ~rvhich would not directly affect CDR conformation). Additionally, evaluate the accessibility of non-CDR residues to solvent.
WO 92/22653 ~ 1 0 ~ ~ ~ ~ PCf'/US92/05126 EXAMPLE ~. En4ineering a Humanized Bist~ecific Ftab')2 Fragment This example demonstrates the construction of a humanized bispecific antibe:'y (BsF4ab')av1 by separate E, coii expression of each Fab' arm followed by directed chemical coupling in vitro. BsFlab')2 v1 ianti-CD3 anti-p185"ER2) was demonstrated to retarget the cytotoxic activity of human CD3+ CTL in vitro against the human breast tumor cell line, SK-BR-3, which overexpresses the p185"Epa product of the protooncogene HER2. This example demonstrates the minimalistic humanization strategy of installing as few murine residues as possible into a human antibody in order to recruit antigen-binding affinity and biological properties comparable to that of the murine parent antibody: This strategy proved very successful for the anti-p185"ERaarm of BsF(ab')2v1. tn contrast BsF(ab')2 v1 binds to T cells via its anti-CD3 arm much less efficiently than does the chimeric BsF(ab')Z
which contains the variable domains of the murine parent anti-CD3 antibody.
Here w~ have constructed additional BsF(ab)2 fragments containing variant anti-CD3 arms with selected murine residues restored in an attempt to improve antibody binding to T cells: One such variant, Bs Ftab')Z v9, was created by replacing six residues in the second hypervariable loop of the anti-CD3 heavy 2t? chain variable domain of BsFfab')a v1 with their counterparts from the murine parent anti-CD3 antibody. BsF4ab')Z v9 binds to T cel)s (Jurkat) much more efficiently than does BsF(ab')~ v1 and almost as efficiently as the chimeric BsFtab')2. This improvement in the efficiency of T cell binding of the humanized BsFtab'I~ is an important step in its development as a potential therapeutic agent for the treatment of p185"'ER~-overexpressing cancers.
Bispecefic antibodies tBsAbs) with specificities for tumor-associated antigens and surface markers on immune effector cells have proved effective for retargeting effector ;cells to kill tumor targets bath in vitro and in vivo treviewed by Fanger; M. W. et aJ., tmrrrunol. Today 10: 92-99 11989);
Fanger; M: W. et' al., lmmunol. Today 12: 51-54 (1991 ); and Nelson, H., Cancer Gells 3: 163-1 ?2 41991 )).' t3s~(ab') z fragments have often been used in preference to intact t3sAbs in retargeted cellular cytotoxicity to avoid the risk of killing innocent bystander cells binding to the Fc region of the antibody. An additional advantage of BsFtab')a over intact BsAbs is that they r~:~!:~'° ~ .:,,' . ;: ' : ,.~-r:, . . ;~ ' ~'~:':' ,::, ;;;. . , ..:v.. ,;.~:. .
W4 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/U592/05126 ,....,.
$~
are generally much simpler to prepare free of contaminating monospecific molecules (reviewed by Songsivilai, S. and Lachmann, P. J., Clin. Exp.
Immunol. 79: 315-321 (1990) and Nolan, O. and O°Kennedy, R., Biochim.
Biophys. Acta 1040: 1-11 (1990)).
BsF(ab')Z fragments are traditionally constructed by directed chemical , coupling of Fab' fragrnents obtained by'limited proteolysis plus mild reduction of the parent rodent monoclonal Ab (Brennan, M. et al , Science 229, 81-83 (1985) and Glennie, M. J, etal.-',°J. lmmunol, 139: 2367-23?5 (1987)).
One such BsF(ab')a fragment (anti-glioma associated antigen / anti-CD3) was found to have clinical efficaoy in glioma patients (Nitta, T. etal., Lancet 335:
36$-371 (1990) and another BsF(ab')2 (anti-indium chelate ! anti-carcinoembryonic antigen) allowed clinical imaging of colorectal carcinoma (Stickney, D. R. etal:, Antibody, Imrrrunocanj. Radiapharm. 2: 1-13 (1989)).
Future BsFtab')2 destined for clinical applications are likely to be constructed from antibodies which are either human or at least "humanized" (Riechmann, L. etal., Nature 332: 323-327 (1988) to reduce their immunogenicity (Hale, G. et al.; Lancet i: 1394-1399 (1988)).
Recently a facile route to a fully humanized BsF(ab')x fragment designed for tumor immunatherapy has been demonstrated (Shalaby, M. R. et al., J.
Exp: Mea! 175: 217-225 (19921): This approach involves separate E. coli expression of each Fab' arm followed by traditional directed chemical coupling in vitro to form the BsF(ab')2. Orie aim of the BsF(ab')a was a humanized version (Carter, P. et al.; Proc. Natl. Acad Sci. USA ( 1992a) and -., Cartel, P., et al., BiolTechnology 10: 163-167 (1992b)) of the marine ~5 monoclonal Ab 4D5 which is directed against the p185"~R2 product of the p~rotooncogene HER2 (c-erbB-2D (Fendiy, B. M. et al.. Cancer Res. 50: 1550-1558 (1989)). The humanization of the antibody 4D5 is shown in Example 1 of this application. The second arm was a minimalistically humanized anti-CD3 antibody (Shalaby etal:'supra) which was created by installing the CDR
loops from the variable domains of the marine parent monoclonal Ab UCHT1 (Beverley; P: C. L. and Callard; R. E., Eur. J. lmmunol. 11: 329-334 (1981 )) into the humanized anti-p185"ERZ antibody. The BsF(ab')2 fragment containing the most potent humanized anti-CD3 variant (v1 ) was demonstrated by flow ' cytometry to bind specifically to a tumor target f . .. ,:~.~ . .v.,.,,. ".;....,. , ., : ~ ~,..:....'.,. :. . w.
. , WO 9Z/22653 ~ ~ tl ~3 ~ ~ ~ PCH'/US92/05126 .., ~I
overexpressing p185"ERZ and to hurnan peripheral blood mononuclear cells carrying CD3. in addition, Bs Flab' )z v1 enhanced the cytotoxic effects of activated human CTL 4-fold against SK-BR-3 tumor cells overexpressing p185'°~Z. The example descries efforts to improve the antigen binding affinity of the humanized anti-CD3 arm by the judicious recruitment of a smelt number of additional murine residues into the minimalistically humanized anti-CD3 variable domains.
MATERIALS AND METH~DS
C~nstruction of mutations in the anti-CD3 variable region ,genes.
The construction of genes encoding humanized anti-CD3 variant 1 (v1 ) variable light (V~) and heavy (V") chain damains in phagemid pUC119 has been described (Shalaby et al. supra): Additional anti-CD3 variants were generated using an efficient site-directed mutagenesis method 4Carter, P., Muta9enesis: a~ practical approach, dM. J. McPherson, Ed.), Chapter 1, IRL
Press, Oxfiord, UK ( 1991 )) using mismatched oligonucleotides which either install or remove unique restriction sites. f?ligonucleotides used are listed below using lowercase o indicate the targeted mutations. Corresponding ~24 coding changes are denoted by the starting amino acid in one letter code followed by the residue numbered acdording to Kabat, E. A. etal., SeQuences of Proteins of Immunplogicat Jnterest, 5'" edition, National Institutes of Health; Bethesda, MD; USA 11991 ); then the replacement amino acid and ~; 'f finally the identity of the anti-CD3 variant:
HX 11; 5' GTAGATAAATCCtctAACACAGCCTAtCTGCAAATG 3' (SEC~:ID. NO. 11 ) VH K75S, v6;
HX12; 5' GTAGATAAATCCAAAtctACAGCCTAtCTGCAAATG 3' 6SEQ.tD. NO. 12) V" N76S; .v7;
HX13, 5' GTA~ATAAATCCtcttctACAGCCTAtCTGCAAATG 3' i (SEQ.ID. NO. 13) V" K75S:N76S' v8;
X14, 5' CTTATAAAGGTGTTtCcACCTATaaCcAgAaatTCAA
GGatCGTTTCACgaTAtcCGTAGATAAATCC 3' (SEQ.ID.ND. 14) V" T5'?S:A6DN:D61 Q:S62K:V63F:G65D, v9;
LX6, 5' CTATACCTCCCGTCTgcatTCTGGAGTCCC 3' (SEQ.ID. NO. 15) ,.. .,~ '..:~:~ . :..' :'.~.., . :y., . . . ~.~.. . ,.
. a . :"f. . .
P
~cr/us~zeomz6 , .
WO lB/~~653 V~ E55H, v11.
Oligonucleotides HX11, HX12 and HX13 each remove a site for BspMl, whereas LX6 removes a site for Xhol and HX14 installs a site for Eco~3V
(bold). Anti-CD3 variant v10 was constructed from v9 by site-directed mutagenesis using oligonucleotide. HX13, Mutants were verified by dideoxynucleotide sequencing. (Sariger, F. et al., ProG. IVatl. .4cad. Sci.
PISA
74: 5463-5467 (1977)).
E, coli expression of Fab' fragrr~ents The expression plasmid, pAK19, for the co-secretion of tight chain and heavy chain Fd' fragment of the most preferred humanized anti-p185"ERz variant, HuMAb4D5-8; is described in Carter et al., 199~b, supra. Briefly, the Fab' expression unit is bicistronic with both chains under the transcriptional cantrof of the phoA promoter. Genes encoding humanized V~
and V" domains are precisely fused on their 5' side to a gene segment encoding the heat-stable enterotoxin II signet sequence and on their 3°
side to human k, C~ and IgG1 C"1 constant domain genes, respectively. The C"1 gene is immediately followed by a sequence encoding the hinge sequence CysAlaAla and followed by a b~cteriophage ~I to transcriptiona) terminator.
Fab' expression plasrv~ids for chimeric and humanized anti-CD3 variants (v1 to v4, Shalaby et at.aupra; v6 to v1 ~, this study) were created from pAK19 by precisely repBacing anti-p185"~Z V~ and V" gene segments with those .~
,~, encoding mursne and ct~rresponding humanized variants of the anti-CD3 ~5 antibody, respedtively; by sub-cloning and site-directed mutagenesis. The Fab' expressign ptasmid for the most potent humanized anti-CD3 variant identified in this study (v9) is designated pAK2~. The anti-p185"~2 Fab' fragment seas secreted fr~m ,~. coli K12 strain 25F2 containing plasmid pAK19 grown for 32 to~40 hr at, 37' C in an aerated 10 liter fermentor. The final cell densigy vvas 120-150 ODSSO and the titer of soluble and functional anti-pi 85"E'~2 Fab' was 1-2 g/titer as judged by antigen binding ELISA
(Carter et al., 199~b, supra). Anti-CD3 Fab' variants were secreted from E coli containing c~rresponding expression plasmids using very similar fermentation protocols. The highest expression titers of chimeric and O 92J22ba3 ~.~ o ~ ~ ~ ~ P~1~S92I051~b humanized anti-GD3 variants ware 2ta0 mgAiter arid 700 mgliiter, rsspeGtively, as judgBd bY total immunoglobulin LISA.
Cansrructlon of esF(ab'ls fragments Fab' fragments ware directly recovered from E. toll fermentation pastes in th0 free thiol form (Fab'-SH) by affinity pu~ificatiar~ on Streptococcal protein G at pH 5 in the presence of ~DTA (Carter et al., 199~b supra).
Thioether linked BsFtab'iz fragments (antnpf $5'~RZ J anti-CD3) were constructed by the procedure of Glannie'et al. supra with the following modifications. Anti-p 1 i35"~ Fob'-SH in t fl0 rriM 'Cris acetate. 8 mM SDTA
(pH ~,O) was reacted with O.t vol of 40 mM N.N'-1,2-phenylenedimatemide (o-PDM) in dinn~athy) lormamide for -'I.5 hr at 20 -C. ~xcass o-PDM was removed by protein G vurifiaation of the Fab' maioimide derivative (Fob'-mal) followed by buffer exchange into 24 rnM sodium acetate, 5 mM I:DTA (pH
5.~) Icoupllng buffer) using o~ntriprep-'~0 concentrators (AmiGOn). The total eoncentration of Fab' variants was estimated from the measured absorbents at 280 nm (Hu~b4D5-8 Fab° a°."' ° '1.56, Carter et al., 1992b, supra).
The free_ti~141 content of Fab' preparations was estimated by reaction with 5, 5'-dithiobis(2-nitrobenzoic ,acid) as desoribed by Creighton, T. E..
protein structura~ a praciical~apprvach, IT. E. Creighton, Ed.). Chapter 7, IRL Press.
Oxford, UK ( 1990), Fquimolar amounts of anti-p185"a" Fob'-ma) (assumivg ' quantitative, reaotlon of Fab'-SH with 4-PDM) and each anti-Ci7S Fab'-SH
variant werecoupled together at a combined concentration of 1 to 2.5 mgJrnl in the Goupl4rtg buffer for to to 48 hr at, 4 'C. The coupling reaction was ~'' ad ju~te~ td 4 mM cysteine ax IpH~ 7.0 and ~ incubated for 15 min at 20 ' C to reduce .any ~Wa~rted disulfide-linked Flab' )= formed. These reduction Gorrditians are sufficient to redi~Ge inter-heavy, chin disulfide bonds with virtually no' reduction of the disulfide between light and heavy chains. Any free thiol~ generated were their blacked with a0 mM iodaacetamida.
BsF(a~'Iz wss isolated f~bm the Coupling reaction by S 9 DO-HR IPharmaoia) 5iz9 eXC,lusion cnr'"omatogrsPhy -I2-5 crrr x 1 d0 Gm) in the presence of P~3S.
The BsFtab'l,.,samplqs ,were passed through a 0.2 mm filter flesh frozen in .
liquid nitrogen aryl stored at ~~-'~Q:'~~
*_.~rade.mark TOTRL P.20 5.& 19/12/20(71 16:23 X416 368 1645 - -_ Oreceived WO'~2/22653 ~ ~ ~ ~ ~ ~~ ~ P~f/US92fOS126 ,-FIoHr cyto~etric analysis of Flab' i?binding to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Culture Collection (Rockviile, MDD (ATCC TIB 152D and Brawn as recommended by the ATCC. Aliquots of 10~ Jurkat cells were incubated with appropriate concentrations of BsFfab'D2 tanti-p185"ER2 / anti-GD8 variantD or control mono-specific'~anti-p185"ER2 F(ab')2 in PBS plus 0.1 °~
~w/vD bovine serum albumin and.10 mM sodium azide for 45 min at 4 "C.
The cells were washed and than incubated with fluorescein-conjugated goat anti-human F(ab'DZ tOrganon Teknika, West Chester, PAD for 45 min at 4 ° C.
Cells were washed and analyzed on a FAGScan tBecton Dickinson and Go., Mountain View, CA1. Cells (8 x 10~D were acquired by list mode and Bated by forward light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~ and at 37 out of 122 positions within VH ~Shalaby et ~l.,su~raD 1992D: Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine «sidues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were ~rigina9ly kept as human sequences in our minimalistic humanization regime.
Thus human residues in VH CDR2 of anti-GD8 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
T57S:A60N:D61 Q:S62K:V63F:G65D (Fig. 5D. Similarly, the human residue E55 in VL CDR2 of anti~CD3 v1 was replaced with histidine from the marine anti-GD3 antibody to generate anti-CD3 v11. In addition, V" framework region tFRD resialues 75 and 76 in anti-CD3 v1 were also replaced with their marine counterparts to creqte anti-CD3 v8: K75S:N76S. VH residues 75 and 76 are located in a loop close to V,~ C~R 1 and CDR2 and therefore might ~.,.,,-.;.: .. .., . .
,...~,~V~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92/OS126 sS
influence antigen binding. Additional variants created by combining mutations at these three sites are described below.
Preparation of BsF(ab°,12 fragments Soluble and functional anti-p185"~R~ and anti-CD3 Fab' fragments were recovered directly from corresponding E. Coli fermentation pastes with the single hinge cysteine predominantly in the free thioi form (75-100 % Fab'-SH) by affinity purification on Streptococcal protein G at pH
5 in the presence of EDTA (Carter et al., 1992b, supra). Thioether-linked BsF(ab')2 fragments were then constructed by directed coupling using o-PDM
as described by Glennie et al., supra. One arm was always the most potent humanized anti-p185"ERZ variant, HuMAb4D5--8 (Carter etal., 1992a, supra) and the other either a chimeric or humanized variant of the anti-CD3 antibody. Anti-p185"E"2 Fab'-SH was reacted with A-PDM to form the rnaleimide derivative (Fab'-mal) and then coupled to the Fab'-SH
for each anti-CD3 variant. F(ab')2 was then purified away from unreacted Fab' by size exclusion chromatography as shown for a representative preparation (BsF(ab')~ v8) in data not shown. The F(ab')Z fragment represents ~- 54~ of the total amount of antibody fragments (by mass) as judged by integration of the chromatograph peaks.
SDS-PAGE analysis of this BsF(ab')a v8 preparation under non-reducing conditions gave one major band with the expected mobility (M, -- 96 kDD as well as several very minor bands (dada not shown). Amino-terminal sequence ; ,~
analysis of the major band after efectroblotting on to polyvinyiidene difiuoride 26 membrane Mat~udaira, P:, J. .Biol. Chew. 282: 10035-10038 (198'7) gave the expected nnixed sequence from a stoichiometric 1:1 mixture of light and heavy chains (V~ l V": D/E, I/~J, QIQ, M/L, TIV, Q/E, S/S) expected for BsF(ab')2. The amino terminal region of both light chains are identical as are both heavy chains and correspond to donsensus human FFi sequences.
We have previously demonstrated that F(ab')2 constructed by directed chemical coup9in~ carry both anti-p185"~''2 and anti-CD3 antigen specificities (Shalaby et aL; supra). The level of contamination of the BsF(ab')2 with monospecific ~(ab' )2 is likely o be very low since mock coupling reactions with either anti-p185"E"2 Fib'-mal or anti-CD3 Fab'-SH alone did not yield detectable 2~~0~~;~~
CVO 92/22653 PC'I'/US92/d5126 - -w.
8 (~
quantities of Flab' )Z. Furthermore the coupling reaction was subjected to a mild reduction step followed by alkylation to remove trace amounts of disulfide-finked Flab' )2 that might be present. SDS-PAGE of the purified F(ab' )2 under reducing conditions gave two major bands with electrophoretic mobility and amino terminal sequence anticipated for free light chain and thioether-linked heavy chain dimers.
Scanning LASER dsnsitometry of a o-PDM coupled F(ab')Z preparation suggest that the minor species together represent --10°~ of the protein.
These minor contaminants were characterized by amino terminal sequence analysis and were tentatively identified on the basis of stoichiometry of light and heavy chain sequences and their electrophoretic mobility (data not shown). These data are consistent with the minor contaminants including imperfect Ftab' )z in which the disulfide bond between light and heavy chains is missing in ane or both arms, trace amounts of Fab' and heavy chain thioether-linked to tight chain.
finding of BsF(ab'Jz to Jurkat cells Binding of BsFtab')2 containing different anti-CD3 variants to Jurkat cells (human acute'T cell IeukemiaD was investigated by flow cytometry (data not shown). BsF(ab')a v9 binds much more efficiently to Jurkat cells than does our starting molecule; BsF(ab°)a v1, and almost as efficiently as the chimer'sc BsFtaka')2. Installation of additional marine residues into anti-CD3 v9 to create v10 (V" K75S:N76S) and v'l2 (V,~ K75S:N76S plus V~ E55H) did s: P
not farther improve, binding of corresponding BsF(ab°)2 to Jurkat cells. Nor did recruitment of these s°reurine residues into anti-CD3 v1 improve Jurkat binding: V~, K75S (v6): d/~ N76S tv7), V~, K75S:N7CS tvB), V' E55ii tv11 ) tnot shown). BsF(ab')2 v9 was chosen for future study since it is amongst the most efficient variants in binding to Jurkat cells and contains fewest marine residues in the humanized anti-CD3 arm. A monospecific anti-p1 B5~'~RZ Flab' )a did not show significant binding to Jurkat cells consistent with the interaqtion being mediated through the anti-CD3 arm.
DISCUSSI~N
A minima(istic strategy was chosen to humanize the anti-p1 B5"E~2 V1'~CD 92/22653 ~ ~ ~ ~ ~ ~ ~ PCTlUS92l0512G
(Carter efi al., 1992a, supra) and anti-CD3 arms (Shalaby et al., supra) of the BsF(ab')2 in this study in an attempt to minimize the potential immunogenicity of the resulting humanized antibody in the clinic. Thus we tried to install the minimum number of marine CDR and FR residues into the context of consensus human variable domain sequences as required to recruit antigen-binding affinity and biological properties comparable to the marine parent antibody. Molecular modeling was used firstly to predict the marine FR
residues which might be important to antigen binding and secondly to predict the marine CDR residues that might not be required. A small number of humanized variants were then constructed to test these predictions.
Our humanization strategy was very successful for the anti-p185"ERz antibody where one out of eight humanized variants (HuMAb4D5-8, IgG 1 ) was identified that bound the p185"~RZ antigen - 3-fold more tightly than the parent marine antibody (Carter at al., 1992a, supra). HuMAb4D5-8 contains a total of five marine FR residues and nine marine CDR residues, including V"
CDR2 residues 60-65, were discarded in favor of human counterparts. In contrast, BsF(ab')2 vl containing the most potent humanized anti-CD3 variant out of four originally constructed (Shalaby etal., supra) binds J6 cells with an affinity (/Cd) of 140 nM which is -- 70-fold weaker than that of the _ corresponding chimetic lBsF(ab')2.
Here we have rest~red T cell binding of the humanized anti-CD3 close to that of the chimeric variant by replacing six human residues in V" CDR2 with their marina aounte~parts: T57S:A60N:D61 C~:S62K:V6SF:G65D (anti,; $
CD3 v9; Fig. 5). It.appears rinore 6ikely that these marine residues enhance antigen binding indirectly by influencing the conformation of residues in the N-tarmirfal part of V" CDR2 rather than by directly contacting antigen.
Firstly, only N-terminal residues in V" CDR2 (50-58) have been found to contact antigen ih one or more of eight crystallographic structures of antibody/antigen complexes (Kabat et al., supra; and Mian, 1. S. at al., J.
lVfot. viol. - 2'! 7: 183-151 ( 1991 ): Fig. 5). Secondly, molecular modeling suggests that residues in the C-terminal part of V" CDR2 are at least partially buried tFig. 5). BsF(ab')a v9 binds to SK-BR-3 breast tumor cells with equal efficiency ~o BsF(ab°)2 v1 and chimeric BsF(ab')Z as anticipated since the anti-p185"ERa arm is identical in all of these molecules (Shalaby et al., supra, not W~O 92!22653 ~ ~ ~ ~ ~ ~j PCf'/US92/05126 shown).
Our novel approach to the construction of BsF(ab')2 fragments exploits an E. coli expression system which secretes humanized Fab' fragments at gram per titer titers and permits their direct recovery as Fab'-SH (Carter et al., 1992b, supra). Traditional vdirected chemical coupling of Fab'-SH
fragments is then used to form BsF(ab')2 in vitro (Brennan et al.,supra; and Glennie et al., supra). This route to Fab'-SH obviates problems which are inherent in their generation from intact antibodies: differences in susceptibility to proteolysis and nonspecific cleavage resulting in heterogeneity, low yield as well as partial reduction that is not completely selective for the hinge disulfide bonds. The strategy of using ~ co/i-derived Fab'-SH containing a single hinge cysteine abolishes some sources of heterogeneity in BsF~ab')2 preparation such as intra-hinge disulfide formation and contamination with intact parent antibody whilst greatly diminishes others, eg. formation of Flab' )3 fragments.
BsF(ab'l2 fragments constructed here were thioether-linked as originally described by Gteenie et a/., supra with future in vivo testing of these molecules in mind-. Thioether bonds, unlike disulfide bonds, are not susceptible'ta cleavage by trace amounts of thiot, which led to the proposal 2Q that thioether-linked Flab' )2 may be more stable than disulfide-(inked F(ab' )2 in vivo (Glennie et al., supra): This hypothesis is supported by our preliminary pharmecokinetic experiments in normal mice which suggest that thioether-finked BsF(ab')Z vl has a 3- fold longer plasma residence time than ~; ~
BsF(ab')2 v.1 iinked'by a single disulfide bond. Qisulfide and thioether-linked chime~ic BsF(ab')Z,were found to be indistinguishable in their efficiency of cell binding and in their retafgeting of CTL cytotoxicity, which suggests that o-PDM directed cou~ating does not compromise binding of the BsF(ab°)2 to either antigen (not shown). Nevertheless the nature of the linkage appears not to be critical since; a disulfide~lir~ked BsF(ab')2 (marine anti-p185"ERZ
i marine anti-CD3) was 'recently shown by others (Nishimura et al., lnt. J.
Cancer 50: 800-804 (192) to have potent anti-tumor activity in nude mice.
Our previous study (Shalaby et al.; supra! together with this one and that of Nishimura~ T. et al., supra improve the potential for using BsF(ab')a in targeted immunotherapy of ~pl g5"ERZ_overexpressing cancers in humans.
. . . ..
. :, . . ° y . . ', . . . .
W(~ 92/22653 ~ ~, Q ~ o ~~ 9 PCT/LJS92/05126 ~~
EXAMPLE 4. Humanization of an anti-CD18 antibody A marine antibody directed against the leukocyte adhesion receptor ~-chain (known as the H52 antibody) was humanized following the methods described above. Figures 6A and 6~ provide amino acid sequence comparisons for the marine and humanized antibody light chains and heavy chains.
... , : .. . .. , ;.
!~O 92/22653 ~ ~ Q ~ ~ y ~ ~ Q Pt.T/U~92/05126 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
(ii) TITLE OF INVENTION: Imamunoglot~ulin Variants (iii) NUMBER OF SEQUENCES: 25 ~ . , , (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco '95 (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A} MEDIUM TYPE: 5.25 inch, 360 K'~ floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(.A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
3G1 (vii) PRIOR AP,PLICAT~ON DATA:
(A) APPLICATION NUMBER: 07/715272 (B) APPLICATION DATE: 14-JUN-1991 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Adler, Carolyn R.
(B) REG1STRATION NUMBER: 32,324 (C) REF'ERENCE/DOCKET NUMBER: 709P1 , r; .~
(ix)- TELECOMMUNICATION TNFORMATION:
~() (A) TELEPkIONE: 415/225-2614 (B) TELEFAX: 415/952-9881 (C} TELEX: 910/371-7168 (2) INFORMATION
FOR SEQ
ID N0:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 109 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear ~ ~ ~
~ ~ '~
~
' .. ~'Vb'Q 92/22b53 T/US92/05125 P(.
(xi) SEQUENCE DESCRIPTION: SEQID
N0:1:
Asp Ile Gln Thr GlnSer ProSer SerLeu SerAla SerVal Met GIy Asp Arg Thr IleThr CysArg AlaSer GlnAsp ValAsn Val Thr Ala Va1 Trp TyrGln GlnLys ProGly LysAla ProLys A1a Leu Leu Ile Ser AlaSer FheLeu GluSer GlyVal ProSer Tyr Arg Fhe Ser Ser ArgSer GlyThr AspFhe ThrLeu ThrIle GIy Ser Ser Leu Pro GluAsp PheAla ThrTyr TyrCys GInGln G1n His Tyr Thr Pro ProThr PheGly G1nGly ThrLys ValGlu Thr 95 100 lOS
I1e Lys Arg Thr 2~a 109 ' (2) INFORMATION FOR
SEQ
ID
N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: acids 120 amino (B) TAPE: amino acid (D) 3,'OPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQID
N0:2:
Glu Val Gln Val GIuSer GlyG1y G1yLeu ValG1n FroGly Leu 1 5 10 15 ,~,~
~e GIy Ser Leu Leu SerCys AlaAla SerGly FheAsn IleLys Arg Asp Thr Tyr His TrpVa1 ArgGln AlaPro GlyLys G1yLeu Ile ~4~ Glu Trp Va1 Arg IleTyr ProThr AsnGly TyrThr ArgTyr Ala Ala Asp Ser Lys GIyArg PheThr IleSer A1aAsp ThrSer Val Lys Asn Thr Tyr LeuGln MetAsn SerLeu ArgAla GluAsp Ala 9~V(~ 92/22653 ~ ~ ~ ~ ~ .j ~ P~'/1JS92/05126 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp G1y Phe Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Leu Va1 Thr Val Ser Ser (2) INFORMATION FOR SEQ ID N0:3:
1~ (i) SEQUENCE CHARACTERISTICS:
(Aj LENGTH: 109, amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Asp Ile G1n Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val 24 Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys A1a Pro Lys Leu Leu Ile Tyr Ala A1a Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr I1e Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys G1n Gln 35 Tyr Asn Sex Leu Pro Tyr Thr Phe Gly GIn Gly Thr Lys Ua1 Glu Ile Lys Arg Thr 109 ' (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
50 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val G1n Pro Gly GIy Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser ....' ,, , '..' ":'. . , ,.~ , .; ~.~'~... ..,;...~ , ,. ..... ' ... v ',:.'.~
. ...... ...
W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ ~CI'/U~92/~5126 q 43 Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 . 40 45 Glu Trp Val Ala Val Ile Ser Glu Asn Gly Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser 65 ?0 ?5 1A Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 '100 105 A1a Met Asp Val Trp Gly G1n Gly Thr Leu Val Thr Val Ser Ser 2~0 (2) INFORMATIONFOR SEQ
ID N0:5:
( i) SEQUENCECHARACTERISTICS:
(A) LENGTH: acids 109 amino (B) TYPE: amino acid (D) TOPOLOGY:
linear (x i) SEQUENCEDESCRIPTION:SEQ ID
N0:5:
Asp Ile Val Thr Gln His LysPhe MetSer ThrSer Val Met Ser 3~ 1 5 10 15 Gly Asp Arg Ser Ile Cys LysAla SerGln AspVal Asn Val Thr ~5, Thr Ala Va1 Trp Tyr Gln LysPro G1yHis SerPro Lys Ala Gln 35 . 40 45 Lsu Leu Ile Ser Ala Phe ArgTyr ThrGly ValPro Asp Tyr Ser . 50 55 60 Arg Phe Thr Asn Arg Gly ThrAsp PheThr PheThr Ile Gly Ser ~,5 ?0 75 Ser Ser Val Ala Glu Leu A1aVal TyrTyr CysGln Gln Gln Asp ~5 80 85 90 His Tyr Thr Pro Pro Phe GlyGly GlyThr LysLeu Glu Thr Thr 95 ~ 100 105 50 Ile Lys Arg Ala V1~~ 92/22653 ~ ~ ~ ~ '~ ~ . F'C°T/6.JS92/AS126 {2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Leu Lys Leu Ser Gys Thr Ala Ser G1y Phe Asn Ile Lys ~ 25 30 Asp Thr Tyr Ile His Trp Val Lys G1n Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Asp Pro Lys Phe Gln Asp Lys A1a Thr Ile Thr A1a Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Val Ser Arg Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp G..y Gly Asp G1y Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Ala Ser Val Thr Val Ser Ser 110 11.5 120 (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27.bases ' (B) TyPE:wucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 bases (B) TYPE: nucleic acid ~t'.~~p ~ . '=J . . . . ' i '~ ~s .~,......, . .. ,...~.:~;'.: .~ , ,:;~. ,m~,:~,.'. ' , .,, ' ~.: . ~ :
' :.'." . ~ . ';. ..,.. .
'WO 92122653 210 3 f~ ~ 9 p~T/US92/OS126 °I 5 (C) STRANDEDNESS: single (D) TOPOLOGX: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 bases (B) TYPE: nucleic acid (Cj STRANDEDNESS: single (D) TOPOLOGY: linear (~ci) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION
FOR SEQ
ID N0:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 bases 34 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (~y) TOPOLOGY: linear (~ci) SEQUENCE ~3ESCRIPTION: SEQ ID N0:10:
TGAGGAGACG GTGACCGTGG TCCCTTGGCC CCAG 34 , 4i (2) INFORMATION
EOTt SEQ
ID NO:11 (i) SEQUENCE CHARACTERISTICS:
(~) LENGTH: 36 bases ~5 (B) 'TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11;
;GTAGATAAAT ~CTCTAACAC AGCCTATCT~ CAAATG 36 YS;,x r.'. ''; :.~.'~ ..,.; ., . !.,'.'..... ;.:.: ~ ,;~:. .;'..~:".. :.,. ,~i -.."~ ;... ' ''.'.".
.7 ::~ ., . .
~''~ a- .:r. . ,t.-, t ...
!< ~,~.~.. '~ ~'%'~ .., '' .Y.....~ ..;9-, v , '.'.. .,.~. ., '' ' ~ .., :;, .. " .' .~, ;, ,;~ ;., 2~.fl~f~~~
WO 92122653 V '~' '~. PC.°T/US92/0~126 (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear, (x~.) SEQUENCE DESCRIPTION: SEQ ID N0:12:
' (2) INFORMATION F'OR SEQ TD NO:13:
(i) SEQUENCE CHARACTERISTICS;
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS; single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
GTAGATAAAT CCTCTTCTAC AGCCTATCTG CAAA1'G 36 (2) INFORt~tATION
FOR SEQ
LD N0:14:
(i) SEQUENCE CHARACTERISTICS:
(~,) ' ~;EN~TH: 68 bases ~5 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) T0P0LOGY: liner ,; r~
(xi) SEQUENCE'DESCRIPTION: SEQ ID N0:14:
CTTATAAAGG TGTTTCCACC TATAACCAGA AATTCAAGGA TCGTTTCACG
$5, ATATCCGTAG ATAAATCC 68 (2) INFORMATION
FOR SEQ
ID NO:15:
50 (i) SEQUENCE CHARACTERISTICS:
(Al LENGTH: 30 bass (g) TYPE: nucleic arid (C) STRANDEDNESS: singly (D) TOPOLOGY: linear k 'n. ,. ~ ..- ~,, .:. ~,' . ~ ~ .~ . , ,~., ,,~... -y... ~ ::. ,. ..... . ...
7 r..~:....,. . ~::; .mt.~ , ..:-... . .. ' . ~. ~ ,. . .... ~.~..'. ,... ~ ~.
-.w . ..
P~'/LJS92/05126 (xi)~SEQUENCE DESCRIPTION: SEQ ID N0:15:
(2) INFORMATION FOR SEQ ID N0:16:
( i) SEQUENCE CHE~RACTERISTICS
(A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:16:
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Va1 Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pra Asp G1y Thr Va1 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser G1y Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile ' 3~ 65 70 75 Ser Asn Leu Glu Gln Glu Asp Ile A1aThr TyrPhe CysG1n Gln Gly Asn Thr Leu Pro Trp Thr Phe AlaGly GlyThr LysLeu Glu 95 100 , 1,05 Ile Lys (2) INFORMATION FOR SEQ ID N0:17:
(i,) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 107 amino acids (B) APE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID,N0:17:
5~: Asp Ile Gln Met Thr Gln Ser Pro SprSer LeuSer AlaSer Val Gly Asp Arg Val Thr Ile Thr Cys ArgAla SerGln AspIle Arg . 20 25 30 WU 92/2263 ~ ~ ~ ~ PGT/LJ892/05126 ~ ~~ ~
B
Asn Tyr TrpTyr GlnGln LysPro GlyLys AlaPro Lys Leu Asn Leu Leu TyrThr SerArg LeuG1u SerGly ValPro Ser Ile Tyx Arg Phe SerGly SerGly ThrAsp TyrThr LeuThr I1e Ser Gly Ser Ser ProGlu AspPhe AlaThr TyrTyr CysGln Gln Leu Gln G1y Asn ProTrp ThxPhe GlyGln GlyThx LysVal Glu Thr Leu 95 '100 105 Ile Lys (2) INFORMATION SEQ
FOR ID
N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) acids LENGTH:
1.07 amino (B) amino TYPE: acid (D) linear TOPOLOGY:
(xi) SEQUENCE SE~QID
DESCRIPTION: N0:18:
Asp Ile ThrGln SexPro SerSer LeuSer AlaSer Val Gln Met Gly Asp Theale ThrCys ArgAla SerGln SerIle Ser ArE
Val Asn Tyr TrpTyr GlnG1n LysPro GlyLys AlaPro Lys Leu Ala 35 40 ~5 Leu Leu Ala'A1aSerSer LeuG1u SerGly ValPro Ser Ile Tyr 50 55 60 ~..a 4~ Arg Ptae SerGly SerGly ThrApp PheThr LeuThr Iie Ser Gly Ser Ser ProGlu AspPhi A1aThr TyrTyr GysG1n Gln Leu Gln Tyr Asn ProTxp ThrPhe GlyGln GlyThr LysVal Glu Ser Leu iii LyS
~.~~
V~iJ 92/22653 ~ ~ ~ c~! ~ ~ ~ PCTlUS92/~5126 (2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOL(?GY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr ~ 25 30 Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met Gly Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr 20 50 55 fi0 Asn Gln Lys Phe Lys Asp Arg Phe Thr Ile Ser Lys Ala Thr Leu 25. Thr Val AspwLys Ser Ser Ser Thr Ala Tyr Leu Met Glu Leu Leu Asn Ser Leu Thr Ser Glu Asp Sex A1aVal TyrTyr CysAla Arg Ser Gly Tyr Tyr G1y Asp Ser Asp ~rpTyr PheAsp ValTrp Gly Ala Gly Thr Thr Val Thr Val Ser Ser (2),INFORMATION FOR SEQ ID ~:r N0:20:
(i),SEQUENCE CHARACTERISTICS:
(A) LENGTH: '122 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID
N0:20:
Glu Val Gln Leu Val Glu Ser Gly GlyGly LeuVa1 GlnPro Gly Gly Ser L~u Arg Leu Ser Cys -AlaAlaSer GlyTyr SerPhe Thr Gly Tyr~Thr Met Ann Trp Val Arg GlnAla ProGly LysGly Leu ~V~O X2/22653 ~ ~ ~ ~ ~ ~ ~ ~"~i'/11S~32/OS126 Glu Trp Val Ala Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe Lys Asp Arg Phe Thr IIe Ser Val Asp Lys Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala G1u Asp Thr Ala Va1 Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Sar Asp Trp Tyr Phe Asp Val Trp Gly Gln G1y Thr Leu Val Thr Val Ser Ser (2) INFORMATION FOR SEQ
ID N0:21:
~0 ( i} SEQUENCE CkIARACTERISTICS:
(A) LENGT~1: 122 aminoacids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE SEQ ID
DESCRIPTION: N0:21:
Glu Val Gln Leu Val Glu G1y GlyGly LeuVal GlnPro Gly Ser Gly Ser Leu Arg Leu Ser Ala AlaSer GlyPhe ThrPhe Ser Cys Ser Tyr Ala Met Ser Trp Arg GlnAla ProGly LysGly Leu Val G1u Trp Val Ser Val Ile Gly AspGly G1ySer ThrTyr Tyr Ser 40 Ala Asp Ser Val Lys Gly Phe ThrIle SerArg AspAsn Ser Arg Lys Asn Thr Leu Tyr Leu Met AsnSer LeuArg AlaGlu Asp Gln Thr A.la VaI Tyr Tyr Cys Arg G1yArg ValGly TyrSer Leu Ala Ser Gly Leu Tyr Asp Tyr GIy GlnGly ThrLeu ValThr Val Trp Ser Ser .
~v~ ~z~zzss~ 2 ~. 0 3 (~ ~ 0 ~c°°rius~zios'z6 (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 454 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRT:?TION: SEQ ID N0:22:
Gln Val G1n Leu Gln Gln Ser G1y Pro Glu Leu Val Lys Pro G1y Ala Ser Val Lys I1e Ser Cys Lys Thr,Ser G1y Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Phe Asn Pro Lys Asn G1y Gly Ser Ser His Asn Gln Arg Phe Met Asp Lys Ala Thr Leu Ala VaI Asp Lys Ser Thr Ser Thr A1a Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Gly Ile Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly Phe Asp ValArg TyrPhe AspVal TrpGly A1aGly ThrThr Val Thr Val SerSer AlaSer ThrLys GlyPro SerVal PhePro Leu AIa Pro SerSex Lys.Ser ThrSer GlyGly ThrAla AlaLeu Gly :140 145 150 Cys Leu ValLys AspTyr PhsPro GluPro ValThr Va1Ser Trp Asn Ser GlyAla LeuThr SerGly ValHis ThrPhe ProAla Val Leu G1n SerSer GlyLeu TyrSer LeuSer SerVal ValThr Val a 185 ~ 190 195 Pro Ser SerSer LeuGly ThrGln ThrTyr IleCys AsnVal Asn His Lys ProSer AsnThr LyrsVal AspLys LysVal GluPro Lys :,''... ...... ..... ,...= . ..:::.:;
i3'~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92105126 (~ Z
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His~,Glu Asp Pro Glu Va1 Lys Phe Asn Trp Tyr 27~5~ 280 285 Val Asp GIy Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu '1'hr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Lle Ser Lys 2~ Ala Lys Gly Pro Arg Pro GlnVal TyrThr LeuPro Pro Gln Glu Ser Arg Glu Met Thr Asn GlnVal SerLeu ThrCys Leu Glu, Lys Val Lys Gly Ty~cPro Asp 'IleAla ValGlu TrpGlu Ser Phe Ser Asn Gly Gln Glu Asn Tyr LysThr ThrPro ProVa1 Leu Pro Asn Asp Ser Asp Ser Phe Leu TyxSer LysLeu ThrVal Asp ~-.e Gly Phe Lys Ser Arg GlriGln Asn Val~'heSerCys SerVal Met Trp Gly 4~5 430 435 Hia Glu Ala His Asn Tyr ~'hrG1n LysSex LeuSer Leu Leia His Ser Pro Gly , Lys (2) TNFORMATIONFOR SEQ :
ID
N0:23 ( j.) SEQUENCECHARACTERISTICS:
(A)' LENGTH: 57 aminoacids (~) TYPE: ami no acid (D)'TOPOLOGY: linear '~V~ 92/22653 ~ ~ ~ PC1'/U~92/0512~6 p o3 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
His His Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe 1'hr Glu Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser G1y Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Sex Cys Ala Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala G1y Ile Asn Pro Lys Asn Gly Gly Thr Ser His Asn Gln Arg Phe Met Asp Arg Phe 110 las 120 Thr Il.eSerVal AspLys SerThr SerThr A1a TyrMet GlnMet 3G Asn Ser LeuArg AlaGlu AspThr AlaVal Tyr TyrCys AlaArg Trp Arg GlyLeu AsnTyr GlyPhe AspVal Arg TyrPhe AspVal Trp Gly GlnGly ThrLeu Va1Thr ValSer Ser AlaSex ThrLys 170 1.75 180 G1y Pro SerVal Phe-Pro LeuAla PrnCys Ser ArgSer ThrSer Glu Sar ThxAla AlaiLeu GlyCys LeuVal Lys AspTyr PhePro 45- Glu Pro ValThr ValSer TrpAsn SerGly Ala LeuThr SerGly Val His ThrPhe ProAla ValLeu GlnSer Ser GlyLeu TyrSer Leu Ser SerVal ValThr Val'ThrSerSer Asn PheGly ThrGln ;:.r F:.:.., P ~
J.,,~, ~.~i,. :.., y 7 !3 >
Gu.
tG 7. .:: k 7 .
.. ~x I .:fin 1 , 4 4 ~0.' .A.-a., . ..>t d~'. ~ r 1 ' .~ 1 ~~.4r ~. , 7f , ,,. > . . ~, .' a"
:,:4" ...
:~ ;. , , F,.., . ...:;~ .;'~',t...y, ;.:. ,";'.~,;: ' .. ;.,.~.'~~o,> , ' m ", ..y'.. .., ' ,.. ' ..'...~~ ~ . .,. .~ , ',~;~ .... ,, ,. ~.:.;
r, . , ' ". . ~ ~ .;,.;~.~ . . ",. v:.,:. , . ;: , , . . ,..,. . ;. ,.. . ~
.~'~.. . ~.:.~.~ . :~ ~ ~ ' ~ .: , ~..,~. ..:.~ .,.
WCD 92/22653 ~ ~ ~ J ~ ~ ~ PC.TlUS92/05126 Ion Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Z'hr Val Glu Arg Lys Cys Cys Val Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 305 ~ 310 315 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 320 ~ 32S 330 Glu Cys Pro Pra Cys Pro Ala Pro Pro Val A1a G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Sex Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Met Ghu Val Hi.s 380 385 ~390 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Va1 Ser Asn Lys Gly Leu Pro Ala Pxo Tle Glu Lys Thr Ile Sex Lys Thr Lys Gly Gln Pro Arg Glu 440 44S 450 ''~
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Va1 Ser Leu Thr Cys Leu Va1 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val.Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Ty~ Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Sir Lys Leu Thr Val Asp Lys Ser Arg Trp Gln G1n Gly ". :.
~V~ 92/22653 ~ ~ ~ ~ ~ ~ e~ PCT/LJS92i~15126 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 'Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 214 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:24:
Asp Va1 G1n Met Thr GIn Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg VaI Thr Ile Asn Cys Arg AlawSer GIn Asp Ile Asn Asn Tyr Leu Asn Trp Tyr GIn Gln Lys Pro Asn Gly Thr Val Lys Leu Leu IIe Tyr Tyr Thr Ser Thr Leu His Ser Gly Va1 Pro Ser Arg Phe Ser Gly Ser G1y Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Al:a Ala Pro Ser Val Phe Ile Phe Pro Pro , 4~0 Ser Asp Glu Gln Leu Lys Ser Gly Thr AIa Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu GIn Ser G1y Asn Ser Gln Glu Ser Val Thr GIu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 50 170 ' 175 180 Leu Ser Lys AIa Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu ~~, r .,,...,.~. , ~ ,.. ~. ...::~., ., ,..: ,,:;... , . :~', '~';. . ' ::' ..
,~::. .....~'~.'y.:, ~,... ., ., ,~,.~:.:.. . .,~ ~,.... ' .;~. .. .
........:. . ;....
CVO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~(:'1'/US92105126 . -~ bb Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Cys Glu (2) INFORMATION D
FOR SEQ N0:25:
I
(i) SEQUENCE
CHARACTERISTICS:
(A) acids LENGTH:
amino (P) amino TYPE: acid (D) linear TOPOLOGY:
(~i) SEQUENCE SEQ ID
DESCRIPTION: N0:25:
Met G1y Ser CysIle IleLeu PheLeu ValAla ThrAla Thr Trp Gly Val Ser AspIle GlnMet ThrGln SexPro SerSer Leu His Ser Ala Val GlyAsp ArgVal ThrIle ThrCys ArgAla Ser Ser Gln Asp Asn AsnTyr LeuAsn TrpTyr GlnGln LysPro Gly Ile Lys Ala Lys LeuLeu IleTyr TyrThr SerThr LeuHis Ser Pro Gly Val Ser ArgPhe SerGly SerGly SerGly ThrAsp Tyr Pro Thr Leu Ile SerSer LeuGln ProGlu AspPhe AlaThr Tyr Thr ~5 95 100 105 Tyr Cys Gln GlyAsn ThrLeu ProPro ThrPhe GlyGln Gly Gln Thr Lys G~LuIleLys ArgThr ValAla AlaPro SexVal Phe Val Ile Phe Pro SerAsp GluGln LeuLys SerGly ThrAla Ser Pro '6Ia1 Val Leu LeuAsn AsnPhe TyrPro ArgGlu AlaLys Val Cys Gln Trp Val AspAsn AlaLeu GlnSer GlyAsn SerGln Glu Lys Ser Va1 G1u GlnAsp SerLys AspSer ThrTyr SerLeu Ser Thr u~r~ :,, ,,.
. ~'~ ~zrzzs~3 ~ ~ o ~ ~ ~ ~ Pf'I'/1J~92/05126 lob Ser Thr heu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val . 200 205 210 Tyr Ala Cys Glu Val Thr His Gln G1y Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
WO 92/22653 ~ 1 0 ~ ~ ~ ~ PCf'/US92/05126 EXAMPLE ~. En4ineering a Humanized Bist~ecific Ftab')2 Fragment This example demonstrates the construction of a humanized bispecific antibe:'y (BsF4ab')av1 by separate E, coii expression of each Fab' arm followed by directed chemical coupling in vitro. BsFlab')2 v1 ianti-CD3 anti-p185"ER2) was demonstrated to retarget the cytotoxic activity of human CD3+ CTL in vitro against the human breast tumor cell line, SK-BR-3, which overexpresses the p185"Epa product of the protooncogene HER2. This example demonstrates the minimalistic humanization strategy of installing as few murine residues as possible into a human antibody in order to recruit antigen-binding affinity and biological properties comparable to that of the murine parent antibody: This strategy proved very successful for the anti-p185"ERaarm of BsF(ab')2v1. tn contrast BsF(ab')2 v1 binds to T cells via its anti-CD3 arm much less efficiently than does the chimeric BsF(ab')Z
which contains the variable domains of the murine parent anti-CD3 antibody.
Here w~ have constructed additional BsF(ab)2 fragments containing variant anti-CD3 arms with selected murine residues restored in an attempt to improve antibody binding to T cells: One such variant, Bs Ftab')Z v9, was created by replacing six residues in the second hypervariable loop of the anti-CD3 heavy 2t? chain variable domain of BsFfab')a v1 with their counterparts from the murine parent anti-CD3 antibody. BsF4ab')Z v9 binds to T cel)s (Jurkat) much more efficiently than does BsF(ab')~ v1 and almost as efficiently as the chimeric BsFtab')2. This improvement in the efficiency of T cell binding of the humanized BsFtab'I~ is an important step in its development as a potential therapeutic agent for the treatment of p185"'ER~-overexpressing cancers.
Bispecefic antibodies tBsAbs) with specificities for tumor-associated antigens and surface markers on immune effector cells have proved effective for retargeting effector ;cells to kill tumor targets bath in vitro and in vivo treviewed by Fanger; M. W. et aJ., tmrrrunol. Today 10: 92-99 11989);
Fanger; M: W. et' al., lmmunol. Today 12: 51-54 (1991 ); and Nelson, H., Cancer Gells 3: 163-1 ?2 41991 )).' t3s~(ab') z fragments have often been used in preference to intact t3sAbs in retargeted cellular cytotoxicity to avoid the risk of killing innocent bystander cells binding to the Fc region of the antibody. An additional advantage of BsFtab')a over intact BsAbs is that they r~:~!:~'° ~ .:,,' . ;: ' : ,.~-r:, . . ;~ ' ~'~:':' ,::, ;;;. . , ..:v.. ,;.~:. .
W4 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/U592/05126 ,....,.
$~
are generally much simpler to prepare free of contaminating monospecific molecules (reviewed by Songsivilai, S. and Lachmann, P. J., Clin. Exp.
Immunol. 79: 315-321 (1990) and Nolan, O. and O°Kennedy, R., Biochim.
Biophys. Acta 1040: 1-11 (1990)).
BsF(ab')Z fragments are traditionally constructed by directed chemical , coupling of Fab' fragrnents obtained by'limited proteolysis plus mild reduction of the parent rodent monoclonal Ab (Brennan, M. et al , Science 229, 81-83 (1985) and Glennie, M. J, etal.-',°J. lmmunol, 139: 2367-23?5 (1987)).
One such BsF(ab')a fragment (anti-glioma associated antigen / anti-CD3) was found to have clinical efficaoy in glioma patients (Nitta, T. etal., Lancet 335:
36$-371 (1990) and another BsF(ab')2 (anti-indium chelate ! anti-carcinoembryonic antigen) allowed clinical imaging of colorectal carcinoma (Stickney, D. R. etal:, Antibody, Imrrrunocanj. Radiapharm. 2: 1-13 (1989)).
Future BsFtab')2 destined for clinical applications are likely to be constructed from antibodies which are either human or at least "humanized" (Riechmann, L. etal., Nature 332: 323-327 (1988) to reduce their immunogenicity (Hale, G. et al.; Lancet i: 1394-1399 (1988)).
Recently a facile route to a fully humanized BsF(ab')x fragment designed for tumor immunatherapy has been demonstrated (Shalaby, M. R. et al., J.
Exp: Mea! 175: 217-225 (19921): This approach involves separate E. coli expression of each Fab' arm followed by traditional directed chemical coupling in vitro to form the BsF(ab')2. Orie aim of the BsF(ab')a was a humanized version (Carter, P. et al.; Proc. Natl. Acad Sci. USA ( 1992a) and -., Cartel, P., et al., BiolTechnology 10: 163-167 (1992b)) of the marine ~5 monoclonal Ab 4D5 which is directed against the p185"~R2 product of the p~rotooncogene HER2 (c-erbB-2D (Fendiy, B. M. et al.. Cancer Res. 50: 1550-1558 (1989)). The humanization of the antibody 4D5 is shown in Example 1 of this application. The second arm was a minimalistically humanized anti-CD3 antibody (Shalaby etal:'supra) which was created by installing the CDR
loops from the variable domains of the marine parent monoclonal Ab UCHT1 (Beverley; P: C. L. and Callard; R. E., Eur. J. lmmunol. 11: 329-334 (1981 )) into the humanized anti-p185"ERZ antibody. The BsF(ab')2 fragment containing the most potent humanized anti-CD3 variant (v1 ) was demonstrated by flow ' cytometry to bind specifically to a tumor target f . .. ,:~.~ . .v.,.,,. ".;....,. , ., : ~ ~,..:....'.,. :. . w.
. , WO 9Z/22653 ~ ~ tl ~3 ~ ~ ~ PCH'/US92/05126 .., ~I
overexpressing p185"ERZ and to hurnan peripheral blood mononuclear cells carrying CD3. in addition, Bs Flab' )z v1 enhanced the cytotoxic effects of activated human CTL 4-fold against SK-BR-3 tumor cells overexpressing p185'°~Z. The example descries efforts to improve the antigen binding affinity of the humanized anti-CD3 arm by the judicious recruitment of a smelt number of additional murine residues into the minimalistically humanized anti-CD3 variable domains.
MATERIALS AND METH~DS
C~nstruction of mutations in the anti-CD3 variable region ,genes.
The construction of genes encoding humanized anti-CD3 variant 1 (v1 ) variable light (V~) and heavy (V") chain damains in phagemid pUC119 has been described (Shalaby et al. supra): Additional anti-CD3 variants were generated using an efficient site-directed mutagenesis method 4Carter, P., Muta9enesis: a~ practical approach, dM. J. McPherson, Ed.), Chapter 1, IRL
Press, Oxfiord, UK ( 1991 )) using mismatched oligonucleotides which either install or remove unique restriction sites. f?ligonucleotides used are listed below using lowercase o indicate the targeted mutations. Corresponding ~24 coding changes are denoted by the starting amino acid in one letter code followed by the residue numbered acdording to Kabat, E. A. etal., SeQuences of Proteins of Immunplogicat Jnterest, 5'" edition, National Institutes of Health; Bethesda, MD; USA 11991 ); then the replacement amino acid and ~; 'f finally the identity of the anti-CD3 variant:
HX 11; 5' GTAGATAAATCCtctAACACAGCCTAtCTGCAAATG 3' (SEC~:ID. NO. 11 ) VH K75S, v6;
HX12; 5' GTAGATAAATCCAAAtctACAGCCTAtCTGCAAATG 3' 6SEQ.tD. NO. 12) V" N76S; .v7;
HX13, 5' GTA~ATAAATCCtcttctACAGCCTAtCTGCAAATG 3' i (SEQ.ID. NO. 13) V" K75S:N76S' v8;
X14, 5' CTTATAAAGGTGTTtCcACCTATaaCcAgAaatTCAA
GGatCGTTTCACgaTAtcCGTAGATAAATCC 3' (SEQ.ID.ND. 14) V" T5'?S:A6DN:D61 Q:S62K:V63F:G65D, v9;
LX6, 5' CTATACCTCCCGTCTgcatTCTGGAGTCCC 3' (SEQ.ID. NO. 15) ,.. .,~ '..:~:~ . :..' :'.~.., . :y., . . . ~.~.. . ,.
. a . :"f. . .
P
~cr/us~zeomz6 , .
WO lB/~~653 V~ E55H, v11.
Oligonucleotides HX11, HX12 and HX13 each remove a site for BspMl, whereas LX6 removes a site for Xhol and HX14 installs a site for Eco~3V
(bold). Anti-CD3 variant v10 was constructed from v9 by site-directed mutagenesis using oligonucleotide. HX13, Mutants were verified by dideoxynucleotide sequencing. (Sariger, F. et al., ProG. IVatl. .4cad. Sci.
PISA
74: 5463-5467 (1977)).
E, coli expression of Fab' fragrr~ents The expression plasmid, pAK19, for the co-secretion of tight chain and heavy chain Fd' fragment of the most preferred humanized anti-p185"ERz variant, HuMAb4D5-8; is described in Carter et al., 199~b, supra. Briefly, the Fab' expression unit is bicistronic with both chains under the transcriptional cantrof of the phoA promoter. Genes encoding humanized V~
and V" domains are precisely fused on their 5' side to a gene segment encoding the heat-stable enterotoxin II signet sequence and on their 3°
side to human k, C~ and IgG1 C"1 constant domain genes, respectively. The C"1 gene is immediately followed by a sequence encoding the hinge sequence CysAlaAla and followed by a b~cteriophage ~I to transcriptiona) terminator.
Fab' expression plasrv~ids for chimeric and humanized anti-CD3 variants (v1 to v4, Shalaby et at.aupra; v6 to v1 ~, this study) were created from pAK19 by precisely repBacing anti-p185"~Z V~ and V" gene segments with those .~
,~, encoding mursne and ct~rresponding humanized variants of the anti-CD3 ~5 antibody, respedtively; by sub-cloning and site-directed mutagenesis. The Fab' expressign ptasmid for the most potent humanized anti-CD3 variant identified in this study (v9) is designated pAK2~. The anti-p185"~2 Fab' fragment seas secreted fr~m ,~. coli K12 strain 25F2 containing plasmid pAK19 grown for 32 to~40 hr at, 37' C in an aerated 10 liter fermentor. The final cell densigy vvas 120-150 ODSSO and the titer of soluble and functional anti-pi 85"E'~2 Fab' was 1-2 g/titer as judged by antigen binding ELISA
(Carter et al., 199~b, supra). Anti-CD3 Fab' variants were secreted from E coli containing c~rresponding expression plasmids using very similar fermentation protocols. The highest expression titers of chimeric and O 92J22ba3 ~.~ o ~ ~ ~ ~ P~1~S92I051~b humanized anti-GD3 variants ware 2ta0 mgAiter arid 700 mgliiter, rsspeGtively, as judgBd bY total immunoglobulin LISA.
Cansrructlon of esF(ab'ls fragments Fab' fragments ware directly recovered from E. toll fermentation pastes in th0 free thiol form (Fab'-SH) by affinity pu~ificatiar~ on Streptococcal protein G at pH 5 in the presence of ~DTA (Carter et al., 199~b supra).
Thioether linked BsFtab'iz fragments (antnpf $5'~RZ J anti-CD3) were constructed by the procedure of Glannie'et al. supra with the following modifications. Anti-p 1 i35"~ Fob'-SH in t fl0 rriM 'Cris acetate. 8 mM SDTA
(pH ~,O) was reacted with O.t vol of 40 mM N.N'-1,2-phenylenedimatemide (o-PDM) in dinn~athy) lormamide for -'I.5 hr at 20 -C. ~xcass o-PDM was removed by protein G vurifiaation of the Fab' maioimide derivative (Fob'-mal) followed by buffer exchange into 24 rnM sodium acetate, 5 mM I:DTA (pH
5.~) Icoupllng buffer) using o~ntriprep-'~0 concentrators (AmiGOn). The total eoncentration of Fab' variants was estimated from the measured absorbents at 280 nm (Hu~b4D5-8 Fab° a°."' ° '1.56, Carter et al., 1992b, supra).
The free_ti~141 content of Fab' preparations was estimated by reaction with 5, 5'-dithiobis(2-nitrobenzoic ,acid) as desoribed by Creighton, T. E..
protein structura~ a praciical~apprvach, IT. E. Creighton, Ed.). Chapter 7, IRL Press.
Oxford, UK ( 1990), Fquimolar amounts of anti-p185"a" Fob'-ma) (assumivg ' quantitative, reaotlon of Fab'-SH with 4-PDM) and each anti-Ci7S Fab'-SH
variant werecoupled together at a combined concentration of 1 to 2.5 mgJrnl in the Goupl4rtg buffer for to to 48 hr at, 4 'C. The coupling reaction was ~'' ad ju~te~ td 4 mM cysteine ax IpH~ 7.0 and ~ incubated for 15 min at 20 ' C to reduce .any ~Wa~rted disulfide-linked Flab' )= formed. These reduction Gorrditians are sufficient to redi~Ge inter-heavy, chin disulfide bonds with virtually no' reduction of the disulfide between light and heavy chains. Any free thiol~ generated were their blacked with a0 mM iodaacetamida.
BsF(a~'Iz wss isolated f~bm the Coupling reaction by S 9 DO-HR IPharmaoia) 5iz9 eXC,lusion cnr'"omatogrsPhy -I2-5 crrr x 1 d0 Gm) in the presence of P~3S.
The BsFtab'l,.,samplqs ,were passed through a 0.2 mm filter flesh frozen in .
liquid nitrogen aryl stored at ~~-'~Q:'~~
*_.~rade.mark TOTRL P.20 5.& 19/12/20(71 16:23 X416 368 1645 - -_ Oreceived WO'~2/22653 ~ ~ ~ ~ ~ ~~ ~ P~f/US92fOS126 ,-FIoHr cyto~etric analysis of Flab' i?binding to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Culture Collection (Rockviile, MDD (ATCC TIB 152D and Brawn as recommended by the ATCC. Aliquots of 10~ Jurkat cells were incubated with appropriate concentrations of BsFfab'D2 tanti-p185"ER2 / anti-GD8 variantD or control mono-specific'~anti-p185"ER2 F(ab')2 in PBS plus 0.1 °~
~w/vD bovine serum albumin and.10 mM sodium azide for 45 min at 4 "C.
The cells were washed and than incubated with fluorescein-conjugated goat anti-human F(ab'DZ tOrganon Teknika, West Chester, PAD for 45 min at 4 ° C.
Cells were washed and analyzed on a FAGScan tBecton Dickinson and Go., Mountain View, CA1. Cells (8 x 10~D were acquired by list mode and Bated by forward light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~ and at 37 out of 122 positions within VH ~Shalaby et ~l.,su~raD 1992D: Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine «sidues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were ~rigina9ly kept as human sequences in our minimalistic humanization regime.
Thus human residues in VH CDR2 of anti-GD8 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
T57S:A60N:D61 Q:S62K:V63F:G65D (Fig. 5D. Similarly, the human residue E55 in VL CDR2 of anti~CD3 v1 was replaced with histidine from the marine anti-GD3 antibody to generate anti-CD3 v11. In addition, V" framework region tFRD resialues 75 and 76 in anti-CD3 v1 were also replaced with their marine counterparts to creqte anti-CD3 v8: K75S:N76S. VH residues 75 and 76 are located in a loop close to V,~ C~R 1 and CDR2 and therefore might ~.,.,,-.;.: .. .., . .
,...~,~V~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92/OS126 sS
influence antigen binding. Additional variants created by combining mutations at these three sites are described below.
Preparation of BsF(ab°,12 fragments Soluble and functional anti-p185"~R~ and anti-CD3 Fab' fragments were recovered directly from corresponding E. Coli fermentation pastes with the single hinge cysteine predominantly in the free thioi form (75-100 % Fab'-SH) by affinity purification on Streptococcal protein G at pH
5 in the presence of EDTA (Carter et al., 1992b, supra). Thioether-linked BsF(ab')2 fragments were then constructed by directed coupling using o-PDM
as described by Glennie et al., supra. One arm was always the most potent humanized anti-p185"ERZ variant, HuMAb4D5--8 (Carter etal., 1992a, supra) and the other either a chimeric or humanized variant of the anti-CD3 antibody. Anti-p185"E"2 Fab'-SH was reacted with A-PDM to form the rnaleimide derivative (Fab'-mal) and then coupled to the Fab'-SH
for each anti-CD3 variant. F(ab')2 was then purified away from unreacted Fab' by size exclusion chromatography as shown for a representative preparation (BsF(ab')~ v8) in data not shown. The F(ab')Z fragment represents ~- 54~ of the total amount of antibody fragments (by mass) as judged by integration of the chromatograph peaks.
SDS-PAGE analysis of this BsF(ab')a v8 preparation under non-reducing conditions gave one major band with the expected mobility (M, -- 96 kDD as well as several very minor bands (dada not shown). Amino-terminal sequence ; ,~
analysis of the major band after efectroblotting on to polyvinyiidene difiuoride 26 membrane Mat~udaira, P:, J. .Biol. Chew. 282: 10035-10038 (198'7) gave the expected nnixed sequence from a stoichiometric 1:1 mixture of light and heavy chains (V~ l V": D/E, I/~J, QIQ, M/L, TIV, Q/E, S/S) expected for BsF(ab')2. The amino terminal region of both light chains are identical as are both heavy chains and correspond to donsensus human FFi sequences.
We have previously demonstrated that F(ab')2 constructed by directed chemical coup9in~ carry both anti-p185"~''2 and anti-CD3 antigen specificities (Shalaby et aL; supra). The level of contamination of the BsF(ab')2 with monospecific ~(ab' )2 is likely o be very low since mock coupling reactions with either anti-p185"E"2 Fib'-mal or anti-CD3 Fab'-SH alone did not yield detectable 2~~0~~;~~
CVO 92/22653 PC'I'/US92/d5126 - -w.
8 (~
quantities of Flab' )Z. Furthermore the coupling reaction was subjected to a mild reduction step followed by alkylation to remove trace amounts of disulfide-finked Flab' )2 that might be present. SDS-PAGE of the purified F(ab' )2 under reducing conditions gave two major bands with electrophoretic mobility and amino terminal sequence anticipated for free light chain and thioether-linked heavy chain dimers.
Scanning LASER dsnsitometry of a o-PDM coupled F(ab')Z preparation suggest that the minor species together represent --10°~ of the protein.
These minor contaminants were characterized by amino terminal sequence analysis and were tentatively identified on the basis of stoichiometry of light and heavy chain sequences and their electrophoretic mobility (data not shown). These data are consistent with the minor contaminants including imperfect Ftab' )z in which the disulfide bond between light and heavy chains is missing in ane or both arms, trace amounts of Fab' and heavy chain thioether-linked to tight chain.
finding of BsF(ab'Jz to Jurkat cells Binding of BsFtab')2 containing different anti-CD3 variants to Jurkat cells (human acute'T cell IeukemiaD was investigated by flow cytometry (data not shown). BsF(ab')a v9 binds much more efficiently to Jurkat cells than does our starting molecule; BsF(ab°)a v1, and almost as efficiently as the chimer'sc BsFtaka')2. Installation of additional marine residues into anti-CD3 v9 to create v10 (V" K75S:N76S) and v'l2 (V,~ K75S:N76S plus V~ E55H) did s: P
not farther improve, binding of corresponding BsF(ab°)2 to Jurkat cells. Nor did recruitment of these s°reurine residues into anti-CD3 v1 improve Jurkat binding: V~, K75S (v6): d/~ N76S tv7), V~, K75S:N7CS tvB), V' E55ii tv11 ) tnot shown). BsF(ab')2 v9 was chosen for future study since it is amongst the most efficient variants in binding to Jurkat cells and contains fewest marine residues in the humanized anti-CD3 arm. A monospecific anti-p1 B5~'~RZ Flab' )a did not show significant binding to Jurkat cells consistent with the interaqtion being mediated through the anti-CD3 arm.
DISCUSSI~N
A minima(istic strategy was chosen to humanize the anti-p1 B5"E~2 V1'~CD 92/22653 ~ ~ ~ ~ ~ ~ ~ PCTlUS92l0512G
(Carter efi al., 1992a, supra) and anti-CD3 arms (Shalaby et al., supra) of the BsF(ab')2 in this study in an attempt to minimize the potential immunogenicity of the resulting humanized antibody in the clinic. Thus we tried to install the minimum number of marine CDR and FR residues into the context of consensus human variable domain sequences as required to recruit antigen-binding affinity and biological properties comparable to the marine parent antibody. Molecular modeling was used firstly to predict the marine FR
residues which might be important to antigen binding and secondly to predict the marine CDR residues that might not be required. A small number of humanized variants were then constructed to test these predictions.
Our humanization strategy was very successful for the anti-p185"ERz antibody where one out of eight humanized variants (HuMAb4D5-8, IgG 1 ) was identified that bound the p185"~RZ antigen - 3-fold more tightly than the parent marine antibody (Carter at al., 1992a, supra). HuMAb4D5-8 contains a total of five marine FR residues and nine marine CDR residues, including V"
CDR2 residues 60-65, were discarded in favor of human counterparts. In contrast, BsF(ab')2 vl containing the most potent humanized anti-CD3 variant out of four originally constructed (Shalaby etal., supra) binds J6 cells with an affinity (/Cd) of 140 nM which is -- 70-fold weaker than that of the _ corresponding chimetic lBsF(ab')2.
Here we have rest~red T cell binding of the humanized anti-CD3 close to that of the chimeric variant by replacing six human residues in V" CDR2 with their marina aounte~parts: T57S:A60N:D61 C~:S62K:V6SF:G65D (anti,; $
CD3 v9; Fig. 5). It.appears rinore 6ikely that these marine residues enhance antigen binding indirectly by influencing the conformation of residues in the N-tarmirfal part of V" CDR2 rather than by directly contacting antigen.
Firstly, only N-terminal residues in V" CDR2 (50-58) have been found to contact antigen ih one or more of eight crystallographic structures of antibody/antigen complexes (Kabat et al., supra; and Mian, 1. S. at al., J.
lVfot. viol. - 2'! 7: 183-151 ( 1991 ): Fig. 5). Secondly, molecular modeling suggests that residues in the C-terminal part of V" CDR2 are at least partially buried tFig. 5). BsF(ab')a v9 binds to SK-BR-3 breast tumor cells with equal efficiency ~o BsF(ab°)2 v1 and chimeric BsF(ab')Z as anticipated since the anti-p185"ERa arm is identical in all of these molecules (Shalaby et al., supra, not W~O 92!22653 ~ ~ ~ ~ ~ ~j PCf'/US92/05126 shown).
Our novel approach to the construction of BsF(ab')2 fragments exploits an E. coli expression system which secretes humanized Fab' fragments at gram per titer titers and permits their direct recovery as Fab'-SH (Carter et al., 1992b, supra). Traditional vdirected chemical coupling of Fab'-SH
fragments is then used to form BsF(ab')2 in vitro (Brennan et al.,supra; and Glennie et al., supra). This route to Fab'-SH obviates problems which are inherent in their generation from intact antibodies: differences in susceptibility to proteolysis and nonspecific cleavage resulting in heterogeneity, low yield as well as partial reduction that is not completely selective for the hinge disulfide bonds. The strategy of using ~ co/i-derived Fab'-SH containing a single hinge cysteine abolishes some sources of heterogeneity in BsF~ab')2 preparation such as intra-hinge disulfide formation and contamination with intact parent antibody whilst greatly diminishes others, eg. formation of Flab' )3 fragments.
BsF(ab'l2 fragments constructed here were thioether-linked as originally described by Gteenie et a/., supra with future in vivo testing of these molecules in mind-. Thioether bonds, unlike disulfide bonds, are not susceptible'ta cleavage by trace amounts of thiot, which led to the proposal 2Q that thioether-linked Flab' )2 may be more stable than disulfide-(inked F(ab' )2 in vivo (Glennie et al., supra): This hypothesis is supported by our preliminary pharmecokinetic experiments in normal mice which suggest that thioether-finked BsF(ab')Z vl has a 3- fold longer plasma residence time than ~; ~
BsF(ab')2 v.1 iinked'by a single disulfide bond. Qisulfide and thioether-linked chime~ic BsF(ab')Z,were found to be indistinguishable in their efficiency of cell binding and in their retafgeting of CTL cytotoxicity, which suggests that o-PDM directed cou~ating does not compromise binding of the BsF(ab°)2 to either antigen (not shown). Nevertheless the nature of the linkage appears not to be critical since; a disulfide~lir~ked BsF(ab')2 (marine anti-p185"ERZ
i marine anti-CD3) was 'recently shown by others (Nishimura et al., lnt. J.
Cancer 50: 800-804 (192) to have potent anti-tumor activity in nude mice.
Our previous study (Shalaby et al.; supra! together with this one and that of Nishimura~ T. et al., supra improve the potential for using BsF(ab')a in targeted immunotherapy of ~pl g5"ERZ_overexpressing cancers in humans.
. . . ..
. :, . . ° y . . ', . . . .
W(~ 92/22653 ~ ~, Q ~ o ~~ 9 PCT/LJS92/05126 ~~
EXAMPLE 4. Humanization of an anti-CD18 antibody A marine antibody directed against the leukocyte adhesion receptor ~-chain (known as the H52 antibody) was humanized following the methods described above. Figures 6A and 6~ provide amino acid sequence comparisons for the marine and humanized antibody light chains and heavy chains.
... , : .. . .. , ;.
!~O 92/22653 ~ ~ Q ~ ~ y ~ ~ Q Pt.T/U~92/05126 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
(ii) TITLE OF INVENTION: Imamunoglot~ulin Variants (iii) NUMBER OF SEQUENCES: 25 ~ . , , (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco '95 (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A} MEDIUM TYPE: 5.25 inch, 360 K'~ floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(.A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
3G1 (vii) PRIOR AP,PLICAT~ON DATA:
(A) APPLICATION NUMBER: 07/715272 (B) APPLICATION DATE: 14-JUN-1991 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Adler, Carolyn R.
(B) REG1STRATION NUMBER: 32,324 (C) REF'ERENCE/DOCKET NUMBER: 709P1 , r; .~
(ix)- TELECOMMUNICATION TNFORMATION:
~() (A) TELEPkIONE: 415/225-2614 (B) TELEFAX: 415/952-9881 (C} TELEX: 910/371-7168 (2) INFORMATION
FOR SEQ
ID N0:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 109 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear ~ ~ ~
~ ~ '~
~
' .. ~'Vb'Q 92/22b53 T/US92/05125 P(.
(xi) SEQUENCE DESCRIPTION: SEQID
N0:1:
Asp Ile Gln Thr GlnSer ProSer SerLeu SerAla SerVal Met GIy Asp Arg Thr IleThr CysArg AlaSer GlnAsp ValAsn Val Thr Ala Va1 Trp TyrGln GlnLys ProGly LysAla ProLys A1a Leu Leu Ile Ser AlaSer FheLeu GluSer GlyVal ProSer Tyr Arg Fhe Ser Ser ArgSer GlyThr AspFhe ThrLeu ThrIle GIy Ser Ser Leu Pro GluAsp PheAla ThrTyr TyrCys GInGln G1n His Tyr Thr Pro ProThr PheGly G1nGly ThrLys ValGlu Thr 95 100 lOS
I1e Lys Arg Thr 2~a 109 ' (2) INFORMATION FOR
SEQ
ID
N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: acids 120 amino (B) TAPE: amino acid (D) 3,'OPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQID
N0:2:
Glu Val Gln Val GIuSer GlyG1y G1yLeu ValG1n FroGly Leu 1 5 10 15 ,~,~
~e GIy Ser Leu Leu SerCys AlaAla SerGly FheAsn IleLys Arg Asp Thr Tyr His TrpVa1 ArgGln AlaPro GlyLys G1yLeu Ile ~4~ Glu Trp Va1 Arg IleTyr ProThr AsnGly TyrThr ArgTyr Ala Ala Asp Ser Lys GIyArg PheThr IleSer A1aAsp ThrSer Val Lys Asn Thr Tyr LeuGln MetAsn SerLeu ArgAla GluAsp Ala 9~V(~ 92/22653 ~ ~ ~ ~ ~ .j ~ P~'/1JS92/05126 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp G1y Phe Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Leu Va1 Thr Val Ser Ser (2) INFORMATION FOR SEQ ID N0:3:
1~ (i) SEQUENCE CHARACTERISTICS:
(Aj LENGTH: 109, amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Asp Ile G1n Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val 24 Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys A1a Pro Lys Leu Leu Ile Tyr Ala A1a Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr I1e Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys G1n Gln 35 Tyr Asn Sex Leu Pro Tyr Thr Phe Gly GIn Gly Thr Lys Ua1 Glu Ile Lys Arg Thr 109 ' (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
50 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val G1n Pro Gly GIy Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser ....' ,, , '..' ":'. . , ,.~ , .; ~.~'~... ..,;...~ , ,. ..... ' ... v ',:.'.~
. ...... ...
W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ ~CI'/U~92/~5126 q 43 Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 . 40 45 Glu Trp Val Ala Val Ile Ser Glu Asn Gly Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser 65 ?0 ?5 1A Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 '100 105 A1a Met Asp Val Trp Gly G1n Gly Thr Leu Val Thr Val Ser Ser 2~0 (2) INFORMATIONFOR SEQ
ID N0:5:
( i) SEQUENCECHARACTERISTICS:
(A) LENGTH: acids 109 amino (B) TYPE: amino acid (D) TOPOLOGY:
linear (x i) SEQUENCEDESCRIPTION:SEQ ID
N0:5:
Asp Ile Val Thr Gln His LysPhe MetSer ThrSer Val Met Ser 3~ 1 5 10 15 Gly Asp Arg Ser Ile Cys LysAla SerGln AspVal Asn Val Thr ~5, Thr Ala Va1 Trp Tyr Gln LysPro G1yHis SerPro Lys Ala Gln 35 . 40 45 Lsu Leu Ile Ser Ala Phe ArgTyr ThrGly ValPro Asp Tyr Ser . 50 55 60 Arg Phe Thr Asn Arg Gly ThrAsp PheThr PheThr Ile Gly Ser ~,5 ?0 75 Ser Ser Val Ala Glu Leu A1aVal TyrTyr CysGln Gln Gln Asp ~5 80 85 90 His Tyr Thr Pro Pro Phe GlyGly GlyThr LysLeu Glu Thr Thr 95 ~ 100 105 50 Ile Lys Arg Ala V1~~ 92/22653 ~ ~ ~ ~ '~ ~ . F'C°T/6.JS92/AS126 {2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Leu Lys Leu Ser Gys Thr Ala Ser G1y Phe Asn Ile Lys ~ 25 30 Asp Thr Tyr Ile His Trp Val Lys G1n Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Asp Pro Lys Phe Gln Asp Lys A1a Thr Ile Thr A1a Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Val Ser Arg Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp G..y Gly Asp G1y Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Ala Ser Val Thr Val Ser Ser 110 11.5 120 (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27.bases ' (B) TyPE:wucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 bases (B) TYPE: nucleic acid ~t'.~~p ~ . '=J . . . . ' i '~ ~s .~,......, . .. ,...~.:~;'.: .~ , ,:;~. ,m~,:~,.'. ' , .,, ' ~.: . ~ :
' :.'." . ~ . ';. ..,.. .
'WO 92122653 210 3 f~ ~ 9 p~T/US92/OS126 °I 5 (C) STRANDEDNESS: single (D) TOPOLOGX: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 bases (B) TYPE: nucleic acid (Cj STRANDEDNESS: single (D) TOPOLOGY: linear (~ci) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION
FOR SEQ
ID N0:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 bases 34 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (~y) TOPOLOGY: linear (~ci) SEQUENCE ~3ESCRIPTION: SEQ ID N0:10:
TGAGGAGACG GTGACCGTGG TCCCTTGGCC CCAG 34 , 4i (2) INFORMATION
EOTt SEQ
ID NO:11 (i) SEQUENCE CHARACTERISTICS:
(~) LENGTH: 36 bases ~5 (B) 'TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11;
;GTAGATAAAT ~CTCTAACAC AGCCTATCT~ CAAATG 36 YS;,x r.'. ''; :.~.'~ ..,.; ., . !.,'.'..... ;.:.: ~ ,;~:. .;'..~:".. :.,. ,~i -.."~ ;... ' ''.'.".
.7 ::~ ., . .
~''~ a- .:r. . ,t.-, t ...
!< ~,~.~.. '~ ~'%'~ .., '' .Y.....~ ..;9-, v , '.'.. .,.~. ., '' ' ~ .., :;, .. " .' .~, ;, ,;~ ;., 2~.fl~f~~~
WO 92122653 V '~' '~. PC.°T/US92/0~126 (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear, (x~.) SEQUENCE DESCRIPTION: SEQ ID N0:12:
' (2) INFORMATION F'OR SEQ TD NO:13:
(i) SEQUENCE CHARACTERISTICS;
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS; single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
GTAGATAAAT CCTCTTCTAC AGCCTATCTG CAAA1'G 36 (2) INFORt~tATION
FOR SEQ
LD N0:14:
(i) SEQUENCE CHARACTERISTICS:
(~,) ' ~;EN~TH: 68 bases ~5 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) T0P0LOGY: liner ,; r~
(xi) SEQUENCE'DESCRIPTION: SEQ ID N0:14:
CTTATAAAGG TGTTTCCACC TATAACCAGA AATTCAAGGA TCGTTTCACG
$5, ATATCCGTAG ATAAATCC 68 (2) INFORMATION
FOR SEQ
ID NO:15:
50 (i) SEQUENCE CHARACTERISTICS:
(Al LENGTH: 30 bass (g) TYPE: nucleic arid (C) STRANDEDNESS: singly (D) TOPOLOGY: linear k 'n. ,. ~ ..- ~,, .:. ~,' . ~ ~ .~ . , ,~., ,,~... -y... ~ ::. ,. ..... . ...
7 r..~:....,. . ~::; .mt.~ , ..:-... . .. ' . ~. ~ ,. . .... ~.~..'. ,... ~ ~.
-.w . ..
P~'/LJS92/05126 (xi)~SEQUENCE DESCRIPTION: SEQ ID N0:15:
(2) INFORMATION FOR SEQ ID N0:16:
( i) SEQUENCE CHE~RACTERISTICS
(A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:16:
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Va1 Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pra Asp G1y Thr Va1 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser G1y Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile ' 3~ 65 70 75 Ser Asn Leu Glu Gln Glu Asp Ile A1aThr TyrPhe CysG1n Gln Gly Asn Thr Leu Pro Trp Thr Phe AlaGly GlyThr LysLeu Glu 95 100 , 1,05 Ile Lys (2) INFORMATION FOR SEQ ID N0:17:
(i,) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 107 amino acids (B) APE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID,N0:17:
5~: Asp Ile Gln Met Thr Gln Ser Pro SprSer LeuSer AlaSer Val Gly Asp Arg Val Thr Ile Thr Cys ArgAla SerGln AspIle Arg . 20 25 30 WU 92/2263 ~ ~ ~ ~ PGT/LJ892/05126 ~ ~~ ~
B
Asn Tyr TrpTyr GlnGln LysPro GlyLys AlaPro Lys Leu Asn Leu Leu TyrThr SerArg LeuG1u SerGly ValPro Ser Ile Tyx Arg Phe SerGly SerGly ThrAsp TyrThr LeuThr I1e Ser Gly Ser Ser ProGlu AspPhe AlaThr TyrTyr CysGln Gln Leu Gln G1y Asn ProTrp ThxPhe GlyGln GlyThx LysVal Glu Thr Leu 95 '100 105 Ile Lys (2) INFORMATION SEQ
FOR ID
N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) acids LENGTH:
1.07 amino (B) amino TYPE: acid (D) linear TOPOLOGY:
(xi) SEQUENCE SE~QID
DESCRIPTION: N0:18:
Asp Ile ThrGln SexPro SerSer LeuSer AlaSer Val Gln Met Gly Asp Theale ThrCys ArgAla SerGln SerIle Ser ArE
Val Asn Tyr TrpTyr GlnG1n LysPro GlyLys AlaPro Lys Leu Ala 35 40 ~5 Leu Leu Ala'A1aSerSer LeuG1u SerGly ValPro Ser Ile Tyr 50 55 60 ~..a 4~ Arg Ptae SerGly SerGly ThrApp PheThr LeuThr Iie Ser Gly Ser Ser ProGlu AspPhi A1aThr TyrTyr GysG1n Gln Leu Gln Tyr Asn ProTxp ThrPhe GlyGln GlyThr LysVal Glu Ser Leu iii LyS
~.~~
V~iJ 92/22653 ~ ~ ~ c~! ~ ~ ~ PCTlUS92/~5126 (2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOL(?GY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr ~ 25 30 Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met Gly Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr 20 50 55 fi0 Asn Gln Lys Phe Lys Asp Arg Phe Thr Ile Ser Lys Ala Thr Leu 25. Thr Val AspwLys Ser Ser Ser Thr Ala Tyr Leu Met Glu Leu Leu Asn Ser Leu Thr Ser Glu Asp Sex A1aVal TyrTyr CysAla Arg Ser Gly Tyr Tyr G1y Asp Ser Asp ~rpTyr PheAsp ValTrp Gly Ala Gly Thr Thr Val Thr Val Ser Ser (2),INFORMATION FOR SEQ ID ~:r N0:20:
(i),SEQUENCE CHARACTERISTICS:
(A) LENGTH: '122 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID
N0:20:
Glu Val Gln Leu Val Glu Ser Gly GlyGly LeuVa1 GlnPro Gly Gly Ser L~u Arg Leu Ser Cys -AlaAlaSer GlyTyr SerPhe Thr Gly Tyr~Thr Met Ann Trp Val Arg GlnAla ProGly LysGly Leu ~V~O X2/22653 ~ ~ ~ ~ ~ ~ ~ ~"~i'/11S~32/OS126 Glu Trp Val Ala Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe Lys Asp Arg Phe Thr IIe Ser Val Asp Lys Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala G1u Asp Thr Ala Va1 Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Sar Asp Trp Tyr Phe Asp Val Trp Gly Gln G1y Thr Leu Val Thr Val Ser Ser (2) INFORMATION FOR SEQ
ID N0:21:
~0 ( i} SEQUENCE CkIARACTERISTICS:
(A) LENGT~1: 122 aminoacids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE SEQ ID
DESCRIPTION: N0:21:
Glu Val Gln Leu Val Glu G1y GlyGly LeuVal GlnPro Gly Ser Gly Ser Leu Arg Leu Ser Ala AlaSer GlyPhe ThrPhe Ser Cys Ser Tyr Ala Met Ser Trp Arg GlnAla ProGly LysGly Leu Val G1u Trp Val Ser Val Ile Gly AspGly G1ySer ThrTyr Tyr Ser 40 Ala Asp Ser Val Lys Gly Phe ThrIle SerArg AspAsn Ser Arg Lys Asn Thr Leu Tyr Leu Met AsnSer LeuArg AlaGlu Asp Gln Thr A.la VaI Tyr Tyr Cys Arg G1yArg ValGly TyrSer Leu Ala Ser Gly Leu Tyr Asp Tyr GIy GlnGly ThrLeu ValThr Val Trp Ser Ser .
~v~ ~z~zzss~ 2 ~. 0 3 (~ ~ 0 ~c°°rius~zios'z6 (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 454 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRT:?TION: SEQ ID N0:22:
Gln Val G1n Leu Gln Gln Ser G1y Pro Glu Leu Val Lys Pro G1y Ala Ser Val Lys I1e Ser Cys Lys Thr,Ser G1y Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Phe Asn Pro Lys Asn G1y Gly Ser Ser His Asn Gln Arg Phe Met Asp Lys Ala Thr Leu Ala VaI Asp Lys Ser Thr Ser Thr A1a Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Gly Ile Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly Phe Asp ValArg TyrPhe AspVal TrpGly A1aGly ThrThr Val Thr Val SerSer AlaSer ThrLys GlyPro SerVal PhePro Leu AIa Pro SerSex Lys.Ser ThrSer GlyGly ThrAla AlaLeu Gly :140 145 150 Cys Leu ValLys AspTyr PhsPro GluPro ValThr Va1Ser Trp Asn Ser GlyAla LeuThr SerGly ValHis ThrPhe ProAla Val Leu G1n SerSer GlyLeu TyrSer LeuSer SerVal ValThr Val a 185 ~ 190 195 Pro Ser SerSer LeuGly ThrGln ThrTyr IleCys AsnVal Asn His Lys ProSer AsnThr LyrsVal AspLys LysVal GluPro Lys :,''... ...... ..... ,...= . ..:::.:;
i3'~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92105126 (~ Z
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His~,Glu Asp Pro Glu Va1 Lys Phe Asn Trp Tyr 27~5~ 280 285 Val Asp GIy Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu '1'hr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Lle Ser Lys 2~ Ala Lys Gly Pro Arg Pro GlnVal TyrThr LeuPro Pro Gln Glu Ser Arg Glu Met Thr Asn GlnVal SerLeu ThrCys Leu Glu, Lys Val Lys Gly Ty~cPro Asp 'IleAla ValGlu TrpGlu Ser Phe Ser Asn Gly Gln Glu Asn Tyr LysThr ThrPro ProVa1 Leu Pro Asn Asp Ser Asp Ser Phe Leu TyxSer LysLeu ThrVal Asp ~-.e Gly Phe Lys Ser Arg GlriGln Asn Val~'heSerCys SerVal Met Trp Gly 4~5 430 435 Hia Glu Ala His Asn Tyr ~'hrG1n LysSex LeuSer Leu Leia His Ser Pro Gly , Lys (2) TNFORMATIONFOR SEQ :
ID
N0:23 ( j.) SEQUENCECHARACTERISTICS:
(A)' LENGTH: 57 aminoacids (~) TYPE: ami no acid (D)'TOPOLOGY: linear '~V~ 92/22653 ~ ~ ~ PC1'/U~92/0512~6 p o3 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
His His Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe 1'hr Glu Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser G1y Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Sex Cys Ala Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala G1y Ile Asn Pro Lys Asn Gly Gly Thr Ser His Asn Gln Arg Phe Met Asp Arg Phe 110 las 120 Thr Il.eSerVal AspLys SerThr SerThr A1a TyrMet GlnMet 3G Asn Ser LeuArg AlaGlu AspThr AlaVal Tyr TyrCys AlaArg Trp Arg GlyLeu AsnTyr GlyPhe AspVal Arg TyrPhe AspVal Trp Gly GlnGly ThrLeu Va1Thr ValSer Ser AlaSex ThrLys 170 1.75 180 G1y Pro SerVal Phe-Pro LeuAla PrnCys Ser ArgSer ThrSer Glu Sar ThxAla AlaiLeu GlyCys LeuVal Lys AspTyr PhePro 45- Glu Pro ValThr ValSer TrpAsn SerGly Ala LeuThr SerGly Val His ThrPhe ProAla ValLeu GlnSer Ser GlyLeu TyrSer Leu Ser SerVal ValThr Val'ThrSerSer Asn PheGly ThrGln ;:.r F:.:.., P ~
J.,,~, ~.~i,. :.., y 7 !3 >
Gu.
tG 7. .:: k 7 .
.. ~x I .:fin 1 , 4 4 ~0.' .A.-a., . ..>t d~'. ~ r 1 ' .~ 1 ~~.4r ~. , 7f , ,,. > . . ~, .' a"
:,:4" ...
:~ ;. , , F,.., . ...:;~ .;'~',t...y, ;.:. ,";'.~,;: ' .. ;.,.~.'~~o,> , ' m ", ..y'.. .., ' ,.. ' ..'...~~ ~ . .,. .~ , ',~;~ .... ,, ,. ~.:.;
r, . , ' ". . ~ ~ .;,.;~.~ . . ",. v:.,:. , . ;: , , . . ,..,. . ;. ,.. . ~
.~'~.. . ~.:.~.~ . :~ ~ ~ ' ~ .: , ~..,~. ..:.~ .,.
WCD 92/22653 ~ ~ ~ J ~ ~ ~ PC.TlUS92/05126 Ion Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Z'hr Val Glu Arg Lys Cys Cys Val Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 305 ~ 310 315 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 320 ~ 32S 330 Glu Cys Pro Pra Cys Pro Ala Pro Pro Val A1a G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Sex Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Met Ghu Val Hi.s 380 385 ~390 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Va1 Ser Asn Lys Gly Leu Pro Ala Pxo Tle Glu Lys Thr Ile Sex Lys Thr Lys Gly Gln Pro Arg Glu 440 44S 450 ''~
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Va1 Ser Leu Thr Cys Leu Va1 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val.Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Ty~ Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Sir Lys Leu Thr Val Asp Lys Ser Arg Trp Gln G1n Gly ". :.
~V~ 92/22653 ~ ~ ~ ~ ~ ~ e~ PCT/LJS92i~15126 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 'Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 214 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:24:
Asp Va1 G1n Met Thr GIn Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg VaI Thr Ile Asn Cys Arg AlawSer GIn Asp Ile Asn Asn Tyr Leu Asn Trp Tyr GIn Gln Lys Pro Asn Gly Thr Val Lys Leu Leu IIe Tyr Tyr Thr Ser Thr Leu His Ser Gly Va1 Pro Ser Arg Phe Ser Gly Ser G1y Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Al:a Ala Pro Ser Val Phe Ile Phe Pro Pro , 4~0 Ser Asp Glu Gln Leu Lys Ser Gly Thr AIa Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu GIn Ser G1y Asn Ser Gln Glu Ser Val Thr GIu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 50 170 ' 175 180 Leu Ser Lys AIa Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu ~~, r .,,...,.~. , ~ ,.. ~. ...::~., ., ,..: ,,:;... , . :~', '~';. . ' ::' ..
,~::. .....~'~.'y.:, ~,... ., ., ,~,.~:.:.. . .,~ ~,.... ' .;~. .. .
........:. . ;....
CVO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~(:'1'/US92105126 . -~ bb Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Cys Glu (2) INFORMATION D
FOR SEQ N0:25:
I
(i) SEQUENCE
CHARACTERISTICS:
(A) acids LENGTH:
amino (P) amino TYPE: acid (D) linear TOPOLOGY:
(~i) SEQUENCE SEQ ID
DESCRIPTION: N0:25:
Met G1y Ser CysIle IleLeu PheLeu ValAla ThrAla Thr Trp Gly Val Ser AspIle GlnMet ThrGln SexPro SerSer Leu His Ser Ala Val GlyAsp ArgVal ThrIle ThrCys ArgAla Ser Ser Gln Asp Asn AsnTyr LeuAsn TrpTyr GlnGln LysPro Gly Ile Lys Ala Lys LeuLeu IleTyr TyrThr SerThr LeuHis Ser Pro Gly Val Ser ArgPhe SerGly SerGly SerGly ThrAsp Tyr Pro Thr Leu Ile SerSer LeuGln ProGlu AspPhe AlaThr Tyr Thr ~5 95 100 105 Tyr Cys Gln GlyAsn ThrLeu ProPro ThrPhe GlyGln Gly Gln Thr Lys G~LuIleLys ArgThr ValAla AlaPro SexVal Phe Val Ile Phe Pro SerAsp GluGln LeuLys SerGly ThrAla Ser Pro '6Ia1 Val Leu LeuAsn AsnPhe TyrPro ArgGlu AlaLys Val Cys Gln Trp Val AspAsn AlaLeu GlnSer GlyAsn SerGln Glu Lys Ser Va1 G1u GlnAsp SerLys AspSer ThrTyr SerLeu Ser Thr u~r~ :,, ,,.
. ~'~ ~zrzzs~3 ~ ~ o ~ ~ ~ ~ Pf'I'/1J~92/05126 lob Ser Thr heu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val . 200 205 210 Tyr Ala Cys Glu Val Thr His Gln G1y Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
Claims (129)
1. A method for making a humanized antibody comprising non-human, import Complementarity Determining Region (CDR)amino acid residues and human Framework Region (FR) amino acid residues, comprising the steps of:
(a) obtaining the amino acid sequences of an import variable domain and of a VH subgroup III consensus human variable domain;
(b) identifying CDR amino acid sequences in the import and the human variable domain sequences;
(c) substituting import CDRs for the corresponding human CDRs;
(d) aligning the amino acid sequences of a FR of the import antibody and the corresponding FR of the consensus variable domain;
(e) identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus variable domain residues;
(f) determining if the non-homologous import amino acid residue is expected to have at least one of the following effects:
(1) non-covalently binds antigen directly;
(2) interacts with a CDR; or (3) participates in the VL-VH interface;
(g) for any non-homologous import antibody amino acid residue which is expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus variable domain FR
sequence; and (h) preparing a humanized antibody which binds antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
(a) obtaining the amino acid sequences of an import variable domain and of a VH subgroup III consensus human variable domain;
(b) identifying CDR amino acid sequences in the import and the human variable domain sequences;
(c) substituting import CDRs for the corresponding human CDRs;
(d) aligning the amino acid sequences of a FR of the import antibody and the corresponding FR of the consensus variable domain;
(e) identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus variable domain residues;
(f) determining if the non-homologous import amino acid residue is expected to have at least one of the following effects:
(1) non-covalently binds antigen directly;
(2) interacts with a CDR; or (3) participates in the VL-VH interface;
(g) for any non-homologous import antibody amino acid residue which is expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus variable domain FR
sequence; and (h) preparing a humanized antibody which binds antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
2. The method of claim 1, having an additional step of determining if any such non-homologous residues are exposed on the surface of the domain or buried within it, and if the residue is exposed, retaining the consensus residue.
3. The method of claim 1, having the additional steps of searching the import variable domain sequence for glycosylation sites, determining if any such glycosylation site is expected to affect the antigen binding or affinity of the antibody, and if so, substituting the glycosylation site into the consensus sequence.
4. The method of claim 1, having the additional steps of searching the consensus variable domain sequence for glycosylation sites which are not present at the corresponding amino acid in the import sequence, and if the glycosylation site is not present in the import sequence, substituting the import amino acid residues for the amino acid residues comprising the consensus glycosylation site.
5. The method of claim 1, having an additional step which comprises aligning import antibody and consensus variable domain FR sequences, identifying import antibody FR
residues which are non- homologous with the aligned consensus FR sequence, and for each such non- homologous import antibody FR residue, determining if the corresponding consensus variable domain residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus amino acid residue at that site.
residues which are non- homologous with the aligned consensus FR sequence, and for each such non- homologous import antibody FR residue, determining if the corresponding consensus variable domain residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus amino acid residue at that site.
6. The method of claim 1, wherein the corresponding consensus residues are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H, and 103H.
7. A method for making a humanized antibody comprising non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, comprising providing an import, non-human antibody variable domain amino acid sequence having CDR
amino acid residues and FR amino acid residues; obtaining the amino acid sequence of a VH subgroup III consensus human antibody variable domain having CDR amino acid residues and FR amino acid residues; substituting non-human CDR amino acid residues for human CDR amino acid residues in the consensus human antibody variable domain; substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H.
and 103H; and preparing a humanized antibody which binds an antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
amino acid residues and FR amino acid residues; obtaining the amino acid sequence of a VH subgroup III consensus human antibody variable domain having CDR amino acid residues and FR amino acid residues; substituting non-human CDR amino acid residues for human CDR amino acid residues in the consensus human antibody variable domain; substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H.
and 103H; and preparing a humanized antibody which binds an antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
8. The method of claim 7, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody.
9. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human antibody variable domain, and further comprising an amino acid substitution at a site selected from the group consisting of:
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 92H, and 93H.
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 92H, and 93H.
10. The humanized antibody variable domain of claim 9, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
11. The humanized antibody variable domain of claim 9, wherein no human (FR) Framework Region (FR) residue other than those set forth in the group has been substituted.
12. A method for making a humanized antibody comprising introducing Complementarity Determining Region (CDR) amino acid residues from an import antibody variable domain into a VH subgroup III consensus human antibody variable domain.
13. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human antibody variable domain and further comprising a non-human import Framework Region (FR) residue, wherein the non-human import FR residue introduces a glycosylation site which affects the antigen binding or affinity of the humanized antibody variable domain.
14. A humanized antibody which binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity and comprises a heavy chain variable domain which comprises non-human import antibody Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human variable domain.
15. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and:
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity:
(b) mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and (c) mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity:
(b) mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and (c) mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.
16. The humanized variant of claim 15 which binds the HER2 receptor with an affinity of about 0.82 nM Kd or better affinity.
17. The humanized variant of claim 16 which binds the HER2 receptor with an affinity of about 0.10 nM Kd.
18. The humanized variant of claim 15 which inhibits proliferation of SK-BR-3 cells incubated for 96 hr with the antibody.
19. The humanized variant of claim 18 wherein the antibody inhibits proliferation of SK-BR-3 cells to about 66% of untreated control or greater inhibition.
20. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and;
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity; and (b) comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity; and (b) comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.
21. The humanized variant of claim 20 which consists of about 1 to about 5 FR substitutions.
22. The humanized variant of claim 20 which comprises a FR substitution at site 73H.
23. The humanized variant of claim 20 which comprises a FR substitution at site 78H.
24. The humanized variant of claim 20 which comprises a FR substitution at site 93H.
25. The humanized variant of claim 20 which comprises a FR substitution at site 66L.
26. The humanized variant of claim 20 which further comprises a FR substitution at site 71H.
27. The humanized variant of claim 26 which comprises FR
substitutions at sites 71H, 73H, 78H, 93H and 66L.
substitutions at sites 71H, 73H, 78H, 93H and 66L.
28. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues; binds the HER2 receptor with better affinity than the non- human parent antibody; and comprises Framework Region (FR) amino acid substitutions at sites 71H, 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.
29. An antibody which binds an antigen and comprises non-human heavy chain variable domain Complementarity Determining Region (CDR) amino acid residues which bind said antigen and VH subgroup III consensus human variable domain Framework Region (FR) amino acid residues; and further comprises non-human light chain variable domain CDR amino acid residues which bind said antigen.
30. The antibody of claim 29, further comprising VL kappa subgroup I consensus human variable domain FR amino acid residues.
31. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution at a site selected from the group consisting of: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H and 92H, utilizing the numbering system set forth in Kabat.
32. The humanized variable domain of claim 31 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
33. The humanized variable domain of claim 31 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
34. The humanized variable domain of claim 31 wherein the human antibody variable domain is a consensus human variable domain.
35. The humanized variable domain of claim 31 wherein the residue at site 4L has been substituted.
36. The humanized variable domain of claim 31 wherein the residue at site 38L has been substituted.
37. The humanized variable domain of claim 31 wherein the residue at site 43L has been substituted.
38. The humanized variable domain of claim 31 wherein the residue at site 44L has been substituted.
39. The humanized variable domain of claim 31 wherein the residue at site 58L has been substituted.
40. The humanized variable domain of claim 31 wherein the residue at site 62L has been substituted.
41. The humanized variable domain of claim 31 wherein the residue at site 65L has been substituted.
42. The humanized variable domain of claim 31 wherein the residue at site 66L has been substituted.
43. The humanized variable domain of claim 31 wherein the residue at site 67L has been substituted.
44. The humanized variable domain of claim 31 wherein the residue at site 68L has been substituted.
45. The humanized variable domain of claim 31 wherein the residue at site 69L has been substituted.
46. The humanized variable domain of claim 31 wherein the residue at site 73L has been substituted.
47. The humanized variable domain of claim 31 wherein the residue at site 85L has been substituted.
48. The humanized variable domain of claim 31 wherein the residue at site 98L has been substituted.
49. The humanized variable domain of claim 31 wherein the residue at site 2H has been substituted.
50. The humanized variable domain of claim 31 wherein the residue at site 4H has been substituted.
51. The humanized variable domain of claim 31 wherein the residue at site 36H has been substituted.
52. The humanized variable domain of claim 31 wherein the residue at site 39H has been substituted.
53. The humanized variable domain of claim 31 wherein the residue at site 43H has been substituted.
54. The humanized variable domain of claim 31 wherein the residue at site 45H has been substituted.
55. The humanized variable domain of claim 31 wherein the residue at site 69H has been substituted.
56. The humanized variable domain of claim 31 wherein the residue at site 70H has been substituted.
57. The humanized variable domain of claim 31 wherein the residue at site 74H has been substituted.
58. The humanized variable domain of claim 31 wherein the residue at site 92H has been substituted.
59. An antibody comprising the humanized variable domain of claim 31.
60. An antibody which binds p185 HER2 and comprises a humanized antibody variable domain, wherein the humanized antibody variable domain comprises non-human Complementarity Determining Region (CDR) amino acid residues which bind p185 HER2 incorporated into a human antibody variable domain, and further comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of:
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
61. The antibody of claim 60 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
62. The antibody of claim 60 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
63. The antibody of claim 60 wherein the human antibody variable domain is a consensus human variable domain.
64. The antibody of claim 60 wherein the residue at site 4L has been substituted.
65. The antibody of claim 60 wherein the residue at site 38L has been substituted.
66. The antibody of claim 60 wherein the residue at site 43L has been substituted.
67. The antibody of claim 60 wherein the residue at site 44L has been substituted.
68. The antibody of claim 60 wherein the residue at site 46L has been substituted.
69. The antibody of claim 60 wherein the residue at site 58L has been substituted.
70. The antibody of claim 60 wherein the residue at site 62L has been substituted.
71. The antibody of claim 60 wherein the residue at site 65L has been substituted.
72. The antibody of claim 60 wherein the residue at site 66L has been substituted.
73. The antibody of claim 60 wherein the residue at site 67L has been substituted.
74. The antibody of claim 60 wherein the residue at site 68L has been substituted.
75. The antibody of claim 60 wherein the residue at site 69L has been substituted.
76. The antibody of claim 60 wherein the residue at site 73L has been substituted.
77. The antibody of claim 60 wherein the residue at site 85L has been substituted.
78. The antibody of claim 60 wherein the residue at site 98L has been substituted.
79. The antibody of claim 60 wherein the residue at site 2H has been substituted.
80. The antibody of claim 60 wherein the residue at site 4H has been substituted.
81. The antibody of claim 60 wherein the residue at site 36H has been substituted.
82. The antibody of claim 60 wherein the residue at site 39H has been substituted.
83. The antibody of claim 60 wherein the residue at site 43H has been substituted.
84. The antibody of claim 60 wherein the residue at site 45H has been substituted.
85. The antibody of claim 60 wherein the residue at site 69H has been substituted.
86. The antibody of claim 60 wherein the residue at site 70H has been substituted.
87. The antibody of claim 60 wherein the residue at site 74H has been substituted.
88. The antibody of claim 60 wherein the residue at site 75H has been substituted.
89. The antibody of claim 60 wherein the residue at site 76H has been substituted.
90. The antibody of claim 60 wherein the residue at site 78H has been substituted.
91. The antibody of claim 60 wherein the residue at site 92H has been substituted.
92. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a consensus human variable domain, and further comprising an amino acid substitution at a site selected from the group consisting of:
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
93. A humanized antibody which lacks immunogenicity compared to a non-human parent antibody upon repeated administration to a human patient in order to treat a chronic disease in that patient , wherein the humanized antibody comprises non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprises an amino acid substitution at a site selected from the group consisting of:
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
94. A humanized variant of a non-human parent antibody which binds an antigen and comprises a human variable domain comprising the most frequently occurring amino acid residues at each location in all. human immunoglobulins of a human heavy chain immunoglobulin subgroup wherein amino acid residues forming Complementarity Determining Regions (CDRs) thereof comprise non-human antibody amino acid residues, and further comprises a Framework Region (FR) substitution where the substituted FR residue: (a) noncovalently binds antigen directly; (b) interacts with a CDR; (c) introduces a glycosylation site which affects the antigen binding or affinity of the antibody; or (d) participates in the VL-VH interface by affecting the proximity or orientation of the VL and VH regions with respect to one another.
95. The humanized variant of claim 94 which binds the antigen up to 3-fold more in the binding affinity than the parent antibody binds antigen.
96. A humanized antibody heavy chain variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution at a site selected from the group consisting of: 24H, 73H, 76H, 78H, and 93H, utilizing the numbering system set forth in Kabat.
97. The humanized variable domain of claim 96 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
98. The humanized variable domain of claim 96 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
99. The humanized variable domain of claim 96 wherein the human antibody variable domain is a consensus human variable domain.
100. The humanized variable domain of claim 96 wherein the residue at site 24H has been substituted.
101. The humanized variable domain of claim 96 wherein the residue at site 73H has been substituted.
102. The humanized variable domain of claim 96 wherein the residue at site 76H has been substituted.
103. The humanized variable domain of claim 96 wherein the residue at site 78H has been substituted.
104. The humanized variable domain of claim 96 wherein the residue at site 93H has been substituted.
105. The humanized variable domain of claim 96 which further comprises an amino acid substitution at site 71H.
106. The humanized variable domain of claim 96 which further comprises amino acid substitutions at sites 71H
and 73H.
and 73H.
107. The humanized variable domain of claim 96 which further comprises amino acid substitutions at sites 71H, 73H and 78H.
108. An antibody comprising the humanized variable domain of claim 96.
109. A humanized variant of a non-human parent antibody which binds an antigen, wherein the humanized variant comprises Complementarity Determining Region (CDR) amino acid residues of the non-human parent antibody incorporated into a human antibody variable domain, and further comprises Framework Region (FR) substitutions at heavy chain positions 71H, 73H, 78H and 93H, utilizing the numbering system set forth in Kabat.
110. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution where the substituted FR residue:
(a) noncovalently binds antigen directly;
(b) interacts with a CDR; or (c) participates in the V L-V H interface by affecting the proximity or orientation of the V L and V H regions with respect to one another, and wherein the substituted FR
residue is at a site selected from the group consisting of: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 24H, 36H, 39H, 43H, 45H, 69H, 70H, 73H, 74H, 76H, 78H, 92H and 93H, utilizing the numbering system set forth in Kabat.
(a) noncovalently binds antigen directly;
(b) interacts with a CDR; or (c) participates in the V L-V H interface by affecting the proximity or orientation of the V L and V H regions with respect to one another, and wherein the substituted FR
residue is at a site selected from the group consisting of: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 24H, 36H, 39H, 43H, 45H, 69H, 70H, 73H, 74H, 76H, 78H, 92H and 93H, utilizing the numbering system set forth in Kabat.
111. The humanized variable domain of claim 110 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
112. The humanized variable domain of claim 110 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
113. A humanized antibody comprising the light chain variable domain sequence in SEQ ID NO: 17.
114. A humanized antibody comprising the heavy chain variable domain sequence in SEQ ID NO: 20.
115. A humanized anti-CD3 antibody comprising the amino acid sequences in SEQ ID NO: 17 and SEQ ID NO: 20.
116. A variable domain of a humanized antibody heavy chain comprising the variable domain sequence within SEQ
ID NO: 23.
ID NO: 23.
117. A variable domain of a humanized antibody light chain comprising the variable domain sequence within SEQ
ID NO: 25.
ID NO: 25.
118. A humanized anti-CD18 antibody comprising the heavy chain variable domain sequence within SEQ ID NO: 23 and the light chain variable domain sequence within SEQ ID
NO: 25.
NO: 25.
119. A polypeptide comprising the following amino acid sequence:
GVPSRFS
GSX2SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK, wherein X1 is E or Y and X2 is R or G.
GVPSRFS
GSX2SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK, wherein X1 is E or Y and X2 is R or G.
120. A polypeptide comprising the following amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCMSGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT
RYADS
SS, wherein X3 is A or R, X4 is T or D, X5 is A or L, X6 is S
or A and X7 is V or Y.
EVQLVESGGGLVQPGGSLRLSCMSGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT
RYADS
SS, wherein X3 is A or R, X4 is T or D, X5 is A or L, X6 is S
or A and X7 is V or Y.
121. The polypeptide of claim 119 comprising the amino acid sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
122. The polypeptide of claim 120 comprising the amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADS
VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADS
VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
123. A humanized antibody comprising the heavy chain variable domain sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV
wherein X1 is V or Y, and wherein the humanized antibody binds p185HER2 more tightly than the non-human import antibody from which the CDR amino acid residues of the humanized antibody are derived.
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV
wherein X1 is V or Y, and wherein the humanized antibody binds p185HER2 more tightly than the non-human import antibody from which the CDR amino acid residues of the humanized antibody are derived.
124. The humanized antibody of claim 123 further comprising the light chain variable domain sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
125. A humanized anti-HER2 antibody which comprises the light chain variable domain amino acid sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSGS
RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
and the heavy chain variable domain amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV
KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS.
CLAIMS:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSGS
RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
and the heavy chain variable domain amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV
KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS.
CLAIMS:
126. A humanized IgG1 antibody comprising the variable domains of Claim 125.
127. A humanized IgG1 antibody comprising human gamma 1 heavy chain constant domains, human light chain constant domains, and the variable domains of Claim 125.
128. A humanized IgG1 antibody comprising human gamma 1 heavy chain constant domains, human kappa 1 light chain constant domains, and the variable domains of Claim 125.
129. A humanized IgG1 antibody comprising human gamma non-A allotype heavy and light chain constant domains and the variable domains of claim 125.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002481259A CA2481259A1 (en) | 1991-06-14 | 1992-06-15 | Method for making humanized antibodies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71527291A | 1991-06-14 | 1991-06-14 | |
US07/715,272 | 1991-06-14 | ||
PCT/US1992/005126 WO1992022653A1 (en) | 1991-06-14 | 1992-06-15 | Method for making humanized antibodies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002481259A Division CA2481259A1 (en) | 1991-06-14 | 1992-06-15 | Method for making humanized antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2103059A1 CA2103059A1 (en) | 1992-12-15 |
CA2103059C true CA2103059C (en) | 2005-03-22 |
Family
ID=24873346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002103059A Expired - Lifetime CA2103059C (en) | 1991-06-14 | 1992-06-15 | Method for making humanized antibodies |
Country Status (14)
Country | Link |
---|---|
US (4) | US6407213B1 (en) |
EP (3) | EP0940468A1 (en) |
JP (4) | JP4124480B2 (en) |
AT (1) | ATE255131T1 (en) |
AU (1) | AU675916B2 (en) |
CA (1) | CA2103059C (en) |
CY (2) | CY2500B1 (en) |
DE (2) | DE122004000008I1 (en) |
DK (1) | DK0590058T3 (en) |
ES (1) | ES2206447T3 (en) |
GE (1) | GEP20074141B (en) |
LU (1) | LU91067I2 (en) |
NL (1) | NL300145I1 (en) |
WO (1) | WO1992022653A1 (en) |
Families Citing this family (3495)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US5948647A (en) * | 1990-10-29 | 1999-09-07 | Chiron Corporation | Nucleic acids encoding antigen-binding sites specific for cancer antigens |
US5849877A (en) * | 1990-10-29 | 1998-12-15 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5811267A (en) * | 1990-10-29 | 1998-09-22 | Chiron Corporation | Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (en) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US6685939B2 (en) | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
DE69233204T2 (en) * | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
EP0578515A3 (en) * | 1992-05-26 | 1995-05-10 | Bristol Myers Squibb Co | Humanized monoclonal antibodies. |
ES2112431T3 (en) * | 1992-08-21 | 1998-04-01 | Genentech Inc | PROCEDURE FOR THE TREATMENT OF AN LFA-1 MEDIATED DISORDER. |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
EP0804235A4 (en) * | 1993-05-04 | 2001-09-19 | Aeres Biomedical Ltd | Antibodies to p-selectin and their uses |
US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
AU3545795A (en) * | 1994-09-08 | 1996-03-27 | Chiron Corporation | A method of improved production of insulin-like growth factor |
US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5573762A (en) * | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
EP0831880A4 (en) * | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | Antibody and antibody fragments for inhibiting the growth of tumors |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
BR9609743A (en) | 1995-07-27 | 1999-03-02 | Genentech Inc | Stable reconstituted formulation method for the preparation of a manufactured article formulation and use of the formation |
GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
WO1997046589A2 (en) | 1996-06-07 | 1997-12-11 | Neorx Corporation | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods |
AU3359497A (en) * | 1996-07-11 | 1998-02-09 | Takara Shuzo Co., Ltd. | Method for effecting site-directed mutagenesis |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US7371376B1 (en) * | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
ZA982371B (en) * | 1997-03-21 | 1998-09-28 | Sankyo Co | Humanized anti-human fas antibody |
US7083786B2 (en) * | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
BRPI9809387B8 (en) * | 1997-04-07 | 2021-05-25 | Genentech Inc | humanized anti-human vascular endothelial growth factor antibody and composition comprising it |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
WO1998045332A2 (en) * | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Humanized antibodies and methods for forming humanized antibodies |
ES2263205T3 (en) * | 1997-04-30 | 2006-12-01 | Hans Klingemann | NATURAL CYTOLITIC CELLULAR STRETCHES AND METHODS OF USE. |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DE69841204D1 (en) | 1997-06-04 | 2009-11-12 | Oxford Biomedica Ltd | Tumor targeted vector |
US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US20020192659A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030092002A1 (en) * | 1997-09-17 | 2003-05-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DK1027437T3 (en) | 1997-10-29 | 2008-11-24 | Genentech Inc | Use of the WNT-1 induced secreted polypeptide WISP-1 |
IL135607A0 (en) | 1997-10-29 | 2001-05-20 | Genentech Inc | Wnt-1 inducible genes |
WO1999027964A1 (en) * | 1997-12-01 | 1999-06-10 | Cfy Biomedicals, Inc. | Multivalent recombinant antibodies for treating hrv infections |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
EP1064382B1 (en) | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Polypeptides homologous to vegf and bmp1 |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
EP1308456B1 (en) * | 1998-05-06 | 2007-08-22 | Genentech, Inc. | Antibody purification by ion exchange chromatography |
ES2261589T3 (en) | 1998-05-06 | 2006-11-16 | Genentech, Inc. | ANTI-HER2 ANTIBODY COMPOSITION. |
AU2003200708B2 (en) * | 1998-05-06 | 2007-01-04 | Genentech, Inc. | Protein purification |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US7387772B1 (en) * | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
WO2000023082A1 (en) * | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
WO2000029431A1 (en) * | 1998-11-17 | 2000-05-25 | Tanox, Inc. | Bispecific molecules cross-linking itim and itam for therapy |
DE69938054T2 (en) * | 1998-11-18 | 2009-02-12 | Genentech, Inc., South San Francisco | ANTIBODY VARIANTS HAVING HIGHER BINDING SAFFINITIES COMPARED TO PARENTAL ANTIBODIES |
WO2000029447A1 (en) * | 1998-11-19 | 2000-05-25 | Smithkline Beecham Corporation | Rhamm antagonist antibodies |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EA004590B1 (en) | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Method for blocking the development or treating or reducing the severity or effects of "transplant against patients" disease |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
IL145674A0 (en) * | 1999-04-06 | 2002-06-30 | Genentech Inc | USE OF ERbB RECEPTOR LIGANDS IN TREATING DIABETES |
WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
CA2373815A1 (en) * | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
TR200103432T2 (en) | 1999-06-01 | 2002-10-21 | Biogen, Inc. | Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases. |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
BR0012195A (en) * | 1999-06-25 | 2002-07-23 | Genentech Inc | Method for treating prostate cancer in a human, article of manufacture and use of an antibody that binds erbb2 |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
CN100482281C (en) | 1999-06-25 | 2009-04-29 | 基因技术股份有限公司 | Method of treatment using anti-ErbB antibody-maytansinoid conjugates |
PL204629B1 (en) | 1999-06-25 | 2010-01-29 | Genentech Inc | Humanized antibodies of anti-ERBB2 and treatment with antibodies of anti-ERBB2 |
US20020068066A1 (en) * | 1999-08-20 | 2002-06-06 | Wenyuan Shi | Method for the treatment and prevention of dental caries |
MXPA02002037A (en) * | 1999-08-27 | 2002-10-31 | Genentech Inc | DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES. |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US6346249B1 (en) * | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
AU1290001A (en) | 1999-11-18 | 2001-05-30 | Oxford Biomedica (Uk) Limited | Antibodies |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
ATE337403T1 (en) * | 1999-12-24 | 2006-09-15 | Genentech Inc | METHOD AND COMPOUNDS FOR EXTENSING THE HALF-LIFE TIMES IN THE EXCRETION OF BIOACTIVE COMPOUNDS |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
AU4574501A (en) | 2000-03-17 | 2001-10-03 | Millennium Pharm Inc | Method of inhibiting stenosis and restenosis |
EP1272647B1 (en) * | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
PT1283214E (en) | 2000-04-21 | 2007-03-30 | Fuso Pharmaceutical Ind | Novel collectins |
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
EP1280923A2 (en) * | 2000-04-28 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 14094, a human trypsin family member and uses thereof |
PT1282443E (en) | 2000-05-19 | 2009-12-04 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
AU2001268363B2 (en) | 2000-06-20 | 2006-08-17 | Biogen Idec Inc. | Treatment of B cell associated diseases |
EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2077276A1 (en) | 2000-06-23 | 2009-07-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
AU9500201A (en) * | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
WO2002018583A2 (en) * | 2000-09-01 | 2002-03-07 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
US20030017491A1 (en) * | 2000-09-14 | 2003-01-23 | Zuo-Rong Shi | Chromogenic in situ hybridization methods, kits, and compositions |
SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
CA2427820A1 (en) * | 2000-11-01 | 2002-06-13 | Elusys Therapeutics, Inc. | Method of producing biospecific molecules by protein trans-splicing |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
WO2002048675A2 (en) * | 2000-12-15 | 2002-06-20 | Transderm Technologies, Llc | Improved compositions and methods for producing antibodies to low molecular weight analytes |
US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
US7132510B2 (en) | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
US20040001822A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
EE05724B1 (en) | 2001-01-05 | 2014-10-15 | Pfizer Inc. | Antibodies to insulin-like growth factor I receptor |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
WO2002060485A2 (en) | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
AU2002237972B2 (en) | 2001-01-31 | 2007-11-29 | Biogen Idec Inc. | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
CA2438513C (en) * | 2001-02-19 | 2013-08-13 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified anti-egfr antibodies with reduced immunogenicity |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
AU2002247826A1 (en) * | 2001-03-13 | 2002-09-24 | University College London | Specific binding members |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
EP1372717A2 (en) | 2001-03-23 | 2004-01-02 | Aphton Corporation | Combination treatment of pancreatic cancer |
US7638598B2 (en) | 2001-04-06 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | ErbB interface peptidomimetics and methods of use thereof |
DE60236735D1 (en) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | ANTIBODIES TO VLA-1 |
CA2444821C (en) | 2001-04-24 | 2012-07-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using anti-angiogenic agents and tnfa |
US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US7132401B2 (en) | 2001-05-22 | 2006-11-07 | Merck & Co., Inc. | Beta-secretase substrates and uses thereof |
IL158921A0 (en) | 2001-05-30 | 2004-05-12 | Genentech Inc | Anti-ngf antibodies for the treatment of various disorders |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
CA2385745C (en) * | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
PT1399186E (en) | 2001-06-13 | 2010-02-23 | Armbruster Biotechnology Gmbh | Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein |
DE50213368D1 (en) * | 2001-06-13 | 2009-04-30 | Immundiagnostik Ag | DETERMINATION OF BONE-SIALOPROTEIN IN BODY FLUIDS FOR ONCOLOGICAL QUESTIONS |
ATE440869T1 (en) | 2001-06-20 | 2009-09-15 | Fibron Ltd | FGFR3 BLOCKING ANTIBODIES, METHOD FOR SCREENING THEREOF, AND USES THEREOF |
CA2633413C (en) | 2001-06-20 | 2012-08-21 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
US7393656B2 (en) | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
CN1671416B (en) * | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | Super-humanized antibodies |
CA2898314A1 (en) | 2001-07-19 | 2003-07-31 | Perian Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
EA007984B1 (en) * | 2001-08-03 | 2007-02-27 | Дженентек, Инк. | TACIs AND BR3 POLYPEPTIDES AND USE THEREOF |
AU2002326531A1 (en) * | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
ATE382053T1 (en) * | 2001-08-27 | 2008-01-15 | Genentech Inc | SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS |
US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
CA2460120A1 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
AR037456A1 (en) | 2001-11-30 | 2004-11-10 | Biogen Inc | ANTIBODIES AGAINST MONOCITARY CHEMOTHOTAL PROTEINS |
AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
KR20040096592A (en) * | 2002-02-21 | 2004-11-16 | 와이어쓰 | Follistatin domain containing proteins |
RU2359697C2 (en) | 2002-02-25 | 2009-06-27 | Элан Фармасьютикалз, Инк. | Injection of agents for inflammation treatment |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20070122406A1 (en) | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP2336185A1 (en) | 2002-03-13 | 2011-06-22 | Biogen Idec Inc. | Anti- alpha v beta 6 antibodies |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
AU2003220439A1 (en) * | 2002-03-19 | 2003-10-08 | Abgenix, Inc. | Methods for treating chronic obstructive pulmonary disease (copd) |
CN103536916B (en) | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | For the method treating TWEAK associated conditions |
DK1501856T3 (en) * | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antibody variants |
JP2005536190A (en) | 2002-04-16 | 2005-12-02 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
US6916904B2 (en) * | 2002-04-24 | 2005-07-12 | Zolaris Biosciences, Llc | Inhibition of immune complex formation |
JP3885658B2 (en) * | 2002-05-13 | 2007-02-21 | 住友電気工業株式会社 | Heterojunction bipolar transistor |
ATE483466T1 (en) | 2002-05-23 | 2010-10-15 | Univ Pennsylvania | FAS PEPTIDE MIMETICS AND THEIR USES |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
JP4753578B2 (en) * | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | Synthetic antibody phage library |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
DK1531791T3 (en) | 2002-06-07 | 2010-11-01 | Dyax Corp | Prevention and restriction of ischemia |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
EP1551453A4 (en) * | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | SPECIFICITY GRAFTING OF A WALL ANTIBODY ON A HUMAN CHARPENTE |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
US20040208877A1 (en) * | 2002-07-01 | 2004-10-21 | Avigdor Levanon | Antibodies and uses thereof |
US20040202665A1 (en) * | 2002-07-01 | 2004-10-14 | Janette Lazarovits | Compositions and methods for therapeutic treatment |
ES2376165T3 (en) * | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4. |
US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
KR101215701B1 (en) | 2002-07-19 | 2012-12-26 | 베스 이스라엘 데코니스 메디칼 센터 | Methods of diagnosing and treating pre-eclampsia or ecalmpsia |
US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
JP2005533863A (en) * | 2002-07-25 | 2005-11-10 | ジェネンテック・インコーポレーテッド | TACI antibodies and their uses |
AU2003263964C1 (en) * | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
PT1534335E (en) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Fcgammariib-specific antibodies and methods of use thereof |
EP1542710B1 (en) * | 2002-08-28 | 2012-09-26 | Dyax Corp. | Methods for preserving organs and tissues |
WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
JP2005538738A (en) * | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス,インコーポレーテッド | Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
PT1556083E (en) * | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
US7255860B2 (en) * | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
AU2003276084B2 (en) | 2002-10-10 | 2009-07-09 | Merck Patent Gmbh | Bispecific anti-Erb-B antibodies and their use in tumor therapy |
EP2301965B1 (en) | 2002-10-16 | 2015-02-25 | Purdue Pharma L.P. | Antibodies that bind cell-associated CA 125/O722P and methods of use thereof |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7608429B2 (en) | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US20040229785A1 (en) * | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
US20040258685A1 (en) * | 2002-11-21 | 2004-12-23 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
US20070048301A1 (en) * | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
US7888479B2 (en) * | 2002-11-27 | 2011-02-15 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactric proteins |
SG2013036975A (en) * | 2002-12-16 | 2016-07-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
KR101086660B1 (en) * | 2002-12-17 | 2011-11-24 | 메르크 파텐트 게엠베하 | Fusion of Mouse 14.18 Antibody That Binds to WD2 with Humanized Antibody (H14.18) and its IL-2 |
ATE431157T1 (en) * | 2002-12-23 | 2009-05-15 | Rinat Neuroscience Corp | METHOD FOR TREATING TAXOL-INDUCED SENSORY NEUROPATHY |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CN102746399B (en) * | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | Anti-ngf antibodies and using method thereof |
CA2510003A1 (en) * | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7488475B2 (en) | 2003-01-21 | 2009-02-10 | Arius Research, Inc. | Antibody therapy of tumors |
CA2513113A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
KR20050114212A (en) | 2003-01-24 | 2005-12-05 | 엘란 파마슈티칼스, 인크. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
ZA200505782B (en) * | 2003-02-01 | 2006-09-27 | Neuralab Ltd | Active immunization to generate antibodies to soluble A-beta |
JP3803790B2 (en) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | Novel diabody-type bispecific antibody |
JP2006525960A (en) | 2003-02-19 | 2006-11-16 | ライナット ニューロサイエンス コーポレイション | Nerve growth factor agonists and NSAIDs and methods for treating pain by administration of compositions comprising them |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
AU2004219592C1 (en) | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
EP1620127A4 (en) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | Methods for treating taxol-induced gut disorder |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
WO2004087059A2 (en) | 2003-03-26 | 2004-10-14 | The University Of Texas | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |
CA2520381A1 (en) * | 2003-03-26 | 2004-10-14 | Sudhir Paul | Proteolytic and covalent antibodies |
WO2004087738A2 (en) * | 2003-03-27 | 2004-10-14 | The University Of Texas | Lupus antibodies for passive immunotherapy of hiv/aids |
AU2004225437B2 (en) * | 2003-03-28 | 2010-05-13 | Cancer Advances, Inc. | Gastrin hormone immunoassays |
JP4869064B2 (en) | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | High concentration antibody and protein preparation |
CA2519870A1 (en) * | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Use of rituximab intravenous compositions to treat rheumatoid arthritis |
EP1613273B1 (en) | 2003-04-11 | 2012-06-13 | MedImmune, LLC | Recombinant il-9 antibodies and uses thereof |
US20080213169A1 (en) * | 2003-04-14 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20080025977A1 (en) * | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7189694B2 (en) * | 2003-04-18 | 2007-03-13 | University Of Florida Research Foundation, Inc. | Inhibitors of autophosphorylation protein kinases |
US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
SI2374819T1 (en) | 2003-05-12 | 2017-09-29 | Helion Biotech Aps | Antibodies to MASP-2 |
CN100387301C (en) * | 2003-05-12 | 2008-05-14 | 佛罗里达大学研究基金公司 | Immunization materials and methods against FIV infection |
US7658927B2 (en) * | 2003-05-12 | 2010-02-09 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DK2361928T3 (en) | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Truncated fragments of alpha synuclein in Lewy body disease |
TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
CA2526080A1 (en) * | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
JP2007536896A (en) * | 2003-06-05 | 2007-12-20 | ジェネンテック・インコーポレーテッド | BLYS antagonists and their uses |
CN1279056C (en) * | 2003-06-06 | 2006-10-11 | 马菁 | Specific antibody of tumor-associated antigen SM5-1 and use thereof |
WO2005003175A2 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
WO2005000086A2 (en) * | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
US20050152906A1 (en) * | 2003-06-30 | 2005-07-14 | Avigdor Levanon | Specific human antibodies |
US20050266009A1 (en) * | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
KR100945327B1 (en) | 2003-07-08 | 2010-03-08 | 제넨테크, 인크. | IL-173A / F heterologous polypeptide and its therapeutic use |
EP1644408A1 (en) * | 2003-07-15 | 2006-04-12 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
US20050058658A1 (en) * | 2003-07-15 | 2005-03-17 | Barros Research Institute | Compositions and methods for immunotherapy of human immunodeficiency virus (HIV) |
MXPA06000508A (en) * | 2003-07-18 | 2006-04-05 | Amgen Inc | Specific binding agents to hepatocyte growth factor. |
EP1648940B1 (en) | 2003-07-28 | 2016-04-27 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
EP1660186B1 (en) * | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
JP2007528723A (en) * | 2003-08-22 | 2007-10-18 | メディミューン,インコーポレーテッド | Antibody humanization |
US20050152894A1 (en) * | 2003-09-05 | 2005-07-14 | Genentech, Inc. | Antibodies with altered effector functions |
GB2406094B (en) * | 2003-09-17 | 2007-06-06 | Antisoma Plc | Modified antibody comprising an amino acid substitution mutation which confers increased stability |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US20050176028A1 (en) * | 2003-10-16 | 2005-08-11 | Robert Hofmeister | Deimmunized binding molecules to CD3 |
JP4948174B2 (en) | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | Multispecific deimmunized CD3-binding agent |
KR101438983B1 (en) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | Monomethylvaline compounds capable of conjugation to ligands |
AR046833A1 (en) * | 2003-11-10 | 2005-12-28 | Schering Corp | ANTI-INTERLEUQUINA ANTIBODIES-10 |
WO2005048938A2 (en) | 2003-11-13 | 2005-06-02 | California Pacific Medical Center | Anti-pecam therapy for metastasis suppression |
PT2161283E (en) | 2003-11-17 | 2014-08-29 | Genentech Inc | Compositions comprising antibodies against cd79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin |
EP1689783B1 (en) | 2003-11-25 | 2010-05-19 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
US20060003412A1 (en) * | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
US20070249809A1 (en) * | 2003-12-08 | 2007-10-25 | Xencor, Inc. | Protein engineering with analogous contact environments |
JP4332558B2 (en) | 2003-12-09 | 2009-09-16 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | Targeted gene delivery to non-phagocytic mammalian cells via intact minicells from bacteria |
ES2384569T3 (en) * | 2003-12-19 | 2012-07-09 | Genentech, Inc. | Fragments of monovalent antibodies useful as therapeutic agents |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US7968690B2 (en) * | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
ITRM20030601A1 (en) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED. |
EP1709080B1 (en) * | 2004-01-09 | 2011-03-09 | Pfizer Inc. | ANTIBODIES TO MAdCAM |
CA2554729A1 (en) * | 2004-01-27 | 2005-08-11 | University Of Southern California | Polymer-bound antibody cancer therapeutic agent |
PT1718338E (en) | 2004-02-02 | 2015-09-21 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
JP5155564B2 (en) | 2004-02-03 | 2013-03-06 | ディアデクサス インコーポレーテッド | Method for detecting Lp-PLA2 activity |
CN1965082A (en) * | 2004-02-06 | 2007-05-16 | 尼莫克斯股份有限公司 | Humanized antibody |
WO2005079479A2 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
ATE452147T1 (en) | 2004-02-19 | 2010-01-15 | Genentech Inc | ANTIBODIES WITH CORRECTED CDR |
US7875598B2 (en) | 2004-03-04 | 2011-01-25 | The Regents Of The University Of California | Compositions useful for the treatment of microbial infections |
AU2005221187B2 (en) * | 2004-03-10 | 2011-09-01 | Trinity Therapeutics, Inc. | Method for inhibiting immune complex formation in a subjetc |
US7273608B2 (en) * | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
DK1735348T3 (en) * | 2004-03-19 | 2012-07-16 | Imclone Llc | Human anti-epidermal growth factor receptor antibody |
US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
MXPA06011199A (en) | 2004-03-31 | 2007-04-16 | Genentech Inc | Humanized anti-tgf-beta antibodies. |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
ES2665758T3 (en) * | 2004-04-07 | 2018-04-27 | Rinat Neuroscience Corp. | Bone cancer pain treatment procedures by administration of a neuronal growth factor antagonist antibody |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
US20060034840A1 (en) * | 2004-04-08 | 2006-02-16 | Agus David B | ErbB antagonists for pain therapy |
US7785903B2 (en) * | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
US20060002930A1 (en) * | 2004-04-16 | 2006-01-05 | Genentech, Inc. | Treatment of disorders |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
KR20070012408A (en) * | 2004-04-16 | 2007-01-25 | 제넨테크, 인크. | 방법 How to increase cell depletion |
EP2286844A3 (en) * | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
CA2566979A1 (en) | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Use of a cd20 antibody in treatment of multiple sclerosis |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
AR049390A1 (en) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
SV2006002143A (en) * | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
EP1773391A4 (en) * | 2004-06-25 | 2009-01-21 | Medimmune Inc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
JP2008505174A (en) | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | Optimized Fc variant |
PT1771474E (en) | 2004-07-20 | 2010-05-03 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
KR20110050567A (en) * | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | HER2 antibody composition |
CN101072587B (en) | 2004-07-26 | 2012-12-26 | 比奥根艾迪克Ma公司 | Anti-cd154 antibodies |
EA016357B1 (en) | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
ATE465181T1 (en) * | 2004-08-05 | 2010-05-15 | Genentech Inc | HUMANIZED ANTI-CMET ANTAGONISTS |
MX2007001469A (en) | 2004-08-06 | 2007-03-26 | Genentech Inc | Assays and methods using biomarkers. |
AU2005271249A1 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
EA013752B1 (en) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN101052654A (en) * | 2004-08-19 | 2007-10-10 | 健泰科生物技术公司 | Polypeptide variants with altered effector function |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
WO2006021894A2 (en) | 2004-08-26 | 2006-03-02 | Engeneic Gene Therapy Pty Limited | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
CN101052653A (en) * | 2004-09-02 | 2007-10-10 | 健泰科生物技术公司 | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
JP2008511337A (en) * | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | Heteromultimeric molecule |
US7662926B2 (en) * | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
US7655229B2 (en) * | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
RU2453558C2 (en) | 2004-09-03 | 2012-06-20 | Дженентек, Инк. | Humanised anti-beta 7 antagonistic antibodies and use thereof |
WO2006031994A2 (en) * | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
EP3073267A1 (en) | 2004-09-21 | 2016-09-28 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8158128B2 (en) | 2004-09-22 | 2012-04-17 | Cancer Advances, Inc. | Monoclonal antibodies to progastrin |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
SI1791565T1 (en) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
MX2007003522A (en) | 2004-09-24 | 2007-06-11 | Beth Israel Hospital | Methods of diagnosing and treating complications of pregnancy. |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
RU2418004C2 (en) | 2004-10-04 | 2011-05-10 | Дженентек, Инк. | Modulators of hepatocyte growth factor activator |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
KR20070073886A (en) * | 2004-10-05 | 2007-07-10 | 제넨테크, 인크. | Toxic Drugs |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
DK1802334T3 (en) | 2004-10-21 | 2012-10-15 | Genentech Inc | Method of treating intraocular neovascular diseases |
JP2008518023A (en) | 2004-10-27 | 2008-05-29 | メディミューン,インコーポレーテッド | Regulation of antibody specificity by altering affinity for cognate antigens |
AU2005302312A1 (en) * | 2004-10-29 | 2006-05-11 | Elusys Therapeutics, Inc. | Use of CR1-binding molecules in clearance and induction of immune responses |
JP2008519863A (en) * | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Auristatin having an aminobenzoic acid unit at the N-terminus |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060222653A1 (en) * | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
EP2808033A1 (en) | 2004-11-19 | 2014-12-03 | Biogen Idec MA Inc. | Treatment for multiple sclerosis |
GB0425713D0 (en) * | 2004-11-23 | 2004-12-22 | Baker Matthew | Immunogencity testing and antibody selection methods |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
EP1833509A4 (en) * | 2004-12-03 | 2008-12-03 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
RU2007125644A (en) * | 2004-12-07 | 2009-01-20 | Дженентек Инк. (Us) | SELECTION OF PATIENTS FOR THERAPY WITH HER INHIBITOR |
ES2434732T3 (en) | 2004-12-15 | 2013-12-17 | Janssen Alzheimer Immunotherapy | Humanized beta-amyloid antibodies for use in improving cognition |
WO2006066171A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
WO2006066049A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
EP2290087A3 (en) | 2004-12-22 | 2011-06-15 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
WO2006073846A2 (en) * | 2004-12-22 | 2006-07-13 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
RU2393483C2 (en) * | 2004-12-23 | 2010-06-27 | Ф.Хоффманн-Ля Рош Аг | Detection of therapeutic antibody in experimental animal |
CN101137673B (en) | 2005-01-05 | 2013-12-04 | 比奥根艾迪克Ma公司 | Cripto binding molecules |
EP2230517A1 (en) | 2005-01-07 | 2010-09-22 | Diadexus, Inc. | OVR110 antibody compositions and methods of use |
AU2006204791A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
MX2007008218A (en) * | 2005-01-13 | 2007-08-17 | Genentech Inc | Treatment method. |
US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
BRPI0606480A (en) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | pharmaceutical compounds |
UA94899C2 (en) * | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Fixed dosing of her antibodies |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
CN113952459B (en) | 2005-02-03 | 2025-02-11 | 综合医院公司 | Methods for treating gefitinib-resistant cancer |
KR101385886B1 (en) | 2005-02-03 | 2014-04-24 | 안티토페 리미티드 | Human antibodies and proteins |
CN101115773B (en) | 2005-02-07 | 2015-06-10 | 罗氏格黎卡特股份公司 | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof |
CA2599589A1 (en) | 2005-02-07 | 2006-08-17 | Genenews,Inc. | Mild osteoarthritis biomarkers and uses thereof |
LT1850873T (en) | 2005-02-08 | 2019-04-10 | Genzyme Corporation | Antibodies to tgfbeta |
CA2595395A1 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
WO2006088950A2 (en) | 2005-02-14 | 2006-08-24 | University Of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
ES2550621T3 (en) | 2005-02-15 | 2015-11-11 | Duke University | Anti-CD19 antibodies and uses in oncology |
CA2597945C (en) | 2005-02-17 | 2016-07-12 | Biogen Idec Ma Inc. | Treating neurological disorders |
MX2007009889A (en) | 2005-02-23 | 2007-09-07 | Genentech Inc | Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor. |
US20060193849A1 (en) * | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
EP2251037B1 (en) | 2005-03-02 | 2015-01-14 | Biogen Idec MA Inc. | KIM-1 antibodies for treatment of TH1/TH2-mediated conditions |
US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
CA2600929A1 (en) * | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
AU2006226192A1 (en) | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
JP2008537488A (en) * | 2005-03-23 | 2008-09-18 | ワイス | Detection of GDF-8 modulating substances |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
EP2674165B1 (en) | 2005-03-31 | 2016-10-12 | The General Hospital Corporation | Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis |
ES2833948T3 (en) | 2005-04-04 | 2021-06-16 | Biogen Ma Inc | Methods for evaluating an immune response to a therapeutic agent |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
AR054260A1 (en) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
WO2006117782A2 (en) | 2005-05-04 | 2006-11-09 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP2301969B1 (en) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
DK1879573T3 (en) | 2005-05-10 | 2013-02-25 | Incyte Corp | MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE AND METHODS FOR USING IT |
US8088908B2 (en) * | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
JP2008545712A (en) * | 2005-05-25 | 2008-12-18 | キュアーディーエム、インク. | Peptides, derivatives and analogs thereof, and methods of using them |
PT1888113E (en) * | 2005-05-27 | 2014-09-04 | Biogen Idec Inc | Tweak binding antibodies |
WO2006132788A2 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
ITRM20050290A1 (en) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
DK2390267T3 (en) | 2005-06-07 | 2013-08-26 | Esbatech A Novartis Co Llc | Stable and soluble antibodies that inhibit TNF (alpha) |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
JP5372500B2 (en) | 2005-06-17 | 2013-12-18 | トレラクス リクイデーティング トラスト | ILT3-binding molecules and uses thereof |
EP1893647A2 (en) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
US8871720B2 (en) * | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
CN102875681A (en) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | Anti-alpha v beta 6 antibodies and uses thereof |
PE20070207A1 (en) * | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
US7456259B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
US7494648B2 (en) * | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
US7452978B2 (en) * | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7452979B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7456258B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
ZA200800970B (en) | 2005-08-15 | 2009-10-28 | Genentech Inc | Gene disruptions, compositions and methods relating thereto |
BRPI0616005A2 (en) | 2005-08-16 | 2011-05-31 | Genentech Inc | method for predicting the sensitivity of a cell or tissue sample, method for inducing apoptosis in a cell or tissue sample, and method of treating a dysfunction |
AU2006283725B2 (en) * | 2005-08-19 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
WO2007027906A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
US20090105138A1 (en) * | 2005-09-06 | 2009-04-23 | Trinity Therapeutics, Inc. | Methods for treating immune mediated neurological diseases |
US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
EP1931709B1 (en) * | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
EP1951757B1 (en) | 2005-10-06 | 2014-05-14 | Xencor, Inc. | Optimized anti-cd30 antibodies |
JP5686953B2 (en) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Compositions comprising cross-species-specific antibodies and uses of the compositions |
ATE518007T1 (en) | 2005-10-21 | 2011-08-15 | Genenews Inc | METHOD AND APPARATUS FOR CORRELING LEVELS OF BIOMARKER PRODUCTS WITH DISEASES |
PE20070796A1 (en) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
CA2903896A1 (en) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007056411A2 (en) * | 2005-11-08 | 2007-05-18 | Genentech, Inc. | Method of producing pan-specific antibodies |
MY153249A (en) | 2005-11-14 | 2015-01-29 | Rinat Neuroscience Corp | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
JP2009515552A (en) * | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α4β7 integrin-reactive humanized immunoglobulin |
CA2630432A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
EP1951892A4 (en) | 2005-11-22 | 2009-01-14 | Univ Pennsylvania | ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES |
JP6088723B2 (en) * | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | Compositions and methods for B cell assays. |
ES2388932T3 (en) * | 2005-12-02 | 2012-10-19 | Genentech, Inc. | Binding polypeptides and uses thereof |
WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
DOP2006000277A (en) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | ANTI MN ANTIBODIES AND METHODS FOR USE |
AR057237A1 (en) | 2005-12-15 | 2007-11-21 | Genentech Inc | METHODS AND COMPOSITIONS TO ACT ON POLYUBIQUITINE |
PT1976880T (en) | 2005-12-21 | 2016-09-28 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
US20090214541A1 (en) * | 2006-01-04 | 2009-08-27 | L'instut National De La Sante Et De La Recherche Medicale | Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies |
AU2007248444B2 (en) | 2006-01-05 | 2012-10-25 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
KR20080087164A (en) | 2006-01-18 | 2008-09-30 | 더 제너럴 하스피탈 코포레이션 | How to increase lymph function |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
WO2009051846A2 (en) | 2007-10-18 | 2009-04-23 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
US20070175313A1 (en) * | 2006-01-31 | 2007-08-02 | Kevin Vandervliet | MP3 player holder assembly |
WO2007114979A2 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
WO2007100711A2 (en) * | 2006-02-24 | 2007-09-07 | Investigen, Inc. | Methods and compositions for detecting polynucleotides |
EP1999148B8 (en) | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
KR20140057635A (en) | 2006-03-15 | 2014-05-13 | 알렉시온 파마슈티칼스, 인코포레이티드 | Treatment of Patients with Paroxysmal Nocturnal Hemorrhage as an Incompatible Substance |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
AR059900A1 (en) | 2006-03-17 | 2008-05-07 | Genentech Inc | ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS |
DK1989231T3 (en) | 2006-03-21 | 2015-08-24 | Genentech Inc | COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
WO2007108152A1 (en) | 2006-03-23 | 2007-09-27 | Tohoku University | High functional bispecific antibody |
EP2004221A2 (en) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Anti-tumor cell antigen antibody therapeutics |
JP4419976B2 (en) | 2006-03-24 | 2010-02-24 | オンキヨー株式会社 | Speaker diaphragm and speaker |
AR059922A1 (en) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
ES2643469T3 (en) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Antibodies that bind to the human tyrosine phosphatase beta protein (HPTP-beta) and uses thereof |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
AU2007297565A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US20090298093A1 (en) * | 2006-04-27 | 2009-12-03 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways |
US20070292936A1 (en) * | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US7745584B2 (en) | 2006-05-22 | 2010-06-29 | California Institute Of Technology | Antibodies to sulfated carbohydrates |
AU2007267579B2 (en) * | 2006-05-25 | 2013-05-30 | Biogen Ma Inc. | Methods of treating stroke |
MX2008015132A (en) | 2006-05-30 | 2008-12-10 | Genentech Inc | Antibodies and immunoconjugates and uses therefor. |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
AU2007258694B2 (en) * | 2006-06-06 | 2011-12-22 | Glaxo Group Limited | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
CA2654304A1 (en) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
AR061246A1 (en) * | 2006-06-06 | 2008-08-13 | Genentech Inc | ANTI-DILL4 ANTIBODIES AND METHODS THAT USE THEM |
AU2007258473B2 (en) * | 2006-06-07 | 2012-08-23 | Altrubio Inc. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
EP2037961B1 (en) | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
AU2007345745C1 (en) * | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
ES2458498T3 (en) | 2006-06-23 | 2014-05-05 | Engeneic Molecular Delivery Pty Ltd. | Targeted administration of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells by means of intact dead bacterial cells |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
WO2008000079A1 (en) | 2006-06-26 | 2008-01-03 | The University Of British Columbia | Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers |
PL2029173T3 (en) | 2006-06-26 | 2017-04-28 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
US7749772B1 (en) | 2006-06-29 | 2010-07-06 | Varian, Inc. | Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol |
DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
US20080003230A1 (en) | 2006-07-03 | 2008-01-03 | Adair Charles D | Composition for modulating the expression of cell adhesion molecules |
SG173364A1 (en) | 2006-07-10 | 2011-08-29 | Biogen Idec Inc | Compositions and methods for inhibiting growth of smad4-deficient cancers |
ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
HUE038454T2 (en) | 2006-08-04 | 2018-10-29 | Medimmune Ltd | Human antibodies to erbb 2 |
EP2520935A3 (en) | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
AR062223A1 (en) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
EP2056709A4 (en) | 2006-08-11 | 2013-05-01 | Univ New Jersey Med | LUMINESCENT COMPOUNDS CONTAINING TWO SENSITIZERS, CONJUGATED, AND USES THEREOF |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
SI2059536T1 (en) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimized antibodies that target cd19 |
EP2441472B1 (en) | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
CA2661782C (en) | 2006-08-28 | 2019-04-16 | La Jolla Institute For Allergy And Immunology | Antagonistic human light-specific human monoclonal antibodies |
US10118970B2 (en) * | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
DK2594586T3 (en) | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
KR101503540B1 (en) | 2006-09-05 | 2015-03-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | Methods and compositions for the treatment of antibody mediated neuropathy |
AU2007292221B2 (en) | 2006-09-06 | 2013-08-29 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20100008910A1 (en) | 2006-09-12 | 2010-01-14 | John Chant | Methods and compositions for the diagnosis and treatment of cancer |
WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
WO2008042941A2 (en) * | 2006-10-04 | 2008-04-10 | Medimmune, Llc | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
SG175596A1 (en) * | 2006-10-11 | 2011-11-28 | Antitope Ltd | T cell epitope databases |
AU2007324135B2 (en) | 2006-10-12 | 2013-06-27 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP5528807B2 (en) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | Compound drug |
EP2076287A2 (en) * | 2006-10-12 | 2009-07-08 | Wyeth | Methods and compositions with reduced opalescence |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CN101687031B (en) * | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
ES2636089T3 (en) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Antibodies and immunoconjugates and uses for them |
ES2524059T3 (en) | 2006-10-27 | 2014-12-03 | Lpath, Inc. | Compositions and procedures of binding to sphingosine-1-phosphate |
AR063760A1 (en) | 2006-11-02 | 2009-02-18 | Genentech Inc | ANTI-FACTOR D HUMANIZED ANTIBODIES AND USES OF THE SAME |
ES2541546T3 (en) * | 2006-11-03 | 2015-07-21 | Wyeth Llc | Substances that inhibit glycolysis in cell culture |
US8129502B2 (en) * | 2006-11-13 | 2012-03-06 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
WO2008058380A1 (en) * | 2006-11-13 | 2008-05-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
BRPI0718609A8 (en) * | 2006-11-13 | 2015-09-29 | Arius Res Inc | CANCER DISEASE MODIFYING ANTIBODIES. |
EP2514439A1 (en) * | 2006-11-15 | 2012-10-24 | Functional Genetics, Inc. | Anti-TSG101antibodies and their uses for treatment of viral infections |
WO2008064306A2 (en) * | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
KR20090110295A (en) | 2006-11-22 | 2009-10-21 | 에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 | Targeted Therapeutics Based on Engineered Proteins for Tyrosine Kinase Receptors Including IGF-IR |
US8444971B2 (en) | 2006-11-27 | 2013-05-21 | Diadexus, Inc. | OVR110 antibody compositions and methods of use |
PL2662091T3 (en) | 2006-12-01 | 2019-05-31 | Novartis Ag | Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases |
US8945565B2 (en) | 2006-12-01 | 2015-02-03 | Selexys Pharmaceuticals Corporation | Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies |
US20110212096A1 (en) | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
US8288110B2 (en) * | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
KR101546441B1 (en) * | 2006-12-20 | 2015-08-24 | 엠엠알글로벌, 인코포레이티드 | Antibodies and methods for making and using them |
DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
NO2740744T3 (en) | 2007-01-09 | 2018-08-25 | ||
WO2008092041A2 (en) | 2007-01-24 | 2008-07-31 | Carnegie Mellon University | Optical biosensors |
US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
AU2008216495A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
DK2125889T3 (en) | 2007-02-21 | 2014-04-14 | Univ Massachusetts | HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND APPLICATIONS THEREOF |
US7771947B2 (en) * | 2007-02-23 | 2010-08-10 | Investigen, Inc. | Methods and compositions for rapid light-activated isolation and detection of analytes |
HUE043966T2 (en) | 2007-02-23 | 2019-09-30 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
EP1972639A3 (en) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
JP2010521154A (en) | 2007-03-13 | 2010-06-24 | アムゲン インコーポレイティッド | K-ras mutation and B-raf mutation and anti-EGFr antibody therapy |
WO2008112269A2 (en) | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
WO2008112988A2 (en) | 2007-03-14 | 2008-09-18 | Novartis Ag | Apcdd1 inhibitors for treating, diagnosing or detecting cancer |
CN101668540A (en) * | 2007-03-22 | 2010-03-10 | 英克隆有限责任公司 | Stable antibody formulations |
DK2125894T3 (en) | 2007-03-22 | 2019-03-18 | Biogen Ma Inc | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
EP1975184A3 (en) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
US20100291024A1 (en) * | 2007-03-30 | 2010-11-18 | Xuebin Qin | Methods and compositions for the treatment of proliferative and pathogenic diseases |
CA2682170A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
WO2009027830A2 (en) | 2007-03-30 | 2009-03-05 | Engeneic Molecular Delivery Pty Ltd. | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
HRP20120759T1 (en) * | 2007-04-03 | 2012-10-31 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
CN101977935A (en) * | 2007-04-23 | 2011-02-16 | 惠氏公司 | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
ES2540807T3 (en) | 2007-05-04 | 2015-07-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Variable domains of rabbit antibodies modified by genetic engineering and uses thereof |
EP2737907A3 (en) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
PL3072525T3 (en) | 2007-05-14 | 2018-07-31 | Astrazeneca Ab | Methods of reducing basophil levels |
JP2010530359A (en) | 2007-05-17 | 2010-09-09 | ジェネンテック, インコーポレイテッド | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
SI2164514T1 (en) | 2007-05-21 | 2017-04-26 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US20090258005A1 (en) * | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
ES2585702T3 (en) | 2007-05-30 | 2016-10-07 | Lpath, Inc | Compositions and methods for lysophosphatidic acid binding |
PE20090321A1 (en) | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
KR20150055103A (en) | 2007-06-12 | 2015-05-20 | 에이씨 이뮨 에스.에이. | Humanized antibodies to amyloid beta |
EA020456B1 (en) | 2007-06-14 | 2014-11-28 | Байоджен Айдек Ма Инк. | Pharmaceutical composition comprising vla-4 binding antibody for subcutaneous or intramuscular administration |
US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
HRP20150007T8 (en) | 2007-06-15 | 2015-08-14 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES |
PL2158221T3 (en) | 2007-06-21 | 2019-02-28 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CL2008001887A1 (en) | 2007-06-29 | 2008-10-03 | Amgen Inc | PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM. |
SG10202005450PA (en) | 2007-07-09 | 2020-07-29 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
WO2009012175A1 (en) | 2007-07-13 | 2009-01-22 | Ventana Medical Systems, Inc. | Antibodies specific for the c-terminal regulatory domain of egfr and their use |
NZ583367A (en) | 2007-07-16 | 2012-10-26 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
KR20100058509A (en) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | Multispecific epitope binding proteins and uses thereof |
EP2185594B1 (en) * | 2007-08-13 | 2016-04-06 | VasGene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
AU2008289442A1 (en) | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
WO2009025846A2 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2013203261B2 (en) * | 2007-08-29 | 2016-07-14 | Sanofi | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
PL2195023T3 (en) | 2007-08-29 | 2018-08-31 | Sanofi | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
EP2570431A3 (en) | 2007-08-30 | 2013-05-01 | CureDM Group Holdings, LLC | Compositions and methods of using proislet peptides and analogs thereof |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US8323647B2 (en) | 2007-09-13 | 2012-12-04 | Delenex Therapeutics Ag | Humanized antibodies against the β-amyloid peptide |
KR102119108B1 (en) | 2007-09-26 | 2020-06-04 | 추가이 세이야쿠 가부시키가이샤 | Modified antibody constant region |
SG10202100638XA (en) | 2007-10-02 | 2021-02-25 | Theranos Ip Co Llc | Modular Point-Of-Care Devices And Uses Thereof |
AU2008311366B2 (en) | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
US20110212076A1 (en) * | 2007-10-15 | 2011-09-01 | King's College London | Viral Therapeutic |
EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009055074A2 (en) * | 2007-10-25 | 2009-04-30 | Wyeth | Erbb2 binding proteins and use thereof |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
AR069097A1 (en) | 2007-10-30 | 2009-12-30 | Genentech Inc | PURIFICATION OF ANTIBODIES BY CATIONIC EXCHANGE CHROMATOGRAPHY |
US20100330097A1 (en) | 2007-11-01 | 2010-12-30 | Hageman Gregory S | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
RU2530561C2 (en) | 2007-11-05 | 2014-10-10 | Медиммун, Ллк | Method of treating scleroderma |
KR101620642B1 (en) | 2007-11-07 | 2016-05-12 | 제넨테크, 인크. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
EA201692127A1 (en) | 2007-11-07 | 2017-08-31 | Селлдекс Терапьютикс Инк. | ANTIBODIES CONNECTING WITH HUMAN DEC-205 |
WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
PT2220116E (en) * | 2007-11-12 | 2012-12-07 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
EP2062920A3 (en) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
US20110053865A1 (en) * | 2007-11-27 | 2011-03-03 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
US8912149B1 (en) | 2007-11-28 | 2014-12-16 | California Institute Of Technology | Glycosaminoglycan mimetics |
JP5490714B2 (en) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | Protein preparation |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
SI2796466T1 (en) | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Humanized antibody molecules specific for IL-31 |
PT2222706E (en) | 2007-12-14 | 2014-07-28 | Novo Nordisk As | Antibodies against human nkg2d and uses thereof |
KR101499278B1 (en) | 2007-12-17 | 2015-03-06 | 화이자 리미티드 | Treatment of interstitial cystitis |
HUE026846T2 (en) | 2007-12-18 | 2016-08-29 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
CN102046658B (en) | 2007-12-21 | 2015-01-07 | 米迪缪尼有限公司 | Binding members for interleukin-4 receptor alpha (IL-4Ralpha) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
JP2011508738A (en) * | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Method and agent for improving targeting of CD138 expressing tumor cells |
CN101932333A (en) * | 2007-12-26 | 2010-12-29 | 瓦西尼斯公司 | Anti-C35 Antibody Combination Therapies and Methods |
WO2009080829A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
WO2009080830A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
HUE044466T2 (en) | 2007-12-26 | 2019-10-28 | Xencor Inc | Fc variants with altered binding to FcRn |
US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
WO2009088805A2 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8557243B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
ES2613963T3 (en) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Cysteine manipulated antibodies for site specific conjugation |
WO2009092805A1 (en) | 2008-01-24 | 2009-07-30 | Novo Nordisk A/S | Humanized anti-human nkg2a monoclonal antibody |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
CL2009000062A1 (en) | 2008-01-31 | 2010-05-14 | Genentech Inc | Humanized anti-cd79b antibody; with free tank modifications; immunoconjugate containing said antibody and a drug; polynucleotide encoding the antibody; vector, host cell; pharmaceutical composition and use of said composition to treat cancer, preferably lymphomas. |
EP3048115B1 (en) | 2008-02-01 | 2019-05-01 | Her Majesty The Queen In Right of Canada as represented by The Minister of Health | Monoclonal antibodies for ebola and marburg viruses |
US9131671B2 (en) | 2008-02-01 | 2015-09-15 | Entogenetics, Inc. | Methods, compositions and systems for production of recombinant spider silk polypeptides |
BRPI0906387A2 (en) | 2008-02-05 | 2015-07-07 | Bristol Myers Squibb Co | Alpha 5 - beta 1 antibodies and their uses |
CA2713981C (en) | 2008-02-08 | 2016-11-01 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
CN106110321A (en) | 2008-03-04 | 2016-11-16 | 莱布瑞斯生物公司 | The method for the treatment of inflammatory pain |
CN101959528A (en) | 2008-03-04 | 2011-01-26 | 辉瑞有限公司 | Approaches to Treating Chronic Pain |
JP2011513432A (en) * | 2008-03-06 | 2011-04-28 | ジェネンテック, インコーポレイテッド | Combination therapy of c-met and HER antagonist |
CN102015766B (en) | 2008-03-10 | 2014-07-16 | 特罗科隆科学有限公司 | Compositions and methods for the therapy and diagnosis of cytomegalovirus |
CA2727792C (en) * | 2008-03-14 | 2017-07-25 | Obschestvo S Ogranichennoi Otvetstvennostyu "Initium-Pharm" | Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
EP3269366B1 (en) | 2008-03-18 | 2020-01-15 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and lapatinib, and methods of use |
AU2009228158B2 (en) | 2008-03-27 | 2014-02-27 | Zymogenetics, Inc. | Compositions and methods for inhibiting PDGFRbeta and VEGF-A |
JP5555223B2 (en) * | 2008-04-02 | 2014-07-23 | マクロジェニクス,インコーポレーテッド | HER2 / neu specific antibody and method of use thereof |
AU2009234389B2 (en) | 2008-04-10 | 2014-08-21 | Cell Signaling Technology, Inc. | Compositions and methods for detecting EGFR mutations in cancer |
AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
WO2009131702A2 (en) | 2008-04-25 | 2009-10-29 | Dyax Corp. | Antibodies against fcrn and use thereof |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
KR20110014607A (en) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | Dual Variable Domain Immunoglobulins and Uses thereof |
EP2439212B1 (en) | 2008-05-02 | 2016-12-21 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
CN102099373A (en) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | Multivalent fibronectin based scaffold domain proteins |
EP3384919A1 (en) | 2008-06-02 | 2018-10-10 | Dana Farber Cancer Institute, Inc. | Cs1 peptides |
MX2010013236A (en) | 2008-06-03 | 2011-02-24 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof. |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2133433A1 (en) | 2008-06-09 | 2009-12-16 | Centre Georges François Leclerc | A method for predicting responsiveness to a treatment with an anti-HER2 antibody |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
ES2431355T3 (en) | 2008-06-17 | 2013-11-26 | Wyeth Llc | Antineoplastic combinations containing HKI-272 and vinorelbine |
RU2588467C3 (en) | 2008-06-25 | 2021-10-20 | Новартис Аг | STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF |
EP3628686B1 (en) | 2008-06-25 | 2021-07-21 | Novartis AG | Humanization of rabbit antibodies using a universal antibody framework |
PT2307457T (en) | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Stable and soluble antibodies inhibiting tnf |
WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
KR101847107B1 (en) | 2008-07-08 | 2018-04-10 | 인사이트 홀딩스 코포레이션 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
PE20110571A1 (en) | 2008-07-15 | 2011-08-29 | Genentech Inc | CONJUGATES DERIVED FROM ANTHRACICLINE, AS ANTITUMORAL COMPOUNDS |
CN102159231B (en) * | 2008-07-18 | 2016-06-15 | 三一治疗公司 | The method treating the ADE of immune-mediated dengue infection and dengue infection (including dengue hemorrhagic fever and dengue shock syndrome) |
US8148088B2 (en) * | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
SG10201702382RA (en) | 2008-08-04 | 2017-05-30 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
PE20150222A1 (en) | 2008-09-03 | 2015-03-02 | Genentech Inc | MULTI-SPECIFIC ANTIBODIES |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
CN102264763B (en) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | Antibody being oriented to DLL4 and uses thereof |
EP2344180A2 (en) | 2008-09-23 | 2011-07-20 | Wyeth LLC | Methods for predicting production of activating signals by cross-linked binding proteins |
EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
PL2356153T3 (en) | 2008-10-01 | 2016-11-30 | Cross-species-specific psmaxcd3 bispecific single chain antibody | |
EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
WO2010045193A1 (en) | 2008-10-14 | 2010-04-22 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
EP2347038A4 (en) * | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | Methods of humanizing and affinity-maturing antibodies |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
CN102264765B (en) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | Anti-MUC1 antibody |
CN102272154A (en) | 2008-10-29 | 2011-12-07 | 惠氏有限责任公司 | Methods for purification of single domain antigen binding molecules |
JP5823867B2 (en) | 2008-10-29 | 2015-11-25 | アブリンクス エン.ヴェー. | Formulation of single domain antigen binding molecule |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010051502A2 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
PL2350304T3 (en) | 2008-10-31 | 2017-06-30 | Janssen Biotech, Inc | Toll-like receptor 3 antagonists |
JP5693460B2 (en) * | 2008-11-12 | 2015-04-01 | セラクローン サイエンシーズ, インコーポレイテッド | Human M2e peptide immunogen |
WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
AU2009323007B2 (en) | 2008-11-25 | 2016-01-28 | H. Lundbeck A/S. | Antagonists of IL-6 to prevent or treat thrombosis |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
US8211434B2 (en) | 2008-11-26 | 2012-07-03 | Allergan, Inc. | KLK-13 antibody inhibitor for treating dry eye |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2370092A1 (en) | 2008-12-03 | 2011-10-05 | Research Development Foundation | Modulation of olfml-3 mediated angiogenesis |
US8401799B2 (en) * | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
KR101370797B1 (en) | 2008-12-05 | 2014-03-14 | 아브락시스 바이오사이언스, 엘엘씨 | Albumin binding peptide-mediated disease targeting |
AU2009322185A1 (en) * | 2008-12-05 | 2011-07-21 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
MX2011005967A (en) | 2008-12-05 | 2011-06-30 | Abraxis Bioscience Llc | Sparc binding peptides and uses thereof. |
NZ717213A (en) | 2008-12-09 | 2017-10-27 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
CA2747248A1 (en) | 2008-12-17 | 2010-07-15 | Sharookh Kapadia | Hepatitis c virus combination therapy |
PT2786762T (en) | 2008-12-19 | 2019-05-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
EP2382234A2 (en) | 2008-12-23 | 2011-11-02 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
CA2748757A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CN102271710A (en) | 2009-01-06 | 2011-12-07 | 国家健康与医学研究院 | B cell depleting agents for the treatment of atherosclerosis |
US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
EP2387584A1 (en) | 2009-01-14 | 2011-11-23 | IQ Therapeutics BV | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2394159B1 (en) | 2009-02-04 | 2018-09-26 | Molecular Innovations | Assays for detecting prorenin, and antibodies used therein |
US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
EP2396652B1 (en) | 2009-02-11 | 2017-12-13 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin |
PT2881402T (en) | 2009-02-12 | 2017-08-23 | Cell Signaling Technology Inc | Mutant ros expression in human liver cancer |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
JP5861223B2 (en) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | Proprotein and its use |
WO2010098863A1 (en) * | 2009-02-26 | 2010-09-02 | Lpath, Inc. | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
US20100248265A1 (en) * | 2009-02-27 | 2010-09-30 | The Salk Institute For Biological Studies | Compositions and methods for diagnosis and treatment of cancer |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
CN104447995A (en) * | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | Bispecific anti-HER antibodies |
PE20160553A1 (en) | 2009-03-20 | 2016-05-18 | Amgen Inc | ANTIBODY SPECIFIC ANTAGONIST FOR ALPHA-4-BETA-7 HETERODIMER |
US8242248B2 (en) * | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
AU2010229479B2 (en) | 2009-03-25 | 2013-03-28 | Genentech, Inc. | Novel anti-alpha5beta1 antibodies and uses thereof |
JP5725508B2 (en) | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | LH type bispecific antibody |
LT3702371T (en) | 2009-03-25 | 2023-01-10 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
MX2011010264A (en) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use. |
AU2010232692C1 (en) | 2009-04-01 | 2017-06-01 | Genentech, Inc. | Treatment of insulin-resistant disorders |
SG175004A1 (en) | 2009-04-02 | 2011-11-28 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
ES2363358B1 (en) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INDESEABLE CELLULAR PROLIFERATION. |
JP5992325B2 (en) | 2009-04-06 | 2016-09-14 | ワイス・エルエルシー | Treatment plans utilizing neratinib for breast cancer |
SG175080A1 (en) * | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
EP2419446A4 (en) * | 2009-04-17 | 2013-01-23 | Lpath Inc | Humanized antibody compositions and methods for binding lysophosphatidic acid |
CN102573907A (en) * | 2009-04-17 | 2012-07-11 | 比奥根艾迪克Ma公司 | Compositions and methods to treat acute myelogenous leukemia |
CA2758523C (en) | 2009-04-18 | 2019-03-12 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
DK2421898T3 (en) | 2009-04-20 | 2016-05-30 | Oxford Biotherapeutics Ltd | Cadherin-17 SPECIFIC ANTIBODIES |
US8609101B2 (en) * | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
HUE028021T2 (en) | 2009-04-29 | 2016-11-28 | Janssen Biotech Inc | Toll-like receptor 3 antagonists |
EP2799453B1 (en) | 2009-04-29 | 2019-04-03 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | ERG2 monoclonal antibodies and their therapeutic use |
TW201825115A (en) | 2009-05-13 | 2018-07-16 | 美商建新公司 | Anti-human cd52 immunoglobulins |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
EP2432803A2 (en) | 2009-05-20 | 2012-03-28 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
WO2010138839A2 (en) | 2009-05-28 | 2010-12-02 | Abraxis Bioscience, Llc | Use of 2 anti-sparc antibodies to predict response to chemotherapy |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
TWI513465B (en) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
EP2448593B1 (en) | 2009-07-03 | 2020-11-25 | Bionor Immuno AS | Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means |
WO2011000054A1 (en) | 2009-07-03 | 2011-01-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
WO2011004899A1 (en) | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
CA2766737A1 (en) | 2009-07-07 | 2011-01-13 | Genentech, Inc. | Diagnosis and treatment of autoimmune demyelinating diseases |
SG177583A1 (en) | 2009-07-09 | 2012-02-28 | Hoffmann La Roche | In vivo tumor vasculature imaging |
MX2012000620A (en) | 2009-07-13 | 2012-01-27 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer. |
EP2454368A4 (en) | 2009-07-17 | 2013-01-09 | Aaron Thomas Tabor | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
EP3404044A1 (en) | 2009-07-24 | 2018-11-21 | F. Hoffmann-La Roche AG | Optimizing the production of antibodies |
DE202010018640U1 (en) | 2009-07-24 | 2019-11-14 | F. Hoffmann-La Roche Ag | stirrer system |
AR077595A1 (en) | 2009-07-27 | 2011-09-07 | Genentech Inc | COMBINATION TREATMENTS |
KR20120089253A (en) | 2009-07-31 | 2012-08-09 | 제넨테크, 인크. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AU2010278959A1 (en) | 2009-07-31 | 2012-02-02 | Amgen Inc. | Polypeptides that bind tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods |
SG178276A1 (en) | 2009-08-06 | 2012-03-29 | Genentech Inc | Method to improve virus removal in protein purification |
US20110039300A1 (en) | 2009-08-10 | 2011-02-17 | Robert Bayer | Antibodies with enhanced adcc functions |
US20110038871A1 (en) | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
CN102498206A (en) | 2009-08-11 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | Production of proteins in glutamine-free cell culture media |
EP3381937A3 (en) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
CN102575298A (en) | 2009-08-14 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | Biological markers for monitoring patient response to VEGF antagonists |
US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
WO2011022472A2 (en) | 2009-08-18 | 2011-02-24 | President And Fellows Of Harvard College | Methods and compositions for the treatment of proliferative and pathogenic diseases |
CA2771186C (en) | 2009-08-28 | 2018-01-02 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
RU2012112550A (en) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
DK2473522T3 (en) | 2009-09-02 | 2016-11-28 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
JP5996429B2 (en) | 2009-09-03 | 2016-09-21 | ジェネンテック, インコーポレイテッド | Method for treatment, diagnosis and monitoring of rheumatoid arthritis |
US8936792B2 (en) | 2009-09-11 | 2015-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with reduced immunogenicity |
BR112012005315A2 (en) | 2009-09-11 | 2016-03-22 | Genentech Inc | method for identifying a patient likely to respond to an anticancer agent, method for identifying a patient who has an increased likelihood of metastasis, method for monitoring the effectiveness of anticancer therapy, and method for dose optimization of a anticancer agent |
AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
CN102712696A (en) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Coiled coil and/or tether containing protein complexes and uses thereof |
BR112012005670A2 (en) | 2009-09-17 | 2017-01-10 | Hoffmann La Roche | '' method for identifying a cancer patient who may benefit from antiagiogenic therapy, method for predicting a cancer patient's responsiveness to antiangiogenic therapy, use of an anti-vegf antibody to improve the effect of treating a cancer patient, method or use, useful kit for performing the method, use of a protein or usom kit useful for performing the method, use of a protein or oligonucleotide or polynecleotide matrix to determine the level of bfgf expression in a method and kit or use |
JP2013505268A (en) | 2009-09-18 | 2013-02-14 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Use of the SPARC microenvironment signature in the treatment of cancer |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
PL2483305T3 (en) | 2009-10-01 | 2017-03-31 | F.Hoffmann-La Roche Ag | Multistep final filtration of immunoglobulin |
UY32914A (en) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
ES2666372T3 (en) | 2009-10-11 | 2018-05-04 | Biogen Ma Inc. | Trials related to anti-VLA-4 |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
PE20121531A1 (en) | 2009-10-15 | 2012-12-22 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN |
EP2488873B1 (en) | 2009-10-16 | 2015-08-05 | Novartis AG | Biomarkers of tumor pharmacodynamic response |
DK2488203T3 (en) * | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
MX2012002013A (en) * | 2009-10-19 | 2012-03-16 | Genentech Inc | Modulators of hepatocyte growth factor activator. |
JP5814925B2 (en) | 2009-10-22 | 2015-11-17 | ジェネンテック, インコーポレイテッド | Anti-hepsin antibody and method of use thereof |
ES2564207T3 (en) | 2009-10-22 | 2016-03-18 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating hepsin activation of macrophage stimulating protein |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN102905727B (en) | 2009-10-30 | 2016-12-07 | 詹森生物科技公司 | IL-17A Antagonist |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
PT2496698T (en) | 2009-11-03 | 2019-04-18 | Hope City | TRUNCED EPIDERMAL GROWTH FACTOR RECEIVER (EGFRT) FOR SELECTION OF TRANSDUCED T CELLS |
US8932588B2 (en) | 2009-11-05 | 2015-01-13 | Teva Pharmaceuticals Australia Pty. Ltd. | Treatment of cancer involving mutated KRAS or BRAF genes |
WO2011062112A1 (en) | 2009-11-18 | 2011-05-26 | 国立大学法人東北大学 | Highly-functional mutant of humanized anti-egfr antibody variable region |
LT2504364T (en) | 2009-11-24 | 2017-11-10 | Medimmune Limited | Targeted binding agents against b7-h1 |
KR101884028B1 (en) | 2009-11-30 | 2018-08-01 | 제넨테크, 인크. | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2) |
CA2782007C (en) * | 2009-11-30 | 2018-07-24 | Biotest Ag | Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
TW201129380A (en) * | 2009-12-04 | 2011-09-01 | Genentech Inc | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
US20120321619A1 (en) | 2009-12-09 | 2012-12-20 | Bayer Intellectual Property Gmbh | Anti-c4.4a antibodies and uses thereof |
EP2509409B1 (en) | 2009-12-10 | 2016-07-27 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
US8937159B2 (en) * | 2009-12-16 | 2015-01-20 | Abbvie Biotherapeutics Inc. | Anti-HER2 antibodies and their uses |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
RU2559542C2 (en) | 2009-12-23 | 2015-08-10 | Дженентек, Инк. | Anti-bv8 antibodies and using them |
WO2011079283A1 (en) * | 2009-12-23 | 2011-06-30 | Bioalliance C.V. | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
AU2010336029B2 (en) | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
US20110159588A1 (en) | 2009-12-30 | 2011-06-30 | Kui Lin | Methods for Modulating a PDGF-AA Mediated Biological Response |
ES2905545T3 (en) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
US9221759B2 (en) | 2010-01-13 | 2015-12-29 | Rutgers, The State University Of New Jersey | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency |
EP2523687B1 (en) | 2010-01-15 | 2017-08-02 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for diagnosis and treatment of cutaneous T cell lymphomas using the NKp46 receptor |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
CA2787755A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
WO2011097527A2 (en) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection of therapeutic moieties using enhanced fc regions |
US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
AU2011218125A1 (en) | 2010-02-18 | 2012-07-19 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
CA2787657A1 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN102167742B (en) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | A fully human anti-HER2 monoclonal antibody, its preparation method and use |
WO2011106723A2 (en) * | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
PL2542590T5 (en) | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Compositions and Methods for Target Immunomodulatory Antibodies and Fusion Proteins |
CN102858362A (en) | 2010-03-11 | 2013-01-02 | 阿布拉西斯生物科学有限责任公司 | SPARC angiogenic domain and methods of use |
RU2584232C2 (en) | 2010-03-22 | 2016-05-20 | Дженентек, Инк. | Compositions and methods used for stabilisation of protein-containing finished forms |
WO2011119661A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
WO2011119979A2 (en) | 2010-03-26 | 2011-09-29 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
EP2552947A4 (en) | 2010-03-26 | 2013-11-13 | Dartmouth College | VISTA, A T-LYMPHOCYTE REGULATORY MEDIA PROTEIN, VISTA BINDING AGENTS AND USE THEREOF |
ES2665592T3 (en) | 2010-03-31 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Anti-CD40 antibodies |
TWI653333B (en) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | Cross-species specific PSMAxCD3 bispecific single chain antibody |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
BR112012025728B1 (en) | 2010-04-09 | 2022-01-11 | Critical Care Diagnostics, Inc | ISOLATED ANTIBODIES OR FRAGMENTS THAT BIND TO SOLUBLE HUMAN ST2, HYBRIDOMA, KIT, AS WELL AS METHODS FOR QUANTIFICATION OF A LEVEL OF HUMAN SOLUBLE ST2 IN A SAMPLE FROM AN INDIVIDUAL, AND FOR PREDICTING THE RISK OF DEATH WITHIN ONE YEAR IN AN INDIVIDUAL |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CN105669865A (en) | 2010-04-13 | 2016-06-15 | 塞尔德克斯医疗公司 | Antibodies that bind human CD27 and uses thereof |
CA2796180A1 (en) | 2010-04-15 | 2011-10-20 | Alper Biotech, Llc | Monoclonal antibodies against her2 antigens, and uses therefor |
LT3202789T (en) | 2010-04-16 | 2020-06-10 | Biogen Ma Inc. | Anti-vla-4 antibodies |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
JP2013531474A (en) * | 2010-04-30 | 2013-08-08 | エスペランス ファーマシューティカルズ, インコーポレイテッド | Soluble peptide-Her2 / neu (human epidermal growth factor receptor 2) ligand conjugate and method of use thereof |
WO2011139985A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
RU2012151500A (en) | 2010-05-03 | 2014-06-10 | Дженентек, Инк. | COMPOSITIONS AND METHODS SUITABLE FOR REDUCING VISCOSITY OF PROTEIN-CONTAINING COMPOSITIONS |
AU2011250970B2 (en) | 2010-05-10 | 2016-12-15 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
PL3299380T3 (en) | 2010-05-25 | 2024-12-16 | F. Hoffmann-La Roche Ag | Methods of purifying polypeptides |
US9995679B2 (en) | 2010-05-25 | 2018-06-12 | Carnegie Mellon University | Targeted probes of cellular physiology |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
KR20130098165A (en) | 2010-06-03 | 2013-09-04 | 제넨테크, 인크. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
KR20130086546A (en) | 2010-06-03 | 2013-08-02 | 아브락시스 바이오사이언스, 엘엘씨 | Use of SPARC Microenvironment Signature in Cancer Treatment |
BR112012030311A2 (en) | 2010-06-08 | 2017-01-24 | Genentech Inc | antibody |
AR081434A1 (en) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
EP2582729A4 (en) | 2010-06-18 | 2014-05-28 | Hoffmann La Roche | ANTI-AXL ANTIBODIES, AND METHODS OF USE. |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011163401A2 (en) | 2010-06-22 | 2011-12-29 | Neogenix Oncology, Inc. | Colon and pancreas cancer specific antigens and antibodies |
HRP20191878T1 (en) | 2010-06-24 | 2019-12-27 | F. Hoffmann - La Roche Ag | Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
PH12013500064A1 (en) | 2010-07-09 | 2013-03-11 | Exelixis Inc | Combinations of kinase inhibitors for the treatment of cancer |
JP2013539962A (en) | 2010-07-09 | 2013-10-31 | ジェネンテック, インコーポレイテッド | Anti-neuropilin antibodies and methods of use |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
BR112013003646B1 (en) | 2010-07-29 | 2021-09-08 | Eleven Biotherapeutics, Inc. | ISOLATED PROTEIN THAT COMPRISES A DOMAIN OF CYTOKINE OF THE INTERLEUKIN-1 (IL-1) CHIMERIC FAMILY, ITS METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USES, AS WELL AS, NUCLEIC ACID, VECTOR, AND HOST CELL |
CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
WO2012015758A2 (en) | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
JP6092773B2 (en) | 2010-07-30 | 2017-03-08 | ノバルティス アーゲー | Fibronectin cradle molecule and its library |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
RU2013106216A (en) | 2010-08-03 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | BIOMARKERS OF CHRONIC Lymphocytic Leukemia |
BR112013002578A2 (en) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | double variable domain immunoglobins and their uses |
KR20140016230A (en) | 2010-08-04 | 2014-02-07 | 시즐 바이오테크놀로지 리미티드 | Methods and compounds for the diagnosis and treatment of |
EP2600898A1 (en) | 2010-08-05 | 2013-06-12 | F.Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
JP2012034668A (en) | 2010-08-12 | 2012-02-23 | Tohoku Univ | Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof |
CA2807664A1 (en) | 2010-08-12 | 2012-02-16 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
BR112013003279A2 (en) | 2010-08-13 | 2016-06-14 | Genentech In | "Methods for treating a disease, method for neutralizing or blocking il-1ß and / or il-18 activity, antibody, uses of an antibody and uses of a monoclonal antibody" |
BR112013002444A2 (en) | 2010-08-13 | 2016-05-24 | Roche Glycart Ag | isolated antibody, polynucleotide and polypeptide, composition, vector, host cell, antibody conjugate, pharmaceutical formulation, use of the antibody, methods of producing an antibody, treating an individual, inducing cell lysis of a tumor cell and diagnosing a disease in an individual |
UA113712C2 (en) | 2010-08-13 | 2017-02-27 | FAP ANTIBODY AND METHODS OF ITS APPLICATION | |
KR20140005864A (en) | 2010-08-16 | 2014-01-15 | 암젠 인코퍼레이티드 | Antibodies that bind myostatin, compositions and methods |
KR101566090B1 (en) | 2010-08-17 | 2015-11-13 | 에프. 호프만-라 로슈 아게 | ANTI-HUMAN IgG1 ANTIBODY |
PL3333188T3 (en) | 2010-08-19 | 2022-05-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
JP5758004B2 (en) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies comprising Fv fragments stabilized by disulfides |
WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
US11077212B2 (en) | 2010-08-24 | 2021-08-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Molecular imaging of cancer cells in vivo |
EP2609117B1 (en) | 2010-08-25 | 2015-09-16 | F.Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2612151B1 (en) | 2010-08-31 | 2017-08-09 | Genentech, Inc. | Biomarkers and methods of treatment |
WO2012030904A2 (en) | 2010-08-31 | 2012-03-08 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
CA3182320A1 (en) | 2010-09-23 | 2012-03-29 | Precision Biologics, Inc. | Colon and pancreas cancer peptidomimetics |
AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
JP5974012B2 (en) | 2010-10-05 | 2016-08-23 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
UY33679A (en) | 2010-10-22 | 2012-03-30 | Esbatech | STABLE AND SOLUBLE ANTIBODIES |
EP3214442A1 (en) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a |
AU2011323820A1 (en) | 2010-10-25 | 2013-05-23 | Biogen Ma Inc. | Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels |
CA2816950C (en) | 2010-11-04 | 2018-11-27 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
CA2816763A1 (en) | 2010-11-05 | 2012-05-10 | Transbio Ltd | Markers of endothelial progenitor cells and uses thereof |
PH12013500933A1 (en) | 2010-11-10 | 2017-08-23 | Genentech Inc | Methods and compositions for neural disease immunotherapy |
ES2544608T3 (en) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Antibody and alaninyl-maitansinol conjugates |
PE20180249A1 (en) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | NEUTRALIZING ANTIBODIES ANTI-CCL20 |
WO2012071554A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
US8728473B2 (en) | 2010-12-01 | 2014-05-20 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
ES2719548T3 (en) | 2010-12-06 | 2019-07-11 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use them to treat cancer |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
EA201790664A1 (en) | 2010-12-20 | 2017-07-31 | Дженентек, Инк. | ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES |
WO2012084829A1 (en) | 2010-12-21 | 2012-06-28 | F. Hoffmann-La Roche Ag | Isoform enriched antibody preparation and method for obtaining it |
ES2524897T3 (en) | 2010-12-21 | 2014-12-15 | F. Hoffmann-La Roche Ag | Chromatography equipment characterization |
JP2014511106A (en) | 2010-12-22 | 2014-05-08 | ジェネンテック, インコーポレイテッド | Anti-PCSK9 antibody and method of use |
EP2655414B1 (en) | 2010-12-23 | 2018-08-29 | Roche Diagniostics GmbH | Bispecific binding agent |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-CD38 . antibody |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
WO2012093068A1 (en) | 2011-01-03 | 2012-07-12 | F. Hoffmann-La Roche Ag | A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
CN111982829A (en) | 2011-01-21 | 2020-11-24 | 拉布拉多诊断有限责任公司 | Systems and methods for maximizing sample usage |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
EP2670422B1 (en) | 2011-02-02 | 2018-10-17 | Emory University | Antagonism of the vip signaling pathway |
MX2013008833A (en) | 2011-02-02 | 2013-12-06 | Amgen Inc | Methods and compositons relating to inhibition of igf-1r. |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
RU2013140685A (en) | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | OPTIONS Fc, METHODS FOR PRODUCING THEM |
HRP20182017T4 (en) | 2011-02-08 | 2021-08-20 | Medimmune, Llc | ANTIBODIES SPECIFICALLY BINDING STAPHYLOCOCCUS AUREUS ALPHAS TOXIN AND METHODS OF ADMINISTRATION |
KR20130118941A (en) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | Improved immunotherapy |
SI3075745T1 (en) | 2011-02-10 | 2018-12-31 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
BR112013020743A2 (en) | 2011-02-14 | 2016-10-18 | Theraclone Sciences Inc | compositions and methods for influenza therapy and diagnosis |
MX353143B (en) | 2011-02-28 | 2017-12-20 | Genentech Inc | Biological markers and methods for predicting response to b-cell antagonists. |
MX342034B (en) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Monovalent antigen binding proteins. |
AR085404A1 (en) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | PROTEINS OF UNION TO ANTIGEN |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
CN103619876A (en) | 2011-03-10 | 2014-03-05 | Hco抗体股份有限公司 | Bispecific three-chain antibody-like molecules |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
AU2012229188A1 (en) | 2011-03-15 | 2013-09-26 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
CN107840894A (en) | 2011-03-25 | 2018-03-27 | 格兰马克药品股份有限公司 | Heterodimer immunoglobulin |
EP2691417B2 (en) | 2011-03-29 | 2024-10-30 | Roche Glycart AG | Antibody fc variants |
JP6130350B2 (en) | 2011-03-30 | 2017-05-17 | アブリンクス エン.ヴェー. | Methods of treating immune disorders with single domain antibodies against TNFα |
MY189494A (en) | 2011-03-31 | 2022-02-16 | Genentech Inc | Methods of administering beta7 integrin antagonists |
SG194048A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
JP2014516511A (en) | 2011-04-07 | 2014-07-17 | ジェネンテック, インコーポレイテッド | Anti-FGFR4 antibody and method of use |
US20140010886A1 (en) | 2011-04-07 | 2014-01-09 | Georgia Tech Research Corporation | Compositions comprising saccharide binding moieties and methods for targeted therapy |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
KR20210021101A (en) | 2011-04-08 | 2021-02-24 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
PL2699264T3 (en) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2012142662A1 (en) | 2011-04-21 | 2012-10-26 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using them b |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | COMPOSITION OF ANTI-α4β7 ANTIBODY |
CN108969469A (en) | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | The preparation of 4 β of anti alpha, 7 antibody |
EP2704735A1 (en) | 2011-05-03 | 2014-03-12 | Genentech, Inc. | Vascular disruption agents and uses thereof |
JP6169561B2 (en) | 2011-05-06 | 2017-07-26 | ザ ガバメント オブ ザ ユナイテツド ステイツ オブ アメリカ アズ リプリゼンテツド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒユーマン サービシズ | Recombinant immunotoxins targeting mesothelin |
ES2567276T3 (en) | 2011-05-12 | 2016-04-21 | Genentech, Inc. | LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides |
EA030462B1 (en) | 2011-05-16 | 2018-08-31 | Дженентек, Инк. | Fgfr1 agonists and methods of use thereof |
EA201990685A1 (en) | 2011-05-17 | 2019-12-30 | Дзе Рокфеллер Юниверсити | NEUTRALIZING HUMAN IMMUNO DEFICIENCY VIRUS ANTIBODIES AND WAYS OF THEIR APPLICATION |
PT3662932T (en) | 2011-05-20 | 2021-05-14 | H Lundbeck As | Anti-cgrp compositions and use thereof |
KR102128628B1 (en) | 2011-05-20 | 2020-06-30 | 앨더바이오 홀딩스 엘엘씨 | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
CN107827982B (en) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | Use of anti-CGRP antibodies and antibody fragments for the prevention or inhibition of photophobia or photophobia in a subject in need thereof |
KR102030531B1 (en) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | Deimmunized serum-binding domains and their use for extending serum half-life |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
EP2714741B1 (en) | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
SG195025A1 (en) | 2011-06-02 | 2013-12-30 | Dyax Corp | Fc RECEPTOR BINDING PROTEINS |
WO2012170071A1 (en) | 2011-06-06 | 2012-12-13 | Elan Pharmaceuticas, Inc | Mcam antagonists and methods of treatment |
CN104024275A (en) | 2011-06-10 | 2014-09-03 | 科里木恩有限公司 | BINDING COMPOUNDS TO HUMAN ss1-ADRENORECEPTOR (ss1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-ssA1-AR ANTIBODIES |
US20140141020A1 (en) * | 2011-06-14 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Anti-cd3 therapies |
CN103596984B (en) | 2011-06-15 | 2016-04-13 | 霍夫曼-拉罗奇有限公司 | The antibody of Anti-human EPO receptor and using method |
MX354663B (en) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes. |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
CA2840537C (en) | 2011-06-28 | 2021-12-14 | Oxford Biotherapeutics Ltd. | Antibodies to adp-ribosyl cyclase 2 |
EP2726098A1 (en) | 2011-06-30 | 2014-05-07 | F.Hoffmann-La Roche Ag | Anti-c-met antibody formulations |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
EP2739310B1 (en) | 2011-08-05 | 2018-04-18 | Research Development Foundation | Improved methods and compositions for modulation of olfml3 mediated angiogenesis |
JP6120848B2 (en) | 2011-08-15 | 2017-04-26 | メディミューン,エルエルシー | Anti-B7-H4 antibody and use thereof |
EP2744824A1 (en) | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Neuregulin antibodies and uses thereof |
WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
AU2012299195B9 (en) | 2011-08-19 | 2018-05-10 | Regeneron Pharmaceuticals, Inc | Anti-Tie2 antibodies uses thereof |
RU2605390C2 (en) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
CA2844141A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
CN103748114B (en) | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T cell activating bispecific antigen binding molecules |
RU2617970C2 (en) | 2011-08-23 | 2017-04-28 | Рош Гликарт Аг | ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION |
PT2748202T (en) | 2011-08-23 | 2018-10-08 | Roche Glycart Ag | Bispecific antigen binding molecules |
MX2014002289A (en) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Tandem fc bispecific antibodies. |
US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
EP2751285B2 (en) | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
EA201490623A1 (en) | 2011-09-12 | 2016-01-29 | Янссен Байотек Инк. | Antagonists of toll-like receptor 3 for the treatment of metabolic and cardiovascular diseases |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
CA2846083A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
CN103930111A (en) | 2011-09-19 | 2014-07-16 | 霍夫曼-拉罗奇有限公司 | Combination therapy comprising a C-MET antagonist and a B-RAF antagonist |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
CA2846432A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
PH12014500483A1 (en) | 2011-09-30 | 2014-04-14 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
PT2750683T (en) | 2011-10-03 | 2018-06-26 | Mx Adjuvac Ab | Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
AU2012319150B2 (en) | 2011-10-05 | 2017-08-17 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
KR20130036993A (en) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | Antibodies specifically binding to epitope in sema domain of c-met |
JP6310394B2 (en) | 2011-10-10 | 2018-04-11 | ゼンコア インコーポレイテッド | Methods for purifying antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | Methods for treating vascular leak syndrome and cancer |
EP2766045B1 (en) | 2011-10-13 | 2016-12-07 | The Regents of The University of California | Treatment of breast cancer with companion diagnostic |
AR088322A1 (en) | 2011-10-14 | 2014-05-28 | Genentech Inc | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE |
EP4234034A3 (en) | 2011-10-14 | 2023-09-20 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
JP6254087B2 (en) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | SCD1 antagonists for treating cancer |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
US20140288279A1 (en) | 2011-10-21 | 2014-09-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
CA2850034A1 (en) | 2011-10-28 | 2013-05-02 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
WO2013063516A1 (en) | 2011-10-28 | 2013-05-02 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
PT3257564T (en) | 2011-11-02 | 2019-03-22 | Hoffmann La Roche | Overload and elute chromatography |
WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
PT2780368T (en) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
CN118515766A (en) | 2011-11-16 | 2024-08-20 | 勃林格殷格翰国际有限公司 | Anti-IL-36R antibodies |
JP2014533700A (en) | 2011-11-21 | 2014-12-15 | ジェネンテック, インコーポレイテッド | Purification of anti-c-MET antibody |
AR088941A1 (en) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | ANTI-FGFR2 ANTIBODIES AND THEIR USES |
AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
RU2014124530A (en) | 2011-11-23 | 2015-12-27 | Идженика, Инк. | ANTIBODIES TO CD98 AND WAYS OF THEIR APPLICATION |
EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
CN104271761B (en) | 2011-11-30 | 2017-03-15 | 霍夫曼-拉罗奇有限公司 | Erbb3 mutation in cancer |
SG11201402737SA (en) | 2011-12-05 | 2014-06-27 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
WO2013087913A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
JP2015502165A (en) | 2011-12-22 | 2015-01-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Expression vector construction, novel production cell generation methods, and their use for recombinant production of polypeptides |
SG11201403445YA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Full length antibody display system for eukaryotic cells and its use |
RU2639519C2 (en) | 2011-12-22 | 2017-12-21 | Ф.Хоффманн-Ля Рош Аг | Expression vector element combination, new methods for obtaining producer cells and their application for recombinant production of polypeptides |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
US20150030602A1 (en) | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
EP2793944A4 (en) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
TWI443107B (en) | 2011-12-29 | 2014-07-01 | Ind Tech Res Inst | Humanized anti-human cell surface antigen CD34 monoclonal antibody and application thereof |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
BR112014015851A2 (en) | 2011-12-30 | 2019-09-24 | Abbvie Inc | double specific binding proteins directed against il-13 and / or il-17 |
CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
WO2013104798A1 (en) | 2012-01-12 | 2013-07-18 | Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences | Modulators of immune responses |
CN104203268A (en) | 2012-01-13 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | Biological markers for identifying patients for treatment with vegf antagonists |
KR20140116490A (en) | 2012-01-18 | 2014-10-02 | 제넨테크, 인크. | Anti-lrp5 antibodies and methods of use |
CN104168920A (en) | 2012-01-18 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | Methods of using FGF19 modulators |
MX360778B (en) | 2012-01-27 | 2018-11-16 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein. |
WO2013114245A1 (en) | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
SG11201404486QA (en) | 2012-01-31 | 2014-11-27 | Genentech Inc | Anti-ig-e m1' antibodies and methods using same |
WO2013113641A1 (en) | 2012-01-31 | 2013-08-08 | Roche Glycart Ag | Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies |
CN104379601B (en) | 2012-02-03 | 2021-04-09 | 霍夫曼-拉罗奇有限公司 | Bispecific antibody molecules and antigen-transfected T-cells and their use in medicine |
RU2644341C2 (en) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Single-chain antibodies and other heteromultimers |
SG11201404703WA (en) | 2012-02-11 | 2014-09-26 | Genentech Inc | R-spondin translocations and methods using the same |
SI2814587T1 (en) | 2012-02-15 | 2018-08-31 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
EP2814468B1 (en) | 2012-02-16 | 2019-06-19 | Santarus, Inc. | Anti-vla1 (cd49a) antibody pharmaceutical compositions |
TWI613215B (en) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof |
CN104220458B (en) * | 2012-02-24 | 2018-08-14 | 阿特根公司 | It is combined with the modification antibody of the motif containing cysteine residues, the modification antibody-drug conjugates containing the modification antibody and its manufacturing method |
JP6407726B2 (en) | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Long-life polypeptide binding molecule |
MX2014010379A (en) | 2012-03-02 | 2015-05-15 | Roche Glycart Ag | Predicitive biomarker for cancer treatment with adcc enhanced antibodies. |
KR20170036142A (en) | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
SI2825558T1 (en) | 2012-03-13 | 2019-08-30 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of ovarian cancer |
EP2638916A1 (en) | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
WO2013142299A1 (en) | 2012-03-20 | 2013-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
RU2650770C2 (en) | 2012-03-27 | 2018-04-17 | Грин Кросс Корпорейшн | Epitopes of epidermal growth factor receptor surface antigen and use thereof |
CN104220457A (en) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | Diagnosis and treatments relating to her3 inhibitors |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
KR20140142719A (en) | 2012-03-30 | 2014-12-12 | 제넨테크, 인크. | Diagnostic methods and compositions for treatment of cancer |
EP2833900B1 (en) | 2012-04-01 | 2018-09-19 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
TWI619729B (en) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | Anti-hla-b*27 antibodies and uses thereof |
WO2013155346A1 (en) | 2012-04-11 | 2013-10-17 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
PL2838998T3 (en) | 2012-04-18 | 2018-04-30 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
BR112014027166A2 (en) | 2012-05-01 | 2017-06-27 | Genentech Inc | antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods. |
US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
US9441039B2 (en) | 2012-05-07 | 2016-09-13 | Amgen Inc. | Anti-erythropoietin antibodies |
KR101505157B1 (en) | 2012-05-08 | 2015-03-24 | 주식회사 종근당 | Anti-ErbB2 Antibody Variants |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
WO2013177470A1 (en) | 2012-05-23 | 2013-11-28 | Genentech, Inc. | Selection method for therapeutic agents |
CA2875624A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
JP5933830B2 (en) | 2012-06-08 | 2016-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Variant selectivity and combination of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of cancer |
CA2875989A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
KR20150023711A (en) | 2012-06-15 | 2015-03-05 | 제넨테크, 인크. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
CN104582736A (en) | 2012-06-21 | 2015-04-29 | 印第安纳大学研究及科技有限公司 | Incretin receptor ligand polypeptide Fc region fusion polypeptide and conjugate with altered Fc effector function |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CA2877533C (en) | 2012-06-22 | 2022-08-16 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
TW201843172A (en) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | anti-EGFR antibody and use thereof |
HK1202334A1 (en) | 2012-06-26 | 2015-09-25 | 霍夫曼-拉罗奇有限公司 | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
EP2863955B1 (en) | 2012-06-26 | 2016-11-23 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
CA2871880A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
JP6445429B2 (en) | 2012-06-27 | 2018-12-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method and use thereof for selecting and generating tailor-made selective and multispecific therapeutic molecules comprising at least two different targeting entities |
CA2871882A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
CA2871112C (en) | 2012-07-04 | 2020-05-12 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
MX353951B (en) | 2012-07-04 | 2018-02-07 | Hoffmann La Roche | Anti-theophylline antibodies and methods of use. |
EP3339328A1 (en) | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
PL2870247T3 (en) | 2012-07-05 | 2019-10-31 | Hoffmann La Roche | Expression and secretion system |
AU2013288931A1 (en) | 2012-07-09 | 2014-12-11 | Genentech, Inc. | Immunoconjugates comprising anti-CD22 antibodies |
TW201408698A (en) | 2012-07-09 | 2014-03-01 | Genentech Inc | Anti-CD79b antibodies and immunoconjugates |
WO2014011518A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
US20140030282A1 (en) | 2012-07-09 | 2014-01-30 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
CA2876730A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
HUE056217T2 (en) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecific anti-VEGF / anti-ANG-2 antibodies and their use in the treatment of ophthalmic vascular diseases |
ES2673847T3 (en) | 2012-07-25 | 2018-06-26 | Celldex Therapeutics, Inc. | Anti KIT antibodies and uses thereof |
MX2015000681A (en) | 2012-08-02 | 2015-04-10 | Hoffmann La Roche | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF. |
JP6464085B2 (en) | 2012-08-07 | 2019-02-06 | ジェネンテック, インコーポレイテッド | Combination therapy for the treatment of glioblastoma |
CN104662045B (en) | 2012-08-07 | 2019-04-05 | 罗切格利卡特公司 | Include two kinds of engineered improved immunotherapies of composition at the antibody with effector functions reduce and raised |
WO2014026033A1 (en) | 2012-08-08 | 2014-02-13 | University Of Florida Research Foundation, Inc. | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats |
JP2015530983A (en) | 2012-08-08 | 2015-10-29 | ロシュ グリクアート アーゲー | Interleukin-10 fusion protein and use thereof |
CN109705218B (en) | 2012-08-09 | 2022-07-19 | 罗切格利卡特公司 | ASGPR antibodies and uses thereof |
FR2994390B1 (en) | 2012-08-10 | 2014-08-15 | Adocia | METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
JP6211084B2 (en) | 2012-08-21 | 2017-10-11 | アカデミア シニカAcademia Sinica | Benzocyclooctyne compounds and uses thereof |
UA115789C2 (en) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Antibody formulations and uses thereof |
ES2747836T3 (en) | 2012-09-06 | 2020-03-11 | Adelaide Research&Innovation Pty Ltd | Methods and products to prevent and / or treat metastatic cancer |
CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
TWI595007B (en) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
WO2014049003A1 (en) | 2012-09-25 | 2014-04-03 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US10087250B2 (en) | 2012-10-08 | 2018-10-02 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
EP2719706A1 (en) | 2012-10-15 | 2014-04-16 | Universität Zürich | Bispecific HER2 ligands for cancer therapy |
US10093740B2 (en) | 2012-10-15 | 2018-10-09 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
PT2908912T (en) | 2012-10-18 | 2020-09-04 | Univ Rockefeller | Broadly-neutralizing anti-hiv antibodies |
AU2013334583B2 (en) | 2012-10-24 | 2018-09-13 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
EP2911692B1 (en) | 2012-10-26 | 2019-08-21 | The University of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
US9492563B2 (en) | 2012-10-30 | 2016-11-15 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
KR20190107184A (en) | 2012-11-01 | 2019-09-18 | 애브비 인코포레이티드 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
EP2914278B1 (en) | 2012-11-05 | 2021-06-02 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
US9725512B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | HER3 antibodies binding to the beta-hairpin of HER3 |
US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
AR093446A1 (en) | 2012-11-13 | 2015-06-10 | Genentech Inc | ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE |
TW201438736A (en) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | Methods of treating ovarian cancer with Dll4 antagonists |
CN105051528A (en) | 2012-11-15 | 2015-11-11 | 弗·哈夫曼-拉罗切有限公司 | Ionic strength-mediated ph gradient ion exchange chromatography |
WO2014078866A2 (en) | 2012-11-19 | 2014-05-22 | Xencor, Inc. | Engineered immunoglobulins with extended in vivo half-life |
ES2778823T3 (en) | 2012-11-20 | 2020-08-12 | Sanofi Sa | Anti-CEACAM5 antibodies and their uses |
ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
WO2014084508A1 (en) | 2012-11-27 | 2014-06-05 | (주)알테오젠 | Composition for stabilizing fusion protein in which protein and fc domain are fused |
BR112015012644A2 (en) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit; |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
PT2928923T (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
RU2015129551A (en) | 2012-12-19 | 2017-01-25 | Эмплиммьюн, Инк. | ANTIBODIES TO HUMAN B7-H4 AND THEIR APPLICATION |
PL2935328T3 (en) | 2012-12-21 | 2019-02-28 | Hoffmann La Roche | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
RU2650756C2 (en) | 2012-12-21 | 2018-04-17 | МЕДИММЬЮН, ЭлЭлСи | Antibodies to h7cr |
ES2871816T3 (en) | 2012-12-27 | 2021-11-02 | Sanofi Sa | Anti-LAMP1 Antibodies and Antibody-Drug Conjugates, and Uses Thereof |
EP3336104A1 (en) | 2012-12-28 | 2018-06-20 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10980804B2 (en) | 2013-01-18 | 2021-04-20 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
CN111044725B (en) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | Evaluation and treatment of bradykinin-mediated disorders |
AU2014207409B2 (en) | 2013-01-20 | 2019-12-19 | Takeda Pharmaceutical Company Limited | Evaluation, assays and treatment of pKal-mediated disorders |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | FUSION PROTEINS FOR MODULATING LYMPHOCYTES T REGULATORS AND EFFECTORS |
CN105431455A (en) | 2013-02-01 | 2016-03-23 | 圣塔玛丽亚生物疗法公司 | Administration of an anti-activin-a compound to a subject |
EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
WO2014126198A1 (en) | 2013-02-15 | 2014-08-21 | 株式会社ペルセウスプロテオミクス | Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same |
EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
CN105358576B (en) | 2013-02-20 | 2020-05-05 | 诺华股份有限公司 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors |
BR112015018418A2 (en) | 2013-02-22 | 2017-07-18 | Hoffmann La Roche | methods for treating cancer, for increasing the effectiveness of a treatment, for postponing and / or preventing cancer development, for increasing sensitivity to a targeted therapy, to extending the sensitivity period, to extending the response duration to a targeted therapy. and pharmaceutical |
AR094873A1 (en) | 2013-02-25 | 2015-09-02 | Genentech Inc | METHODS AND COMPOSITIONS TO DETECT AND TREAT MUTANTS OF AKT RESISTANT TO DRUGS |
SG11201504497TA (en) | 2013-02-26 | 2015-09-29 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
MX2015010843A (en) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules. |
RU2015140915A (en) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | BSPECIFIC ANTI-BINDING MOLECULES ACTIVATING T-CELLS |
WO2014131715A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
CA2902505A1 (en) | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
CA2902263A1 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
CA2904713A1 (en) | 2013-03-11 | 2014-10-09 | Amgen Inc. | Protein formulations comprising darbepoetin |
JP6445519B2 (en) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドMedImmune Limited | Pyrrolobenzodiazepine and its conjugates |
SG11201506244VA (en) | 2013-03-13 | 2015-09-29 | Prothena Biosciences Ltd | Tau immunotherapy |
ES2731779T3 (en) | 2013-03-13 | 2019-11-19 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CA2904630A1 (en) | 2013-03-13 | 2014-10-02 | Sanofi | Compositions comprising anti-cd38 antibodies and carfilzomib |
JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
SG11201507447PA (en) | 2013-03-13 | 2015-10-29 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
CA2905070A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
EA201591750A1 (en) | 2013-03-14 | 2016-05-31 | Дженентек, Инк. | ANTIBODIES AGAINST B7-H4 AND IMMUNOCONJUGATES |
ES2790420T3 (en) | 2013-03-14 | 2020-10-27 | Scripps Research Inst | Conjugates of antibodies and targeting agents uses of the same |
CA2903480A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
PE20151893A1 (en) | 2013-03-14 | 2015-12-30 | Parkash Gill | TREATMENT OF CANCER USING ANTIBODIES THAT BIND GRP78 ON THE CELLULAR SURFACE |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
MX2015011444A (en) | 2013-03-15 | 2015-12-16 | Genentech Inc | Compositions and methods for diagnosis and treatment of hepatic cancers. |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
ES2769574T3 (en) | 2013-03-15 | 2020-06-26 | Michael C Milone | Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CN105451767B (en) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | Multivalence and monovalent polyspecific compound and application thereof |
BR112015023262B8 (en) | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Isolated antibody, immunoconjugate, pharmaceutical formulation and uses of antibody |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
RS57393B1 (en) | 2013-03-15 | 2018-09-28 | Hoffmann La Roche | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
JP6448614B2 (en) | 2013-03-15 | 2019-01-09 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | Methods and compositions for generation and use of conformation specific antibodies |
KR102158924B1 (en) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
JP6594855B2 (en) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | Heterodimeric protein |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
EP2968537A1 (en) | 2013-03-15 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
JP6469644B2 (en) | 2013-03-15 | 2019-02-13 | アムジエン・インコーポレーテツド | Methods and compositions related to anti-CCR7 antigen binding proteins |
MX2015012326A (en) | 2013-03-15 | 2016-03-08 | Genentech Inc | Anti-crth2 antibodies and their use. |
AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
EP2970475A1 (en) | 2013-03-15 | 2016-01-20 | Biogen MA Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
JP2016522793A (en) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | Bispecific binding protein directed against IL-1β and / or IL-17 |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
AU2014240101B2 (en) | 2013-03-15 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
NZ712903A (en) | 2013-03-18 | 2018-07-27 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
AU2014241162A1 (en) | 2013-03-27 | 2015-10-22 | Cedars-Sinai Medical Center | Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways |
CA2904095A1 (en) | 2013-03-27 | 2014-10-02 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
WO2014163558A1 (en) | 2013-04-01 | 2014-10-09 | Moreinx Ab | Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
BR112015024926A2 (en) | 2013-04-16 | 2017-10-10 | Genentech Inc | compositions, article of manufacture, methods for treating a cancer patient, for evaluating a composition, for evaluating biological activity, for producing a composition and for evaluating the fragmentation of a composition and variant of pertuzumab |
US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
CN105324124A (en) | 2013-04-19 | 2016-02-10 | 赛腾制药 | Cytokine-derived therapy for reduced vascular leak syndrome |
PE20190920A1 (en) | 2013-04-29 | 2019-06-26 | Hoffmann La Roche | MODIFIED ANTIBODIES OF BINDING TO HUMAN FCRN AND METHODS OF USE |
PE20151925A1 (en) | 2013-04-29 | 2015-12-26 | Hoffmann La Roche | ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE FCRN BINDING AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES |
CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
EP2992331A4 (en) | 2013-04-30 | 2017-03-29 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
US10239951B2 (en) * | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
KR101453462B1 (en) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Antibodies Capable of Binding Specifically to HER2 |
PH12021550015A1 (en) | 2013-05-20 | 2022-05-11 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
HK1232243A1 (en) | 2013-05-24 | 2018-01-05 | 米迪缪尼有限公司 | Anti-b7-h5 antibodies and their uses |
DK3004174T3 (en) | 2013-05-31 | 2019-07-22 | Zymeworks Inc | HEATER MULTIMATES WITH REDUCED OR DOWN-REGULATED EFFECTOR FUNCTION |
CA2913011A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
HRP20200812T1 (en) | 2013-05-31 | 2020-08-07 | Genentech, Inc. | ANTIBODIES AGAINST TEICHONIC ACID OF CELL WALL AND CONJUGATES |
SG11201509982UA (en) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
AU2014280846B2 (en) | 2013-06-13 | 2020-11-05 | University Of South Australia | Methods for detecting prostate cancer |
PE20160716A1 (en) | 2013-06-14 | 2016-08-11 | Bayer Pharma AG | ANTI-TWEAKR ANTIBODY AND ITS USES |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP3010548A1 (en) | 2013-06-21 | 2016-04-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
JP6450381B2 (en) | 2013-07-05 | 2019-01-09 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | Soluble MIC neutralizing monoclonal antibody for treating cancer |
JP6546162B2 (en) | 2013-07-05 | 2019-07-17 | ゲンマブ エー/エス | Humanized or chimeric CD3 antibodies |
WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9951131B2 (en) | 2013-07-12 | 2018-04-24 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
BR112016000231A8 (en) | 2013-07-12 | 2019-12-31 | Genentech Inc | methods for identifying separation conditions with ion exchange chromatography and for analysis of polypeptide compositions |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
TW201920262A (en) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | Anti-activin A antibody and use thereof |
WO2015015448A2 (en) | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
KR102516152B1 (en) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | Afucosylated anti-fgfr2iiib antibodies |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
BR112016002685A2 (en) | 2013-08-07 | 2018-01-30 | Astute Medical Inc | timp2 assays that perform better on biological samples |
AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
DK3036320T4 (en) | 2013-08-19 | 2024-05-06 | Biogen Ma Inc | CONTROL OF PROTEIN GLYCOSYRATION USING CULTURE MEDIA ADDITION AND CELL CULTURE PROCESS PARAMETERS |
US20160237399A1 (en) | 2015-02-18 | 2016-08-18 | Biogen Ma Inc. | Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters |
WO2015027120A1 (en) | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
MX2016002798A (en) | 2013-09-05 | 2016-07-21 | Genentech Inc | Method for chromatography reuse. |
JP6486368B2 (en) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | Activation of human iNKT cells using glycolipids containing modified glycosyl groups |
US11545241B1 (en) | 2013-09-07 | 2023-01-03 | Labrador Diagnostics Llc | Systems and methods for analyte testing and data management |
PT3041513T (en) | 2013-09-08 | 2020-09-07 | Kodiak Sciences Inc | Factor viii zwitterionic polymer conjugates |
IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
US9481729B2 (en) | 2013-09-11 | 2016-11-01 | The University Of Hong Kong | Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof |
HK1226081A1 (en) | 2013-09-12 | 2017-09-22 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
CN104193828B (en) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously |
BR112016004450A2 (en) | 2013-09-17 | 2017-10-17 | Genentech Inc | methods for treating a disease, for increasing the effectiveness of a treatment, for postponing and / or preventing the development of recurrence and / or resistance of a disease, for increasing sensitivity to an inhibitor, for extending the sensitivity period for an inhibitor and for extend response time to an inhibitor |
HK1222569A1 (en) | 2013-09-17 | 2017-07-07 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
EP3903599A1 (en) | 2013-09-25 | 2021-11-03 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
EA036927B1 (en) | 2013-10-11 | 2021-01-15 | Оксфорд Биотерепьютикс Лтд | Conjugated antibodies against ly75 for the treatment of cancer |
CN105612182B (en) | 2013-10-11 | 2019-12-10 | 豪夫迈·罗氏有限公司 | Multispecific domain exchange consensus variable light chain antibodies |
WO2015054670A1 (en) | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Nsp4 inhibitors and methods of use |
CN111239415B (en) | 2013-10-17 | 2024-03-26 | 综合医院公司 | Methods of identifying subjects responsive to treatment for autoimmune diseases and compositions for treating the same |
EP3057615B1 (en) | 2013-10-18 | 2021-02-24 | F.Hoffmann-La Roche Ag | Anti-rspo antibodies and methods of use |
WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
JP6657098B2 (en) | 2013-10-21 | 2020-03-04 | ダイアックス コーポレーション | Diagnosis and treatment of autoimmune diseases |
SG11201603127WA (en) | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
JP2016538275A (en) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ, エセ.アー. | Production of T-cell retargeting heterodimeric immunoglobulins |
CN104628846B (en) | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | Method for purifying recombinant protein |
KR102404285B1 (en) | 2013-11-06 | 2022-05-31 | 아스튜트 메디컬 인코포레이티드 | Assays for igfbp7 having improved performance in biological samples |
EP3466445A1 (en) | 2013-11-06 | 2019-04-10 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
EP3068798B1 (en) | 2013-11-12 | 2020-10-07 | OGD2 Pharma | Human igg1 derived antibody with pro-apoptotic activity |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
EA201691027A1 (en) | 2013-11-20 | 2016-12-30 | Ридженерон Фармасьютикалз, Инк. | APLNR MODULATORS AND THEIR APPLICATION |
RS60882B1 (en) | 2013-11-21 | 2020-11-30 | Hoffmann La Roche | Anti-alpha-synuclein antibodies and methods of use |
KR102357906B1 (en) | 2013-11-27 | 2022-02-03 | 자임워크스 인코포레이티드 | Bispecific antigen-binding constructs targeting her2 |
AU2014363944B2 (en) | 2013-12-09 | 2020-03-26 | Allakos Inc. | Anti-Siglec-8 antibodies and methods of use thereof |
JP2017502002A (en) | 2013-12-09 | 2017-01-19 | ニューヨーク・ユニバーシティ | Composition and method for phagocytic cell delivery of anti-staphylococcal agents |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
AU2014362238A1 (en) | 2013-12-13 | 2016-06-09 | Genentech, Inc. | Anti-CD33 antibodies and immunoconjugates |
CA2929565A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
KR102433591B1 (en) | 2013-12-17 | 2022-08-18 | 제넨테크, 인크. | Anti-cd3 antibodies and methods of use |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
JP2017501167A (en) | 2013-12-17 | 2017-01-12 | ジェネンテック, インコーポレイテッド | Combination therapy comprising OX40 binding agonist and PD-1 axis binding antagonist |
US20150174242A1 (en) | 2013-12-19 | 2015-06-25 | Mayo Foundation For Medical Education And Research | Monovalent anti-cd3 adjuvants |
WO2015095539A1 (en) | 2013-12-20 | 2015-06-25 | Genentech, Inc. | Dual specific antibodies |
JP6793902B2 (en) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | Adjustable chimeric antigen receptor |
DK3083680T3 (en) | 2013-12-20 | 2020-03-16 | Hoffmann La Roche | Humanized anti-Tau (pS422) antibodies and methods for use |
US20160289633A1 (en) | 2013-12-20 | 2016-10-06 | Biogen Ma Inc. | Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality |
KR20160099087A (en) | 2013-12-20 | 2016-08-19 | 에프. 호프만-라 로슈 아게 | Bispecific her2 antibodies and methods of use |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
MY182431A (en) | 2013-12-24 | 2021-01-25 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
SG11201605215YA (en) | 2013-12-25 | 2016-08-30 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
KR20160104628A (en) | 2014-01-03 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
KR102278429B1 (en) | 2014-01-03 | 2021-07-16 | 에프. 호프만-라 로슈 아게 | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
CN111057147B (en) | 2014-01-06 | 2023-11-10 | 豪夫迈·罗氏有限公司 | Monovalent blood brain barrier shuttle module |
EP3094654B1 (en) | 2014-01-14 | 2020-03-11 | The Medical College of Wisconsin, Inc. | Targeting clptm1l for treatment and prevention of cancer |
MX382848B (en) | 2014-01-15 | 2025-03-13 | Hoffmann La Roche | FC REGION VARIANTS WITH MODIFIED NEONATAL FC RECEPTOR (FCRN) BINDING AND MAINTAINED α-PROTEIN BINDING PROPERTIES. |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
AU2015209481C1 (en) | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
SI3097122T1 (en) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
US20170043034A1 (en) | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
KR102465042B1 (en) | 2014-01-31 | 2022-11-09 | 다이이찌 산쿄 가부시키가이샤 | Anti-her2 antibody-drug conjugate |
US9840543B2 (en) | 2014-01-31 | 2017-12-12 | Boehringer Ingelheim International Gmbh | Anti-BAFF antibodies |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
EA201992609A1 (en) | 2014-02-06 | 2020-03-04 | Ф.Хоффманн-Ля Рош Аг | FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS |
US20150246963A1 (en) | 2014-02-08 | 2015-09-03 | Genentech, Inc. | Methods of treating alzheimer's disease |
TWI785472B (en) | 2014-02-08 | 2022-12-01 | 美商建南德克公司 | Methods of treating alzheimer's disease |
EP3105253B1 (en) | 2014-02-12 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-jagged1 antibodies and methods of use |
KR20150097304A (en) | 2014-02-18 | 2015-08-26 | 삼성전자주식회사 | Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins |
SG11201606870XA (en) | 2014-02-21 | 2016-09-29 | Genentech Inc | Anti-il-13/il-17 bispecific antibodies and uses thereof |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
DK3110446T3 (en) | 2014-02-28 | 2022-02-28 | Allakos Inc | Methods and compositions for treating Siglec-8-associated diseases |
PT3122757T (en) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Charged linkers and their uses for conjugation |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
ES2784749T3 (en) | 2014-03-10 | 2020-09-30 | Richter Gedeon Nyrt | Immunoglobulin purification with the use of precleaning steps |
RS59077B1 (en) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
TW201623331A (en) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | Anti-MCAM antibodies and associated methods of use |
EP3116907A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
US10407506B2 (en) | 2014-03-12 | 2019-09-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
EP3116906A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
WO2015136468A1 (en) | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
JP6722110B2 (en) * | 2014-03-14 | 2020-07-15 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Humanized antibody with increased stability |
EP3116486B1 (en) | 2014-03-14 | 2019-12-04 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
ES2897765T3 (en) | 2014-03-14 | 2022-03-02 | Hoffmann La Roche | Methods and compositions for the secretion of heterologous polypeptides |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
TWI754319B (en) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
LT3119431T (en) | 2014-03-21 | 2024-03-12 | Teva Pharmaceuticals International Gmbh | ANTAGONISTIC ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS OF USE THEREOF |
WO2015148531A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
US11124760B2 (en) | 2014-03-24 | 2021-09-21 | Biogen Ma Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
CA2939246A1 (en) | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
EP3122768A2 (en) | 2014-03-27 | 2017-02-01 | Yeda Research and Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
KR20230022270A (en) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Bispecific antibodies that bind to cd38 and cd3 |
CR20160500A (en) | 2014-03-31 | 2016-12-14 | Genentech Inc | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
AU2015241038A1 (en) | 2014-03-31 | 2016-10-13 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists |
SG10202107077QA (en) | 2014-04-02 | 2021-07-29 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
MX395149B (en) | 2014-04-07 | 2025-03-24 | Novartis Ag | COMBINATION THERAPIES INCLUDING A CHIMERALIC CD19 ANTIGEN RECEPTOR FOR CANCER. |
JP6744856B2 (en) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | Blood-brain barrier shuttle containing antibody that recognizes α-synuclein |
WO2015155976A1 (en) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | (anti-her2 antibody)-drug conjugate |
RU2016144176A (en) | 2014-04-11 | 2018-05-14 | МЕДИММЬЮН, ЭлЭлСи | SPECIFIC ANTIBODIES TO HER2 |
ES2910443T3 (en) | 2014-04-16 | 2022-05-12 | Biocon Ltd | Stable protein formulations comprising a molar excess of sorbitol |
ES2845650T3 (en) | 2014-04-18 | 2021-07-27 | Acceleron Pharma Inc | Procedures to increase red blood cell levels and treat sickle cell disease |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
MX2016014007A (en) | 2014-04-25 | 2017-01-11 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab. |
JP6983511B2 (en) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Methods and Compositions for Treating Metastatic Breast Cancer and Other Cancers in the Brain |
US11602525B2 (en) | 2014-04-25 | 2023-03-14 | Rinat Neuroscience Corp. | Antibody-drug conjugates with high drug loading |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
AP2016009564A0 (en) | 2014-04-27 | 2016-11-30 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
PT3137114T (en) | 2014-04-30 | 2021-02-26 | Pfizer | Anti-ptk7 antibody-drug conjugates |
CR20160561A (en) | 2014-05-01 | 2017-05-03 | Genentech Inc | ANTI-FACTOR D ANTIBODY VARIATIONS AND THEIR USES |
HUE063273T2 (en) | 2014-05-06 | 2024-01-28 | Hoffmann La Roche | Production of heteromultimeric proteins using mammalian cells |
WO2015173325A2 (en) | 2014-05-16 | 2015-11-19 | Ablynx Nv | Improved immunoglobulin variable domains |
WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
JP2017524371A (en) | 2014-05-23 | 2017-08-31 | ジェネンテック, インコーポレイテッド | MIT biomarkers and methods of use |
WO2015184004A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
AU2015267051B2 (en) | 2014-05-27 | 2022-03-17 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
PT3148579T (en) | 2014-05-28 | 2021-03-11 | Ludwig Inst For Cancer Res Ltd | ANTI-GITR ANTIBODIES AND METHODS OF THEIR USE |
KR102366644B1 (en) | 2014-05-30 | 2022-02-22 | 상하이 헨리우스 바이오테크, 인크. | Anti-epidermal growth factor receptor (egfr) antibodies |
WO2015191715A1 (en) | 2014-06-11 | 2015-12-17 | Genentech, Inc. | Anti-lgr5 antibodies and uses thereof |
CN107073109B (en) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity |
BR112016029226A2 (en) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | methods and compositions for treating ulcers |
JP2017517552A (en) | 2014-06-13 | 2017-06-29 | ジェネンテック, インコーポレイテッド | Treatment and prevention of anticancer drug resistance |
TWI713453B (en) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | Interferon alpha and omega antibody antagonists |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
CA2947504A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Anti-brdu antibodies and methods of use |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016004370A1 (en) | 2014-07-03 | 2016-01-07 | Genentech, Inc. | Polypeptide expression systems |
EP3166688B1 (en) | 2014-07-08 | 2024-08-21 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
KR102360693B1 (en) | 2014-07-11 | 2022-02-08 | 벤타나 메디컬 시스템즈, 인코포레이티드 | Anti-pd-l1 antibodies and diagnostic uses thereof |
US9914774B2 (en) | 2014-07-11 | 2018-03-13 | Genentech, Inc. | Notch pathway inhibition |
WO2016011052A1 (en) | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
WO2016009436A1 (en) | 2014-07-15 | 2016-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Isolated polypeptides of cd44 and uses thereof |
JP7054622B2 (en) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | Treatment of cancer with humanized anti-BCMA chimeric antigen receptor |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
RU2747384C2 (en) | 2014-07-21 | 2021-05-04 | Новартис Аг | Cancer treatment with chimeric cd33 antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
JP2017528433A (en) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | Low immunoenhancing dose of mTOR inhibitor and CAR combination |
EP3708227A1 (en) | 2014-07-22 | 2020-09-16 | Sutro Biopharma, Inc. | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies |
US10487151B2 (en) | 2014-07-23 | 2019-11-26 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72) |
JP2017524359A (en) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Biomarkers useful for the treatment of IL-23A related diseases |
US20160060360A1 (en) | 2014-07-24 | 2016-03-03 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
BR112017001579A2 (en) | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable cd3 antibodies and methods of use |
MX367787B (en) | 2014-07-29 | 2019-09-06 | Cellectis | ROR1 (NTRKR1) CHEMERICAL ANTIGEN RECEPTORS SPECIFIC FOR CANCER IMMUNOTHERAPY. |
EP3194432B1 (en) | 2014-07-31 | 2019-04-10 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
WO2016016859A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
EP3174903B1 (en) | 2014-07-31 | 2024-04-10 | Amgen Research (Munich) GmbH | Bispecific single chain antibody construct with enhanced tissue distribution |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
JP6692343B2 (en) | 2014-08-01 | 2020-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Anti-CD45RC antibody for use as a drug |
SI3177643T1 (en) | 2014-08-04 | 2019-08-30 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
WO2016020856A2 (en) | 2014-08-05 | 2016-02-11 | MabQuest SA | Immunological reagents |
JP6919118B2 (en) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | Treatment of cancer with GFRα-4 chimeric antigen receptor |
EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
KR102616429B1 (en) | 2014-08-19 | 2023-12-26 | 노파르티스 아게 | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
ES2797754T3 (en) | 2014-08-28 | 2020-12-03 | Pfizer | Stability-modulating linkers for use with drug-antibody conjugates |
DK3189073T3 (en) | 2014-09-04 | 2020-03-30 | Cellectis | TROPHOBLAST GLYCOPROTEIN (5T4, TPBG) -Specific Chimeric Antigen Receptors for Cancer Therapy |
JP6899321B2 (en) | 2014-09-08 | 2021-07-07 | アカデミア シニカAcademia Sinica | Activation of human iNKT cells using glycolipids |
EP3191136A1 (en) | 2014-09-08 | 2017-07-19 | Michaela Arndt | Construct for the delivery of a molecule into the cytoplasm of a cell |
EP3191527B1 (en) | 2014-09-10 | 2020-01-15 | F.Hoffmann-La Roche Ag | Galactoengineered immunoglobulin 1 antibodies |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
KR20170052600A (en) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | Cysteine engineered antibodies and conjugates |
CN114106185A (en) | 2014-09-12 | 2022-03-01 | 基因泰克公司 | anti-HER 2 antibodies and immunoconjugates |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
MA40579A (en) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anti-cll-1 antibodies and immunoconjugates |
US10059768B2 (en) | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP3194400A1 (en) | 2014-09-17 | 2017-07-26 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CN114621969A (en) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CA2957148A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
WO2016044588A1 (en) | 2014-09-19 | 2016-03-24 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
JP6694877B2 (en) | 2014-09-23 | 2020-05-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Anti-IL-25 antibody and use thereof |
SI3262071T1 (en) | 2014-09-23 | 2020-07-31 | F. Hoffmann-La Roche Ag | Method of using anti-cd79b immunoconjugates |
SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
EP3201226A2 (en) | 2014-10-03 | 2017-08-09 | Massachusetts Institute of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
US9921230B2 (en) | 2014-10-08 | 2018-03-20 | Rhode Island Hospital | Methods for diagnosis and treatment of concussion or brain injury |
US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
KR20210013299A (en) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | Butyrylcholinesterase zwitterionic polymer conjugates |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
US10040844B2 (en) | 2014-10-22 | 2018-08-07 | The Regents Of The University Of California | Proteolytic release of cell surface antigens for phage biopanning |
KR102781429B1 (en) | 2014-10-31 | 2025-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Altering gene expression in modified t cells and uses thereof |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
WO2016070001A1 (en) | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
US20160161485A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
KR20170080675A (en) | 2014-11-05 | 2017-07-10 | 제넨테크, 인크. | Anti-fgfr2/3 antibodies and methods using same |
US10066002B2 (en) | 2014-11-05 | 2018-09-04 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
BR112017009152A2 (en) | 2014-11-05 | 2018-03-06 | Genentech Inc | Two-chain protein production methods in bacteria |
CN107073126A (en) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Combination treatment comprising OX40 combinations activator and TIGIT inhibitor |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
HRP20191766T1 (en) | 2014-11-06 | 2019-12-27 | F. Hoffmann - La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
RU2713131C1 (en) | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | EMBODIMENTS OF Fc-REGION WITH MODIFIED BINDING PROPERTIES OF FcRn AND PROTEIN A |
HK1243440A1 (en) | 2014-11-10 | 2018-07-13 | F. Hoffmann-La Roche Ag | Anti-interleukin-33 antibodies and uses thereof |
JP2018500882A (en) | 2014-11-10 | 2018-01-18 | ジェネンテック, インコーポレイテッド | Animal model of nephropathy and drug for treating it |
AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
WO2016075612A1 (en) | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
KR102588377B1 (en) | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Antigen binding molecules comprising a tnf family lignad trimer |
US20160166685A1 (en) | 2014-11-17 | 2016-06-16 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
EP3221359B1 (en) | 2014-11-17 | 2020-05-27 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
US10434177B2 (en) | 2014-11-17 | 2019-10-08 | Carnegie Mellon University | Activatable two-component photosensitizers |
DK3221349T3 (en) | 2014-11-19 | 2021-01-04 | Axon Neuroscience Se | Humanized tau antibodies in Alzheimer's disease |
EP3221364B1 (en) | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
CN107250158B (en) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use |
JP6779876B2 (en) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibody and how to use it |
HUE059632T2 (en) | 2014-11-20 | 2022-12-28 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
RS60615B1 (en) | 2014-11-20 | 2020-08-31 | Hoffmann La Roche | Common light chains and methods of use |
CN107074955B (en) | 2014-11-20 | 2021-06-22 | 豪夫迈·罗氏有限公司 | T cell activating bispecific antigen binding molecules against FolR1 and CD3 |
US11033637B2 (en) | 2014-11-21 | 2021-06-15 | University Of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3581585A1 (en) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
WO2016086189A2 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
IL252467B (en) | 2014-11-26 | 2022-06-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
WO2016082044A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
US10208108B2 (en) | 2014-11-28 | 2019-02-19 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to ricin toxin |
US10233256B2 (en) * | 2014-11-28 | 2019-03-19 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to ricin toxin |
EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
MX2017007055A (en) | 2014-12-03 | 2017-11-08 | Genentech Inc | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof. |
JP6721590B2 (en) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Multispecific antibody |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016090040A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
MA41119A (en) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA |
AU2015358325A1 (en) | 2014-12-05 | 2017-05-25 | Genentech, Inc. | Anti-CD79b antibodies and methods of use |
WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
MX2017007491A (en) | 2014-12-10 | 2018-05-04 | Genentech Inc | Blood brain barrier receptor antibodies and methods of use. |
WO2016094837A2 (en) | 2014-12-11 | 2016-06-16 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
SMT202500043T1 (en) | 2014-12-15 | 2025-03-12 | Univ California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
EP3234120A4 (en) | 2014-12-15 | 2018-05-16 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
JP2018503368A (en) | 2014-12-18 | 2018-02-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Assay methods and methods for determining antibodies that induce CDC |
EP3945096A1 (en) | 2014-12-19 | 2022-02-02 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
CN120271705A (en) | 2014-12-19 | 2025-07-08 | 中外制药株式会社 | Anti-myostatin antibodies, polypeptides comprising variant FC regions, and methods of use |
KR20230044338A (en) | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | Anti-c5 antibodies and methods of use |
IL284291B2 (en) | 2014-12-19 | 2025-02-01 | Lundbeck Seattle Biopharmaceuticals Inc | Humanized anti-acth antibodies and use thereof |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
CA2972048C (en) | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CN107428823B (en) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | Combinations and methods of use of two or more anti-C5 antibodies |
WO2016116626A1 (en) | 2015-01-23 | 2016-07-28 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
EP3247281B1 (en) | 2015-01-23 | 2020-12-02 | The University of North Carolina at Chapel Hill | Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
EP3248013B1 (en) | 2015-01-24 | 2020-07-15 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016120220A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
TWI711631B (en) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI781507B (en) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI786505B (en) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
HK1245882A1 (en) | 2015-01-28 | 2018-08-31 | F. Hoffmann-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
WO2016123593A1 (en) | 2015-01-30 | 2016-08-04 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CN107636170A (en) | 2015-02-04 | 2018-01-26 | 健泰科生物技术公司 | Mutant Smoothened and How to Use It |
AU2016215535B2 (en) | 2015-02-04 | 2021-09-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
JP6959869B2 (en) | 2015-02-23 | 2021-11-05 | シーガル セラピューティクス エスアーエス | Non-natural semaphorins 3 and their medical use |
CA2972099A1 (en) | 2015-02-26 | 2016-09-01 | Genentech, Inc. | Integrin beta7 antagonists and methods of treating crohn's disease |
DK3265123T5 (en) | 2015-03-03 | 2024-09-16 | Kymab Ltd | ANTIBODIES, USES AND METHODS |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
HK1247936A1 (en) | 2015-03-06 | 2018-10-05 | F. Hoffmann-La Roche Ag | Ultrapurified dsba and dsbc and methods of making and using the same |
EP3267994A4 (en) | 2015-03-09 | 2018-10-31 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
JP2018511797A (en) | 2015-03-16 | 2018-04-26 | ジェネンテック, インコーポレイテッド | IL-13 detection and quantification method and use in diagnosis and treatment of Th2-related diseases |
JP6968698B2 (en) | 2015-03-17 | 2021-11-24 | メモリアル スローン ケタリング キャンサー センター | Anti-MUC16 antibody and its use |
EP3069734A1 (en) | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
EA201992756A3 (en) | 2015-03-18 | 2020-06-30 | Сиэтл Дженетикс, Инк. | ANTIBODIES AGAINST CD48 AND THEIR CONJUGATES |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
CN107530428B (en) | 2015-03-23 | 2022-05-13 | 震动疗法股份有限公司 | Antibodies to ICOS |
KR102749339B1 (en) | 2015-03-23 | 2025-01-03 | 바이엘 파마 악티엔게젤샤프트 | Anti-CEACAM6 antibodies and their uses |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
MX2017012423A (en) | 2015-03-30 | 2018-01-26 | Dyax Corp | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack. |
US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
SG11201707490SA (en) | 2015-04-03 | 2017-10-30 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
HK1252957A1 (en) | 2015-04-06 | 2019-06-06 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
MA41919A (en) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
KR20180002653A (en) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | Antigen binding complexes having an agonistic activity activity and methods of use |
US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
JP6999421B2 (en) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | Anti-sortilin antibody and how to use it |
LT3280729T (en) | 2015-04-08 | 2022-08-10 | Novartis Ag | CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) EXPRESSING CELL |
TWI787645B (en) | 2015-04-13 | 2022-12-21 | 美商輝瑞股份有限公司 | Cd3-specific antibodies, therapeutic bispecific antibodies and their uses |
MX2017013156A (en) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim Int | Methods of treating diseases. |
WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
HK1250236A1 (en) | 2015-04-15 | 2018-12-07 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
MA53243A (en) | 2015-04-17 | 2021-06-23 | Bristol Myers Squibb Co | COMPOSITIONS COMPRISING A COMBINATION OF IPILIMUMAB AND NIVOLUMAB |
EA201792193A1 (en) | 2015-04-17 | 2018-05-31 | Эмджен Рисерч (Мьюник) Гмбх | CONSTRUCTIONS OF BISPECIFIC ANTIBODIES FOR CDH3 AND CD3 |
EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
KR20240093813A (en) | 2015-04-24 | 2024-06-24 | 제넨테크, 인크. | Multispecific antigen-binding proteins |
PL3286315T3 (en) | 2015-04-24 | 2021-11-02 | F. Hoffmann-La Roche Ag | METHODS OF IDENTIFICATION OF BACTERIA CONTAINING BINDING POLYPEPTIDES |
US20160319009A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
EP3288584A2 (en) | 2015-04-30 | 2018-03-07 | President and Fellows of Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
WO2016179003A1 (en) | 2015-05-01 | 2016-11-10 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
US20160326234A1 (en) * | 2015-05-07 | 2016-11-10 | Andrew Hiatt | Monoclonal antibody cocktails for treatment of ebola infections |
TWI820377B (en) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | Anti-ox40 antibodies and methods of use thereof |
KR20180018525A (en) | 2015-05-08 | 2018-02-21 | 젠코어 인코포레이티드 | Heterozygous antibodies that bind CD3 and tumor antigens |
EP4238994A3 (en) | 2015-05-11 | 2024-02-07 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
JP7048319B2 (en) | 2015-05-12 | 2022-04-05 | ジェネンテック, インコーポレイテッド | Treatment and diagnosis methods for cancer |
US10906982B2 (en) | 2015-05-15 | 2021-02-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
HUE051661T2 (en) | 2015-05-18 | 2021-03-29 | Tcr2 Therapeutics Inc | Compositions and medical uses for tcr reprogramming using fusion proteins |
AU2016263513A1 (en) | 2015-05-20 | 2017-11-23 | Cellectis | Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy |
JP6688551B2 (en) | 2015-05-21 | 2020-04-28 | ハープーン セラピューティクス,インク. | Trispecific binding proteins and methods of use |
WO2016191750A1 (en) | 2015-05-28 | 2016-12-01 | Genentech, Inc. | Cell-based assay for detecting anti-cd3 homodimers |
CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
ES2789500T5 (en) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
CN107771182A (en) | 2015-05-29 | 2018-03-06 | 豪夫迈·罗氏有限公司 | Humanized anti-Ebola virus glycoprotein antibody and method of use |
IL292708B2 (en) | 2015-05-30 | 2024-08-01 | Molecular Templates Inc | Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them |
HRP20241134T1 (en) | 2015-05-30 | 2024-11-22 | F. Hoffmann-La Roche Ag | METHODS OF TREATMENT OF HER2-POSITIVE PREVIOUSLY UNTREATED METASTATIC BREAST CANCER |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
AU2016270858B2 (en) | 2015-06-05 | 2022-04-28 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
WO2016200835A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
HK1252272A1 (en) | 2015-06-08 | 2019-05-24 | 豪夫迈‧罗氏有限公司 | Methods of treating cancer using anti-ox40 antibodies |
CN116063499A (en) | 2015-06-12 | 2023-05-05 | 艾利妥 | anti-CD 33 antibodies and methods of use thereof |
TW201709932A (en) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | CD123 antibody and its conjugate |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
HK1255483A1 (en) | 2015-06-15 | 2019-08-16 | 基因泰克公司 | Antibodies and immunoconjugates |
PE20180330A1 (en) | 2015-06-16 | 2018-02-13 | Genentech Inc | AFFINITY MATURED AND HUMANIZED ANTIBODIES FOR FCRH5 AND METHODS FOR THEIR USE |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
JP6996983B2 (en) | 2015-06-16 | 2022-02-21 | ジェネンテック, インコーポレイテッド | Anti-CLL-1 antibody and how to use |
AU2016278239B9 (en) | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
CA2986592A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
WO2016207094A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
PE20221007A1 (en) | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY |
EP3313882B1 (en) | 2015-06-24 | 2020-03-11 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
CN113929779B (en) | 2015-06-24 | 2025-02-25 | 豪夫迈·罗氏有限公司 | Humanized anti-Tau (pS422) antibodies and methods of use |
WO2016207091A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
EP3514174B1 (en) | 2015-06-29 | 2021-03-31 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
EP3313885A1 (en) | 2015-06-29 | 2018-05-02 | H. Hoffnabb-La Roche Ag | Type ii anti-cd20 antibody for use in organ transplantation |
CA2986796A1 (en) | 2015-06-30 | 2017-01-05 | Seattle Genetics, Inc. | Anti-ntb-a antibodies and related compositions and methods |
EP3319994B1 (en) | 2015-07-06 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
LT3319995T (en) | 2015-07-07 | 2019-07-10 | F. Hoffmann-La Roche Ag | COMPOUND TREATMENT WITH ANTI-HER-2 ANTIBODY-DRUG CONJUGATE AND BCL-2 INHIBITOR |
CN108449940B (en) | 2015-07-12 | 2021-06-08 | 杭州多禧生物科技有限公司 | Conjugated bridging linkers to cell-binding molecules |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TWI833685B (en) | 2015-07-31 | 2024-03-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | Method of predicting the bioavailability of an antibody |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
JOP20160154B1 (en) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
US10286080B2 (en) | 2015-08-03 | 2019-05-14 | Wayne State University | IgA Fc-folate conjugates, pharmaceutical compositions and methods to treat cancer |
KR102824235B1 (en) | 2015-08-04 | 2025-06-25 | 악셀레론 파마 인코포레이티드 | Methods for treating myeloproliferative disorders |
HU231463B1 (en) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Method for increasing the galactose content of recombinant proteins |
WO2017024146A1 (en) | 2015-08-05 | 2017-02-09 | Janssen Biotech, Inc. | Anti-cd154 antibodies and methods of using them |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
CN108495641A (en) | 2015-08-11 | 2018-09-04 | 塞勒克提斯公司 | The cell for immunotherapy for targeting CD38 antigens and the engineering inactivated for CD38 genes |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
FI3334761T3 (en) | 2015-08-13 | 2023-08-14 | Univ New York | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
US10852309B2 (en) | 2015-08-25 | 2020-12-01 | Prothena Biosciences Limited | Methods for detecting phosphorylated alpha-synuclein |
IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide assembly and methods of making and using the same |
EP3932953A1 (en) | 2015-08-28 | 2022-01-05 | F. Hoffmann-La Roche AG | Anti-hypusine antibodies and uses thereof |
WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
KR20180039172A (en) | 2015-09-01 | 2018-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | Use of anti-CD40 antibodies for the treatment of lupus nephritis |
AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
MX2018003005A (en) | 2015-09-18 | 2018-04-11 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof. |
TWI811716B (en) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | Methods of treating inflammatory diseases |
CA2999369C (en) | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
EA201890785A1 (en) | 2015-09-23 | 2018-10-31 | Ридженерон Фармасьютикалз, Инк. | OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION |
US11142565B2 (en) | 2015-09-24 | 2021-10-12 | Abvitro Llc | Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope |
CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
JP7628764B2 (en) | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | mod folkpon edge cargogo search carrier Signalsure procedure always Subaturch curl carrieresert match experiencesch suffer with Japan missed crgoc car |
WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
MX2018003689A (en) | 2015-09-29 | 2018-04-30 | Celgene Corp | Pd-1 binding proteins and methods of use thereof. |
PE20181367A1 (en) | 2015-09-30 | 2018-08-27 | Janssen Biotech Inc | AGONIST ANTIBODIES THAT SPECIFICALLY BIND HUMAN CD40 AND METHODS OF USE |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
US20180282410A1 (en) | 2015-10-02 | 2018-10-04 | Hoffmann-La Roche Inc. | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
CN108026179A (en) | 2015-10-02 | 2018-05-11 | 豪夫迈·罗氏有限公司 | With reference to mesothelin and the bispecific T cell activation antigen binding molecules of CD3 |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
UA125962C2 (en) | 2015-10-02 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Bispecific antibodies specific for a costimulatory tnf receptor |
AR106199A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN |
MY190297A (en) | 2015-10-02 | 2022-04-12 | Hoffmann La Roche | Anti-pd1 antibodies and methods of use |
JP6937746B2 (en) | 2015-10-02 | 2021-09-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific anti-CD19 × CD3T cell-activating antigen-binding molecule |
HRP20211357T1 (en) | 2015-10-02 | 2021-11-26 | F. Hoffmann - La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
PE20181004A1 (en) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
KR20180075537A (en) | 2015-10-06 | 2018-07-04 | 제넨테크, 인크. | Methods for treating multiple sclerosis |
US20170247467A1 (en) | 2015-10-07 | 2017-08-31 | Hoffmann-La Roche Inc. | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
WO2017064716A1 (en) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201518675D0 (en) | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
JP2018534927A (en) | 2015-10-22 | 2018-11-29 | ジョンス セラピューティクス, インコーポレイテッド | Gene signature that determines ICOS expression |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
US11267875B2 (en) | 2015-10-28 | 2022-03-08 | Yale University | Humanized anti-DKK2 antibody and uses thereof |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
MX2018005036A (en) | 2015-10-29 | 2018-08-01 | Hoffmann La Roche | Anti-variant fc-region antibodies and methods of use. |
JP2018536650A (en) | 2015-10-30 | 2018-12-13 | ジェネンテック, インコーポレイテッド | Anti-factor D antibody variant conjugates and uses thereof |
CN116333125A (en) | 2015-10-30 | 2023-06-27 | 银河生物技术有限责任公司 | Antibodies that bind death receptor 4 and death receptor 5 |
PT3368578T (en) | 2015-10-30 | 2021-05-06 | H Hoffnabb La Roche Ag | Anti-htra1 antibodies and methods of use thereof |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
EP3371206B1 (en) | 2015-11-02 | 2021-04-14 | F. Hoffmann-La Roche AG | Methods of making fucosylated and afucosylated forms of a protein |
US11235063B2 (en) | 2015-11-03 | 2022-02-01 | Merck Patent Gmbh | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
DK3370768T3 (en) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND USES THEREOF |
JP2019503985A (en) | 2015-11-03 | 2019-02-14 | グリコミメティクス, インコーポレイテッド | Monoclonal antibodies, methods and compositions for the production of hematopoietic stem cells, and methods of using them |
WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
CN118725134A (en) | 2015-11-08 | 2024-10-01 | 豪夫迈·罗氏有限公司 | Methods for screening multispecific antibodies |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
EP3377533A2 (en) | 2015-11-19 | 2018-09-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
JP7072507B2 (en) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | Methods for treating eye disorders |
CN106729743B (en) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof |
IL291926B2 (en) | 2015-11-23 | 2024-06-01 | Five Prime Therapeutics Inc | FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment |
TWI778491B (en) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
CN109415437B (en) | 2015-12-02 | 2022-02-01 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof |
US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
EP3383497A4 (en) | 2015-12-04 | 2019-06-12 | The Regents of The University of California | NEW ANTIBODIES FOR THE TREATMENT OF CANCERS |
KR20180085800A (en) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | CD3 and heterodimeric antibodies that bind to PSMA |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
CN108290954B (en) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Use of type II anti-CD 20 antibodies to reduce anti-drug antibody formation |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
AU2016366521A1 (en) | 2015-12-11 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade |
CN108602893A (en) | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | Inhibitors of plasma kallikrein and its purposes for the treatment of hereditary angioedema breaking-out |
MY196756A (en) | 2015-12-14 | 2023-05-03 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
NZ743713A (en) | 2015-12-15 | 2020-01-31 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
MA44072A (en) | 2015-12-17 | 2018-10-24 | Janssen Biotech Inc | ANTIBODIES SPECIFICALLY BINDING TO HLA-DR AND THEIR USES |
BR112018009067A8 (en) | 2015-12-18 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | anti-c5 antibodies and methods of use |
EA201891420A1 (en) | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION |
CN105646704B (en) * | 2015-12-28 | 2019-11-15 | 广西医科大学 | Anti-p185erbB2 human-mouse chimeric antibody ChAb26, mammary gland-specific expression vector, transgenic FVB mouse and preparation method thereof |
IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
CN107531795B (en) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | PCSK9 antibody, antigen-binding fragment thereof and medical application thereof |
AR107303A1 (en) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | METHODS OF TREATMENT OF POSITIVE CANCER FOR ACE USING ANTAGONISTS OF AXISION TO AXIS PD-1 AND ANTI-ACE / ANTI-CD3, USE, COMPOSITION, KIT |
MX395252B (en) | 2016-01-08 | 2025-03-25 | Altrubio Inc | Tetravalent anti-psgl-1 antibodies and uses thereof |
EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
BR112018014762A2 (en) | 2016-01-20 | 2018-12-26 | Genentech Inc | method of treating (early) alzheimer's disease |
JP2019506398A (en) | 2016-01-21 | 2019-03-07 | ファイザー・インク | Epidermal growth factor receptor variant III and CD3 single and bispecific antibodies and their use |
US20210198368A1 (en) | 2016-01-21 | 2021-07-01 | Novartis Ag | Multispecific molecules targeting cll-1 |
EP3964529B1 (en) | 2016-01-22 | 2025-03-26 | Mabquest SA | Non-blocking pd1 specific antibodies |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
CN109073635A (en) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | Method for measuring T cell dependence bispecific antibody |
CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
FI3411404T3 (en) | 2016-02-03 | 2023-01-31 | T CELL ACTIVATING PSMA AND CD3 BISPECIFIC ANTIBODY CONSTRUCTS | |
HUE057220T2 (en) | 2016-02-03 | 2022-04-28 | Amgen Res Munich Gmbh | Bcma and cd3 bispecific t cell engaging antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
EP3411069B1 (en) | 2016-02-04 | 2024-07-10 | The Scripps Research Institute | Humanized anti-cd3 antibodies, conjugates and uses thereof |
WO2017139417A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
BR112018016461A2 (en) | 2016-02-12 | 2019-10-01 | Janssen Pharmaceutica Nv | antibodies and anti-sight fragments, their uses and their identification methods |
CA3011900A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
GB201603291D0 (en) * | 2016-02-25 | 2016-04-13 | Binding Site Group The Ltd | Antibodies |
CA3015839A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | Connexin (cx)43 hemichannel-binding antibodies and uses thereof |
WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US10941447B2 (en) | 2016-02-29 | 2021-03-09 | Rhode Island Hospital | Diagnostics for pulmonary arterial hypertension and sudden cardiac death |
AU2017228055B2 (en) | 2016-03-01 | 2024-04-04 | University Of Rijeka Faculty Of Medicine | Antibodies specific to human poliovirus receptor (PVR) |
MX2018010562A (en) | 2016-03-02 | 2019-02-20 | Eisai R&D Man Co Ltd | ANTIBODY AND PHARMACO CONJUGATES BASED ON ERIBULIN AND METHODS FOR USE. |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
KR102355950B1 (en) | 2016-03-04 | 2022-01-26 | 제이엔 바이오사이언시즈 엘엘씨 | Antibodies to TIGIT |
EP3216458A1 (en) | 2016-03-07 | 2017-09-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified vascular endothelial growth factor a (vegf-a) and its medical use |
TW201808978A (en) | 2016-03-08 | 2018-03-16 | 中央研究院 | Methods for modular synthesis of N-glycans and arrays thereof |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
MX2018011169A (en) | 2016-03-14 | 2018-12-06 | Millennium Pharm Inc | Method of preventing graft versus host disease. |
MX2018011025A (en) | 2016-03-14 | 2019-01-10 | Millennium Pharm Inc | Methods of treating or preventing graft versus host disease. |
TWI759287B (en) | 2016-03-15 | 2022-04-01 | 日商中外製藥股份有限公司 | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | DIAGNOSTIC METHOD FOR CHRONIC INFLAMMATORY BOWEL DISEASE THROUGH T2 RNASE |
MA43724B1 (en) | 2016-03-22 | 2023-06-28 | Hoffmann La Roche | BI-SPECIFIC PROTEASE-ACTIVATED T-CELL MOLECULES |
UA127308C2 (en) | 2016-03-22 | 2023-07-19 | Ф. Хоффманн-Ля Рош Аг | Protease-activated t cell bispecific molecules |
CN111363041B (en) | 2016-03-23 | 2022-02-22 | 苏州创胜医药集团有限公司 | Novel anti-PD-L1 antibodies |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
AU2017239018A1 (en) | 2016-03-24 | 2018-08-16 | Bayer As | Radio-pharmaceutical complexes |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
MY202022A (en) | 2016-03-28 | 2024-03-29 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
EP3436475A1 (en) | 2016-03-29 | 2019-02-06 | STCube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
CA3018382A1 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
KR102367074B1 (en) | 2016-03-29 | 2022-02-25 | 주식회사 에스티큐브 | Dual function antibodies specific for glycosylated PD-L1 and methods of use thereof |
AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
WO2017173091A1 (en) | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
WO2017173327A1 (en) | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
KR101796277B1 (en) | 2016-04-12 | 2017-11-13 | 앱클론(주) | Antibodies Binding Specifically to HER2 with Improved Stability |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
US11510966B2 (en) | 2016-04-15 | 2022-11-29 | Evive Biotechnology (Shanghai) Ltd | Use of IL-22 in treating necrotizing enterocolitis |
IL262366B2 (en) | 2016-04-15 | 2024-07-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
EP3443008A1 (en) | 2016-04-15 | 2019-02-20 | Medimmune Limited | ANTI-PrP ANTIBODIES AND USES THEREOF |
SG11201808632YA (en) | 2016-04-15 | 2018-10-30 | Alder Biopharmaceuticals Inc | Anti-pacap antibodies and uses thereof |
ES2850428T3 (en) | 2016-04-15 | 2021-08-30 | Hoffmann La Roche | Cancer monitoring and treatment procedures |
EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
WO2017181139A2 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
EP3443120A2 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
EP3560956A3 (en) | 2016-04-15 | 2020-01-01 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
ES2944607T3 (en) | 2016-04-15 | 2023-06-22 | Novartis Ag | Compositions and methods for the selective expression of chimeric receptors for the antigen |
MA44723A (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Giving a bispecific formulation that binds to CD33 and CD3 for use in a modality for the treatment of myeloid leukemia |
KR20230110820A (en) | 2016-04-22 | 2023-07-25 | 오비아이 파머 인코퍼레이티드 | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
US12054550B2 (en) | 2016-04-28 | 2024-08-06 | Biomunex Pharmaceuticals | Bispecific antibodies targeting EGFR and HER2 |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
HUE060258T2 (en) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunotherapy |
MX2018013342A (en) | 2016-05-02 | 2019-05-09 | Hoffmann La Roche | The contorsbody - a single chain target binder. |
SG11201809331RA (en) | 2016-05-02 | 2018-11-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
EP3241847A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Her-2 binding antibodies |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
EP3455254B1 (en) | 2016-05-11 | 2021-07-07 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
CN109311987A (en) | 2016-05-13 | 2019-02-05 | 生物蛋白有限公司 | Anti- ROR2 antibody, antibody fragment and their immunoconjugates with and application thereof |
KR102410778B1 (en) | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
MX2018014047A (en) | 2016-05-17 | 2019-06-20 | Genentech Inc | Stromal gene signatures for diagnosis and use in immunotherapy. |
EP4019019B1 (en) | 2016-05-20 | 2024-02-07 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
CN109313200B (en) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | Bioanalytical methods for characterizing site-specific antibody-drug conjugates |
JP7267012B2 (en) | 2016-05-27 | 2023-05-01 | アジェナス インコーポレイテッド | Anti-TIM-3 antibody and method of use thereof |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
ES3008636T3 (en) | 2016-06-02 | 2025-03-24 | Immunocore Ltd | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
CA3025995C (en) | 2016-06-06 | 2023-08-08 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
AU2017277288B2 (en) | 2016-06-09 | 2024-05-16 | Omeros Corporation | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
KR102495601B1 (en) | 2016-06-10 | 2023-02-06 | 리제너론 파마슈티칼스 인코포레이티드 | Anti-GITR Antibodies and Their Uses |
MA45255A (en) | 2016-06-14 | 2019-04-17 | Xencor Inc | BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES |
EP3472197A1 (en) | 2016-06-15 | 2019-04-24 | Sutro Biopharma, Inc. | Antibodies with engineered ch2 domains, compositions thereof and methods of using the same |
SG11201810777WA (en) | 2016-06-17 | 2018-12-28 | Genentech Inc | Purification of multispecific antibodies |
BR112018073628A2 (en) | 2016-06-17 | 2019-02-26 | Chugai Seiyaku Kabushiki Kaisha | antimiostatin antibodies and methods of use |
US12071487B2 (en) | 2016-06-17 | 2024-08-27 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | Cd3 binding antibodies |
CN116143918A (en) | 2016-06-24 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
EP3478714A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7016470B2 (en) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
JP7017013B2 (en) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
WO2018007314A1 (en) | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
PT3482210T (en) | 2016-07-06 | 2021-07-28 | Prothena Biosciences Ltd | Assay for detecting total and s129 phosphorylated alpha-synuclein |
WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US20180008672A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
SG11201811015RA (en) | 2016-07-12 | 2019-01-30 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
EP3484488B1 (en) | 2016-07-12 | 2023-08-09 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
MX2018015853A (en) | 2016-07-14 | 2019-08-21 | Genmab As | Multispecific antibodies against cd40 and cd137. |
SG11201900344YA (en) | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
MA45674A (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | METHODS AND MATERIALS FOR EVALUATING A RESPONSE TO PLASMOBLAST AND PLASMOCYTE DEPLÉTION TREATMENTS |
RS62011B1 (en) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Compositions comprising actriia polypeptides for use in treating pulmonary hypertension |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018017673A1 (en) | 2016-07-20 | 2018-01-25 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
WO2018017964A2 (en) | 2016-07-21 | 2018-01-25 | Emory University | Ebola virus antibodies and binding agents derived therefrom |
US10377833B2 (en) | 2016-07-22 | 2019-08-13 | Beijing Mabworks Biotech Co., Ltd. | Bispecific anti-HER2 antibody |
AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
CN107446045A (en) | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | A kind of anti-HER2 antibody, its pharmaceutical composition and purposes |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
CN110072545A (en) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | Immunogenicity/therapeutic glycan pool object and application thereof |
EA201990226A1 (en) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOFIBROSIS |
WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
JP2019523301A (en) | 2016-07-28 | 2019-08-22 | ノバルティス アーゲー | Combination therapy of chimeric antigen receptor and PD-1 inhibitor |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
CA3027018A1 (en) | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
WO2018023121A1 (en) | 2016-07-29 | 2018-02-01 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
MX2019001184A (en) | 2016-07-29 | 2019-09-26 | Juno Therapeutics Inc | Anti-idiotypic antibodies against anti-cd19 antibodies. |
BR112019002035A2 (en) | 2016-08-01 | 2019-05-14 | Novartis Ag | cancer treatment using a chimeric antigen receptor in combination with an inhibitor of a m2 pro-macrophage molecule |
JP7109789B2 (en) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | Compositions and methods for TCR reprogramming using fusion proteins |
KR20190036528A (en) | 2016-08-03 | 2019-04-04 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Collapse of Fc receptor participation in macrophage enhancement efficacy of anti-SIRPalpha antibody therapy |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
JP7250674B2 (en) | 2016-08-08 | 2023-04-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | CANCER TREATMENT AND DIAGNOSTIC METHOD |
JP7093767B2 (en) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | Pyrrolobenzodiazepine prodrug and its antibody conjugate |
EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
JP7009448B2 (en) | 2016-08-12 | 2022-02-10 | ヤンセン バイオテツク,インコーポレーテツド | Fc genetically engineered anti-TNFR superfamily member antibody with enhanced agonist activity and how to use it |
CN109716127B (en) | 2016-08-15 | 2022-06-14 | 豪夫迈·罗氏有限公司 | Chromatographic method for quantifying nonionic surfactant in composition containing nonionic surfactant and polypeptide |
AU2017313405B2 (en) | 2016-08-17 | 2024-09-26 | Compugen Ltd. | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
TWI764917B (en) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | Antibodies, binding fragments, and methods of use |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018042385A2 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
US11168148B2 (en) | 2016-09-07 | 2021-11-09 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
EP3512549A4 (en) | 2016-09-14 | 2020-06-17 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
CA3037144A1 (en) | 2016-09-16 | 2018-03-22 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EA201990747A1 (en) | 2016-09-19 | 2019-10-31 | METHODS FOR TREATING IMMUNE DISORDERS WITH APPLICATION OF PROTEINS BINDING PD – 1 | |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
RU2759334C2 (en) | 2016-09-21 | 2021-11-12 | Нексткьюр, Инк. | Antibodies against siglec-15 and their application methods |
WO2018057802A1 (en) | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
KR102557643B1 (en) | 2016-09-23 | 2023-07-20 | 제넨테크, 인크. | Use of IL-13 antagonists to treat atopic dermatitis |
SG10202102617QA (en) | 2016-09-23 | 2021-04-29 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
CA3036632A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
JP7066691B2 (en) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Bispecific anti-MUC16-CD3 antibody and anti-MUC16 drug complex |
ES3013602T3 (en) | 2016-09-28 | 2025-04-14 | Kite Pharma Inc | Antigen binding molecules and methods of use thereof |
ES2897217T3 (en) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Bispecific antibodies against p95HER2 |
JP7050770B2 (en) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Method for preparing antibody drug conjugate |
JP2019529509A (en) | 2016-10-05 | 2019-10-17 | アクセレロン ファーマ インコーポレーテッド | Compositions and methods for treating kidney disease |
MX2019003934A (en) | 2016-10-06 | 2019-07-10 | Genentech Inc | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER. |
BR112019006781A2 (en) | 2016-10-07 | 2019-07-30 | Novartis Ag | chimeric antigen receptors for cancer treatment |
IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
CN109789211A (en) | 2016-10-07 | 2019-05-21 | 第一三共株式会社 | Treatment based on the patience cancer that Anti-HER 2-drug conjugates are bestowed |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
MA46529A (en) | 2016-10-11 | 2019-08-21 | Agenus Inc | ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE |
EP3526254A1 (en) | 2016-10-12 | 2019-08-21 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
EP3525815A2 (en) | 2016-10-13 | 2019-08-21 | Massachusetts Institute of Technology | Antibodies that bind zika virus envelope protein and uses thereof |
RU2019114175A (en) | 2016-10-14 | 2020-11-16 | Ксенкор, Инк. | BISPECIFIC HETERODYMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA FC-FUSION PROTEINS AND ANTIBODY FRAGMENTS TO PD-1 |
EP4032906A1 (en) | 2016-10-14 | 2022-07-27 | Boehringer Ingelheim International GmbH | Methods of treating diseases |
MX2019004690A (en) | 2016-10-19 | 2019-09-27 | Invenra Inc | ANTIBODY CONSTRUCTS. |
TW202300515A (en) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | Anti-chikv antibodies and uses thereof |
KR20190084264A (en) | 2016-10-25 | 2019-07-16 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Monoclonal antibody that binds to the CD160 transverse soma |
KR20240128132A (en) | 2016-10-26 | 2024-08-23 | 세다르스-신나이 메디칼 센터 | Neutralizing anti-tl1a monoclonal antibodies |
AU2017348365A1 (en) | 2016-10-28 | 2019-05-23 | Astute Medical, Inc. | Use of antibodies to TIMP-2 for the improvement of renal function |
JP2019535250A (en) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | Anti-MIC antibody and method of use |
WO2018085495A2 (en) | 2016-11-02 | 2018-05-11 | Board Of Regents, The University Of Texas System | Dissolvable films and methods of their use |
KR20190088480A (en) | 2016-11-02 | 2019-07-26 | 조운스 테라퓨틱스, 인크. | Antibodies to PD-1 and uses thereof |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
CN109906030B (en) | 2016-11-04 | 2022-03-18 | 安健基因公司 | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
CN110505880A (en) | 2016-11-04 | 2019-11-26 | 基因泰克公司 | Treatment of HER2-positive breast cancer |
JP7045724B2 (en) | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | Anti-Family 19, member A5 antibody with sequence similarity and its uses |
EP3538539A2 (en) | 2016-11-08 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
WO2018086139A1 (en) | 2016-11-14 | 2018-05-17 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
EP3541836A1 (en) | 2016-11-15 | 2019-09-25 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
EP3541408B1 (en) | 2016-11-15 | 2024-11-13 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
CA3042435A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | anti-HLA-G antibody and use thereof |
JOP20190100A1 (en) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | Anti-gitr antigen-binding proteins and methods of use thereof |
KR102477612B1 (en) | 2016-11-21 | 2022-12-14 | 쿠레아브 게엠베하 | Anti-gp73 antibodies and immunoconjugates |
TWI822055B (en) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | Conjugated biological molecules, pharmaceutical compositions and methods |
CN110177803A (en) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | For using fusion protein to carry out the composition and method that TCR is reprogramed |
CN110198955A (en) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | Prostate-specific membrane antigen conjugated protein |
CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
EA201900312A1 (en) | 2016-11-29 | 2019-12-30 | Регенерон Фармасьютикалз, Инк. | METHODS OF TREATMENT OF PROLACTIN-RECEPTOR OF POSITIVE BREAST CANCER |
TWI857389B (en) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
DK3551660T5 (en) | 2016-12-07 | 2024-09-02 | Agenus Inc | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USING THEREOF |
CN118634323A (en) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | Antibodies and methods of use thereof |
TW202328181A (en) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
CA3046293A1 (en) | 2016-12-12 | 2018-06-21 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
CN110381997A (en) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases |
BR112019011199A2 (en) | 2016-12-12 | 2019-10-08 | Genentech Inc | method to treat an individual who has prostate cancer and kits |
CA3047230A1 (en) | 2016-12-15 | 2018-06-21 | The National Institute for Biotechnology in the Negev Ltd. | Anti-pcna monoclonal antibodies and use thereof |
US11325968B2 (en) | 2016-12-16 | 2022-05-10 | H. Lundbeck A/S | Alpha-synuclein antibodies |
WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
CN111868086B (en) | 2016-12-19 | 2024-07-16 | 免疫医疗有限公司 | Anti-LIF antibodies and uses thereof |
WO2018115960A1 (en) | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
KR102692708B1 (en) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
MX2019007411A (en) | 2016-12-21 | 2019-08-29 | Hoffmann La Roche | Re-use of enzymes in in vitro glycoengineering of antibodies. |
JP6952115B2 (en) | 2016-12-21 | 2021-10-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Methods for in vitro glycan engineering of antibodies |
CN116284402A (en) | 2016-12-21 | 2023-06-23 | 特尼奥生物股份有限公司 | Heavy chain-only anti-BCMA antibodies |
MX2019006266A (en) | 2016-12-21 | 2019-08-21 | Hoffmann La Roche | In vitro glycoengineering of antibodies. |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
JOP20190134A1 (en) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | Anti-neuropilin antigen-binding proteins and methods of use thereof |
EP3562844A1 (en) | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
MA47200A (en) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE |
US10995137B2 (en) | 2017-01-04 | 2021-05-04 | H. Lundbeck A/S | Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
EP3565845A4 (en) | 2017-01-06 | 2020-10-07 | Biosion, Inc. | ERBB2 ANTIBODIES AND THEIR USES |
WO2018132597A1 (en) | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
BR112019012847A2 (en) | 2017-01-17 | 2019-12-10 | Daiichi Sankyo Co Ltd | antibody or antibody functional fragment, polynucleotide, expression vector, host cells, method for producing an antibody of interest or antibody functional fragment and for producing an antibody-drug conjugate, antibody-drug conjugate, pharmaceutical composition , antitumor drug; and, method of treating a tumor. |
DK3570884T3 (en) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subcutaneous HER2 antibody formulations |
MX2019008538A (en) | 2017-01-20 | 2019-11-05 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods. |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
SG10201908697XA (en) | 2017-01-31 | 2019-10-30 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
RU2771485C2 (en) | 2017-02-10 | 2022-05-04 | Дженентек, Инк. | Antibodies against tryptase, their compositions and applications |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
WO2018152181A1 (en) | 2017-02-14 | 2018-08-23 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
BR112019017197A2 (en) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics Inc | proteins that bind to her2, nkg2d and cd16 |
WO2018156785A1 (en) | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
AU2018224094B2 (en) | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
CN111148760A (en) | 2017-02-27 | 2020-05-12 | 卡拉斯医疗有限公司 | Antibody constructs and methods of treating cancer |
JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US20200061031A1 (en) | 2017-02-28 | 2020-02-27 | Kinki University | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate |
KR20190134631A (en) | 2017-03-01 | 2019-12-04 | 제넨테크, 인크. | How to diagnose and treat cancer |
FI3589661T3 (en) | 2017-03-02 | 2024-01-31 | Genentech Inc | Adjuvant treatment of her2-positive breast cancer |
BR112019017500A2 (en) | 2017-03-03 | 2020-04-14 | Rinat Neuroscience Corp | anti-gitr antibodies and methods of using them |
SI3592769T1 (en) | 2017-03-09 | 2024-10-30 | Genmab A/S | Antibodies against pd-l1 |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
EP3596126A4 (en) | 2017-03-15 | 2021-03-03 | Tsinghua University | NOVEL ANTI-TRKB ANTIBODIES |
EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
JOP20180021A1 (en) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | Anti-phf-tau antibodies and uses thereof |
HRP20231382T1 (en) | 2017-03-16 | 2024-02-16 | Alpine Immune Sciences, Inc. | PD-L1 VARIANT OF IMMUNOMODULATING PROTEINS AND THEIR USE |
UA129242C2 (en) | 2017-03-22 | 2025-02-26 | Дженентек, Інк. | OPTIMIZED ANTIBODY COMPOSITION FOR TREATMENT OF EYE DISEASES |
CA3055985A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
CN108623686A (en) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | Anti- OX40 antibody and application thereof |
EA201992278A1 (en) | 2017-03-27 | 2020-03-03 | Селджин Корпорейшн | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENOUS |
CA3056837A1 (en) | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
WO2018183173A1 (en) | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
CN110382542B (en) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Bispecific antigen-binding molecules targeting co-stimulatory TNF receptors |
EP3601345A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
AU2018241252B2 (en) | 2017-03-30 | 2024-09-19 | The University Of Queensland | Chimeric molecules and uses thereof |
CN119285787A (en) | 2017-03-31 | 2025-01-10 | 健玛保控股有限公司 | Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof |
CA3058175A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
PE20200010A1 (en) | 2017-04-03 | 2020-01-06 | Hoffmann La Roche | ANTIBODIES THAT JOIN STEAP-1 |
US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
EP3606947B1 (en) | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
BR112019020485A2 (en) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | PPARY AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
MX2019011770A (en) | 2017-04-03 | 2020-01-09 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15. |
TWI704158B (en) | 2017-04-04 | 2020-09-11 | 瑞士商赫孚孟拉羅股份公司 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
JP6997212B2 (en) | 2017-04-05 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antibodies that specifically bind to PD1 and LAG3 |
EP3606954B1 (en) | 2017-04-05 | 2022-07-20 | F. Hoffmann-La Roche AG | Anti-lag3 antibodies |
MX2019012017A (en) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods. |
KR102732040B1 (en) | 2017-04-11 | 2024-11-21 | 인히브릭스 바이오사이언스, 인크. | Multispecific polypeptide constructs with limited CD3 binding and methods using the same |
CN108690138A (en) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | It is a kind of can be with people CD19 or CD20 and people the CD3 bispecific antibody combined and its application |
MX2019012187A (en) | 2017-04-13 | 2019-11-25 | Hoffmann La Roche | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer. |
TWI842672B (en) | 2017-04-13 | 2024-05-21 | 美商艾吉納斯公司 | Anti-cd137 antibodies and methods of use thereof |
CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
SG11201909516VA (en) | 2017-04-14 | 2019-11-28 | Tollnine Inc | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
WO2018191660A1 (en) | 2017-04-14 | 2018-10-18 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
RU2665790C1 (en) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Monoclonal pd-l1 antibody |
JP2020517750A (en) * | 2017-04-19 | 2020-06-18 | エイピーエイ− アドバンスト・テクノロジーズ・リミテッドApa− Advanced Technologies Ltd. | Fusogenic liposomes, compositions, kits and uses thereof for the treatment of cancer |
KR20190141686A (en) | 2017-04-21 | 2019-12-24 | 제넨테크, 인크. | Use of KLK5 antagonists to treat diseases |
CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
EP4230649A3 (en) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
IL319308A (en) | 2017-04-26 | 2025-04-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Constructs specifically recognizing glypican 3 and uses thereof |
CA3059468A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
EP3615052B1 (en) | 2017-04-27 | 2023-01-25 | The University of Hong Kong | Use of hcn inhibitors for treatment of cancer |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
AR111651A1 (en) | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
TWI805582B (en) | 2017-05-01 | 2023-06-21 | 美商艾吉納斯公司 | Anti-tigit antibodies and methods of use thereof |
CU24636B1 (en) | 2017-05-02 | 2022-12-12 | Prothena Biosciences Ltd | ANTIBODIES RECOGNIZING TAU IN RESIDUES 257-271 OR 320-334 OF SEQ ID NO: 1 |
JP2020518638A (en) | 2017-05-05 | 2020-06-25 | アラコス インコーポレイテッド | Methods and compositions for treating allergic eye diseases |
MA48763A (en) | 2017-05-05 | 2020-04-08 | Amgen Inc | PHARMACEUTICAL COMPOSITION INCLUDING BISPECIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION |
JP7161494B2 (en) | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods of treating eye diseases with APLNR antagonists and VEGF inhibitors |
EP3401328A1 (en) | 2017-05-10 | 2018-11-14 | Bayer Pharma Aktiengesellschaft | One step antibody humanization by golden gate based germline framework region shuffling |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
EP3625251A1 (en) | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
TW202504644A (en) | 2017-05-15 | 2025-02-01 | 日商第一三共股份有限公司 | Use of antibody-drug conjugates |
WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
WO2018213304A1 (en) | 2017-05-16 | 2018-11-22 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
CN110944718A (en) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | Cyclodextrin protein drug conjugates |
WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
US20200079850A1 (en) | 2017-05-24 | 2020-03-12 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
CA3064869A1 (en) | 2017-05-26 | 2018-11-29 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
CN111010867B (en) | 2017-05-30 | 2023-05-12 | 俄克拉何马大学董事会 | Anti-doublecortin-like kinase 1 antibodies and methods of use thereof |
CA3065300A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
EP3630835A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CA3064331A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
CN118772278A (en) | 2017-06-02 | 2024-10-15 | 辉瑞公司 | FLT3 specific antibodies and uses thereof |
KR20200014304A (en) | 2017-06-02 | 2020-02-10 | 에프. 호프만-라 로슈 아게 | Type II anti-CD20 antibodies and anti-CD20 / anti-CD3 bispecific antibodies for the treatment of cancer |
CR20190550A (en) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE |
JP2020522562A (en) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand |
WO2018226861A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
KR102772810B1 (en) | 2017-06-15 | 2025-02-28 | 캔서 어드밴시스 아이엔씨 | Compositions and methods for inducing humoral and cellular immunity against tumors and cancers |
MX2019015563A (en) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anti-bcma heavy chain-only antibodies. |
KR102742528B1 (en) | 2017-06-20 | 2024-12-16 | 테네오바이오, 인코포레이티드 | Anti-BCMA heavy chain-only antibody |
EA201992502A1 (en) | 2017-06-20 | 2020-04-22 | Эмджен Инк. | METHOD FOR TREATING OR REDUCING THE INTENSITY OF METABOLIC DISORDERS WITH APPLICATION OF PROTEINS BINDING THE GASTROINhibitor PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GL 1 AGONISTS |
EP3641830A1 (en) | 2017-06-23 | 2020-04-29 | Velosbio Inc. | Ror1 antibody immunoconjugates |
WO2019005756A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
CU20200002A7 (en) | 2017-07-14 | 2020-11-30 | Pfizer | ANTIBODIES AGAINST MADCAM |
CN111094334A (en) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | Antibodies and methods for diagnosis and treatment of hepatitis B virus infection |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
EP3655034A1 (en) | 2017-07-21 | 2020-05-27 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN111448210B (en) | 2017-07-26 | 2024-05-14 | 四十七公司 | Anti-SIRP-α antibodies and related methods |
WO2019020606A1 (en) | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody |
US20200207859A1 (en) | 2017-07-26 | 2020-07-02 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
WO2019025299A1 (en) | 2017-07-31 | 2019-02-07 | F. Hoffmann-La Roche Ag | Three-dimensional structure-based humanization method |
CA3057447A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
CN116333131A (en) | 2017-08-04 | 2023-06-27 | 健玛保 | Binding agents that bind to PD-L1 and CD137 and uses thereof |
CA3070297A1 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
CA3073383C (en) | 2017-08-23 | 2023-10-31 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
AU2018323470B2 (en) | 2017-08-28 | 2025-04-24 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
US11318212B2 (en) | 2017-08-31 | 2022-05-03 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
AU2018327171B2 (en) | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
KR20200045520A (en) | 2017-09-07 | 2020-05-04 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | Antibodies to programmed cell death protein 1 |
MX2020002802A (en) | 2017-09-13 | 2020-10-12 | Teneobio Inc | Heavy chain antibodies binding to ectoenzymes. |
US11464784B2 (en) | 2017-09-15 | 2022-10-11 | The Regents Of The University Of California | Inhibition of aminocylase 3 (AA3) in the treatment of cancer |
CA3075087A1 (en) | 2017-09-18 | 2019-03-21 | Sutro Biopharma, Inc. | Anti- folate receptor alpha antibody conjugates and their uses |
EP3684413A1 (en) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
EP3684803A1 (en) | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
AU2018341454B2 (en) | 2017-09-26 | 2023-09-28 | The Regents Of The University Of California | Compositions and methods for treating cancer |
PE20210002A1 (en) | 2017-09-27 | 2021-01-05 | Incyte Corp | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS |
JP2021502955A (en) | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | Administration regimen for the treatment of synuclein disease |
CR20210381A (en) | 2017-09-29 | 2021-09-09 | Chugai Pharmaceutical Co Ltd | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
MX2020003125A (en) | 2017-09-29 | 2020-10-01 | Daiichi Sankyo Co Ltd | ANTIBODY-DERIVATE PYRROLOBENZODIAZEPINE CONJUGATE. |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
CA3076632A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
RU2698048C2 (en) | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody to il-5rα |
EA039662B1 (en) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
CN118497126A (en) | 2017-10-04 | 2024-08-16 | 赫斯佩瑞克斯股份公司 | Articles and methods for personalized cancer therapy |
PE20210042A1 (en) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | METHODS TO DETECT TRANSTIRETIN |
US11753458B2 (en) | 2017-10-10 | 2023-09-12 | Alpine Immune Sciences, Inc. | CTLA-4 variant immunomodulatory proteins and uses thereof |
JP2020536967A (en) | 2017-10-12 | 2020-12-17 | イミュノウェイク インコーポレイテッド | VEGFR-antibody light chain fusion protein |
CN118978600A (en) | 2017-10-13 | 2024-11-19 | 哈普恩治疗公司 | Trispecific proteins and methods of use |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
JP2020536894A (en) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Tumor treatment |
CN111712515A (en) | 2017-10-18 | 2020-09-25 | 高山免疫科学股份有限公司 | Variant ICOS ligand immunomodulatory proteins and related compositions and methods |
MX2020003497A (en) | 2017-10-20 | 2020-07-22 | Hoffmann La Roche | Method for generating multispecific antibodies from monospecific antibodies. |
WO2019084427A1 (en) | 2017-10-27 | 2019-05-02 | Kite Pharma, Inc. | T cell receptor antigen binding molecules and methods of use thereof |
AU2018358883A1 (en) | 2017-10-30 | 2020-04-23 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
CA3076027A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
WO2019086497A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
JP7092881B2 (en) | 2017-11-01 | 2022-06-28 | エフ.ホフマン-ラ ロシュ アーゲー | TriFab Contour Body |
CN111246884A (en) | 2017-11-01 | 2020-06-05 | 豪夫迈·罗氏有限公司 | Novel Antigen Binding Molecules Containing Trimers of TNF Family Ligands |
CN111295392A (en) | 2017-11-01 | 2020-06-16 | 豪夫迈·罗氏有限公司 | Compbody – multivalent target conjugate |
PL3707510T3 (en) | 2017-11-06 | 2024-09-30 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
MX2020004691A (en) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates. |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20200085828A (en) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
EP3708589A4 (en) | 2017-11-08 | 2021-08-11 | Kyowa Kirin Co., Ltd. | BIS SPECIFIC ANTIBODY BINDING TO CD40 AND EPCAM |
AU2018369784B2 (en) | 2017-11-14 | 2023-06-01 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
CN111655732B (en) * | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | anti-HER 2 antibodies or antigen binding fragments thereof and chimeric antigen receptors comprising same |
US11730763B2 (en) | 2017-11-14 | 2023-08-22 | Arcellx, Inc. | Multifunctional immune cell therapies |
IL274652B1 (en) | 2017-11-14 | 2025-04-01 | Arcellx Inc | D-domain containing polypeptides and uses thereof |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CN111433223B (en) | 2017-11-29 | 2024-08-27 | 诺和诺德A/S(股份有限公司) | Lyophilized preparation of anti-transthyretin monoclonal antibody |
KR102791781B1 (en) | 2017-12-01 | 2025-04-09 | 화이자 인코포레이티드 | Anti-CXCR5 antibodies and compositions and uses thereof |
MX2020005640A (en) | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer. |
AR113862A1 (en) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER |
EP3724229A1 (en) | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
WO2019118266A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
PE20201339A1 (en) | 2017-12-19 | 2020-11-25 | Univ Rockefeller | HUMAN IGG HR DOMAIN VARIANTS WITH IMPROVED EFFECTIVE FUNCTION |
IL319982A (en) | 2017-12-19 | 2025-05-01 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
CA3084105A1 (en) | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/wt1 |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
KR102823263B1 (en) | 2017-12-22 | 2025-06-24 | 테네오바이오, 인코포레이티드 | Heavy chain antibody binding to CD22 |
WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
JP7391868B2 (en) | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス, インク. | Antibody against LILRB2 |
CN115925943A (en) | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | Anti-PD-L1 antibodies and uses thereof |
KR20200104364A (en) | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | CD3-delta/epsilon heterodimer specific antibody |
WO2019129136A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-pd-l1 antibody and uses thereof |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
WO2019133902A2 (en) | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
JP7314146B2 (en) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | Cytotoxicity-inducing therapeutic agent |
AU2018396964C1 (en) | 2017-12-28 | 2024-10-03 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against PD-L1 |
JP7369127B2 (en) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Single domain antibodies against TIGIT and variants thereof |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
EP3731864A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche SA | Anti-vegf antibodies and methods of use |
EP3732193A1 (en) | 2017-12-29 | 2020-11-04 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
BR112020013236A2 (en) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | immunomodulatory proteins from multiple domains and methods of their use |
EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
SG11202006348VA (en) | 2018-01-05 | 2020-07-29 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
AU2019205542A1 (en) | 2018-01-08 | 2020-07-16 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
US11402380B2 (en) | 2018-01-25 | 2022-08-02 | Emory University | Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity |
BR112020013405A2 (en) | 2018-01-25 | 2020-12-01 | Acm Biolabs Pte Ltd. | polymerosomes comprising a soluble encapsulated antigen, as well as methods of its manufacture and use |
KR20200115546A (en) | 2018-01-26 | 2020-10-07 | 제넨테크, 인크. | IL-22 Fc fusion protein and method of use |
MX2020007628A (en) | 2018-01-26 | 2020-10-12 | Genentech Inc | Compositions and methods of use. |
EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
BR112020015641A2 (en) | 2018-02-01 | 2021-01-05 | Pfizer Inc. | SPECIFIC ANTIBODIES FOR CD70 AND ITS USES |
SG11202006883QA (en) | 2018-02-01 | 2020-08-28 | Pfizer | Chimeric antigen receptors targeting cd70 |
TWI860665B (en) | 2018-02-01 | 2024-11-01 | 大陸商信達生物製藥(蘇州)有限公司 | Full-human anti-b cell mature antigen (bcma) single chain antibody and use thereof |
CN118772288A (en) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules and methods of use |
UY38080A (en) | 2018-02-08 | 2019-08-30 | Amgen Inc | LOW PH PHARMACEUTICAL FORMULATION |
BR112020016190A2 (en) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
CA3226165A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
SG11202006583VA (en) | 2018-02-09 | 2020-08-28 | Genmab As | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
US20220211805A1 (en) | 2018-02-09 | 2022-07-07 | Acceleron Pharma Inc. | Methods for treating heterotopic ossification |
US11591399B2 (en) | 2018-02-14 | 2023-02-28 | Abba Therapeutics Ag | Anti-human PD-L2 antibodies |
US20200377609A1 (en) | 2018-02-14 | 2020-12-03 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
CN111787949A (en) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | Variant CD3-binding domains and their use in combination therapy for the treatment of disease |
MX2020008502A (en) | 2018-02-21 | 2020-09-25 | Genentech Inc | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS. |
WO2019161439A1 (en) | 2018-02-23 | 2019-08-29 | Cartherics Pty. Ltd. | T cell disease treatment targeting tag-72 |
CN111836831A (en) | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | Administration for Anti-TIGIT Antagonist Antibody and Anti-PD-L1 Antagonist Antibody Therapy |
CR20230030A (en) | 2018-02-27 | 2023-03-10 | Incyte Corp | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
MX387358B (en) | 2018-02-28 | 2025-03-18 | Pfizer | IL-15 VARIANTS AND THEIR USES |
MA52417A (en) | 2018-03-01 | 2021-01-06 | Regeneron Pharma | BODY COMPOSITION MODIFICATION PROCESSES |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
CN112105639B (en) | 2018-03-05 | 2024-09-27 | 詹森药业有限公司 | Anti-PHF-tau antibodies and uses thereof |
US12180301B2 (en) | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
BR112020017701A2 (en) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | ANTI-NGF ANTIBODIES AND METHODS OF THE SAME |
CA3093745A1 (en) | 2018-03-12 | 2019-09-19 | Genmab A/S | Antibodies |
AU2019236372B2 (en) | 2018-03-13 | 2024-06-20 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies |
TWI841551B (en) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1bb (cd137) agonists |
PT3765525T (en) | 2018-03-13 | 2023-10-03 | Zymeworks Bc Inc | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
EP4183804A1 (en) | 2018-03-14 | 2023-05-24 | Boehringer Ingelheim International GmbH | Use of il-36r antibodies for treatment of inflammatory bowel disease |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
PE20210665A1 (en) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES |
HUE062414T2 (en) | 2018-03-26 | 2023-10-28 | Glycanostics S R O | Means and methods for glycoprofiling of a protein |
US11993658B2 (en) | 2018-03-26 | 2024-05-28 | Sutro Biopharma, Inc. | Anti-BCMA antibodies and treatment methods |
EP3775184A1 (en) | 2018-03-29 | 2021-02-17 | F. Hoffmann-La Roche AG | Modulating lactogenic activity in mammalian cells |
PE20211235A1 (en) | 2018-03-29 | 2021-07-08 | Univ California | VARIANTS OF LFA3 AND THE COMPOSITIONS AND USES OF THEM |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
JP2021519771A (en) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | How to treat a tumor |
JP7104458B2 (en) | 2018-04-02 | 2022-07-21 | 上海博威生物医薬有限公司 | Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
WO2019195561A2 (en) | 2018-04-06 | 2019-10-10 | BioLegend, Inc. | Anti-tetraspanin 33 agents and compositions and methods for making and using the same |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
US10654944B2 (en) | 2018-04-10 | 2020-05-19 | Y-Biologics Inc. | Cell engaging binding molecules |
US20190330366A1 (en) | 2018-04-11 | 2019-10-31 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
MA52231A (en) | 2018-04-12 | 2021-02-17 | Fundacio Privada Inst Catalana De Recerca I Estudis Avancats | COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER |
MX2020010732A (en) | 2018-04-13 | 2020-11-09 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl. |
US11648317B2 (en) | 2018-04-13 | 2023-05-16 | Genentech, Inc. | Stable anti-CD79B immunoconjugate formulations |
AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
KR20210010862A (en) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
WO2019209952A2 (en) | 2018-04-23 | 2019-10-31 | Emory University | Vip antagonists and uses in treating cancer |
MA52366A (en) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | OPTIMIZED ANTI-TL1A ANTIBODIES |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
CA3097711A1 (en) | 2018-04-30 | 2019-11-07 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
BR112020022035A2 (en) | 2018-04-30 | 2021-02-02 | Takeda Pharmaceutical Company Limited | type 1 (cb1) cannabinoid receptor binding proteins and uses thereof |
US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019213416A1 (en) | 2018-05-02 | 2019-11-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
US12324841B2 (en) | 2018-05-07 | 2025-06-10 | Genmab A/S | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate |
IL278400B2 (en) | 2018-05-07 | 2024-03-01 | Genmab As | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer |
WO2019217450A1 (en) | 2018-05-08 | 2019-11-14 | Rhode Island Hospital | Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications |
JP7590871B2 (en) | 2018-05-09 | 2024-11-27 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Anti-MSR1 antibodies and methods of use thereof |
JP2021522801A (en) | 2018-05-09 | 2021-09-02 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | Antibodies specific for humannectin 4 |
US11970532B2 (en) | 2018-05-10 | 2024-04-30 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
WO2019214624A1 (en) | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
EP3794031A2 (en) | 2018-05-14 | 2021-03-24 | MedImmune Limited | Antibodies against lif and dosage forms thereof |
EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
SG11202010493XA (en) | 2018-05-18 | 2020-11-27 | Glycotope Gmbh | Anti-muc1 antibody |
MA52940A (en) | 2018-05-18 | 2021-04-28 | Incyte Corp | FUSION PYRIMIDINE DERIVATIVES USED AS A2A / A2B INHIBITORS |
WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
KR102584675B1 (en) | 2018-05-23 | 2023-10-05 | 화이자 인코포레이티드 | Antibodies specific for GUCY2c and their uses |
ES2984950T3 (en) | 2018-05-23 | 2024-10-31 | Pfizer | CD3-specific antibodies and their uses |
KR102822623B1 (en) | 2018-05-23 | 2025-06-20 | 싱가포르국립대학교 | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
SG11202011270QA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Anti-cd3 antibodies and uses thereof |
EP3802607A2 (en) | 2018-05-24 | 2021-04-14 | Janssen Biotech, Inc. | Monospecific and multispecific anti-tmeff2 antibodies and there uses |
EA202092839A1 (en) | 2018-05-24 | 2021-02-12 | Янссен Байотек, Инк. | PSMA LINKING AGENTS AND THEIR APPLICATIONS |
SG11202011082UA (en) | 2018-05-25 | 2020-12-30 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
JP7441165B2 (en) | 2018-05-28 | 2024-02-29 | 第一三共株式会社 | Treatment of HER2 mutant cancer by anti-HER2 antibody-drug conjugate administration |
US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
US12172986B2 (en) | 2018-06-01 | 2024-12-24 | Eisai R&D Management Co., Ltd | Splicing modulator antibody-drug conjugates and methods of use |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
KR20210056288A (en) | 2018-06-01 | 2021-05-18 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | Compositions for treating diseases or conditions and uses thereof |
CN112867394B9 (en) | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | Anti-VLA-4 antibodies with reduced effector function |
WO2019235426A1 (en) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | Antigen-binding molecule showing changed half-life in cytoplasm |
TWI851577B (en) | 2018-06-07 | 2024-08-11 | 美商思進公司 | Camptothecin conjugates |
JP7438988B2 (en) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | BCMA chimeric antigen receptor and its use |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
JP7511308B2 (en) | 2018-06-18 | 2024-07-05 | ユーリカ セラピューティックス, インコーポレイテッド | Prostate-specific membrane antigen (psma) targeting constructs and uses thereof |
JP2021529516A (en) | 2018-06-18 | 2021-11-04 | アンウィタ バイオサイエンシス, インク. | Cytokine fusion protein and its use |
MA52300A (en) | 2018-06-18 | 2021-04-21 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTI-NEOPLASICS AGENTS FOR USE IN THE TREATMENT OF CANCER |
KR20210030366A (en) | 2018-06-20 | 2021-03-17 | 인사이트 코포레이션 | Anti-PD-1 antibodies and uses thereof |
MY205387A (en) | 2018-06-21 | 2024-10-18 | Regeneron Pharma | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
JP2021528435A (en) | 2018-06-22 | 2021-10-21 | ゲンマブ エー/エス | A method for producing a controlled mixture of two or more different antibodies |
US12275797B2 (en) | 2018-06-22 | 2025-04-15 | Genmab Holding B.V. | Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof |
MX2020014091A (en) | 2018-06-23 | 2021-05-27 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor. |
TWI853822B (en) | 2018-06-27 | 2024-09-01 | 台灣浩鼎生技股份有限公司 | Glycosynthase variants for glycoprotein engineering and methods of use |
JP7504808B2 (en) | 2018-06-29 | 2024-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-CD40 antibodies for use in the treatment of autoimmune diseases |
EP3813800B1 (en) | 2018-06-29 | 2025-05-07 | Incyte Corporation | Formulations of an axl/mer inhibitor |
SG11202010990TA (en) | 2018-06-29 | 2020-12-30 | Alector Llc | Anti-sirp-beta1 antibodies and methods of use thereof |
US11884729B2 (en) | 2018-06-29 | 2024-01-30 | ApitBio, Inc | Anti-L1CAM antibodies and uses thereof |
CR20210047A (en) | 2018-07-02 | 2021-05-21 | Amgen Inc | ANTI-STEAP1 ANTIGEN BINDING PROTEIN |
JP7554742B2 (en) | 2018-07-03 | 2024-09-20 | マレンゴ・セラピューティクス,インコーポレーテッド | Anti-TCR antibody molecules and uses thereof |
CN112424228B (en) | 2018-07-04 | 2024-08-09 | 豪夫迈·罗氏有限公司 | Novel bispecific agonistic 4-1BB antigen binding molecules |
MA53097A (en) | 2018-07-05 | 2021-05-12 | Incyte Corp | MERGED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CN119552251A (en) | 2018-07-13 | 2025-03-04 | 艾利妥 | Anti-sortilin antibodies and methods of use thereof |
WO2020018556A1 (en) | 2018-07-16 | 2020-01-23 | Amgen Inc. | Method of treating multiple myeloma |
CN112839644A (en) | 2018-07-18 | 2021-05-25 | 豪夫迈·罗氏有限公司 | Methods of treating lung cancer with PD-1 axis binding antagonists, antimetabolites and platinum agents |
TWI838389B (en) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF |
JP2021531007A (en) | 2018-07-20 | 2021-11-18 | ピエール、ファーブル、メディカマン | Receptor for VISTA |
TWI841577B (en) | 2018-07-20 | 2024-05-11 | 美商表面腫瘤學公司 | Anti-cd112r compositions and methods |
SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
CN112789294A (en) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | Multispecific polypeptide constructs containing constrained CD3 binding domains and receptor binding regions and methods of use thereof |
US20210283269A1 (en) | 2018-07-25 | 2021-09-16 | Daiichi Sankyo Company, Limited | Effective method for manufacturing antibody-drug conjugate |
KR20210040059A (en) | 2018-07-27 | 2021-04-12 | 다이이찌 산쿄 가부시키가이샤 | Protein Recognizing the Drug Site of an Antibody-Drug Conjugate |
WO2020025532A1 (en) | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2020027100A1 (en) | 2018-07-31 | 2020-02-06 | 第一三共株式会社 | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
SG11202013248YA (en) | 2018-07-31 | 2021-02-25 | Amgen Inc | Pharmaceutical formulations of masked antibodies |
TWI701041B (en) | 2018-08-01 | 2020-08-11 | 日商中外製藥股份有限公司 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
CN110790840A (en) | 2018-08-01 | 2020-02-14 | 三生国健药业(上海)股份有限公司 | Antibodies that bind to human HER2, methods of making and uses thereof |
JOP20210022A1 (en) | 2018-08-03 | 2021-01-28 | Amgen Inc | Antibody constructs for CLDN18.2 and CD3 |
EP3831854A4 (en) | 2018-08-03 | 2022-05-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
AU2019320336B2 (en) | 2018-08-06 | 2025-06-05 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
EA202091888A1 (en) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR |
UA128584C2 (en) | 2018-08-10 | 2024-08-21 | Чугаі Сейяку Кабусікі Кайся | Anti-cd137 antigen-binding molecule and utilization thereof |
KR20210043618A (en) | 2018-08-10 | 2021-04-21 | 제넨테크, 인크. | Cell culture strategies to modulate protein glycosylation |
AU2019321490A1 (en) | 2018-08-13 | 2021-02-18 | Inhibrx Biosciences, Inc. | Ox40-binding polypeptides and uses thereof |
US12103968B2 (en) | 2018-08-16 | 2024-10-01 | The Johns Hopkins University | Antibodies to human ZnT8 |
TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
EP3836966A4 (en) | 2018-08-17 | 2022-06-08 | Ab Studio Inc. | CATALYTIC ANTIBODIES AND METHODS OF USE THEREOF |
JP7481255B2 (en) | 2018-08-23 | 2024-05-10 | 第一三共株式会社 | Antibody-drug conjugate sensitivity markers |
EA202190601A1 (en) | 2018-08-23 | 2021-07-14 | Ридженерон Фармасьютикалз, Инк. | ANTI-Fc ANTIBODIES EPSILON-R1 ALPHA (FCER1A), BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING FCΕR1Α AND CD3 AND THEIR APPLICATION |
WO2020043670A1 (en) | 2018-08-27 | 2020-03-05 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct |
EP3844188A1 (en) | 2018-08-28 | 2021-07-07 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
CN113056304A (en) | 2018-08-30 | 2021-06-29 | 戴埃克斯有限公司 | Plasma kallikrein inhibitors for the treatment of hereditary angioedema episodes and uses thereof |
MX2021002225A (en) | 2018-08-30 | 2021-07-16 | Tcr2 Therapeutics Inc | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING THROUGH THE USE OF FUSION PROTEINS. |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
AU2019331018A1 (en) | 2018-08-31 | 2021-03-11 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
BR112021003472A2 (en) | 2018-09-06 | 2021-05-18 | Daiichi Sankyo Company, Limited | cyclic dinucleotide derivative and antibody-drug conjugate thereof |
SG11202100888WA (en) | 2018-09-07 | 2021-02-25 | Pfizer | Anti-avb8 antibodies and compositions and uses thereof |
AU2019337759A1 (en) | 2018-09-10 | 2021-03-11 | Legend Biotech Ireland Limited | Single-domain antibodies against CD33 and constructs thereof |
EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
KR20210082444A (en) | 2018-09-11 | 2021-07-05 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | Improved anti-FLT3 antigen binding protein |
EP3849600A1 (en) | 2018-09-12 | 2021-07-21 | ACM Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
WO2020056170A1 (en) | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
BR112021004982A2 (en) | 2018-09-17 | 2021-06-08 | Biocontac Co., Ltd. | antibody, polynucleotide, expression vector, transformed cell, methods to produce an antibody, to prevent or inhibit cancer and cancer metastasis, to diagnose cancer or cancer metastasis, to treat a disease and to diagnose a disease, pharmaceutical composition, compositions for diagnosis and composition for prevention or treatment of a disease and use of the antibody |
US20220047716A1 (en) | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
US20210371537A1 (en) | 2018-09-18 | 2021-12-02 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
EP3853251A1 (en) | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
EP3853611A1 (en) | 2018-09-19 | 2021-07-28 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for bladder cancer |
US20220177587A1 (en) | 2018-09-19 | 2022-06-09 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
CN112912109A (en) | 2018-09-20 | 2021-06-04 | 第一三共株式会社 | Treatment of HER 3-mutated cancer by administration of anti-HER 3 antibody-drug conjugates |
US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
EP3853249A4 (en) * | 2018-09-21 | 2022-06-22 | The University of North Carolina at Chapel Hill | SYNTHETIC BINDERS TO LIMIT PERMEATION BY SLIME |
EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
CN112839959A (en) | 2018-09-21 | 2021-05-25 | 特尼奥生物股份有限公司 | Method for purifying heterodimeric multispecific antibodies |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CN120058958A (en) | 2018-09-24 | 2025-05-30 | 视点制药公司 | Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF |
EP3856343A1 (en) | 2018-09-25 | 2021-08-04 | Biolegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
IL297931B2 (en) | 2018-09-25 | 2025-03-01 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
CA3113541A1 (en) | 2018-09-26 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
KR20210086619A (en) | 2018-09-27 | 2021-07-08 | 셀진 코포레이션 | SIRPα binding protein and methods of use thereof |
US11208487B2 (en) | 2018-09-27 | 2021-12-28 | Tizona Therapeutics | Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies |
EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
TW202028239A (en) | 2018-09-28 | 2020-08-01 | 美商安進公司 | Antibodies against soluble bcma |
US20210380675A1 (en) | 2018-09-28 | 2021-12-09 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
JP2022511396A (en) | 2018-10-01 | 2022-01-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecule with trivalent binding to CD40 |
AU2019355252A1 (en) | 2018-10-01 | 2021-04-01 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
AU2019352017A1 (en) | 2018-10-03 | 2021-05-06 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
BR112021006055A2 (en) | 2018-10-04 | 2021-07-20 | Genmab Holding B.V. | pharmaceutical composition, use of the pharmaceutical composition, and, methods for inducing cell death or for inhibiting the growth and/or proliferation of a tumor cell and for treating an individual. |
US20220010020A1 (en) | 2018-10-05 | 2022-01-13 | Five Prime Therapeutics, Inc. | Anti-FGFR2 Antibody Formulations |
CN112823168A (en) | 2018-10-08 | 2021-05-18 | 苏黎世大学 | Tetrameric polypeptide that binds HER2 |
US20200109200A1 (en) | 2018-10-09 | 2020-04-09 | Genentech, Inc. | Methods and systems for determining synapse formation |
JP7644706B2 (en) | 2018-10-11 | 2025-03-12 | アムジエン・インコーポレーテツド | Downstream processing of bispecific antibody constructs |
EP3864044A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
CA3115285A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
JP7627210B2 (en) | 2018-10-15 | 2025-02-07 | ジェネンテック, インコーポレイテッド | Methods of treating residual breast cancer with trastuzumab emtansine |
JP2022512744A (en) | 2018-10-18 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment for sarcomatoid kidney cancer |
MA53933A (en) | 2018-10-21 | 2021-08-25 | Slsg Ltd Llc | MULTI-IMMUNOTHERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
CN113056287A (en) | 2018-10-24 | 2021-06-29 | 豪夫迈·罗氏有限公司 | Conjugated chemical degradation inducers and methods of use |
WO2020086328A1 (en) | 2018-10-25 | 2020-04-30 | The Medical College Of Wisconsin, Inc. | Targeting clptm1l for treatment and prevention of cancer |
AU2019367218A1 (en) | 2018-10-26 | 2021-06-03 | TeneoFour, Inc. | Heavy chain antibodies binding to CD38 |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
TWI844571B (en) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
EP3873944A1 (en) | 2018-10-31 | 2021-09-08 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
RU2724469C2 (en) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody which specifically binds to cd20 |
EP3877407A1 (en) | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
EP3877413A1 (en) | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
JP7527281B2 (en) | 2018-11-06 | 2024-08-02 | ジェンマブ エー/エス | Antibody preparations |
HU231514B1 (en) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture |
BR112021008624A2 (en) | 2018-11-08 | 2021-09-28 | Prothena Biosciences Limited | ANTIBODIES THAT RECOGNIZE TAU |
CA3118966A1 (en) | 2018-11-15 | 2020-05-22 | Byondis B.V. | Humanized anti-sirpa antibodies |
WO2020102555A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
AU2019385497A1 (en) | 2018-11-20 | 2021-06-17 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
EP3884276A2 (en) | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
PE20211786A1 (en) | 2018-11-26 | 2021-09-09 | Forty Seven Inc | HUMANIZED ANTIBODIES AGAINST C-KIT |
WO2020112870A1 (en) | 2018-11-28 | 2020-06-04 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
KR20210135987A (en) | 2018-11-30 | 2021-11-16 | 알파인 이뮨 사이언시즈, 인코포레이티드 | CD86 variant immunomodulatory protein and uses thereof |
IL283522B2 (en) | 2018-12-03 | 2025-03-01 | Agensys Inc | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |
EP3891186A1 (en) | 2018-12-05 | 2021-10-13 | MorphoSys AG | Multispecific antigen-binding molecules |
AU2018451747A1 (en) | 2018-12-06 | 2021-06-17 | F. Hoffmann-La Roche Ag | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody |
WO2020118293A2 (en) | 2018-12-07 | 2020-06-11 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
US20200207812A1 (en) | 2018-12-07 | 2020-07-02 | Coherus Biosciences, Inc. | Methods for producing recombinant proteins |
EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
BR112021011119A2 (en) | 2018-12-11 | 2022-01-25 | Daiichi Sankyo Co Ltd | pharmaceutical composition |
MX2021005878A (en) | 2018-12-13 | 2021-07-16 | Eisai R&D Man Co Ltd | Herboxidiene splicing modulator antibody-drug conjugates and methods of use. |
IL283890B1 (en) | 2018-12-14 | 2025-07-01 | Boehringer Ingelheim Io Canada Inc | Anti-periostin antibodies and uses thereof |
EP3894543A1 (en) | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
EP3669890A1 (en) | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
US20220025055A1 (en) | 2018-12-18 | 2022-01-27 | Boehringer Ingelheim Io Canada, Inc. | Flt3 agonist antibodies and uses thereof |
EP3898688A1 (en) | 2018-12-18 | 2021-10-27 | Catapult Therapeutics B.V. | The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd) |
EA202191580A1 (en) | 2018-12-19 | 2021-11-01 | Ридженерон Фармасьютикалз, Инк. | SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION |
KR20210104758A (en) | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | Bispecific anti-MUC16 X anti-CD28 antibodies and uses thereof |
AR117327A1 (en) | 2018-12-20 | 2021-07-28 | 23Andme Inc | ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM |
CA3124356A1 (en) | 2018-12-20 | 2020-06-25 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
WO2020132230A2 (en) | 2018-12-20 | 2020-06-25 | Genentech, Inc. | Modified antibody fcs and methods of use |
WO2020130125A1 (en) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | Combination of antibody-drug conjugate and kinase inhibitor |
AR117728A1 (en) | 2018-12-21 | 2021-08-25 | Hoffmann La Roche | CD28 ANTIGEN BINDING SUPERAGONIST MOLECULES WITH TUMOR TARGET |
EP3897845A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
CA3123338A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
AR117468A1 (en) | 2018-12-21 | 2021-08-11 | Hoffmann La Roche | ANTIBODY JOINING VEGF AND IL-1b AND METHODS OF USE |
AU2019403404B2 (en) | 2018-12-21 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
EA202191763A1 (en) | 2018-12-21 | 2022-03-10 | Озе Иммьюнотерапьютикс | BIFUNCTIONAL ANTI-PD-1/SIRP MOLECULE |
CN111349162A (en) | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | Humanized anti-PD-1 antibodies and uses thereof |
SG11202102859TA (en) | 2018-12-21 | 2021-04-29 | Hoffmann La Roche | Antibodies binding to cd3 |
MX2021007320A (en) | 2018-12-21 | 2021-07-07 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules. |
CN113454113A (en) | 2018-12-21 | 2021-09-28 | 23与我公司 | Antibodies to IL-36 and methods of use thereof |
SG11202106116QA (en) | 2018-12-21 | 2021-07-29 | Genentech Inc | Methods of producing polypeptides using a cell line resistant to apoptosis |
US20220064301A1 (en) | 2018-12-26 | 2022-03-03 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
TWI874345B (en) | 2019-01-07 | 2025-03-01 | 美商因荷布瑞克斯生物科學公司 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
TWI852977B (en) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
US20220112283A1 (en) | 2019-01-13 | 2022-04-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
TW202515617A (en) | 2019-01-14 | 2025-04-16 | 美商建南德克公司 | Rna molecules for use in cancer therapies |
CN111434692B (en) | 2019-01-15 | 2021-12-31 | 浙江道尔生物科技有限公司 | Anti-CLD18A2 Nanobody and Its Application |
CN113645953B (en) | 2019-01-17 | 2025-03-25 | 英美偌科有限公司 | Formulations |
CN113330030A (en) | 2019-01-17 | 2021-08-31 | 拜耳公司 | Method for determining whether a subject is suitable for treatment with an agonist of soluble guanylate cyclase (sGC) |
BR112021014276A2 (en) | 2019-01-22 | 2021-09-28 | Genentech, Inc. | ISOLATED IGA ANTIBODIES, ISOLATED IGG-IGA FUSION MOLECULES, ISOLATED NUCLEIC ACID, HOST CELL, METHOD FOR PRODUCING AN ANTIBODY, TO TREAT AN INDIVIDUAL, TO INCREASE THE EXPRESSION OF DIMERS, TRIMERS OR TETRAMERS, TO INCREASE THE PRODUCTION OF POLYMERS, TO INCREASE The production of dimers, to increase the production of a polymer, to decrease the production of polymers, to increase the transient expression of an antibody, to express dimers of fusion molecules, to express dimers, trimers or tetramers, to purify an antibody, TO PURIFY AN OLIOMER STATE OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY |
CN120248098A (en) | 2019-01-23 | 2025-07-04 | 豪夫迈·罗氏有限公司 | Method for producing multimeric proteins in eukaryotic host cells |
JP7538130B2 (en) | 2019-01-23 | 2024-08-21 | タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド | Anti-PD-L1 diabodies and uses thereof |
EP3914616A1 (en) | 2019-01-23 | 2021-12-01 | Encefa | Cd31 competitors and uses thereof |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
WO2022080481A1 (en) | 2020-10-16 | 2022-04-21 | 日本メジフィジックス株式会社 | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
EP3915581A4 (en) | 2019-01-24 | 2023-03-22 | Chugai Seiyaku Kabushiki Kaisha | Novel cancer antigens and antibodies of said antigens |
AU2020216295A1 (en) | 2019-01-28 | 2021-09-09 | Maple Biotech Llc | PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
JP2022519273A (en) | 2019-02-05 | 2022-03-22 | シージェン インコーポレイテッド | Anti-CD228 antibody and antibody drug conjugate |
CN113412121A (en) | 2019-02-12 | 2021-09-17 | 瑞泽恩制药公司 | Compositions and methods for binding complement and target antigens using bispecific antibodies |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
CN113423730B (en) | 2019-02-15 | 2024-01-05 | 上海药明合联生物技术有限公司 | Method for preparing antibody-drug conjugates with improved homogeneity |
US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
TWI857009B (en) | 2019-02-15 | 2024-10-01 | 大學健康網絡 | Fcmr-binding molecules and uses thereof |
EP3927430A1 (en) | 2019-02-18 | 2021-12-29 | Pfizer Inc. | Method of treatment of chronic low back pain |
EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
AU2020228033A1 (en) | 2019-02-26 | 2021-09-16 | Inspirna, Inc. | High-affinity anti-MERTK antibodies and uses thereof |
KR20210133237A (en) | 2019-02-27 | 2021-11-05 | 제넨테크, 인크. | Dosing for treatment with anti-TIGIT and anti-CD20 or anti-CD38 antibodies |
MX2021010441A (en) | 2019-03-01 | 2021-09-21 | Allogene Therapeutics Inc | CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS DIRECTED TO DLL3. |
MX2021010390A (en) | 2019-03-01 | 2021-11-17 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3. |
CA3131953A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
CN111670201A (en) | 2019-03-01 | 2020-09-15 | 荣昌生物制药(烟台)股份有限公司 | Her2 concomitant diagnosis immunohistochemical detection antibody and application thereof |
CN113544149B (en) | 2019-03-03 | 2024-11-15 | 普罗塞纳生物科学有限公司 | Antibodies that recognize tau |
KR20210138588A (en) | 2019-03-08 | 2021-11-19 | 제넨테크, 인크. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
EP3938396A1 (en) | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
CR20210467A (en) | 2019-03-14 | 2021-10-07 | Genentech Inc | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
WO2020186132A1 (en) | 2019-03-14 | 2020-09-17 | Dyax Corp. | Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein |
KR20210144679A (en) | 2019-03-21 | 2021-11-30 | 알로젠 테라퓨틱스 인코포레이티드 | How to Improve TCRαβ+ Cell Depletion Efficiency |
WO2020196475A1 (en) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
TWI856078B (en) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | Antibody-pyrrolobenzodiazepine derivative conjugate, preparation method thereof and use thereof |
US20220168438A1 (en) | 2019-03-27 | 2022-06-02 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
KR20220047536A (en) | 2019-04-01 | 2022-04-18 | 레이크파르마, 인코퍼레이티드 | BTLA-binding (CD272) antibody for modulation of immune response and treatment of disease |
HU231498B1 (en) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Development of affinity chromatography of immunoglobulins using pre-binding flocculation |
AU2020252556A1 (en) | 2019-04-05 | 2021-10-21 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
JP7301155B2 (en) | 2019-04-12 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecules containing lipocalin muteins |
US20220218785A1 (en) | 2019-04-17 | 2022-07-14 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
JP2022528804A (en) | 2019-04-18 | 2022-06-15 | ジェネンテック, インコーポレイテッド | Antibody titer test |
US20220143094A1 (en) | 2019-04-19 | 2022-05-12 | Chugai Seiyaku Kabushiki Kaisha | Chimeric receptor that recognizes engineered site in antibody |
WO2020214937A1 (en) | 2019-04-19 | 2020-10-22 | Allogene Therapeutics, Inc. | Antibodies against 4g7-derived chimeric antigen receptors |
CN113747944A (en) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | Methods of treating prostate cancer with anti-PSMA/CD 3 antibodies |
BR112021020867A2 (en) | 2019-04-19 | 2022-01-04 | Genentech Inc | Antibodies, nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, uses of the antibody, method of treating an individual with cancer, and method of reducing clearance |
RU2734432C1 (en) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody which specifically binds gitr |
JP7650818B2 (en) | 2019-04-26 | 2025-03-25 | アロジーン セラピューティクス,インコーポレイテッド | Methods for Producing Allogeneic CAR T Cells |
CN113728003A (en) | 2019-04-30 | 2021-11-30 | 吉加根公司 | Recombinant polyclonal proteins and methods of use thereof |
CA3134918A1 (en) | 2019-05-03 | 2020-11-12 | John Lee | Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same |
CN114269376A (en) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | Methods of treating cancer with anti-PD-L1 antibodies |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
CN114040926A (en) | 2019-05-04 | 2022-02-11 | 印希比股份有限公司 | Polypeptides that bind CD123 and uses thereof |
WO2020227072A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd33-binding polypeptides and uses thereof |
KR20220004751A (en) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a binding polypeptides and uses thereof |
JP2022531894A (en) | 2019-05-09 | 2022-07-12 | ゲンマブ ビー.ブイ. | Administration regimen of anti-DR5 antibody combination for use in the treatment of cancer |
EP3966239A1 (en) | 2019-05-09 | 2022-03-16 | Boehringer Ingelheim International GmbH | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
US20220409734A1 (en) | 2019-05-10 | 2022-12-29 | Yutaka Nishimoto | Antibody drug conjugates |
WO2020231954A1 (en) | 2019-05-10 | 2020-11-19 | The University Of North Carolina At Chapel Hill Office Of Technology Commercialization | Methods, systems, and computer readable media for generating images of microvasculature using ultrasound |
BR112021022815A2 (en) | 2019-05-14 | 2021-12-28 | Genentech Inc | Methods to treat follicular lymphoma, kits, immunoconjugates and polatuzumab vedotin |
PH12021552831A1 (en) | 2019-05-20 | 2023-01-16 | Servier Lab | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
EP3959293B1 (en) | 2019-05-20 | 2024-11-13 | NIRvana Sciences Inc. | Narrow emission dyes, compositions comprising same, and methods for making and using same |
BR112021023048A2 (en) | 2019-05-21 | 2022-04-19 | Novartis Ag | cd19 binding molecules and uses thereof |
TWI762925B (en) | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
US12037378B2 (en) | 2019-05-21 | 2024-07-16 | Novartis Ag | Variant CD58 domains and uses thereof |
SG11202112453TA (en) | 2019-05-23 | 2021-12-30 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
WO2020238730A1 (en) | 2019-05-24 | 2020-12-03 | 三优生物医药(上海)有限公司 | Novel cldn18.2 binding molecule |
JP7313730B2 (en) * | 2019-05-29 | 2023-07-25 | ヘッジホッグ,インコーポレイテッド | Antibody with improved endothelin receptor A binding ability |
AR119264A1 (en) | 2019-06-05 | 2021-12-09 | Genentech Inc | METHOD FOR REUSE OF CHROMATOGRAPHY |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
CA3142440A1 (en) | 2019-06-07 | 2020-12-10 | Amgen Inc. | Bispecific binding constructs |
KR20220031616A (en) | 2019-06-11 | 2022-03-11 | 알렉터 엘엘씨 | Anti-Sortilin Antibodies for Use in Therapy |
JP7580406B2 (en) | 2019-06-13 | 2024-11-11 | アロジーン セラピューティクス,インコーポレイテッド | Anti-TALEN Antibodies and Uses Thereof |
KR20220034784A (en) | 2019-06-13 | 2022-03-18 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
WO2020252442A1 (en) | 2019-06-13 | 2020-12-17 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
CR20210622A (en) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Multispecific heavy chain antibodies binding to cd22 and cd3 |
EP3986933A1 (en) | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
JP2022537269A (en) | 2019-06-21 | 2022-08-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Use of Bispecific Antigen Binding Molecules that Bind MUC16 and CD3 in Combination with 4-1BB Costimulation |
MX2021015888A (en) | 2019-06-26 | 2022-03-22 | Hoffmann La Roche | Fusion of an antibody binding cea and 4-1bbl. |
TWI877179B (en) | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | Anti-angpt2 antibodies |
JP7354306B2 (en) | 2019-06-27 | 2023-10-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Novel ICOS antibodies and tumor-targeting antigen-binding molecules containing them |
MX2021015694A (en) | 2019-06-28 | 2022-03-11 | Genentech Inc | COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS. |
BR112021026410A2 (en) | 2019-07-01 | 2022-02-08 | Tonix Pharma Ltd | Anti-cd154 antibodies and uses thereof |
JP2022538139A (en) | 2019-07-02 | 2022-08-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Immune complex comprising mutant interleukin-2 and anti-CD8 antibody |
SG11202111943UA (en) | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
WO2021007338A1 (en) | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
AU2020309958A1 (en) | 2019-07-10 | 2021-12-23 | Chugai Seiyaku Kabushiki Kaisha | Claudin-6 binding molecules and uses thereof |
WO2021005232A1 (en) | 2019-07-11 | 2021-01-14 | Umc Utrecht Holding B.V. | Intranasal administration of neutralising antiviral antibodies |
AR119382A1 (en) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
US20220273809A1 (en) | 2019-07-19 | 2022-09-01 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
EP4043490A4 (en) | 2019-07-19 | 2023-08-16 | Sinocelltech Ltd. | HUMANIZED ANTI-VEGF FAB ANTIBODY FRAGMENT AND USE THEREOF |
EP4001306A4 (en) | 2019-07-19 | 2023-11-15 | Sinocelltech Ltd. | Humanized anti-vegf monoclonal antibody |
US20210030885A1 (en) | 2019-07-22 | 2021-02-04 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
WO2021016598A1 (en) | 2019-07-25 | 2021-01-28 | Immunowake Inc. | Methods of measuring cell-mediated killing by effectors |
CA3148591A1 (en) | 2019-07-26 | 2021-02-04 | Amgen Inc. | Anti-il13 antigen binding proteins |
BR112022001492A2 (en) | 2019-07-26 | 2022-03-22 | Sinocelltech Ltd | Humanized anti-il17a antibody and use thereof |
CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
MX2022001049A (en) | 2019-07-26 | 2022-05-03 | Janssen Biotech Inc | PROTEINS COMPRISING DOMAINS BINDING TO THE KALLYCHREIN-RELATED PEPTIDASE 2 ANTIGEN AND THEIR USES. |
KR20220038415A (en) | 2019-07-26 | 2022-03-28 | 벤더르빌트 유니버시티 | Human monoclonal antibody to enterovirus D68 |
US20230374130A1 (en) | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
AU2020319677A1 (en) | 2019-07-31 | 2022-01-06 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab |
JP2022543551A (en) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibody that binds to GPRC5D |
WO2021022083A2 (en) | 2019-07-31 | 2021-02-04 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
EP4003409A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
JP2022543553A (en) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibody that binds to GPRC5D |
PH12022550246A1 (en) | 2019-08-01 | 2023-06-26 | Incyte Corp | A dosing regimen for an ido inhibitor |
TWI832183B (en) | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | Antibodies that bind to pathological tau species and uses thereof |
WO2021023860A1 (en) | 2019-08-07 | 2021-02-11 | Db Biotech, As | Improved horseradish peroxidase polypeptides |
KR20220116575A (en) | 2019-08-12 | 2022-08-23 | 비온드 바이오로직스 엘티디 | Antibodies against ilt2 and use thereof |
AU2020328507A1 (en) | 2019-08-12 | 2022-03-17 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
MX2022001882A (en) | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40. |
CN114555118A (en) | 2019-08-15 | 2022-05-27 | 健玛保 | Pharmaceutical compositions comprising bispecific antibodies against CD3 and CD20 and uses thereof |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
AU2020335928A1 (en) | 2019-08-30 | 2022-02-17 | Agenus Inc. | Anti-CD96 antibodies and methods of use thereof |
US20220313835A1 (en) | 2019-09-03 | 2022-10-06 | Bolt Biotherapeutics, Inc. | Aminoquinoline compounds, immunoconjugates, and uses thereof |
KR20220084033A (en) | 2019-09-04 | 2022-06-21 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Antibodies specific for IL20-RB and use thereof for treating acute exacerbation of chronic obstructive pulmonary disease |
US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
EP4028416A1 (en) | 2019-09-10 | 2022-07-20 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
US20240043512A1 (en) | 2019-09-11 | 2024-02-08 | Imcare Biotech, Llc | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
US20230257479A1 (en) | 2019-09-12 | 2023-08-17 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
WO2021050645A1 (en) | 2019-09-12 | 2021-03-18 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
KR20220064983A (en) | 2019-09-18 | 2022-05-19 | 노파르티스 아게 | NKG2D fusion protein and uses thereof |
WO2021055577A2 (en) | 2019-09-18 | 2021-03-25 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
RU2753282C2 (en) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
JP2022549218A (en) | 2019-09-20 | 2022-11-24 | ジェネンテック, インコーポレイテッド | Anti-tryptase antibody medication |
TWI859339B (en) | 2019-09-24 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |
TWI764291B (en) | 2019-09-24 | 2022-05-11 | 財團法人工業技術研究院 | Anti-tigit antibodies and methods of use |
KR20220088428A (en) | 2019-09-26 | 2022-06-27 | 주식회사 에스티큐브앤컴퍼니 | Antibodies specific for glycosylated CTLA-4 and methods of use thereof |
PE20221110A1 (en) | 2019-09-27 | 2022-07-11 | Genentech Inc | DOSE ADMINISTRATION FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES |
CN114746119A (en) | 2019-09-27 | 2022-07-12 | 詹森生物科技公司 | Anti-CEACAM antibodies and uses thereof |
EP4036116A4 (en) | 2019-09-27 | 2024-01-24 | Nanjing GenScript Biotech Co., Ltd. | Anti-vhh domain antibodies and use thereof |
WO2021067242A1 (en) | 2019-09-30 | 2021-04-08 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
US20220363753A1 (en) | 2019-09-30 | 2022-11-17 | Nekonal S.A.R.L. | Anti-tirc7 antigen binding proteins |
WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
US20210101982A1 (en) | 2019-10-04 | 2021-04-08 | Seattle Genetics, Inc. | Anti-pd-l1 antibodies and antibody-drug conjugates |
EP4037710A1 (en) | 2019-10-04 | 2022-08-10 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
BR112022006620A2 (en) | 2019-10-08 | 2022-08-30 | Nectin Therapeutics Ltd | ANTIBODIES AGAINST POLYOVIRUS RECEPTOR (PVR) AND THEIR USES |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CA3152623A1 (en) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anti-tn antibodies and uses thereof |
WO2021072210A1 (en) | 2019-10-11 | 2021-04-15 | Coherus Biosciences, Inc. | Methods of purifying ranibizumab or a ranibizumab variant |
WO2021072182A1 (en) | 2019-10-11 | 2021-04-15 | Coherus Biosciences, Inc. | Methods for producing ranibizumab |
MX2022004443A (en) | 2019-10-18 | 2022-05-02 | Genentech Inc | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma. |
US20220396628A1 (en) | 2019-10-23 | 2022-12-15 | Kite Pharma, Inc. | Anti-idiotypic antigen binding molecules and methods of use thereof |
KR20220103721A (en) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof |
TWI857167B (en) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | Thienoazepine immunoconjugates, and uses thereof |
KR20220121792A (en) | 2019-11-04 | 2022-09-01 | 씨젠 인크. | Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection |
US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
IL292757A (en) | 2019-11-05 | 2022-07-01 | Merck Patent Gmbh | Tigit antibodies and their uses |
CN115066613A (en) | 2019-11-06 | 2022-09-16 | 基因泰克公司 | Diagnostic and therapeutic methods for treating hematologic cancers |
TW202131954A (en) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
US20230027495A1 (en) | 2019-11-07 | 2023-01-26 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
MX2022005676A (en) | 2019-11-13 | 2022-10-27 | Amunix Pharmaceuticals Inc | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same. |
EP4058485A1 (en) | 2019-11-13 | 2022-09-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
CN114945369A (en) | 2019-11-15 | 2022-08-26 | 思进公司 | Method of combining tucatinib and anti-HER2 antibody-drug conjugates for the treatment of HER2-positive breast cancer |
BR112022008172A2 (en) | 2019-11-15 | 2022-07-12 | Hoffmann La Roche | STABLE AQUEOUS COMPOSITION, METHOD TO OBTAIN A PHARMACEUTICAL COMPOSITION AND DOSAGE FORM |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
EP4069736A1 (en) | 2019-12-04 | 2022-10-12 | MedImmune Limited | Antibodies against lif and uses thereof |
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
CN115335399A (en) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | Anti-idiotype antibodies directed against GPRC5D target binding domains and related compositions and methods |
EP4069741A1 (en) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
WO2021113701A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
CR20220329A (en) | 2019-12-13 | 2022-11-23 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
CR20230210A (en) | 2019-12-13 | 2023-06-14 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
WO2021124073A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
US11987632B2 (en) | 2019-12-18 | 2024-05-21 | Hoffmann-La Roche Inc. | Antibodies binding to HLA-A2/MAGE-A4 |
EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
JP2023506956A (en) | 2019-12-20 | 2023-02-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | IL-37 fusion proteins and uses thereof |
IL293626A (en) | 2019-12-20 | 2022-08-01 | Pfizer | Treatment with antibody-drug conjugates specific for the her2 site |
AR120832A1 (en) | 2019-12-20 | 2022-03-23 | Amgen Inc | MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS |
CN114828895A (en) | 2019-12-23 | 2022-07-29 | 卫材R&D管理有限公司 | Method for preparing eribulin-based antibody-drug conjugates |
CA3165504A1 (en) | 2019-12-23 | 2021-07-01 | Genentech, Inc. | Apolipoprotein l1-specific antibodies and methods of use |
CN113045655A (en) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
KR20220119467A (en) | 2019-12-27 | 2022-08-29 | 아피메트 게엠베하 | Methods of making the bispecific FCYRIII X CD30 antibody construct |
KR20240035914A (en) | 2019-12-27 | 2024-03-18 | 추가이 세이야쿠 가부시키가이샤 | Anti-ctla-4 antibody and use thereof |
TWI877278B (en) | 2019-12-30 | 2025-03-21 | 美商思進公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
US20210205311A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors |
CN114929278A (en) | 2020-01-06 | 2022-08-19 | 瓦西尼斯公司 | anti-CCR 8 antibodies and uses thereof |
CN115243763A (en) | 2020-01-08 | 2022-10-25 | 里珍纳龙药品有限公司 | Treatment of fibrodysplasia ossificans progressiva |
EP4087866A1 (en) | 2020-01-09 | 2022-11-16 | F. Hoffmann-La Roche AG | New 4-1bbl trimer-containing antigen binding molecules |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
JP2023510854A (en) | 2020-01-13 | 2023-03-15 | 武田薬品工業株式会社 | Plasma kallikrein inhibitors and their use for treating pediatric hereditary angioedema attacks |
EP4090681A1 (en) | 2020-01-17 | 2022-11-23 | Biolegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021148983A1 (en) | 2020-01-24 | 2021-07-29 | Pfizer Inc. | Anti-e-selectin antibodies, compositions and methods of use |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CA3168832A1 (en) | 2020-01-29 | 2021-08-05 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
EP4097143A1 (en) | 2020-01-31 | 2022-12-07 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
CA3169661A1 (en) | 2020-01-31 | 2021-08-05 | Celgene Corporation | Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma |
CN115397459A (en) | 2020-01-31 | 2022-11-25 | 基因泰克公司 | Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines |
EP4100059A1 (en) | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
AU2021220887B2 (en) | 2020-02-10 | 2024-11-21 | Shanghai Escugen Biotechnology Co., Ltd. | CLDN18.2 antibody and use thereof |
EP4105238A4 (en) | 2020-02-10 | 2024-03-27 | Shanghai Escugen Biotechnology Co., Ltd. | Claudin 18.2 antibody and use thereof |
IL295310A (en) | 2020-02-11 | 2022-10-01 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
TW202140012A (en) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
JP2023527609A (en) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | FLT3 binding proteins and methods of use |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
WO2021173844A1 (en) | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
WO2021170067A1 (en) | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | Anti-cd137 construct and use thereof |
JP2023516941A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs, multispecific antibodies and uses thereof |
CA3169523A1 (en) | 2020-02-28 | 2021-09-02 | Jaume Pons | Transglutaminase-mediated conjugation |
MX2022010860A (en) | 2020-03-06 | 2022-12-02 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors. |
CN115768465A (en) | 2020-03-06 | 2023-03-07 | Ona疗法有限公司 | anti-CD 36 antibodies and their use to treat cancer |
CA3168173A1 (en) | 2020-03-06 | 2021-09-10 | Robert Babb | Anti-gitr antibodies and uses thereof |
EP4118105A2 (en) | 2020-03-09 | 2023-01-18 | Pfizer Inc. | Cd80-fc fusion protein and uses thereof |
EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
PE20240020A1 (en) | 2020-03-13 | 2024-01-04 | Janssen Biotech Inc | MATERIALS AND METHODS FOR THE UNION OF SIGLEC-3/CD33 |
AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
CN115298221A (en) | 2020-03-18 | 2022-11-04 | 健玛保 | Antibodies that bind B7H4 |
WO2021188749A1 (en) | 2020-03-19 | 2021-09-23 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
CN115427454A (en) | 2020-03-19 | 2022-12-02 | 安进公司 | Antibodies against mucin 17 and uses thereof |
BR112022018847A2 (en) | 2020-03-24 | 2022-11-22 | Genentech Inc | ANTIBODIES, NUCLEIC ACID, HOST CELL, CONJUGATES, PHARMACEUTICAL COMPOSITION, LONG-ACTION DELIVERY DEVICE FOR OCULAR DELIVERY, METHOD FOR TREAT A DISORDER AND USE OF THE ANTIBODY |
CA3176257A1 (en) | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
TW202202620A (en) | 2020-03-26 | 2022-01-16 | 美商建南德克公司 | Modified mammalian cells |
PT4045533T (en) | 2020-03-26 | 2024-02-14 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
WO2021198034A1 (en) | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
WO2021202590A1 (en) | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
US20230107644A1 (en) | 2020-04-01 | 2023-04-06 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2021202948A2 (en) | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
US20230183342A1 (en) | 2020-04-06 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
KR20210124867A (en) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
WO2021204998A1 (en) | 2020-04-10 | 2021-10-14 | Heidelberg Immunotherapeutics Gmbh | Natural antibodies in prophylaxis and therapy |
CA3168460A1 (en) | 2020-04-15 | 2021-10-21 | F. Hoffmann-La Roche Ag | Immunoconjugates |
US11701427B2 (en) | 2020-04-16 | 2023-07-18 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
CN115843268A (en) | 2020-04-17 | 2023-03-24 | 纽约大学 | Therapeutic MuSK antibodies |
CA3173134A1 (en) | 2020-04-20 | 2021-10-28 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
AU2021259861A1 (en) | 2020-04-24 | 2022-11-17 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2021222181A2 (en) | 2020-04-27 | 2021-11-04 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
KR20230003114A (en) | 2020-04-28 | 2023-01-05 | 사이노셀테크 엘티디. | TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
MX2021015024A (en) | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof. |
CN115715220A (en) | 2020-04-29 | 2023-02-24 | 特尼奥生物股份有限公司 | Multispecific heavy chain antibodies with modified heavy chain constant regions |
UY39191A (en) | 2020-04-29 | 2021-11-30 | Teneobio Inc | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS |
CN115803057A (en) | 2020-04-29 | 2023-03-14 | 特纳奥尼公司 | Methods of treating multiple myeloma |
CN116963782A (en) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | Antibody drug conjugates comprising anti-TROP-2 antibodies |
JP2023524271A (en) | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | Elastase-substrate peptide linker immunoconjugates and uses thereof |
CA3178885A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
AU2021267402A1 (en) | 2020-05-08 | 2022-11-24 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
CN111995681B (en) | 2020-05-09 | 2022-03-08 | 华博生物医药技术(上海)有限公司 | anti-TIGIT antibody, preparation method and application thereof |
CA3183602A1 (en) | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2021228917A1 (en) | 2020-05-15 | 2021-11-18 | F. Hoffmann-La Roche Ag | Prevention of visible particle formation in parenteral protein solutions |
EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
CN115605185A (en) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions |
HRP20241488T1 (en) | 2020-05-26 | 2025-02-14 | Boehringer Ingelheim International Gmbh | ANTI-PD-1 ANTIBODIES |
CA3184189A1 (en) | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
TW202210101A (en) | 2020-05-29 | 2022-03-16 | 美商安進公司 | Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3 |
AU2021281417A1 (en) | 2020-05-29 | 2022-12-08 | 23Andme, Inc. | Anti-CD200R1 antibodies and methods of use thereof |
IL298538A (en) | 2020-05-29 | 2023-01-01 | Seagen Inc | Methods for treating her2-positive cancer with tocatinib in combination with trastuzumab and oxaliplatin-based chemotherapy |
BR112022024629A2 (en) | 2020-06-02 | 2023-02-23 | Dynamicure Biotechnology Llc | ANTI-CD93 CONSTRUCTS AND THEIR USES |
CN113754775A (en) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | Bispecific antibody for resisting PD-L1 and HER2 |
CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
CN115803062A (en) | 2020-06-03 | 2023-03-14 | 博泰康医药公司 | Antibodies to trophoblast cell surface antigen 2 (TROP-2) |
AU2021283933A1 (en) | 2020-06-04 | 2023-01-05 | Amgen Inc. | Bispecific binding constructs |
US20220119513A1 (en) | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
JP2023527918A (en) | 2020-06-08 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Anti-HBV antibody and method of use |
CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
CA3181143A1 (en) * | 2020-06-12 | 2021-12-16 | Heechung KWON | Multi-targeting recombinant herpes simplex viruses and use thereof |
CA3181820A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
AU2021292511A1 (en) | 2020-06-17 | 2023-02-16 | Janssen Biotech, Inc. | Materials and methods for the manufacture of pluripotent stem cells |
JP2023531200A (en) | 2020-06-18 | 2023-07-21 | ジェネンテック, インコーポレイテッド | Treatment with anti-TIGIT antibody and PD-1 axis binding antagonist |
EP4168446A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 and folr1 |
EP4168445A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Immune activating fc domain binding molecules |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
EP4168456A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 |
CA3177239A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific antibodies |
KR20230025672A (en) | 2020-06-19 | 2023-02-22 | 에프. 호프만-라 로슈 아게 | Antibodies that bind to CD3 and CD19 |
JP2023532234A (en) | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Anti-CD73 antibody and its use |
WO2021259880A1 (en) | 2020-06-22 | 2021-12-30 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
PH12022553167A1 (en) | 2020-06-23 | 2024-03-04 | Hoffmann La Roche | Agonistic cd28 antigen binding molecules targeting her2 |
WO2021259227A1 (en) | 2020-06-23 | 2021-12-30 | 江苏康缘药业股份有限公司 | Anti-cd38 antibody and use thereof |
US20230256110A1 (en) | 2020-06-24 | 2023-08-17 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
US20230330243A1 (en) | 2020-06-24 | 2023-10-19 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
WO2021260578A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
CN116249717A (en) | 2020-06-24 | 2023-06-09 | 普罗塞纳生物科学有限公司 | Antibodies recognizing sortilin |
IL299161A (en) | 2020-06-24 | 2023-02-01 | Genentech Inc | Apoptosis resistant cell lines |
EP4172203A1 (en) | 2020-06-25 | 2023-05-03 | F. Hoffmann-La Roche AG | Anti-cd3/anti-cd28 bispecific antigen binding molecules |
EP4172179A4 (en) | 2020-06-25 | 2024-11-20 | Amunix Pharmaceuticals, Inc. | Her-2 targeted bispecific compositions and methods for making and using the same |
MX2022015375A (en) | 2020-06-29 | 2023-01-16 | Genmab As | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer. |
JP2023532122A (en) | 2020-06-29 | 2023-07-26 | ジェネンテック, インコーポレイテッド | Fixed dose combination of pertuzumab plus trastuzumab |
CA3189297A1 (en) | 2020-06-30 | 2022-01-06 | Nathan Trinklein | Multi-specific antibodies binding to bcma |
AU2021298632A1 (en) | 2020-06-30 | 2023-01-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-CD70 antibody and application thereof |
CA3184618A1 (en) | 2020-07-02 | 2022-01-06 | John C. Timmer | Polypeptides comprising modified il-2 polypeptides and uses thereof |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
CN116390772A (en) | 2020-07-07 | 2023-07-04 | 博泰康医药公司 | Novel maytansine analogs as ADC payloads and their use in cancer treatment |
JP2023532764A (en) | 2020-07-07 | 2023-07-31 | エフ. ホフマン-ラ ロシュ アーゲー | Alternative surfactants as stabilizers for therapeutic protein formulations |
CN116390771A (en) | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | Camptothecin analogs conjugated to glutamine residues in proteins and uses thereof |
BR112023000707A2 (en) | 2020-07-14 | 2023-01-31 | Hoffmann La Roche | BINDING ASSAY FOR A FIXED DOSE COMBINATION, PROTEIN, KITS, COMPOSITIONS AND METHODS FOR EVALUATING A FIXED DOSE COMPOSITION, MAKING A COMPOSITION AND FOR ANALYZING THE PROTEIN CONTENT OF A FIXED DOSE COMBINATION |
PE20231093A1 (en) | 2020-07-16 | 2023-07-18 | Novartis Ag | ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTISPECIFIC BINDING MOLECULES |
EP4183799A4 (en) | 2020-07-17 | 2025-02-26 | Daiichi Sankyo Co Ltd | Method for producing antibody-drug conjugate |
EP4182346A1 (en) | 2020-07-17 | 2023-05-24 | Pfizer Inc. | Therapeutic antibodies and their uses |
MX2023000617A (en) | 2020-07-17 | 2023-02-13 | Genentech Inc | Anti-notch2 antibodies and methods of use. |
KR20230042055A (en) | 2020-07-20 | 2023-03-27 | 다이이찌 산쿄 가부시키가이샤 | Combinations of anti-HER2 antibody-drug conjugates with HER dimerization inhibitors |
CR20230017A (en) | 2020-07-21 | 2023-02-17 | Genentech Inc | Antibody-conjugated chemical inducers of degradation of brm and methods thereof |
US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
US20230295274A1 (en) | 2020-07-27 | 2023-09-21 | Single Cell Technology, Inc. | Anti-sars coronavirus-2 spike protein antibodies |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
EP4188384A1 (en) | 2020-07-29 | 2023-06-07 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist |
KR20230133832A (en) | 2020-07-29 | 2023-09-19 | 다이내믹큐어 바이오테크놀로지 엘엘씨 | Anti-CD93 constructs and uses thereof |
AU2021317111A1 (en) | 2020-07-29 | 2023-03-30 | Janssen Biotech, Inc. | Proteins comprising HLA-G antigen binding domains and their uses |
BR112023001740A2 (en) | 2020-08-03 | 2023-02-28 | Hoffmann La Roche | ANTIGEN-BINDING RECEPTORS, TRANSDUCED T-CELL, ISOLATED POLYNUCLEOTIDE, VECTOR, KIT, METHOD FOR TREAT A DISEASE IN A SUBJECT AND INDUCE LYSIS OF A TARGET CELL AND USE OF ANTIGEN-BINDING RECEPTOR |
TW202212354A (en) | 2020-08-03 | 2022-04-01 | 美商健生生物科技公司 | Materials and methods for multidirectional biotransportation in virotherapeutics |
WO2022029080A1 (en) | 2020-08-03 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
IL300388A (en) | 2020-08-04 | 2023-04-01 | Pfizer | Treatment with site specific her2 antibody-drug conjugates |
WO2022031652A1 (en) | 2020-08-04 | 2022-02-10 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
EP4192868A1 (en) | 2020-08-05 | 2023-06-14 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
WO2022029011A1 (en) | 2020-08-06 | 2022-02-10 | BioNTech SE | Binding agents for coronavirus s protein |
PE20230983A1 (en) | 2020-08-07 | 2023-06-21 | Genentech Inc | LIGAND FUSION PROTEINS FOR FLT3 AND METHODS OF USE |
MX2023001776A (en) | 2020-08-12 | 2023-03-10 | Biond Biologics Ltd | Antibodies against ilt2 and use thereof. |
AU2021326516A1 (en) | 2020-08-13 | 2023-04-13 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
TW202221026A (en) | 2020-08-14 | 2022-06-01 | 瑞士商Ac 免疫有限公司 | Humanized anti-TDP-43 binding molecules and uses thereof |
EP4199954A4 (en) | 2020-08-18 | 2024-12-25 | Omeros Corporation | MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHODS FOR DETECTION OF COMPLEMENT FACTOR D |
KR20230048150A (en) | 2020-08-21 | 2023-04-10 | 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. | Antibodies that specifically bind to glycosylated CEACAM5 |
EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
WO2022047243A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
CN116648507A (en) | 2020-08-28 | 2023-08-25 | 基因泰克公司 | CRISPR/Cas9 multiple knockout of host cell proteins |
US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
JPWO2022044248A1 (en) | 2020-08-28 | 2022-03-03 | ||
IL300835A (en) | 2020-09-02 | 2023-04-01 | Genmab As | Antibody therapy |
JP2023540526A (en) | 2020-09-04 | 2023-09-25 | ノヴァロック バイオセラピューティクス, リミテッド | Nectin-4 antibody and its use |
US20250122282A2 (en) | 2020-09-04 | 2025-04-17 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
CN116782933A (en) | 2020-09-10 | 2023-09-19 | 健玛保 | Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
WO2022053656A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
MX2023002545A (en) | 2020-09-10 | 2023-03-14 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma. |
EP4210746A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
KR20230066392A (en) | 2020-09-10 | 2023-05-15 | 젠맵 에이/에스 | Bispecific antibodies to CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
WO2022054009A2 (en) | 2020-09-12 | 2022-03-17 | Astrazeneca Uk Limited | A scoring method for an anti-her2 antibody-drug conjugate therapy |
PE20231575A1 (en) | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | ANTIBODIES THAT BIND IL1RAP AND USES OF THESE |
JP7454106B2 (en) | 2020-09-15 | 2024-03-21 | バイエル・アクチエンゲゼルシヤフト | Novel anti-A2AP antibodies and their uses |
TW202227478A (en) | 2020-09-15 | 2022-07-16 | 德商拜恩迪克公司 | Agents and methods for targeted delivery to cells |
KR20230070259A (en) | 2020-09-18 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | Antigen Binding Molecules That Bind to CD38 and/or CD28, and Uses Thereof |
TW202229344A (en) | 2020-09-21 | 2022-08-01 | 德商百靈佳殷格翰國際股份有限公司 | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
CN116209680A (en) | 2020-09-24 | 2023-06-02 | 莫佛塞斯公司 | A novel human antibody that binds to human CD3ε |
IL301404A (en) | 2020-09-28 | 2023-05-01 | Seagen Inc | Human anti-LIV1 antibodies for cancer therapy |
DE102020125465A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer |
TW202229312A (en) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers |
DE102020125457A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer |
MX2023003749A (en) | 2020-10-02 | 2023-04-24 | Genmab As | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3. |
IL301547A (en) | 2020-10-05 | 2023-05-01 | Genentech Inc | Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies |
CN116568708A (en) | 2020-10-07 | 2023-08-08 | 硕腾服务有限责任公司 | anti-NGF antibodies and methods of use thereof |
AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
MX2023004047A (en) | 2020-10-09 | 2023-04-27 | Astrazeneca Uk Ltd | Combination of antibody-drug conjugate and parp1 selective inhibitor. |
EP4228693A4 (en) | 2020-10-13 | 2024-12-18 | Janssen Biotech, Inc. | Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii |
CA3196940A1 (en) | 2020-10-14 | 2022-04-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof |
US20240084014A1 (en) | 2020-10-16 | 2024-03-14 | Qlsf Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
EP4232040A1 (en) | 2020-10-20 | 2023-08-30 | F. Hoffmann-La Roche AG | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
WO2022084400A1 (en) | 2020-10-20 | 2022-04-28 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
TW202233671A (en) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg-conjugated anti-mertk antibodies and methods of use |
KR20230110523A (en) | 2020-10-22 | 2023-07-24 | 얀센 바이오테크 인코포레이티드 | Proteins Comprising a Delta-Like Ligand 3 (DLL3) Antigen Binding Region and Uses Thereof |
US20220127344A1 (en) | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
KR20230112632A (en) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | Fusion with CD8 antigen binding molecules to modulate immune cell function |
US20230400467A1 (en) | 2020-10-26 | 2023-12-14 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022090181A1 (en) | 2020-10-28 | 2022-05-05 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
KR20230095113A (en) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies and Anti-CD79B Antibody Drug Conjugates |
JP2023548878A (en) | 2020-11-04 | 2023-11-21 | ザ ロックフェラー ユニバーシティー | Neutralizing anti-SARS-COV-2 antibody |
WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
MX2023005130A (en) | 2020-11-04 | 2023-05-25 | Genentech Inc | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies. |
KR20230104229A (en) | 2020-11-06 | 2023-07-07 | 암젠 인크 | Polypeptide constructs that bind CD3 |
CA3199976A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
CA3198064A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
JP2023547506A (en) | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | Combination therapy of anti-CD19 agents and B-cell targeting agents to treat B-cell malignancies |
TW202233680A (en) | 2020-11-06 | 2022-09-01 | 德商安美基研究(慕尼黑)公司 | Multitargeting bispecific antigen-binding molecules of increased selectivity |
US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
AU2021377614B2 (en) | 2020-11-11 | 2025-05-15 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
KR20230106645A (en) | 2020-11-11 | 2023-07-13 | 다이이찌 산쿄 가부시키가이샤 | Combination of antibody-drug conjugate with anti-SIRPα antibody |
US20230398230A1 (en) | 2020-11-12 | 2023-12-14 | Daiichi Sankyo Company, Limited | Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate |
CN116635062A (en) | 2020-11-13 | 2023-08-22 | 诺华股份有限公司 | Combination Therapies Using Cells Expressing Chimeric Antigen Receptors (CARs) |
CN117916261A (en) | 2020-11-16 | 2024-04-19 | 豪夫迈·罗氏有限公司 | Combination therapy with FAP-targeted CD40 agonists |
PE20231556A1 (en) | 2020-11-16 | 2023-10-03 | Hoffmann La Roche | GLYCOFORMS FROM MANNOSE FACTORIES |
AU2021383611A1 (en) | 2020-11-17 | 2023-06-29 | Peter Maccallum Cancer Institute | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
TW202233684A (en) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | Heavy chain antibodies binding to folate receptor alpha |
CA3199589A1 (en) | 2020-11-19 | 2022-05-27 | Ping Li | Long-acting nerve growth factor polypeptides and uses thereof |
US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
CN116761635A (en) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | BCL-XL inhibitor antibody drug conjugates and methods of use thereof |
CN112480248B (en) | 2020-11-24 | 2023-05-05 | 三优生物医药(上海)有限公司 | Molecules that specifically bind to CLD18A2 |
CN114539418A (en) | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | Bispecific antibodies and uses thereof |
TW202241436A (en) | 2020-11-30 | 2022-11-01 | 美商英塞特公司 | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022119976A1 (en) | 2020-12-01 | 2022-06-09 | Aptevo Research And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
EP4255930A1 (en) | 2020-12-02 | 2023-10-11 | Alector LLC | Methods of use of anti-sortilin antibodies |
CN116783217A (en) | 2020-12-03 | 2023-09-19 | 安进公司 | Immunoglobulin constructs with multiple binding domains |
IL303381A (en) | 2020-12-04 | 2023-08-01 | Hoffmann La Roche | PH-dependent mutant interleukin-2 polypeptides |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
IL303295A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Multispecific antibodies and antibody combinations |
CA3200895A1 (en) | 2020-12-07 | 2022-06-16 | Ugur Sahin | Antibody and taxane combination therapy |
BR112023008265A2 (en) | 2020-12-07 | 2024-02-06 | UCB Biopharma SRL | ANTIBODIES AGAINST INTERLEUKIN-22 |
TW202237639A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
TW202237638A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
US20240042050A1 (en) | 2020-12-11 | 2024-02-08 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
CN116744978A (en) | 2020-12-11 | 2023-09-12 | 博尔特生物治疗药物有限公司 | Anti-HER2 immunoconjugates and their uses |
IL303502A (en) | 2020-12-11 | 2023-08-01 | Genentech Inc | Combination therapies for the treatment of HER2 cancer |
EP4259782A1 (en) | 2020-12-14 | 2023-10-18 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
PE20240819A1 (en) | 2020-12-17 | 2024-04-18 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THEIR USE |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
FI4267105T3 (en) | 2020-12-28 | 2025-06-17 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
KR20230157940A (en) | 2020-12-29 | 2023-11-17 | 인사이트 코포레이션 | Combination therapy comprising A2A/A2B inhibitors, PD-1/PD-L1 inhibitors and anti-CD73 antibodies |
IL303992A (en) | 2020-12-29 | 2023-08-01 | Cemm Forschungszentrum F?R Molekulare Medizin Gmbh | Anti-april antibodies and uses thereof |
EP4271482A2 (en) | 2020-12-31 | 2023-11-08 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
EP4274658A1 (en) | 2021-01-06 | 2023-11-15 | F. Hoffmann-La Roche AG | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
CA3207098A1 (en) | 2021-01-06 | 2022-07-14 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
KR20230131205A (en) | 2021-01-13 | 2023-09-12 | 에프. 호프만-라 로슈 아게 | combination therapy |
TW202241925A (en) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | Peptides displayed by hla for use in immunotherapy against different types of cancers |
US12060411B2 (en) | 2021-01-15 | 2024-08-13 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies |
KR20230147092A (en) | 2021-01-22 | 2023-10-20 | 바이원큐어 테라퓨틱스, 인크. | Anti-HER-2/TROP-2 constructs and uses thereof |
AU2022213743A1 (en) | 2021-01-28 | 2023-06-15 | Nanjing Chempion Biotechnology Co., Ltd. | Conjugate and use thereof |
JP2024506831A (en) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Compositions and methods for treating cytokine release syndrome |
US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
TW202241454A (en) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | Novel method for producing antibody-immunostimulator conjugate |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
TW202245811A (en) | 2021-02-03 | 2022-12-01 | 美商異基因治療有限公司 | Formulations and processes for car t cell drug products |
JP2024505987A (en) | 2021-02-04 | 2024-02-08 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Anti-TNFR2 antibodies and their uses |
JP2024505674A (en) | 2021-02-05 | 2024-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-IL1RAP antibody |
CA3206413A1 (en) | 2021-02-11 | 2022-08-18 | Pinchas TSUKERMAN | Antibodies against cd112r and uses thereof |
TW202302626A (en) | 2021-02-15 | 2023-01-16 | 日商武田藥品工業股份有限公司 | Cell therapy compositions and methods for modulating tgf-b signaling |
CA3208060A1 (en) | 2021-02-17 | 2022-08-25 | Jessie-Farah Fecteau | Anti-cd30l antibodies and uses thereof |
WO2022178090A2 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
JP2024506931A (en) | 2021-02-19 | 2024-02-15 | インヒブルクス インコーポレイテッド | Preparation of DR5-binding polypeptide |
WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
US20240226162A9 (en) | 2021-02-25 | 2024-07-11 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
EP4298129A1 (en) | 2021-02-26 | 2024-01-03 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
US20240124572A1 (en) | 2021-02-26 | 2024-04-18 | Bayer Aktiengesellschaft | INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING |
US20220340662A1 (en) | 2021-03-01 | 2022-10-27 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
TW202317612A (en) | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
CA3210069A1 (en) | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
TW202302646A (en) | 2021-03-05 | 2023-01-16 | 美商當康生物科技有限公司 | Anti-vista constructs and uses thereof |
KR20230156051A (en) | 2021-03-09 | 2023-11-13 | 에프. 호프만-라 로슈 아게 | Combination therapy of PD-1-targeted IL-2 variant immunoconjugate and FAP/4-1BB binding molecule |
EP4304724A1 (en) | 2021-03-09 | 2024-01-17 | F. Hoffmann-La Roche AG | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
CN117500830A (en) | 2021-03-09 | 2024-02-02 | 根马布股份公司 | Multispecific binding agents against CD40 and CD137 in therapy |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cldn6 |
IL305758A (en) | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CA3210971A1 (en) | 2021-03-12 | 2022-09-15 | Bart-Jan DE KREUK | Non-activating antibody variants |
CN117062839A (en) | 2021-03-12 | 2023-11-14 | 基因泰克公司 | anti-KLK 7 antibodies, anti-KLK 5 antibodies, multispecific anti-KLK 5/KLK7 antibodies, and methods of use |
WO2022191313A1 (en) | 2021-03-12 | 2022-09-15 | 第一三共株式会社 | Glycan, and method for producing medicine containing glycan |
AU2022238526A1 (en) | 2021-03-15 | 2023-09-07 | F. Hoffmann-La Roche Ag | Compositions and methods of treating lupus nephritis |
US20240174746A1 (en) | 2021-03-18 | 2024-05-30 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
EP4314814A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
WO2022204274A1 (en) | 2021-03-23 | 2022-09-29 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
JP2024512567A (en) | 2021-03-23 | 2024-03-19 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | Diagnosis and treatment methods for T-cell lymphoma |
KR20230160314A (en) | 2021-03-24 | 2023-11-23 | 얀센 바이오테크 인코포레이티드 | Antibodies targeting CD22 and CD79B |
JP2024510777A (en) | 2021-03-24 | 2024-03-11 | ヤンセン バイオテツク,インコーポレーテツド | Proteins containing CD3 antigen binding domain and uses thereof |
US20240150466A1 (en) | 2021-03-25 | 2024-05-09 | Dynamicure Biotechnology Llc | Anti-igfbp7 constructs and uses thereof |
WO2022201122A1 (en) | 2021-03-26 | 2022-09-29 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
EP4313162A1 (en) | 2021-03-26 | 2024-02-07 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
CN117940168A (en) | 2021-03-26 | 2024-04-26 | 博尔特生物治疗药物有限公司 | 2-amino-4-carboxamide-benzazepine immunoconjugate and its use |
BR112023018061A2 (en) | 2021-03-30 | 2023-10-03 | Bayer Ag | ANTI-SEMA3A ANTIBODIES AND USES THEREOF |
EP4314032A1 (en) | 2021-03-30 | 2024-02-07 | F. Hoffmann-La Roche AG | Protease-activated polypeptides |
JP7624255B2 (en) | 2021-03-31 | 2025-01-30 | 日本マイクロバイオファーマ株式会社 | Method for producing antibody-drug conjugate and enzyme used therein |
US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
TW202313681A (en) | 2021-04-02 | 2023-04-01 | 美商安進公司 | Mageb2 binding constructs |
TW202304994A (en) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | Agonistic anti-il-2r antibodies and methods of use |
JP2024514107A (en) | 2021-04-06 | 2024-03-28 | テネオバイオ, インコーポレイテッド | Anti-CD19 antibody and CAR-T construct |
WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
TW202304524A (en) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022218957A1 (en) | 2021-04-12 | 2022-10-20 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
AR125344A1 (en) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | ANTI-C1S ANTIBODY |
KR20230171952A (en) | 2021-04-16 | 2023-12-21 | 테네오바이오, 인코포레이티드 | Anti-CD20 antibody and CAR-T structure |
WO2022225880A1 (en) | 2021-04-19 | 2022-10-27 | Genentech, Inc. | Modified mammalian cells |
WO2022223651A1 (en) | 2021-04-23 | 2022-10-27 | F. Hoffmann-La Roche Ag | Prevention or mitigation of nk cell engaging agent-related adverse effects |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202302649A (en) | 2021-04-26 | 2023-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Anti-nectin-4 antibody, anti-nectin-4 antibody-drug conjugate and medicinal use thereof |
EP4329887A1 (en) | 2021-04-28 | 2024-03-06 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
CN117545778A (en) | 2021-04-30 | 2024-02-09 | 皮埃尔法布雷医药公司 | Novel stable anti-VISTA antibodies |
AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
EP4329818A1 (en) | 2021-04-30 | 2024-03-06 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
US20240254224A1 (en) | 2021-05-03 | 2024-08-01 | UCB Biopharma SRL | Antibodies |
US20240218057A1 (en) | 2021-05-06 | 2024-07-04 | The Rockefeller University | Neutralizing anti- sars-cov-2 antibodies and methods of use thereof |
US20240384006A1 (en) | 2021-05-06 | 2024-11-21 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
CN119236056A (en) | 2021-05-07 | 2025-01-03 | 高山免疫科学股份有限公司 | Administration and therapeutic methods using TACI-Fc fusion immunomodulatory proteins |
AR125815A1 (en) | 2021-05-07 | 2023-08-16 | Genmab As | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES THAT BIND B7H4 AND CD3 |
TW202310876A (en) | 2021-05-12 | 2023-03-16 | 美商建南德克公司 | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
BR112023023775A2 (en) | 2021-05-14 | 2024-02-20 | Genentech Inc | METHODS FOR TREATING AN INDIVIDUAL WITH A CD20-POSITIVE CELL PROLIFERATIVE DISORDER AND FOR TREATING A POPULATION OF INDIVIDUALS WITH A CD20-POSITIVE CELL PROLIFERATIVE DISORDER |
JP2024518545A (en) | 2021-05-14 | 2024-05-01 | ジェネンテック, インコーポレイテッド | TREM2 agonists |
CN115448917A (en) | 2021-05-19 | 2022-12-09 | 上海迪诺医药科技有限公司 | Nitrogen-containing compound, conjugate containing nitrogen-containing compound and application of conjugate |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
US20240366777A1 (en) | 2021-05-19 | 2024-11-07 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate combination therapy with bevacizumab |
EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
WO2022251311A1 (en) | 2021-05-25 | 2022-12-01 | Seagen Inc. | Methods of quantifying anti-cd40 antibodies |
AR126009A1 (en) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
US11572412B2 (en) | 2021-06-04 | 2023-02-07 | Boehringer Ingelheim International Gmbh | Anti-SIRP-alpha antibodies |
EP4351633A1 (en) | 2021-06-08 | 2024-04-17 | Biontech Cell & Gene Therapies Gmbh | Agents and methods for activation and targeting of immune effector cells |
WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
AU2022293999A1 (en) | 2021-06-14 | 2023-11-30 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
WO2022262959A1 (en) | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
US20240279341A1 (en) | 2021-06-16 | 2024-08-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
EP4355785A1 (en) | 2021-06-17 | 2024-04-24 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
CN117794948A (en) | 2021-06-18 | 2024-03-29 | 特里尼生物公司 | Antibodies that bind to human fibrin or fibrinogen gamma C domain and methods of using the same |
JP2024522234A (en) | 2021-06-18 | 2024-06-11 | アリゲーター・バイオサイエンス・アーベー | Novel combination therapy and uses thereof |
TW202315891A (en) | 2021-06-21 | 2023-04-16 | 丹麥商珍美寶股份有限公司 | Binding agent dosing schedule |
MX2023014683A (en) | 2021-06-22 | 2024-01-12 | Regeneron Pharma | Anti-egfrviii antibody drug conjugates and uses thereof. |
WO2022269473A1 (en) | 2021-06-23 | 2022-12-29 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
CN117616123B (en) | 2021-06-25 | 2024-11-08 | 中外制药株式会社 | Anti-CTLA-4 antibodies |
AR126236A1 (en) | 2021-06-25 | 2023-10-04 | Chugai Pharmaceutical Co Ltd | USE OF THE ANTI-CTLA-4 ANTIBODY |
CA3221281A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
EP4363450A1 (en) | 2021-07-01 | 2024-05-08 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
JP2024527324A (en) | 2021-07-01 | 2024-07-24 | デナリ セラピューティクス インコーポレイテッド | Oligonucleotide conjugates targeted to the transferrin receptor |
WO2023279092A2 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202320857A (en) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | Linkers, drug linkers and conjugates thereof and methods of using the same |
TW202317633A (en) | 2021-07-08 | 2023-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CN115812082A (en) | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | Antibody specifically recognizing CD40 and its application |
IL309856A (en) | 2021-07-14 | 2024-02-01 | Genentech Inc | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
AU2022311053A1 (en) | 2021-07-15 | 2023-12-14 | BioNTech SE | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
TW202309102A (en) | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | Cd8-targeted modified il-2 polypeptides and uses thereof |
TW202321283A (en) | 2021-07-20 | 2023-06-01 | 美商英伊布里克斯公司 | Cd8-binding polypeptides and uses thereof |
KR20240036570A (en) | 2021-07-22 | 2024-03-20 | 에프. 호프만-라 로슈 아게 | Heterodimeric Fc domain antibodies |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
AU2022318255A1 (en) | 2021-07-27 | 2024-01-18 | Morphosys Ag | Combinations of antigen binding molecules |
MX2024001214A (en) | 2021-07-28 | 2024-02-12 | Hoffmann La Roche | Methods and compositions for treating cancer. |
JP2024529502A (en) | 2021-07-30 | 2024-08-06 | オーエヌエー セラピューティクス エセ.エレ. | Anti-CD36 Antibodies and Their Use for Treating Cancer - Patent application |
AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
JP2024528217A (en) | 2021-08-03 | 2024-07-26 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antibodies and methods of use |
US20240336697A1 (en) | 2021-08-07 | 2024-10-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2023019200A1 (en) | 2021-08-11 | 2023-02-16 | Viela Bio, Inc. | Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease |
EP4384553A1 (en) | 2021-08-13 | 2024-06-19 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
CA3229139A1 (en) | 2021-08-20 | 2023-02-23 | Pavel Strop | Nectin-4 antibodies and conjugates |
AU2022332285A1 (en) | 2021-08-23 | 2024-02-15 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
CA3228822A1 (en) | 2021-08-26 | 2023-03-02 | Jan Tkac | Glycoprotein biomarkers for diagnosing cancer |
EP4392454A1 (en) | 2021-08-27 | 2024-07-03 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
IL310885A (en) | 2021-08-27 | 2024-04-01 | H Lundbeck As | Treatment of cluster headache using anti-cgrp antibodies |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
EP4397762A1 (en) | 2021-08-31 | 2024-07-10 | Taisho Pharmaceutical Co., Ltd. | Anti-growth hormone antibody |
KR20240051162A (en) | 2021-09-02 | 2024-04-19 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | Anti-CECAM6 antibody with reduced side effects |
EP4399227A1 (en) | 2021-09-06 | 2024-07-17 | Genmab A/S | Antibodies capable of binding to cd27, variants thereof and uses thereof |
WO2023038548A1 (en) | 2021-09-08 | 2023-03-16 | Акционерное общество "БИОКАД" | Bispecific antibody comprising a heterodimer based on mhc proteins |
AU2022346688A1 (en) | 2021-09-14 | 2024-04-04 | Glycanostics S.R.O | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
CN118369344A (en) | 2021-09-16 | 2024-07-19 | 阿博莱斯制药公司 | Anti-human CD45RC binding domain and its use |
TW202327650A (en) | 2021-09-23 | 2023-07-16 | 美商思進公司 | Methods of treating multiple myeloma |
US20250019455A1 (en) | 2021-09-24 | 2025-01-16 | Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
CA3232382A1 (en) | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof |
JPWO2023053282A1 (en) | 2021-09-29 | 2023-04-06 | ||
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
MX2024003797A (en) | 2021-09-30 | 2024-06-19 | Seagen Inc | B7-h4 antibody-drug conjugates for the treatment of cancer. |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
US20250002600A1 (en) | 2021-10-06 | 2025-01-02 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
CA3233512A1 (en) | 2021-10-06 | 2023-04-13 | Alexander Muik | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |
TW202330610A (en) | 2021-10-08 | 2023-08-01 | 丹麥商珍美寶股份有限公司 | Antibodies binding to cd30 and cd3 |
CN116064598B (en) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
IL311956A (en) | 2021-10-08 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Method for preparing a prefilled syringe formulation |
AR127273A1 (en) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF |
CN118139648A (en) | 2021-10-14 | 2024-06-04 | 豪夫迈·罗氏有限公司 | Alternative PD1-IL7v immunoconjugates for treating cancer |
CN118215674A (en) | 2021-10-14 | 2024-06-18 | 豪夫迈·罗氏有限公司 | Novel interleukin-7 immunoconjugates |
EP4419558A1 (en) | 2021-10-19 | 2024-08-28 | Alector LLC | Anti-cd300lb antibodies and methods of use thereof |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
EP4422697A1 (en) | 2021-10-29 | 2024-09-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
CN118451108A (en) | 2021-10-29 | 2024-08-06 | 思进公司 | Methods for treating cancer using a combination of anti-PD-1 antibody and anti-CD30 antibody-drug conjugate |
KR20240102981A (en) | 2021-11-02 | 2024-07-03 | 비스테라, 인크. | FC variants with abolished binding to FCgammaR and C1Q |
IL312060A (en) | 2021-11-03 | 2024-06-01 | Affimed Gmbh | Bispecific CD16A binders |
JP2024541058A (en) | 2021-11-03 | 2024-11-06 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Specific conjugation of antibodies |
AU2022381918A1 (en) | 2021-11-03 | 2024-06-13 | Affimed Gmbh | Bispecific cd16a binders |
KR20240099315A (en) | 2021-11-05 | 2024-06-28 | 아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) | Monoclonal antibodies against carcinoembryonic antigens and uses thereof |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
CA3236006A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
CA3235206A1 (en) | 2021-11-16 | 2023-05-25 | Davide BASCO | Novel molecules for therapy and diagnosis |
US20250073346A1 (en) | 2021-11-18 | 2025-03-06 | Oxford Bio Therapeutics Ltd | Pharmaceutical combinations |
KR20240125925A (en) | 2021-11-18 | 2024-08-20 | 아스트라제네카 유케이 리미티드 | Combination of antibody-drug conjugates and PARP1 selective inhibitors |
PE20241755A1 (en) | 2021-11-19 | 2024-08-28 | Mirobio Ltd | ENGINEERED PD-1 ANTIBODIES AND THEIR USES |
WO2023094413A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
CN118284625A (en) | 2021-11-26 | 2024-07-02 | 豪夫迈·罗氏有限公司 | Combination therapy of anti-TYRP 1/anti-CD 3 bispecific antibodies and TYRP 1-specific antibodies |
WO2023100975A1 (en) | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | Method for preparing antibody-containing formulation |
EP4440625A1 (en) | 2021-12-01 | 2024-10-09 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
EP4441095A1 (en) | 2021-12-01 | 2024-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing anti-cd95l monoclonal antibodies |
EP4445911A1 (en) | 2021-12-06 | 2024-10-16 | Beijing SoloBio Genetechnology Co., Ltd. | Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition |
AR127887A1 (en) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND PLAP |
WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
US20250051440A1 (en) | 2021-12-14 | 2025-02-13 | Institut National de la Santé et de la Recherche Médicale | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
WO2023114829A1 (en) | 2021-12-15 | 2023-06-22 | Genentech, Inc. | Stabilized il-18 polypeptides and uses thereof |
CN118574849A (en) | 2021-12-17 | 2024-08-30 | 上海复宏汉霖生物技术股份有限公司 | Anti-OX 40 antibodies and methods of use |
JP2024547020A (en) | 2021-12-17 | 2024-12-26 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | Anti-OX40 antibodies, multispecific antibodies and methods of use thereof |
CR20240246A (en) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM |
CN119013293A (en) | 2021-12-22 | 2024-11-22 | 因赛特公司 | Therapeutic paradigm of anti-CD 19 antibody therapy |
MX2024007543A (en) | 2021-12-23 | 2024-07-04 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody. |
CA3240724A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
US20250161305A1 (en) | 2021-12-28 | 2025-05-22 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
TW202330619A (en) | 2021-12-28 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Anti-ror1 antibody, anti-ror1 antibody-drug conjugate and the pharmaceutical use thereof |
TW202334193A (en) | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
US20250066477A1 (en) | 2022-01-05 | 2025-02-27 | Inhibrx Biosciences, Inc. | Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof |
PE20242347A1 (en) | 2022-01-07 | 2024-12-16 | Johnson And Johnson Entpr Innovation Inc | MATERIALS AND METHODS FOR IL-1 BETA BINDING PROTEINS |
US20230287138A1 (en) | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
EP4471005A1 (en) | 2022-01-24 | 2024-12-04 | Beijing Chempion Biotechnology Co., Ltd. | Conjugate and use thereof |
AR128331A1 (en) | 2022-01-26 | 2024-04-17 | Genentech Inc | CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE |
AR128330A1 (en) | 2022-01-26 | 2024-04-17 | Genentech Inc | CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE |
EP4469159A1 (en) | 2022-01-27 | 2024-12-04 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
MX2024008833A (en) | 2022-01-28 | 2024-07-25 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma. |
CN118647402A (en) | 2022-01-28 | 2024-09-13 | 健玛保 | Bispecific antibodies targeting CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
AU2023212994A1 (en) | 2022-01-28 | 2024-08-08 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
EP4472998A1 (en) | 2022-02-02 | 2024-12-11 | BioNTech SE | Cyclic epitope tags |
IL314538A (en) | 2022-02-02 | 2024-09-01 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
EP4475884A1 (en) | 2022-02-09 | 2024-12-18 | Janssen Biotech, Inc. | Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes |
EP4479427A1 (en) | 2022-02-16 | 2024-12-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023156587A1 (en) | 2022-02-18 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
US20250163169A1 (en) | 2022-02-25 | 2025-05-22 | Institut National de la Santé et de la Recherche Médicale | Antibodies for preventing the cleavage of cd95l by metalloproteases |
TW202400228A (en) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | Dosing regimens for mitigation of cytokine release syndrome |
US20250207169A1 (en) | 2022-03-02 | 2025-06-26 | Daiichi Sankyo Company, Limited | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
CN119451982A (en) | 2022-03-02 | 2025-02-14 | 拜奥穆尼克斯制药 | Bispecific antibodies that bind to HER-3 and HER-2 or EGFR |
EP4486769A1 (en) | 2022-03-02 | 2025-01-08 | Heidelberg ImmunoTherapeutics GmbH | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
KR20240155334A (en) | 2022-03-09 | 2024-10-28 | 메르크 파텐트 게엠베하 | Anti-GD2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
US20250205350A1 (en) | 2022-03-10 | 2025-06-26 | Vivasor, Inc. | Antibody-Drug Conjugates and Uses Thereof |
CN119173530A (en) | 2022-03-11 | 2024-12-20 | 詹森药业有限公司 | Multispecific antibodies and their uses |
KR20240159846A (en) | 2022-03-11 | 2024-11-06 | 얀센 파마슈티카 엔브이 | Multispecific antibodies and uses thereof |
KR20240168351A (en) | 2022-03-11 | 2024-11-29 | 마브링크 바이오사이언스 | Antibody-drug conjugates and uses thereof |
CN119173532A (en) | 2022-03-11 | 2024-12-20 | 詹森药业有限公司 | Multispecific antibodies and their uses |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
IL314907A (en) | 2022-03-15 | 2024-10-01 | Yeda Res & Dev | Antibodies against GITR and their uses |
EP4493933A1 (en) | 2022-03-16 | 2025-01-22 | AstraZeneca UK Limited | A scoring method for an anti-trop2 antibody-drug conjugate therapy |
US20240103010A1 (en) | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
JP2025513714A (en) | 2022-03-22 | 2025-04-30 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | CD3-specific deimmunized antibodies |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
EP4499708A1 (en) | 2022-03-25 | 2025-02-05 | Shanghai Henlius Biotech, Inc. | Anti-msln antibodies and methods of use |
AR128876A1 (en) | 2022-03-28 | 2024-06-19 | Hoffmann La Roche | ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES |
JP2025511000A (en) | 2022-03-28 | 2025-04-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Interferon gamma variants and antigen-binding molecules containing the same |
JP2025510828A (en) | 2022-04-01 | 2025-04-15 | ジェネンテック, インコーポレイテッド | Hydroxypropyl methylcellulose derivatives for stabilizing polypeptides |
GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
EP4504780A1 (en) | 2022-04-01 | 2025-02-12 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
CN116925223A (en) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | Anti-PD-1 monoclonal antibodies and their derivatives and uses |
KR20250004721A (en) | 2022-04-06 | 2025-01-08 | 마이로바이오 리미티드 | Engineered CD200R antibodies and uses thereof |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
KR20250004725A (en) | 2022-04-08 | 2025-01-08 | 인히브릭스 바이오사이언스, 인크. | Combination therapy with DR5 agonist and PLK1 inhibitor or CDK inhibitor |
AU2023250038A1 (en) | 2022-04-08 | 2024-11-14 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
JP2025512342A (en) | 2022-04-13 | 2025-04-17 | ジェネンテック, インコーポレイテッド | Pharmaceutical compositions and methods of use of therapeutic proteins |
EP4508081A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
KR20250005335A (en) | 2022-04-26 | 2025-01-09 | 추가이 세이야쿠 가부시키가이샤 | Syringe with built-in filter containing pharmaceutical preparation |
EP4514391A1 (en) | 2022-04-27 | 2025-03-05 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2023212675A1 (en) | 2022-04-28 | 2023-11-02 | Allogene Therapeutics Inc. | Methods for donor cell analysis |
EP4514389A1 (en) | 2022-04-29 | 2025-03-05 | Purinomia Biotech, Inc. | Methods and compositions for treating eosinophil driven diseases and disorders |
EP4514845A1 (en) | 2022-04-29 | 2025-03-05 | Broadwing Bio LLC | Bispecific antibodies and methods of treating ocular disease |
CN119630698A (en) | 2022-04-29 | 2025-03-14 | 博闻生物有限责任公司 | Angiopoietin-related protein 7 specific antibody and its use |
KR20250021400A (en) | 2022-04-29 | 2025-02-12 | 브로드윙 바이오 엘엘씨 | Complement factor H-related 4-specific antibodies and uses thereof |
WO2023213814A1 (en) | 2022-05-02 | 2023-11-09 | Pierre Fabre Medicament | New formulation of anti vista antibody |
TW202406934A (en) | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
EP4519311A1 (en) | 2022-05-05 | 2025-03-12 | Inhibrx Biosciences, Inc. | Albumin-binding polypeptides and uses thereof |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
CN119487065A (en) | 2022-05-09 | 2025-02-18 | 舒泰神(北京)生物制药股份有限公司 | Antibodies specifically recognizing GDF15 and their applications |
WO2023218378A1 (en) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
AR129268A1 (en) | 2022-05-11 | 2024-08-07 | Hoffmann La Roche | ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
AU2023269546A1 (en) | 2022-05-12 | 2024-11-14 | BioNTech SE | Binding agents capable of binding to cd27 in combination therapy |
CN119451985A (en) | 2022-05-12 | 2025-02-14 | 健玛保 | BINDING AGENTS CAPABLE OF BINDING CD27 IN COMBINATION THERAPY |
AU2023268600A1 (en) | 2022-05-12 | 2024-11-07 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023218099A1 (en) | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
WO2023222557A1 (en) | 2022-05-17 | 2023-11-23 | Bayer Aktiengesellschaft | Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations |
EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
IL316767A (en) | 2022-05-18 | 2025-01-01 | Regeneron Pharma | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
EP4525927A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
TW202410919A (en) | 2022-05-23 | 2024-03-16 | 美商英伊布里克斯公司 | Dr5 agonist and iap antagonist combination therapy |
JP2025517490A (en) | 2022-05-26 | 2025-06-05 | ファイザー・インク | Anti-TNFR2 Antibodies and Methods of Use Thereof |
CN119278051A (en) | 2022-05-26 | 2025-01-07 | 康姆普根有限公司 | Anti-TIGIT antibody preparations |
CN119278212A (en) | 2022-05-31 | 2025-01-07 | 辉瑞大药厂 | Anti-BMP9 antibodies and methods of use thereof |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
CN119856056A (en) | 2022-06-07 | 2025-04-18 | 基因泰克公司 | Methods for determining the efficacy of lung cancer treatment comprising anti-PD-L1 antagonists and anti-TIGHT antagonist antibodies |
EP4536290A1 (en) | 2022-06-08 | 2025-04-16 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
CN119343464A (en) | 2022-06-09 | 2025-01-21 | 艾洛基治疗公司 | Methods for detecting genomic abnormalities in cells |
EP4536704A2 (en) | 2022-06-10 | 2025-04-16 | Horizon Therapeutics Ireland DAC | Igf1r antibodies |
AU2023283838A1 (en) | 2022-06-11 | 2025-01-23 | Inhibrx Biosciences, Inc. | Fcrn-binding polypeptides and uses thereof |
EP4536358A1 (en) | 2022-06-13 | 2025-04-16 | Genentech Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
CN120035602A (en) | 2022-06-17 | 2025-05-23 | 辉瑞公司 | IL-12 variants, anti-PD 1 antibodies, fusion proteins and uses thereof |
WO2023247050A1 (en) | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
MA71328A (en) | 2022-06-30 | 2025-04-30 | Sutro Biopharma, Inc. | ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES |
EP4554978A1 (en) | 2022-07-13 | 2025-05-21 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
EP4554619A1 (en) | 2022-07-15 | 2025-05-21 | Danisco US Inc. | Methods for producing monoclonal antibodies |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
AU2023309556A1 (en) | 2022-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
TW202417503A (en) | 2022-07-19 | 2024-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
AR129995A1 (en) | 2022-07-22 | 2024-10-23 | Genentech Inc | ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES |
EP4558823A1 (en) | 2022-07-22 | 2025-05-28 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
EP4558151A1 (en) | 2022-07-22 | 2025-05-28 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
AU2023313120A1 (en) | 2022-07-28 | 2025-02-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
MA71630A (en) | 2022-07-29 | 2025-05-30 | Alector Llc | TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND THEIR USES |
TW202413424A (en) | 2022-08-01 | 2024-04-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | Immunomodulatory proteins and related methods |
KR20250034106A (en) | 2022-08-03 | 2025-03-10 | 화이자 인코포레이티드 | Anti-IL27R antibodies and methods of use thereof |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
CN120077064A (en) | 2022-08-05 | 2025-05-30 | 詹森生物科技公司 | Transferrin receptor binding protein for the treatment of brain tumors |
CN120051495A (en) | 2022-08-05 | 2025-05-27 | 詹森生物科技公司 | CD98 binding constructs for the treatment of brain tumors |
CN119654163A (en) | 2022-08-09 | 2025-03-18 | 魁尔斯弗生物治疗股份有限公司 | Antibodies that bind to CLEC12A |
AU2023325086A1 (en) | 2022-08-16 | 2025-01-09 | Allogene Therapeutics Inc. | In vitro method for inhibiting hhv-6 infection |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
IL319060A (en) | 2022-08-18 | 2025-04-01 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
IL318702A (en) | 2022-08-19 | 2025-03-01 | Evive Biotechnology Shanghai Ltd | Formulations comprising g-csf and uses thereof |
IL319125A (en) | 2022-08-22 | 2025-04-01 | Abdera Therapeutics Inc | Dll3 binding molecules and uses thereof |
CN120153254A (en) | 2022-09-01 | 2025-06-13 | 基因泰克公司 | Methods for the treatment and diagnosis of bladder cancer |
AU2023334858A1 (en) | 2022-09-01 | 2025-03-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
CN120077071A (en) | 2022-09-07 | 2025-05-30 | 当康生物技术有限责任公司 | Anti-VISTA constructs and their uses |
WO2024051804A1 (en) | 2022-09-08 | 2024-03-14 | 江苏恒瑞医药股份有限公司 | Anti-ilt4 antibody and pharmaceutical use thereof |
JPWO2024053574A1 (en) | 2022-09-09 | 2024-03-14 | ||
AU2023343470A1 (en) | 2022-09-14 | 2025-02-06 | Amgen Inc. | Bispecific molecule stabilizing composition |
CN119836438A (en) | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | Anti-idiotype antibodies to B-cell maturation antigen (BCMA) |
CN119894933A (en) | 2022-09-20 | 2025-04-25 | 普米斯生物技术(珠海)有限公司 | Antibodies and their use in anti-tumor |
CN119894936A (en) * | 2022-09-20 | 2025-04-25 | 普米斯生物技术(珠海)有限公司 | Anti-HER 2 antibodies and uses thereof |
WO2024067344A1 (en) | 2022-09-27 | 2024-04-04 | 舒泰神(北京)生物制药股份有限公司 | Antibody for specifically recognizing light and use thereof |
US20240101718A1 (en) | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
WO2024068572A1 (en) | 2022-09-28 | 2024-04-04 | F. Hoffmann-La Roche Ag | Improved protease-activatable t cell bispecific antibodies |
CN119948048A (en) | 2022-09-29 | 2025-05-06 | 豪夫迈·罗氏有限公司 | Protease-activated polypeptides |
EP4345113A1 (en) | 2022-09-30 | 2024-04-03 | SDS Optic Spolka Akcyjna | Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof |
WO2024067841A1 (en) | 2022-09-30 | 2024-04-04 | 上海迪诺医药科技有限公司 | Benzazepine derivative, conjugate containing same, and use thereof |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
AU2023356984A1 (en) | 2022-10-05 | 2025-03-20 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
CN119998323A (en) | 2022-10-07 | 2025-05-13 | 基因泰克公司 | Methods of treating cancer using anti-C motif chemokine receptor 8 (CCR 8) antibodies |
TW202430211A (en) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and imids |
TW202423970A (en) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and cd38 antibodies |
AU2023358500A1 (en) | 2022-10-10 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Methods for reducing alloantibody levels in subjects in need of solid organ transplantation |
TW202423969A (en) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and proteasome inhibitors |
WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
GB202215115D0 (en) | 2022-10-13 | 2022-11-30 | Univ Nottingham | VEGF antibodies |
WO2024083790A1 (en) | 2022-10-17 | 2024-04-25 | Institut Gustave Roussy | Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target |
AU2023365454A1 (en) | 2022-10-18 | 2025-04-03 | Meiji Seika Pharma Co., Ltd. | Therapeutic agent for t cell malignancies |
WO2024083021A1 (en) | 2022-10-20 | 2024-04-25 | 北京三诺佳邑生物技术有限责任公司 | Antibody combination specifically binding to trail or fasl, and bispecific antibody |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
CN120112796A (en) | 2022-10-25 | 2025-06-06 | 基因泰克公司 | Methods for the treatment and diagnosis of multiple myeloma |
WO2024094822A1 (en) | 2022-11-02 | 2024-05-10 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating richter's syndrome |
AU2023372538A1 (en) | 2022-11-03 | 2025-05-01 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
WO2024097741A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations |
IL320029A (en) | 2022-11-08 | 2025-06-01 | Genentech Inc | Compositions and methods of treating childhood onset idiopathic nephrotic syndrome |
WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
WO2024104933A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Antigen binding molecules |
AU2023379743A1 (en) | 2022-11-17 | 2025-07-03 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
AU2023381445A1 (en) | 2022-11-17 | 2025-06-05 | Polygon Therapeutics | Anti-cd8 alpha depleting antibodies |
TW202440623A (en) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof |
CN120282803A (en) | 2022-11-30 | 2025-07-08 | 第一三共株式会社 | Combination of antibody-drug conjugates and DNMT inhibitors |
AU2023401158A1 (en) | 2022-12-01 | 2025-05-29 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
CN119998314A (en) | 2022-12-08 | 2025-05-13 | 长春百克生物科技股份公司 | Antibodies that specifically bind RSV |
WO2024129594A1 (en) | 2022-12-12 | 2024-06-20 | Genentech, Inc. | Optimizing polypeptide sialic acid content |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
CN120265662A (en) | 2022-12-14 | 2025-07-04 | 艾洛基治疗公司 | CD70 anti-idiotype antibody |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024133052A1 (en) | 2022-12-19 | 2024-06-27 | Universität Basel Vizerektorat Forschung | T-cell receptor fusion protein |
US20240269308A1 (en) | 2022-12-21 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
TW202432187A (en) | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | Cereblon degrader conjugates, and uses thereof |
WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
AR131638A1 (en) | 2023-01-18 | 2025-04-16 | Genentech Inc | MULTISPECIFIC ANTIBODIES AND THEIR USES |
AR131636A1 (en) | 2023-01-20 | 2025-04-16 | Hoffmann La Roche | Recombinant FC-domain polypeptides - IL2 variant and membrane-anchored antigen-binding polypeptide therapy |
WO2024156672A1 (en) | 2023-01-25 | 2024-08-02 | F. Hoffmann-La Roche Ag | Antibodies binding to csf1r and cd3 |
WO2024163009A1 (en) | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
TW202436339A (en) | 2023-01-31 | 2024-09-16 | 瑞士商赫孚孟拉羅股份公司 | Use for treating cancer selected from non-small cell lung cancer or triple negative breast cancer |
US20240269263A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
WO2024165146A1 (en) | 2023-02-07 | 2024-08-15 | Biontech Cell & Gene Therapies Gmbh | Immune effector cells stably and transiently expressing nucleic acids |
WO2024165045A1 (en) | 2023-02-09 | 2024-08-15 | Beigene, Ltd. | Self-stabilizing linker conjugates |
US20240327538A1 (en) | 2023-02-10 | 2024-10-03 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen and methods for making and using the same |
WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
WO2024170543A1 (en) | 2023-02-14 | 2024-08-22 | Institut National de la Santé et de la Recherche Médicale | Anti-cd44 antibodies and uses thereof |
US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
WO2024186690A2 (en) | 2023-03-03 | 2024-09-12 | Enosi Therapeutics Corporation | Oligo-trap fusion proteins (ofps) and uses thereof |
WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
WO2024184287A1 (en) | 2023-03-06 | 2024-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist |
WO2024187062A1 (en) | 2023-03-08 | 2024-09-12 | Amgen Inc. | Controlled-ice nucleation lyophilization process for bispecific molecules |
WO2024184494A1 (en) | 2023-03-08 | 2024-09-12 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
US20240343820A1 (en) | 2023-03-09 | 2024-10-17 | Kite Pharma, Inc. | Antigen binding molecules and methods of use |
WO2024191785A1 (en) | 2023-03-10 | 2024-09-19 | Genentech, Inc. | Fusions with proteases and uses thereof |
WO2024191983A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules |
WO2024188965A1 (en) | 2023-03-13 | 2024-09-19 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody |
AR132121A1 (en) | 2023-03-14 | 2025-05-28 | Odyssey Therapeutics Inc | ANTI-CD25 ANTIGEN BINDING PROTEINS AND THEIR USES |
WO2024188356A1 (en) | 2023-03-16 | 2024-09-19 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Ilt7-targeting antibodies and uses thereof |
WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
TW202440636A (en) | 2023-03-21 | 2024-10-16 | 美商傳記55有限公司 | Cd19/cd38 multispecific antibodies |
TW202438114A (en) | 2023-03-23 | 2024-10-01 | 瑞士商百濟神州瑞士有限責任公司 | Bioactive conjugate, preparation method therefor and use thereof |
WO2024200637A2 (en) | 2023-03-29 | 2024-10-03 | Boehringer Ingelheim International Gmbh | Dosing schedule of a her2 inhibitor |
TW202446789A (en) | 2023-03-31 | 2024-12-01 | 美商建南德克公司 | Anti-alpha v beta 8 integrin antibodies and methods of use |
WO2024208776A1 (en) | 2023-04-03 | 2024-10-10 | F. Hoffmann-La Roche Ag | Agonistic split antibodies |
WO2024208777A1 (en) | 2023-04-03 | 2024-10-10 | F. Hoffmann-La Roche Ag | All-in-one agonistic antibodies |
WO2024211235A1 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
AR132290A1 (en) | 2023-04-05 | 2025-06-11 | Genmab As | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES THAT BIND TO CD30 AND CD3 |
WO2024211234A1 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2024211236A2 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
WO2024213754A1 (en) | 2023-04-13 | 2024-10-17 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
US20240343805A1 (en) | 2023-04-14 | 2024-10-17 | Incyte Corporation | USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY |
WO2024216064A1 (en) | 2023-04-14 | 2024-10-17 | Twist Bioscience Corporation | Compositions and methods related to dkk1 binders |
US20240400696A1 (en) | 2023-04-17 | 2024-12-05 | Amunix Pharmaceuticals, Inc. | Compositions targeting epidermal growth factor receptor and methods for making and using the same |
WO2024220546A2 (en) | 2023-04-17 | 2024-10-24 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
WO2024220256A1 (en) | 2023-04-18 | 2024-10-24 | Qlsf Biotherapeutics, Inc. | Antibodies binding to ly6g6d |
WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
WO2024218260A1 (en) | 2023-04-18 | 2024-10-24 | Institut Gustave Roussy | Detecting tumor-associated-macrophages in pancreatic cancer |
WO2024218650A1 (en) | 2023-04-19 | 2024-10-24 | Pfizer Inc. | Lilrb1 and lilrb2 antibodies and methods of use thereof |
WO2024227154A1 (en) | 2023-04-28 | 2024-10-31 | Broadwing Bio Llc | Complement component 3 (c3)-specific antibodies and uses thereof |
GB202306345D0 (en) | 2023-04-28 | 2023-06-14 | Immunocore Ltd | Binding molecules |
WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024231320A1 (en) | 2023-05-08 | 2024-11-14 | F. Hoffmann-La Roche Ag | Targeted interferon alpha fusion proteins and methods of use |
WO2024233646A1 (en) | 2023-05-10 | 2024-11-14 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202509071A (en) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | Antibodies capable of binding to ox40, variants thereof and uses thereof |
WO2024235870A1 (en) | 2023-05-15 | 2024-11-21 | Argenx B.V. | Antibodies for use in agrin-deficient disorders |
TW202509065A (en) | 2023-05-16 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | Pd-1-regulated il-2 immunoconjugates and uses thereof |
WO2024238787A1 (en) | 2023-05-17 | 2024-11-21 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
WO2024238790A1 (en) | 2023-05-17 | 2024-11-21 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
WO2024243217A1 (en) | 2023-05-25 | 2024-11-28 | BioLegend, Inc. | Ceacam6 binding antibodies and antigen-binding fragments thereof |
TW202448933A (en) | 2023-05-31 | 2024-12-16 | 美商建南德克公司 | Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies |
TW202515604A (en) | 2023-05-31 | 2025-04-16 | 瑞典商阿斯特捷利康公司 | Methods, compositions, and combinations for the treatment of ovarian cancer |
WO2024246086A1 (en) | 2023-06-01 | 2024-12-05 | F. Hoffmann-La Roche Ag | Immunostimulatory antigen binding molecules that specifically bind to bcma |
TW202504918A (en) | 2023-06-01 | 2025-02-01 | 瑞士商赫孚孟拉羅股份公司 | Bispecific antibodies targeting bcma and cd28 |
WO2024254455A1 (en) | 2023-06-08 | 2024-12-12 | Genentech, Inc. | Macrophage signatures for diagnostic and therapeutic methods for lymphoma |
EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
TW202510911A (en) | 2023-06-14 | 2025-03-16 | 美商安進公司 | T cell engager masking molecules |
WO2024256623A1 (en) | 2023-06-16 | 2024-12-19 | Heidelberg Immunotherapeutics Gmbh | Novel anti-hsv antibody |
WO2024263710A1 (en) | 2023-06-20 | 2024-12-26 | Allogene Therapeutics, Inc. | Methods of detection for engineered cells |
WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
TW202504929A (en) | 2023-06-22 | 2025-02-01 | 美商建南德克公司 | Methods and compositions for cancer treatment |
US20250011450A1 (en) | 2023-06-22 | 2025-01-09 | Genentech, Inc. | Antibodies and uses thereof |
WO2024263195A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
WO2024263904A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
WO2024261733A1 (en) | 2023-06-23 | 2024-12-26 | H. Lundbeck A/S | Combinational treatment |
TW202500197A (en) | 2023-06-29 | 2025-01-01 | 瑞士商百濟神州瑞士有限責任公司 | Bioactive conjugates, preparation method and use thereof |
WO2025006846A2 (en) | 2023-06-29 | 2025-01-02 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
TW202500198A (en) | 2023-06-29 | 2025-01-01 | 瑞士商百濟神州瑞士有限責任公司 | Bioactive conjugates, preparation method and use thereof |
WO2025003511A1 (en) | 2023-06-30 | 2025-01-02 | Morphosys Ag | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
WO2025002410A1 (en) | 2023-06-30 | 2025-01-02 | Evive Biotechnology (Shanghai) Ltd | G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia |
WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
WO2025021277A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Agents and methods for targeted delivery of cytokines to immune cells |
US20250051432A1 (en) | 2023-07-23 | 2025-02-13 | Incyte Corporation | Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody |
WO2025021118A1 (en) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | Ligand-drug conjugate and linker for conjugation |
WO2025021838A1 (en) | 2023-07-26 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
WO2025026553A1 (en) | 2023-08-02 | 2025-02-06 | BioNTech SE | Agents and methods for targeted delivery to cells |
WO2025034715A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Gucy2c antibodies and uses thereof |
WO2025032510A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Stabilized cd3 antigen binding agents and methods of use thereof |
WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
WO2025032070A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Anti-a-beta protein antibodies, methods and uses thereof |
WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
WO2025036892A1 (en) | 2023-08-14 | 2025-02-20 | Morphosys Ag | Cycat halfbody molecules comprising sterically occluding moieties |
WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
WO2025038732A1 (en) | 2023-08-15 | 2025-02-20 | Gigagen, Inc. | Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof |
WO2025038736A1 (en) | 2023-08-15 | 2025-02-20 | Gigagen, Inc. | Methods of analyzing recombinant polyclonal proteins |
WO2025040567A1 (en) | 2023-08-18 | 2025-02-27 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
WO2025040598A2 (en) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
WO2025048887A1 (en) | 2023-09-01 | 2025-03-06 | Inhibrx Biosciences, Inc. | Ox40 agonist therapy |
WO2025048860A1 (en) | 2023-09-01 | 2025-03-06 | Inhibrx Biosciences, Inc. | Ox40 agonist therapy |
US20250101101A1 (en) | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
WO2025045250A1 (en) | 2023-09-03 | 2025-03-06 | Kira Pharmaceuticals (Us) Llc | Anti-human factor d antibody constructs and uses thereof |
WO2025054320A1 (en) | 2023-09-05 | 2025-03-13 | Tizona Therapeutics | Anti-ackr4 antibodies, compositions and uses thereof |
WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
WO2025059508A1 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Compositions and methods of reducing immunogenicity and improving stability of antibodies |
WO2025068207A1 (en) | 2023-09-25 | 2025-04-03 | F. Hoffmann-La Roche Ag | ANTIBODY THAT BINDS TO C3bBb |
WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
WO2025072313A1 (en) | 2023-09-27 | 2025-04-03 | BioLegend, Inc. | Anti-gpc4 antibodies |
US12122842B1 (en) | 2023-09-27 | 2024-10-22 | R&D Systems, Inc. | Human CD30-specific binding proteins and uses thereof |
WO2025072888A2 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19 |
WO2025076081A1 (en) | 2023-10-03 | 2025-04-10 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
WO2025076389A1 (en) | 2023-10-06 | 2025-04-10 | Seagen Inc. | Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates |
WO2025074328A1 (en) | 2023-10-06 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Use of anti-sirp-alpha antibodies to treat cancer |
WO2025074337A1 (en) | 2023-10-06 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Use of anti-sirp-alpha antibodies to treat a liver disease or disorder |
US20250114469A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE |
US20250122306A1 (en) | 2023-10-13 | 2025-04-17 | Sutro Biopharma, Inc. | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |
WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
WO2025078699A1 (en) | 2023-10-13 | 2025-04-17 | Nanocell Therapeutics Holdings B.V. | Means and methods for delivery of agents to immune effector cells |
WO2025085489A1 (en) | 2023-10-17 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof |
WO2025082777A1 (en) | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
WO2025082870A1 (en) | 2023-10-19 | 2025-04-24 | Bayer Aktiengesellschaft | Anti-gpc3 antibodies and radioconjugates thereof |
WO2025088496A1 (en) | 2023-10-24 | 2025-05-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |
WO2025087681A1 (en) | 2023-10-26 | 2025-05-01 | Morphosys Ag | Bispecific antibodies against cd3 and cd20 |
WO2025096626A1 (en) | 2023-10-31 | 2025-05-08 | Seagen Inc. | Methods of treating cancers using anti-cd30 antibody-drug conjugates |
EP4552657A1 (en) | 2023-11-07 | 2025-05-14 | Bayer Aktiengesellschaft | Radiopharmaceutical complexes and combinations |
WO2025101982A1 (en) | 2023-11-10 | 2025-05-15 | Pfizer Inc. | Anti-migis-alpha antibodies and methods of use thereof |
WO2025106474A1 (en) | 2023-11-14 | 2025-05-22 | Genentech, Inc. | Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies |
CN117224689B (en) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | The use of combined anti-HER2 antibodies and chemotherapeutic agents in the treatment of gastric cancer |
WO2025106634A1 (en) | 2023-11-17 | 2025-05-22 | Genentech, Inc. | Mcl-1 inhibitor compounds and use in antibody drug conjugates |
US20250163168A1 (en) | 2023-11-17 | 2025-05-22 | Pfizer Inc. | Novel antibodies and antibody conjugates for the treatment of metabolic disorders |
WO2025117639A1 (en) | 2023-11-27 | 2025-06-05 | Profoundbio Us Co. | Antibodies and methods for ptk7 detection |
WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
WO2025114555A1 (en) | 2023-11-30 | 2025-06-05 | Oncospear Aps | Anti-cd163 antibodies with improved adcc capabilities |
EP4563596A1 (en) | 2023-11-30 | 2025-06-04 | OncoSpear ApS | Anti-cd163 antibodies with improved adcc capabilities |
WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
WO2025120513A1 (en) | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
WO2025122745A1 (en) | 2023-12-05 | 2025-06-12 | Genentech, Inc. | Combination therapies for treatment of her2 cancer |
WO2025120015A1 (en) | 2023-12-06 | 2025-06-12 | Institut National de la Santé et de la Recherche Médicale | Cd5 targeting antibodies with depleting and t or b-cell activation effects |
WO2025122695A1 (en) | 2023-12-06 | 2025-06-12 | Incyte Corporation | Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors |
WO2025122885A1 (en) | 2023-12-08 | 2025-06-12 | Absci Corporation | Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use |
WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
WO2025120583A2 (en) | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF |
WO2025125118A1 (en) | 2023-12-11 | 2025-06-19 | F. Hoffmann-La Roche Ag | Protease activatable fc domain binding molecules |
WO2025128839A1 (en) | 2023-12-13 | 2025-06-19 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease with anti igf-1r antagonistic antibodies |
WO2025125386A1 (en) | 2023-12-14 | 2025-06-19 | F. Hoffmann-La Roche Ag | Antibodies that bind to folr1 and methods of use |
WO2025129010A1 (en) | 2023-12-14 | 2025-06-19 | Genentech, Inc. | Methods of structure determination using antibodies |
WO2025133707A1 (en) | 2023-12-19 | 2025-06-26 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
WO2025132503A1 (en) | 2023-12-20 | 2025-06-26 | F. Hoffmann-La Roche Ag | Antibodies binding to ceacam5 |
WO2025137086A1 (en) | 2023-12-20 | 2025-06-26 | Genentech, Inc. | Reducing alpha-gal |
WO2025132522A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
WO2025133042A2 (en) | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4845198A (en) | 1984-05-21 | 1989-07-04 | Immunex Corporation | Hybridoma antibody which binds IL-2 receptor |
DE3689123T2 (en) | 1985-11-01 | 1994-03-03 | Xoma Corp | MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2188941B (en) | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
AU625613B2 (en) | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
JP2646007B2 (en) | 1988-01-30 | 1997-08-25 | 財団法人 化学及血清療法研究所 | Gene fragment encoding anti-HIV antibody variable region, anti-HIV chimeric antibody expressed using the same, and method for producing the same |
DE68909441T2 (en) | 1988-02-12 | 1994-02-10 | British Tech Group | Modified antibodies. |
FI895955A7 (en) | 1988-04-15 | 1989-12-13 | Protein Design Labs Inc | IL-2 receptor-specific "chimeric" antibodies |
ATE119198T1 (en) | 1988-04-16 | 1995-03-15 | Celltech Ltd | METHOD FOR PRODUCING PROTEINS USING RECOMBINANT DNA. |
EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
IE64966B1 (en) | 1988-10-19 | 1995-09-20 | Dow Chemical Co | A novel family of high affinity modified antibodies for cancer treatment |
ATE102631T1 (en) | 1988-11-11 | 1994-03-15 | Medical Res Council | CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3048632B2 (en) | 1989-06-02 | 2000-06-05 | ザ ジョーンズ ホプキンズ ユニヴァーシティ スクール オブ メディスン | Monoclonal antibody against β-chain of leukocyte adhesion receptor, method for producing the antibody, and its application |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
DK0429242T3 (en) | 1989-11-17 | 1995-10-16 | Unilever Plc | Specific binding agents |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
NZ236792A (en) | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
EP0438312A3 (en) | 1990-01-19 | 1992-07-01 | Merck & Co. Inc. | Recombinant human anti-cd18 antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
GB9019553D0 (en) | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
HU219537B (en) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
EP0519596B1 (en) * | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2149529C (en) | 1992-11-16 | 2006-05-02 | Fernado J. R. Do Couto | Peptides and anti-sense peptides with broad neoplastic specificity |
WO1994012214A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
KR20010071271A (en) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | Treatment of Human Tumors with Radiation and Inhibitors of Growth Factor Receptor Tyrosine Kinases |
-
1992
- 1992-06-15 JP JP50110393A patent/JP4124480B2/en not_active Expired - Lifetime
- 1992-06-15 DE DE200412000008 patent/DE122004000008I1/en active Pending
- 1992-06-15 EP EP99105252A patent/EP0940468A1/en not_active Withdrawn
- 1992-06-15 DK DK92914220T patent/DK0590058T3/en active
- 1992-06-15 WO PCT/US1992/005126 patent/WO1992022653A1/en active IP Right Grant
- 1992-06-15 EP EP03020814A patent/EP1400536A1/en not_active Withdrawn
- 1992-06-15 EP EP92914220A patent/EP0590058B1/en not_active Expired - Lifetime
- 1992-06-15 US US08/146,206 patent/US6407213B1/en not_active Expired - Lifetime
- 1992-06-15 AT AT92914220T patent/ATE255131T1/en active
- 1992-06-15 AU AU22509/92A patent/AU675916B2/en not_active Expired
- 1992-06-15 DE DE69233254T patent/DE69233254T2/en not_active Expired - Lifetime
- 1992-06-15 LU LU91067C patent/LU91067I2/en unknown
- 1992-06-15 CA CA002103059A patent/CA2103059C/en not_active Expired - Lifetime
- 1992-06-15 ES ES92914220T patent/ES2206447T3/en not_active Expired - Lifetime
- 1992-08-21 US US07/934,373 patent/US5821337A/en not_active Expired - Lifetime
-
2000
- 2000-11-02 US US09/705,686 patent/US6639055B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/705,392 patent/US6719971B1/en not_active Expired - Fee Related
-
2004
- 2004-04-05 NL NL300145C patent/NL300145I1/en unknown
- 2004-06-07 JP JP2004168507A patent/JP2005000169A/en not_active Withdrawn
-
2005
- 2005-01-14 CY CY0500006A patent/CY2500B1/en unknown
- 2005-10-26 JP JP2005311080A patent/JP2006083180A/en active Pending
-
2006
- 2006-01-16 CY CY2006001C patent/CY2006001I2/en unknown
- 2006-07-07 GE GEAP20069499A patent/GEP20074141B/en unknown
-
2008
- 2008-06-18 JP JP2008158861A patent/JP4836147B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1992022653A1 (en) | 1992-12-23 |
ES2206447T3 (en) | 2004-05-16 |
EP0590058A1 (en) | 1994-04-06 |
CY2006001I2 (en) | 2011-02-02 |
US5821337A (en) | 1998-10-13 |
DE69233254T2 (en) | 2004-09-16 |
JP2005000169A (en) | 2005-01-06 |
US6639055B1 (en) | 2003-10-28 |
CY2006001I1 (en) | 2010-07-28 |
DE69233254D1 (en) | 2004-01-08 |
US6719971B1 (en) | 2004-04-13 |
CY2500B1 (en) | 2005-09-02 |
EP0590058B1 (en) | 2003-11-26 |
AU2250992A (en) | 1993-01-12 |
CA2103059A1 (en) | 1992-12-15 |
ATE255131T1 (en) | 2003-12-15 |
JP4836147B2 (en) | 2011-12-14 |
AU675916B2 (en) | 1997-02-27 |
JP4124480B2 (en) | 2008-07-23 |
EP0940468A1 (en) | 1999-09-08 |
EP1400536A1 (en) | 2004-03-24 |
DE122004000008I1 (en) | 2005-06-09 |
NL300145I1 (en) | 2004-06-01 |
GEP20074141B (en) | 2007-07-10 |
JP2008291036A (en) | 2008-12-04 |
JP2006083180A (en) | 2006-03-30 |
DK0590058T3 (en) | 2004-03-29 |
US6407213B1 (en) | 2002-06-18 |
LU91067I2 (en) | 2004-04-02 |
JPH06508267A (en) | 1994-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2103059C (en) | Method for making humanized antibodies | |
US6800738B1 (en) | Method for making humanized antibodies | |
US6054297A (en) | Humanized antibodies and methods for making them | |
US5869619A (en) | Modified antibody variable domains | |
JP4157160B2 (en) | Methods for the preparation of modified antibody variable regions | |
Weiner | Fully human therapeutic monoclonal antibodies | |
CN106029697B (en) | Canine antibodies with modified CH2-CH3 sequences | |
US6506883B2 (en) | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use | |
Jolliffe | Humanized antibodies: enhancing therapeutic utility through antibody engineering | |
US20250154281A1 (en) | Anti-steap1 antigen-binding protein | |
CA3019740A1 (en) | Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia | |
JP2016523264A (en) | Antibodies against Toso | |
US20240209085A1 (en) | Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3 | |
Hozumi et al. | Recombinant antibody technology: its advent and advances | |
WO2001023431A1 (en) | Derivatives of antibody against ganglioside gm2 | |
Zettlitz et al. | Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70) | |
HK1062916A (en) | Method for making humanized antibodies | |
US20030229207A1 (en) | Modified antibody variable domains | |
JP4808841B2 (en) | LO-CD2a antibodies that inhibit T cell activation and proliferation and methods of use thereof | |
EP2402371A1 (en) | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof | |
HK1050696B (en) | Immunoglobulin variants for specific fc epsilon receptors | |
HK1050696A1 (en) | Immunoglobulin variants for specific fc epsilon receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDC | Discontinued application reinstated | ||
MKEX | Expiry |